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ABSTRACT 
A standard truly predictive in vitro hepatic model has been sought for reducing animal testing, 
increasing drug development efficiency and improving prediction of adverse drug reactions. 
The liver is the main organ responsible for xenobiotic metabolism, being particularly exposed 
to chemicals and its metabolites. The currently available hepatic in vitro models are 
insufficient. Those present low biotransformation activity, quickly lose its differentiated 
phenotype in vitro and/or have relevant interspecies differences. Therefore, the differentiation 
of stem cells (SC) into hepatocyte-like cells (HLC) has been suggested as an alternative 
approach to provide a representative human hepatic model. However, a functional 
hepatocyte-like phenotype has not yet been achieved.  
In this thesis, we intended to demonstrate that by (i) using a human neonatal mesenchymal 
stem cell (hnMSC) source, UCX®, (ii) designing a protocol to differentiate this hnMSC into HLC 
using the cytokines and growth factors present during liver embryogenesis and (iii) resorting 
to 3D culture conditions would provide an environment closer to the in vivo, and allow a more 
representative cellular morphology, gene expression and biological behaviour of the 
hepatocyte.  
Umbilical cord matrix hnMSC were selected for the hepatic differentiation due to its high 
availability, expansion capacity and genomic stability upon expansion, and, due to its more 
primordial origin, its higher differentiation capacity relative to other MSC sources. The hepatic 
differentiation protocol was step-wise developed under 2D cell culture conditions. FGF-2 at 4 
ng/mL and the absence of FGF-4 resulted in an improved endoderm commitment and foregut 
induction during the first step of the differentiation protocol. The epigenetic modifiers 
trichostatin A (TSA), 5-azacytidine (5-AZA) and dimethyl sulfoxide (DMSO) were tested for an 
improved hepatoblast formation and maturation to HLC. The 21 day-long protocol was 
extended up to day 34, when a global gene expression analysis was performed. 
Transcriptomic analyses placed HLC between the HepG2 cell line and hpHep and distant from 
hnMSC and allowed us to understand how close we were from the hepatocyte transcriptome. 
HLC were also characterized up to day 34 at protein and functional level. DMSO at the 
concentration of 1 % and the cell passage day 17 of the differentiation with 24h of 5-AZA 
treatment, resulted in the best tested protocol. HLC were able to store glycogen, produce 
albumin and urea and express genes encoding for key hepatic enzymes. Most importantly, 
HLCs displayed stable UGTs, EROD (CY1A1/2), ECOD (CYP2B6, 1A2 and 2E1), CYP1A1, 
CYP2C9 and CYP3A4-dependent activities for 13 days at levels comparable to those 
observed in cultured primary rat hepatocytes. The presence of the hepatic drug transporters 
 x 
OATP-C and MRP-2 and evaluation of CYP450 activity and induction of a wide range of 
enzymes was observed for the first time on hnMSC derived HLCs.  
To further mimic the in vivo developing liver and thus achieve a more mature hepatic 
phenotype we established the 3D cultures. hnMSC 3D cultures aimed at evaluating hnMSC 
self-assembling capacity as well as the effect of this cell culture condition on its proliferation 
and/or differentiation potential. Viable and low proliferative hnMSC spheroids were obtained 
by resorting to (i) dynamic cultures using spinner flask suspension cultures (SFSC); and (ii) 
static cultures using ultra-low attachment (ULA) plates. In addition, 3D culture primed the 
hnMSC to produce a rich ECM and was successfully adapted to serum free conditions, which 
is particularly relevant for the hepatic differentiation.  
3D culture of HLCs was established as spheroids, formed in ULA plates, and into a hollow-
fiber perfused bioreactor designed for high density hepatocyte culture. 3D-HLC showed a 
partial hepatic zonation, observed by immunofluorescence and glycogen storage staining, and 
an improved hepatic functionality relative to 2D-HLC, namely by converting drugs into its 
specific metabolites and by producing higher amounts of glutathione. A thorough evaluation 
of 3D-HLCs biotransformation competency was confirmed using the model drug nevirapine 
(NVP). 3D HLCs distinguished from 2D-HLC by producing all phase I and II metabolites and 
by showing the modulation of phase I, II and III enzymes expression upon 10 days of NVP 
treatment. HLC thilomic profile was also presented for the first time. NVP resulted in an 
increased glutathione synthesis and oxidation in 3D HLC indicating a higher susceptibility to 
NVP toxic metabolites relative to 2D-HLC. 
The thesis that hnMSC were capable of differentiation into HLC was here proved. By resorting 
to 3D culture conditions a more representative hMSC-based in vitro model of the liver 
physiological conditions was developed, extensively characterized and reinforced by the NVP 
study. This work highlights the relevance of stem cell derived HLC as an alternative model to 
study drug metabolism and unveil toxicity alerts associated with drug metabolism and 
bioactivation. The cellular system here developed is a step towards the 3 R´s implementation 
in terms of mechanistic studies as well as high-throughput drug screening. 
 
Keywords: 
Umbilical-cord matrix mesenchymal stem cells; Hepatic differentiation; Three-dimensional cell 
cultures; In vitro alternative models; In vitro toxicology  
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RESUMO 
O processo de desenvolvimento de um novo fármaco é dispendioso, longo e tem uma taxa 
de sucesso de apenas 11 %. A falta de eficácia ou segurança das moléculas em 
desenvolvimento correspondem a cerca de 30 % da taxa de insucesso, que ocorre 
maioritariamente nas fases IIb e III. Pelo que, é essencial compreender melhor e o mais 
precocemente possível os mecanismos de ação e toxicidade das moléculas em 
desenvolvimento. Para isso, são necessários modelos celulares mais relevantes. que utilizem 
células humanas para evitar as diferenças entre espécies, e que sejam fisiologicamente mais 
representativos, permitindo assim reduzir os custos e a experimentação animal. 
O fígado é um órgão essencial para o processo de avaliação da segurança e eficácia de 
novas moléculas devido ao seu papel na biotransformação. O processo de biotransformação 
regula, de certa forma, a disponibilidade de um fármaco e seus metabolitos em circulação, 
em particular no que respeita aos fármacos de administração oral. Quer a molécula mãe quer 
os seus produtos de biotransformação podem ser responsáveis pelos efeitos tóxicos dos 
xenóbioticos diretamente no fígado ou em outros órgãos. Assim, o estudo da 
biotransformação e da hepatotoxicidade é particularmente importante no desenvolvimento 
não clínico. As linhas celulares atualmente utilizadas em estudos in vitro, como as células 
HepG2 (de origem tumoral), apresentam uma capacidade de biotransformação baixa e pouco 
representativa, enquanto os hepatócitos primários (isolados de tecidos animais ou de biopsias 
humanas), perdem a sua capacidade de biotransformação com o tempo em cultura. Os 
hepatócitos primários humanos apresentam ainda uma disponibilidade muito limitada. Para 
tentar colmatar as falhas dos atuais modelos in vitro, a diferenciação de células estaminais 
(CE) em células tipo-hepatócito (CTH) tem sido sugerida como uma fonte alternativa de 
células humanas. No entanto, ainda não foi possível originar com sucesso uma população de 
CTH madura derivada de CE. 
Neste sentido, a tese aqui apresentada pretendeu demonstrar que (i) utilizando células 
estaminais mesenquimais humanas isoladas da matriz do cordão umbilical (UCX®), (ii) 
desenvolvendo um protocolo de diferenciação baseado no conhecimento das citoquinas e 
fatores de crescimento envolvidos no desenvolvimento embrionário do fígado e (iii) 
recorrendo a sistemas de cultura tridimensionais (3D) resultaria num ambiente in vitro mais 
semelhante ao dos tecidos in vivo, proporcionando uma morfologia celular, expressão génica 
e comportamento biológico mais representativo do hepatócito. Como tal, permitindo a 
obtenção de CTH funcionais e competentes. 
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A escolha da população específica de células estaminais mesenquimais neonatais humanas 
(CEMnh) neste trabalho prende-se com a sua elevada capacidade de proliferação e 
estabilidade cromossómica, elevada disponibilidade e reduzidas questões éticas. A origem 
neonatal desta população de CEMnh surge também como uma vantagem destas por 
apresentarem uma menor marca epigenética do estilo de vida e idade do dador, uma 
capacidade de diferenciação superior em comparação com outras células estaminais 
mesenquimais, e numa reduzida imunogenicidade, que permite uma potencial aplicação 
clínica das células diferenciadas. 
O protocolo de diferenciação hepática foi primeiramente desenvolvido em culturas em 
monocamada (2D). Os três passos do protocolo de diferenciação hepática in vitro 
compreendem o comprometimento com a linhagem endodérmica, a diferenciação hepática 
em hepatoblastos e a sua maturação em CTH. Neste processo, o comprometimento com a 
linhagem endodérmica e a indução da parte anterior do trato gastrointestinal foram 
melhorados pela presença de FGF-2 a 4 ng/mL e pela ausência de FGF-4. Os modificadores 
epigenéticos tricostatina A (TSA), 5-azacitidina (5-AZA) e dimetil sulfóxido (DMSO) foram 
também testados nas etapas de formação de hepatoblastos e de maturação em CTH. O 
protocolo de diferenciação tem a duração de 21 dias sendo que a cultura de CTH foi mantida 
e monitorizada até ao dia 34. O protocolo com DMSO à concentração de 1 %, uma passagem 
celular ao dia 17 e a adição de 5-AZA a este dia resultou no melhor protocolo testado. As 
CTH demonstraram capacidade de armazenar glicogénio, produzir albumina e ureia e 
expressar genes essenciais para as funções dos hepatócitos. As CTH mostram também 
atividade de UGT, EROD (CY1A1/2), ECOD (CYP2B6, 1A2 e 2E1), CYP1A1, CYP2C9 e 
CYP3A4 que se manteve ao longo de 13 dias em cultura, com níveis comparáveis aos 
observados em culturas de hepatócitos primários isolados de rato. A avaliação da atividade 
e indução de uma vasta gama de enzimas do CYP450 assim como atividade de enzimas de 
fase II e a presença dos transportadores hepáticos OATP-C e MRP-2 foi observada pela 
primeira vez em CTH derivadas CEMhn. Finalmente, a análise global de expressão génica 
(transcriptómica) ao dia 34 da diferenciação mostrou que as CTH se posicionam entre a linha 
celular HepG2 e os hepatócitos primários humanos e distantes das células indiferenciadas. 
Esta análise permitiu-nos avaliar a proximidade entre o transcriptoma das CTH e o do 
hepatócito humano. 
No sentido de obter um fenótipo de CTH mais relevante as CEMnh foram cultivadas sob a 
forma de esferoides com o objetivo de avaliar a sua viabilidade em 3D e qual o efeito deste 
tipo de cultura no seu potencial de diferenciação e proliferação. Os esferoides foram obtidos 
através de (i) culturas dinâmicas em suspensão em sistemas de vasos agitados (SSVA) e de 
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(ii) culturas estáticas usando placas de cultura de baixa aderência (PCBA). As culturas 3D de 
CEMnh foram caracterizadas de acordo a dimensão dos esferoides, a viabilidade celular e a 
capacidade de produzir matriz extracelular. Nestas condições de cultura, os esferoides 
mostraram uma reduzida capacidade de proliferação, como observado pela marcação com 
Ki-67 e pela quantificação da biomassa, e conduziram à secreção de uma matriz extracelular 
rica, constituída por colagénio tipo I e IV, fibronectina e laminina. As CEMnh, mantidas sob a 
forma de esferoides, também mantiveram as suas características de células estaminais 
mesenquimais durante pelo menos 3 dias em cultura, nomeadamente a capacidade de 
diferenciação em adipócitos, osteoblastos e condroblastos. Desta forma, assegurando que a 
diferenciação seria iniciada em CEMnh indiferenciadas. Estas culturas foram ainda adaptadas 
a condições de cultura sem soro, essencial para as suas futuras aplicações clínicas e na 
diferenciação hepática. 
A diferenciação em CTH foi então implementada em 3D (i) sob a forma de esferoides (PCBA) 
e (ii) num bioreactor de perfusão de fibra oca, desenvolvido para a cultura de hepatócitos. As 
culturas 3D mostraram uma zonação hepática parcial, observada pela coloração de 
glicogénio e pela deteção dos transportadores hepáticos OATP-C e MRP-2 por 
imunofluorescência. O fenótipo das CTH nas culturas tridimensionais também se distinguiu 
das culturas em monocamada pela maior capacidade de converter fármacos como o 
bupropion e o diclofenac nos seus metabolitos de fase I e de sintetizar glutationa. Uma 
avaliação mais profunda da capacidade de biotransformação das CTH foi avaliada utilizando 
o fármaco nevirapina (NVP) como modelo. O tratamento com NVP, pelo período de 10 dias, 
resultou na produção de todos os metabolitos de fase I e II de NVP nas culturas 3D por 
oposição às culturas 2D onde os metabolitos de fase II foram detetados em muito baixas 
quantidades. As CTH em 3D também mostraram modulação da expressão génica de enzimas 
de fase I, II e III enquanto as culturas 2D apenas mostraram modulação de enzimas de fase 
I. O perfil tiolómico foi determinado pela primeira vez em CTH. O tratamento com NVP alterou 
particularmente o perfil tiolómico da cultura 3D, tendo as CTH mostrado um aumento da 
síntese de glutationa assim como um aumento do seu estado de oxidação, indicando que as 
CTH em 3D apresentam uma maior suscetibilidade à NVP e aos seus metabolitos tóxicos. 
Em suma, a utilização destas CEMnh e o protocolo de diferenciação desenvolvido nesta tese 
permitiram obter células do tipo hepatócito. A tese de que as condições de cultura 
tridimensionais, na presença de citocinas e factores de crescimento envolvidos no 
desenvolvimento embrionário do fígado resultaria num modelo hepático in vitro mais 
representativo foi aqui comprovada, e reforçada pelo estudo da biotransformação da 
nevirapina. Assim, o sistema celular aqui desenvolvido destaca a importância da 
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diferenciação de células estaminais em CTH como um modelo alternativo para o estudo do 
metabolismo e toxicidade de fármacos, particularmente dos que dependem de bioactivação. 
Desta forma, este trabalho apresenta-se como mais um passo no sentido da implementação 
da política dos 3 Rs indo também ao encontro das necessidades da indústria farmacêutica 
em termos da sua aplicação para estudos de mecanismos farmacológicos e toxicológicos 
bem como o estudo inicial de um elevado número de moléculas (high-throughput screening). 
Palavras-chave: 
Células estaminais da matriz do cordão umbilical; Diferenciação hepática; Culturas celulares 
tridimensionais; Modelos alternativos; Toxicologia in vitro  
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1 Chapter 1. General Introduction 
 
Part of the scientific content of the present chapter has been included in the following 
publications: 
Cipriano M, Oliveira NG, Miranda JP. Revisiting 3D liver models for drug metabolism and 
toxicology studies: A critical perspective. (submitted for publication) 
Cipriano M, Miranda JP. Strategies for deriving stem cells into hepatocyte-like cells and its 
drug screening potential applications. (in preparation) 
 
Chapter 1 
 2 
Earlier and better understanding of drug mechanisms of action and toxicity is essential to 
improve the R&D process of a new drug [1, 2]. In fact, there is a relevant number of drug 
withdrawals for toxicological reasons, of which 21 % is due to hepatotoxicity [3]. The liver is 
the main organ responsible for xenobiotic metabolism, being particularly exposed to chemicals 
and its metabolites. Moreover, the hepatocyte is a particularly complex cell type that presents 
more individual functions than other ~200 terminally differentiated cell types in the human 
body [4].  
1.1 Liver physiology and function 
The liver is composed of 4 lobes, contains 5 cell types and distinct extracellular matrix (ECM) 
compositions. The liver parenchymal cells are the hepatocytes and the non-parenchymal cells 
are Kupffer cells, sinusoidal endothelial cells, bile duct epithelial cells and Ito cells (stellate 
cells). Hepatocytes represent 60 % of the liver’s cells, about 80 % of liver total cell mass and 
are responsible for the liver’s synthetic and metabolic functions. Hepatocytes are arranged in 
single-cell thick plates as represented in Figure 1.1. 
 
Figure 1.1 Multiscale liver tissue structures contribute to the diverse functional roles of the liver. 
Hierarchical structure of the liver consisting of repeated functional tissue units, the liver lobules [5].  
Regardless of hepatocytes’ morphological similarity, its functions vary per its location within 
the hepatic lobule, namely when located either closer to the periportal vein or to the central 
vein (Figure 1.2). This phenomenon is named hepatic zonation. Periportal hepatocytes are 
characterized by higher oxygen presence, glycogen synthesis from lactate and urea 
production since the blood that irrigates these hepatocytes flows from the whole circulation. 
On the other hand, the perivenus phenotype is exposed to lower oxygen pressure, and 
presents higher xenobiotic metabolism and glycogen synthesis from glucose given that these 
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cells are partially irrigated by blood flowing from the enterohepatic circulation [6, 7]. In the 
hepatic lobule, the blood flows toward the hepatic vein within the space of Disse contacting 
with the exposed surface areas of the hepatocyte plates, where toxins and nutrients within the 
blood stream are extracted by the hepatocytes. Kupffer cells are liver macrophages residing 
in the sinusoids. Their functions include phagocytosis of old red blood cells and bacteria as 
well as heme conversion into bilirubin. Sinusoidal endothelial cells are fenestrated allowing 
proteins to pass freely through the sinusoidal endothelium into the space of Disse, where they 
directly contact with hepatocytes, in a bi-directional fashion, meaning that proteins and other 
substances produced, stored or processed by the liver can also be transferred back into the 
blood. Bile duct epithelial cells line the interlobular bile ducts within the portal triads. Finally, 
Ito or stellate cells are found in the space of Disse and play an important role in liver fibrosis 
once these cells are responsible for collagen production [7, 8].  
 
Figure 1.2 Distribution of extracellular matrix (ECM) in the liver acinus. A basement membrane is localized 
in the periportal and perivenous regions. Adapted from [7].  
Besides the cellular component, the liver ECM composition and stiffness is of major 
importance for the maintenance of the parenchymal and non-parenchymal cell function. As 
represented in Figure 1.2, the hepatic parenchyma ECM is constituted by fibronectin and type 
I and III collagen, whereas the basal membrane, surrounding the blood vessels, is composed 
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by laminin, type IV collagen and perlecan. The endothelial sinusoids lack a basal lamina since 
the liver has no continuous barrier between epithelial cell surface and the plasma [7]. 
1.2 Role of liver in absorption, distribution, metabolism, excretion and toxicity 
(ADMET) 
The liver is a unique organ regarding the large number of vital functions. Its main functions 
are nutrient homeostasis, by storing glycogen through glucose metabolism; ammonia 
detoxification, by synthetizing urea; filtration of particulates; protein synthesis, such as 
albumin; biotransformation of endo and xenobiotics; cholesterol synthesis and homeostasis; 
formation of bilirrubin and billiary secretion [9]. It is, thus, strategically located to maintain the 
body’s metabolic homeostasis and it plays an essential role in ADMET (absorption, 
distribution, metabolism, excretion and toxicity) process for most drugs. In fact, the liver is one 
of the first organs contacting with oral xenobiotics after the process of absorption, through the 
portal vein. Within the liver, the distribution of molecules is facilitated by: (i) the capillary 
endothelium porosity, since the hepatic sinusoids present fenestrae that have 50 to 150 nm in 
diameter; (ii) the presence of specialized membrane transporters; (iii) accumulation in cell 
organelles and reversible intracellular binding. The hepatocytes’ high exposure to xenobiotics 
and its metabolic defence mechanisms contribute to molecules biotransformation and 
subsequent excretion. About 73 % of the 200 most prescribed drugs suffer biotransformation 
as primary elimination pathway, whereas, 22 % and 5 % suffer renal and biliary elimination, 
respectively (Figure 1.3.) [10]. The biotransformation mechanisms are classified as phase I, 
II and III reactions as schematically represented in Figures 1.3 and 1.4. 
1.2.1 Phase I metabolism 
Phase I reactions are responsible for the increase in compounds’ polarity by introducing or 
unmasking a functional group (e.g., -OH, -COOH, -NH2, or -SH) within a molecule to enhance 
its hydrophilicity. It can occur through direct introduction of the functional group or by modifying 
existing functionalities. This might result in the reduction of ketones or aldehydes to alcohols, 
the oxidation of alcohols to acids, hydrolysis of ester and amides, the reduction of azo and 
nitro compounds or also the oxidative N-, O-, and S-dealkylation. Several enzymes are 
responsible for phase I reactions; those include the cytochrome P450 (CYP450) enzymes, 
flavin-containing monooxygenases (FMOs), monoamine oxidases (MAOs) and xanthine 
oxidase/aldehyde oxidase (XO/AO) [10, 11]. As represented in Figure 1.3, CYP450 enzymes 
are responsible for 75 % of the drug metabolism of the 200 most prescribed drugs. There is a 
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total of 18 human CYP450 gene families among which only three have a role in xenobiotic 
metabolism, whereas the remaining families are involved in cholesterol biosynthesis, vitamin 
D metabolism, bile acid metabolism and biosynthesis catabolism of steroids [7, 12]. CYP3A, 
CYP2C and CYP1A are the most important enzyme families involved in drug metabolism, 
being responsible for 70 % of drug biotransformation, representing 50 % of CYP450 enzymes 
in the liver. The overall CYP450 metabolism shows a different distribution of metabolized 
drugs by each CYP450 enzyme (Table 1.1) when compared to the data presented in Figure 
1.3, that refers to the 200 most prescribed drugs. In fact, the relative amount of CYP450 
enzymes in the liver is not directly correlated with the extension of drugs biotransformation 
and its activity is susceptible of specific induction, which results in an altered capacity to 
biotransform its substrates (Table 1.1).  
 
Figure 1.3 Elimination and Metabolism of the top 200 most prescribed drugs in 2002. [10, 11] 
1.2.2 Phase II metabolism 
Phase II reactions are characterized by the addition of a functional group through conjugation 
reactions performed by UDP-Glucuronosyltransferases (UGT), Sulfotransferases (SULT), 
Glutathione transferases (GST), aminoacid transferases, N-Acetytransferase (NAT) or 
Methytransferases (MT).  
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Figure 1.4 Elimination and Metabolism of drugs by the hepatocyte. Lipophilic xenobiotics (X) flow in sinusoidal 
blood and diffuse through the endothelial cell fenestrations into the space of Disse while still protein bound. Drugs 
may enter the hepatocyte by active transport or passive diffusion. Inside the cell, a drug will typically encounter a 
specific phase I enzyme, e.g. a CYP450 enzyme, capable of binding to the drug, and converting it to more water 
soluble and chemically reactive metabolites (X*). Typically, the resultant metabolite undergoes conjugation to a 
polar ligand in a reaction catalyzed by phase II enzymes. The resultant conjugated metabolite is then secreted by 
efflux transporters into the biliary canaliculus for excrection in bile, or secreted back into sinusoidal blood for 
ultimate excretion in urine, referred to as phase III metabolites. [7, 9, 13]. 
UGTs are responsible for 35 % of phase II drug metabolism being also important in bilirubin, 
steroid hormone, thyroid hormone, bile acid, and fat-soluble vitamin metabolism [14]. There 
are two broad families named UGT1 and UGT2, also known as the phenol/bilirubin family and 
the steroid/bile salt family, respectively. The liver is the major organ for glucuronidation, being 
UGT1A1 and UGT2B7 the most relevant enzymes for drug metabolism in the human liver [15].  
SULTs are divided into four families, with the cytosolic SULTs being the most relevant 
enzymes for xenobiotic metabolism. In humans three SULT families, SULT1, SULT2, and 
SULT4, have been identified, containing at least 13 distinct members [16]. Within SULT1 
family the isoform SULT1A1 was identified in a variety of species whereas SULT1A2, 
SULT1A3 and SULT1A4 were only identified in humans. In fact, SULT1A1 is the most 
expressed SULT in human liver [16]. SULT1A1 and SULT1A3 are abundantly expressed in 
the fetal liver whereas in adult liver SULT1A3 expression is much lower [16]. 
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Table 1.1 Relative abundance of human CYP450 enzymes and their contribution to drug metabolism.  
 Enzyme content in liver (% total CYP450) 
Metabolized drugs 
by enzyme (%) 
Examples of 
common substrates 
Examples of 
common inducers 
CYP3A4/5 29-30 % 30.2 % Testosterone 
Rifampicin 
Phenobarbital 
Carbamazepine 
CYP2D6 1.5-4 % 20 % 
Codeine  
Timolol 
Flecainide 
Dextromethorphan 
Piperidines 
Dexamethasone 
Rifampicin 
CYP2C9 12 % 12.8 % 
(S) - Warfarin 
Phenytoin 
Rosiglitazone 
Tolbutamide 
Rifampicin 
Carbamazepine 
CYP2C8 7% 4.7 % 
Ibuprofen 
Paclitaxel 
Cerivastatin 
Rifampicin 
Carbamazepine 
CYP2C19 0.2 % 6.8 % 
Amitriptyline 
Diazepam 
Phenobarbital 
Lansoprazole 
(R/S) - Warfarin 
Rifampicin 
Prednisone 
CYP1A2 12-13 % 8.9 % 
Caffeine 
Melatonin 
(R) - Warfarin 
Rifampicin 
Phenobarbital 
CYP2E1 7 % 3 % Ethanol 
Paracetamol 
Acetone 
Ethanol 
CYP2B6 0.2-5 % 7.2 % 
Nictoine 
Bupropion 
Cyclophosphamide 
Efavirenz 
Clotrimazole 
Rifampicin 
Phenobarbital 
Adapted from [17, 18] 
GSTs are divided into two super-families comprising cytoplasmic and membrane bound 
enzymes. The cytoplasmic GSTs might also be present in nucleolus, mitochondria and 
peroxisomes and are responsible for 18 % of drug metabolism (Figure 1.3). This superfamily 
comprises five classes: a (A1-A4), µ (M1-M5), p (P1), k (K1) and q (T1, T2) [19]. In the liver, 
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GSTa is the most predominant class followed by GSTµ [20]. GSTs reduce the formation of 
hydroperoxides of fatty acids, phospholipids, cholesterol, and act against the redox-cycling of 
some quinone containing compounds, through glutathione conjugation. Thus, GST is part of 
the defence mechanisms against reactive oxygen species. GSTs have also an important role 
on the transport of a wide variety of both endogenous and exogenous compounds [21]. 
Glutathione (GSH) conjugation is not always enzymatic since hydrophobic molecules 
containing an electrophilic atom might react non-enzymatically with glutathione. This includes 
a variety of electrophilic xenobiotics resulting in glutathione conjugates that are thioethers, 
formed by nucleophilic attack of glutathione thiolate anion (GS−) with an electrophilic carbon 
atom in the xenobiotic containing electrophilic heteroatoms (O, N, or S) [9].  
1.2.3 Phase III metabolism 
Phase III reactions comprise the role of the transport of endo and xenobiotics and its 
metabolites. The hepatic transporters can be classified as (i) influx transporters, located in the 
sinusoidal/basolateral membrane, responsible for the uptake of molecules into the 
hepatocytes; and (ii) efflux transporters, that are mostly located in the canalicular/apical 
membranes, but may also be located in the sinusoidal/basolateral membrane as represented 
in Figure 1.5. The influx transporters include the Na+/bile acid cotransport protein (NTCP) and 
three families of organic ion exchanger transporters: OATP, the organic anion transporter 
protein family; OCT, the organic cation transporter family; and OAT, the organic anion 
transporter family [7]. The OATP family is also named as glycoprotein transporters, particularly 
important for drug transport and bilirubin uptake. OATP1B1 and OATP1B3 are liver specific, 
being OATPC1A2 and OATP2B1 also present in liver [22]. The efflux transporters include the 
ATP-binding cassette (ABC) family and the organic solute transporter a/b (OSTa / OSTb), 
responsible for bile acid transport. The canalicular/apical ABC family transporters comprise 
two functional classes: (i) the solute transporters such as the cation transporter multidrug 
resistance protein 1 (MDR1) also known as P-glycoprotein 1, the bile salt export pump (BSEP), 
the xenobiotic transporter breast cancer resistance protein (BCRP), and the multidrug 
resistance-associated protein 2 (MRP-2) also known as multi-specific organic anion 
transporter 2; and (ii) the translocators such as the phospholipid flippase MDR3, and the ABC 
half transporters involved in cholesterol transport ABCG5/8. On the sinusoidal/basolateral 
membrane there is the OSTa/OSTb transporter and the ABC transporters: MRP1 that 
transports various organic anions including GSH, glucuronide and sulfate conjugates of 
several drugs; MRP3 that is an organic anion transporter that primarily transports bile salts 
and drugs into the blood; MRP4 and MRP5 that can transport cyclic nucleotides and 
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nucleoside analogues; and MRP6, which substrate specificity is still unclear. The more 
relevant hepatic transporters involved in drug transport are OATP1B1, MRP-2, BCRP and 
MDR1 [7]; whereas MRP1 and MRP3 expression is more relevant in cholestatic conditions, 
when both are substantially induced. Thus, the existence of this transporters allow large (>400 
Da) amphiphilic molecules, xenobiotics or its metabolites to be eliminated by the hepatocytes 
[9]. 
 
Figure 1.5 Schematic representation of the hepatic transporters in the sinusoidal/basolateral and in the 
canalicular/apical membrane of hepatocytes. [7, 9, 13]. 
1.2.4 Regulation of the metabolism of xenobiotics: the role of nuclear receptors 
Detoxifying enzymatic and transport systems, comprising phase I, II and III enzymes, are 
regulated at the gene expression level by nuclear receptors. Nuclear receptors are activated 
by both xenobiotics and endogenous lipophilic substances, being also named as xenosensors 
or lipid sensors, respectively. The nuclear receptor gene superfamily is divided into: (i) nuclear 
steroid hormone receptors and (ii) the orphan nuclear receptors. The nuclear steroid hormone 
receptors are activated by endogenous steroid hormones binding to the DNA as homodimers.  
Examples of nuclear steroid hormone receptors include the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), estrogen receptor (ER), androgen receptor (AR) and 
progesterone receptor (PR). The orphan nuclear receptors bind to the DNA as heterodimers 
with the retinoid X receptor (RXR).  The orphan nuclear receptors include the constitutive 
androstane receptor (CAR), the pregnane X receptor (PXR), and the peroxisome proliferator 
activated receptor-alpha (PPARα) being frequently activated by xenobiotics [23]. The aryl 
hydrocarbon receptor (AhR) also plays an important role as xenosensor although not falling 
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into the nuclear receptor family [24]. PXR and CAR expression is also mediated by the GR. 
Examples of prototypical chemical inducers of these receptor systems include phenobarbital, 
a CAR activator; rifampicin, a human PXR activator; and the fibrate drug, clofibrate, a PPARα 
activator [24, 25]. 
The mechanism of xenosensor activation is similar for the different receptors. Briefly, it 
consists in the ligand binding to the receptor in the cytoplasm, the interaction with co-
activators, dimerization with a partner protein forming a DNA-binding heterodimer, 
translocation to the nucleus, binding to DNA through response elements, recruitment of 
transcription factors and gene transcription, resulting in increased mRNA levels of xenobiotic-
biotransforming enzymes and transporters [9, 26].  
In drug metabolism, PXR and CAR are the most relevant nuclear receptors, regulating a 
number of genes involved in drug metabolism and transport such as CYP3A, CYP1A, 
CYP2C9, members of the UGT, SULT and carboxylesterase families and the hepatic 
transporters OATP1, MDR1 and MRP2 [27], as represented in Table 1.2. CAR alone is also 
known to upregulate the genes CYP2B, CYP2C, CYP3A, NADPH-CYP reductase, SULTs, 
UGTs, and GSTs, as well as the hepatic transporters MRP3 and MRP4 [24]. AhR regulates 
CYP1A induction [24, 28]. 
The molecular regulation of phase II enzymes is still not fully understood and the available 
studies are more scarce than for phase I and III enzymes [15]. UGTs and SULTs induction, 
inhibition and regulation mechanisms are the ones with higher impact on xenobiotic 
metabolism, followed by GSTs. In fact, the difficulty of studying phase II enzymes relies on its 
broad substrate and unclear regulation mechanisms, since phase II metabolism commonly 
depends on the exposure to phase I metabolites and on the rate of drug and metabolites 
transport into and out of the hepatocytes. UGT regulation may be mediated through AhR 
(UGT1A6 and UGT1A9 induction), CAR and PXR (UGT1A1). SULTs regulation is still 
controversial. Although it is agreed that both GR and PXR upregulate SULT1A and SULT2A 
in rat, human SULT1A expression is not altered by glucocorticoids [29]. 
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Table 1.2 Xenosensors target genes associated with xenobiotic metabolism and transport in humans and 
rodent animal models.  
 Human Animal Models 
 Gene Receptor Gene Origin Receptor 
Phase I 
enzymes 
CYP2A6 PXR CYP1a1 Mouse CAR 
CYP2B6 CAR/PXR CYP1a2 Mouse CAR 
CYP2C8 CAR/PXR CYP2a4 Mouse CAR 
CYP2C9 CAR/PXR CYP2b10 Mouse CAR/PXR 
CYP2C19 CAR/PXR CYP2B1/2 Rat CAR/PXR 
CYP3A4 CAR/PXR CYP2c29 Mouse CAR 
CYP3A7 PXR CYP3a11 Mouse CAR/PXR 
CYP4F12 PXR CYP3A2 Rat PXR 
CYP7A1 PXR CYP3A23 Rat PXR 
FMO5 CAR    
Phase II 
enzymes 
UGT1A1 CAR/PXR/AhR Ugt1a1 Mouse CAR/PXR 
UGT1A3 PXR Ugt1a6 Mouse CAR 
UGT1A6 PXR Ugt1a9 Mouse CAR/PXR 
GSTA1 PXR Ugt2b1 Mouse CAR 
  Ugt2b5 Mouse PXR 
  Gsta1/2 Mouse CAR/PXR 
  Gst (α,π,μ) Mouse PXR 
  Sult2a1 Mouse CAR/PXR 
  Sult1e1 Mouse CAR/PXR 
  Sult2a2 Mouse CAR/PXR 
SULT1A1 CAR SULT1A1 Rat PXR 
  SULT1B1 Rat PXR 
  SULT2A3/4 Rat PXR 
Phase III 
enzymes 
MDR1 CAR/PXR Mdr1a Mouse CAR/PXR 
MRP2 CAR/PXR Mdr1b Mouse PXR 
MRP3 CAR Mrp1 Mouse CAR 
MRP4 CAR Mrp2 Mouse CAR/PXR 
OATP2 PXR    
Adapted from [24, 28] 
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1.3 Mechanisms of drug induced hepatotoxicity 
The liver has a unique differentiation and regeneration capacity, quickly reacting to injury and 
cell loss through biochemical reactions and cellular processes, based on complex gene 
regulation activities. The highly active biotransformation activity of the liver contributes to the 
first-passage effect that avoids the exposure of the organism to high concentrations of oral 
xenobiotics. As such, the metabolism and elimination processes are essential for the liver’s 
protective role but also makes it more exposed to molecule’s toxic effects displayed by a 
plethora of chemicals. Thus, the liver is also a key target organ of xenobiotic toxicity. One of 
the major safety regards on new drug development is drug induced liver injury (DILI). DILI has 
an incidence of 1-2 cases per 100,000 people. However, it should be noted that DILI accounts 
for more than 50 % of acute liver failure occurrences and represents one of the major causes 
of withdrawal of drugs from the market [30]. Some examples are bromofenac, ebrotinin and 
troglitazone, or even nevirapine (NVP), risperidone, trovafloxacin and nefazone that were 
labeled with hepatic black box warnings [31, 32].  
DILI can be classified as intrinsic or idiosyncratic hepatotoxicity, and the latter can be an 
allergic immune-mediated hypersensitivity, or non-allergic metabolic injury [33]. Intrinsic 
hepatotoxicity is direct, dose-dependent and predictable whereas idiosyncratic hepatotoxicity 
occurs without obvious dose-dependency, in an unpredictable fashion and with a short latency 
time particularly after re-exposure [34, 35]. Idiosyncratic hepatotoxicity is particularly difficult 
to mimic in in vitro models. As such, in vitro hepatotoxicity models are mainly focused on 
accessing metabolism related toxicity, namely on identifying potential metabolites of the 
parent drug and its mechanisms of toxicity. Moreover, this is essential in the early stages of 
drug development and thus, only intrinsic hepatotoxicity will be further mentioned. Intrinsic 
toxicity can occur through direct damage, through failure of repairing mechanisms and through 
immune mediated responses, attributed directly to the interaction of the ultimate toxic 
molecule, the parent drug or the product if its biotransformation, with an endogenous target 
through non-covalent or covalent binding, hydrogen abstraction, electron transfer or enzymatic 
reactions resulting in dysfunction or destruction of target molecules. Specifically, toxicity may 
occur through the interaction of toxicants with proteins, impairing its function or by alteration 
of its conformation or structure. Toxicants may also interact with protein critical moieties, such 
as thiol groups, that are commonly related to enzymes catalytic activity. Thereby, molecular 
toxicity may lead to impairment of internal and external cellular maintenance.  
Impairment of internal maintenance can be due to ATP depletion, Ca2+ accumulation and 
ROS/RNS (reactive oxygen species/reactive nitrogen species) generation which may result in 
General Introduction 
 13 
cell apoptosis [9, 36]. Nimesulide, a non-steroidal anti-inflammatory drug (NSAID), is reported 
to cause severe hepatotoxicity through molecular mechanisms involved in deranged oxidant-
antioxidant homeostasis and mitochondrial dysfunction. In fact, nimesulide toxicity is related 
to redox imbalance along with oxidative stress, reduction of NADPH and GSH pools and, 
consequently, increased superoxide and secondary ROS/RNS generation. This alteration on 
redox equilibrium leads to oxidative damage of cellular macromolecules [37]. Additionally, 
nimesulide causes mitochondrial activity reduction, mitochondria depolarization and 
membrane permeability loss followed by release of apoptotic proteins [37]. Another common 
direct hepatotoxic drug is paracetamol that can lead to fatal liver damage and is an example 
of the importance of the balance of metabolic pathways on xenobiotics toxicity. This drug is 
metabolized mainly by conjugation with sulfate and glucuronic acid and, to a lesser extent, by 
oxidation through microsomal mono-oxygenases. Paracetamol oxidation generates N-acetyl-
p-benzoquinone imine (NAPQI) a toxic metabolite that is detoxified by glutathione conjugation. 
Overdose of paracetamol originates an increased concentration of NAPQI that results from 
the saturation of the conjugation pathways and depletion of cofactors, namely of sulfate pools 
and favours the oxidative metabolism of paracetamol, depleting all the glutathione pool. 
Consequently, not only the glutathione pool is depleted, but also, the NAPQI (toxic metabolite) 
accumulates in the organism exerting its toxicity which leads to hepatic necrosis [38]. 
Paracetamol toxicity is also related to Ca2+ accumulation and activation of endonucleases, 
DNA damage and necrotic and apoptotic cell death through its protein-arylating intermediate 
metabolite [39].  
Impairment of the external maintenance of the tissue can have a major impact when a tissue 
is unable to perform its main functions. The deregulation of the biotransformation processes 
may result in altered transporter and enzyme functions that may originate intrahepatic 
cholestasis leading to toxic accumulation of metabolism products in hepatocytes [39, 40]. The 
inhibition of hepatic synthesis of coagulation factors by exposure to coumarins, is also an 
example of this mechanism of toxicity: coumarins do not directly harm the liver. However, the 
synthesis of coagulation factors in the liver is impaired by overexposure to coumarins, 
resulting in whole body damage since this inhibition may cause death by hemorrhagic shock 
[9].  
Hepatotoxicity may also be a consequence of impaired molecular repair mechanisms of (i) 
proteins, as occurs by thioredoxin reduction of oxidized thiol catalytic moieties, with 
methionine sulfoxide reductases catalyzing the latter process; of (ii) lipids, as occurs when 
lipoperoxidation is counteracted by the presence of reductants and glutathione peroxidase 
and reductase; and of (iii) DNA. DNA has high reactivity with electrophiles and free radicals 
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but nuclear DNA is remarkably stable due to the availability of repair mechanisms such as 
direct repair, excision repair and recombinant repair. The mitochondrial DNA, however, lacks 
histones and efficient repair mechanisms and therefore is more prone to damage [9]. Cellular 
and tissue repair is well present in response to toxic stimuli reverting damage through 
elimination of injured cells by apoptosis or necrosis and regeneration of the tissue by 
proliferation and production of new extracellular matrix. In fact, inappropriate repair and 
adaptation to a repeated exposure to a xenobiotic can result in tissue necrosis, fibrosis or 
carcinogenesis. Tissue necrosis occurs when molecular repair mechanisms are inefficient, 
are depleted or the molecular damage is not readily reversible [9]. Hepatic fibrosis, cirrhosis, 
results from chronic exposure to chemicals such as methotrexate, high doses of retinol 
(vitamin A) and iron intoxication. Those chemicals trigger stellate cells to respond to cytokines 
and growth factors secreted by non-parenchymal cells (NPC), including themselves. This 
results in an induction of extracellular matrix production during tissue repair that does not 
cease properly. Thus, there is an excessive deposition of extracellular matrix of abnormal 
composition [9]. Carcinogenesis can result from failure of DNA repair that leads to mutation of 
critical genes, inappropriate control of regulatory gene regions over expression of critical 
genes, failure to induce apoptosis, and failure to terminate cell proliferation [9], being inorganic 
arsenic an example of an hepatic carcinogenic [41]. 
Furthermore, adaptation to toxicity may result from biological changes causing: (i) diminished 
delivery of toxicant to the target, (ii) decreased susceptibility of the target, (iii) increased 
capacity of the repairing mechanisms or (iv) strengthening of the mechanisms that 
compensate for toxicant-inflicted dysfunctions. Induction or inhibition of several enzymes, 
such as detoxifying enzymes, e.g. from the CYP450 family, repair enzymes as thioredoxins, 
as well as induction of tolerance of cellular receptors [9], are examples of adaptation 
mechanisms presenting an indirect toxicity problem of many drugs, which is especially 
relevant in multiple drug prescription. Widely prescribed drugs are potent CYP450 enzyme 
inducers, e.g. phenobarbital, omeprazole and rifampicin (Table 1.1), or inhibitors, e.g. as 
fluoxetine, proton pump inhibitors and ciprofloxacin. Consequently, the biotransformation of 
other drugs that are substrates of CYP450 enzymes, or of other phase II enzymes and hepatic 
transporters, can be severely altered when taken simultaneously. Some xenobiotics, such as 
efavirenz or nevirapine, might also be simultaneously the substrate and the inducer of an 
enzyme or transporter and can regulate its own biotransformation (auto-inducer). Enzyme 
induction is included within the pharmacokinetic tolerance concept, which is defined by an 
alteration of drug disposition or metabolism as a function of time upon exposure to a 
compound resulting in a time-dependent change in the presentation of the active moiety to the 
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target receptor. Consequently, this can lead to overdose reactions or to sub-therapeutic 
exposures to drugs when normal doses are taken [9, 24, 42]. 
Overall, drug induced hepatotoxicity may involve metabolism of toxic reactive intermediates 
and covalent interactions with cell constituents. It may also interfere with membrane transport, 
biosynthesis processes or immunological mechanisms. The occurrence of hepatic damage 
may vary, depending on the nature of immune responsiveness as well as factors related to 
genetics, dietary habits and other behaviour and environment-related factors. Hence, risk 
factors are important parameters to consider when predicting potential hepatotoxicity risks. 
Risk factors are genetic polymorphisms, environmental influences on metabolizing enzymes, 
hormonal factors once women are statistically more sensitive, and immunological and pre-
existing liver diseases, which is especially important in HIV patients with B or C hepatitis and 
fatty liver [36]. Genetic polymorphisms are particularly relevant risk factors regarding drug-
metabolizing enzymes. Genetic polymorphisms are reported to affect drugs biotransformed 
by CYP2C9, CYP2C19 and CYP2B6 subfamilies, the hepatic transporters MDR1, BCRP, 
MRPs and OATP1B1, among others [10, 43, 44]. Some genetic polymorphisms have a 
confirmed impact in therapy and are commonly considered in drug development and in drug 
treatment (biomarkers of susceptibility). Some examples are: CYP2D6 that has a clinical 
impact on the bioactivation of drugs such as codeine, tramadol or tamoxifen within low or 
extensive metabolizers; UGT1A1, that results in benign hyperbilirubinemia, known as Gilbert–
Meulengracht disease, and its genotype identification is recommended in the drug label of the 
topoisomerase inhibitor irinotecan; and NAT2 polymorphisms. NAT2 polymorphism is 
reflected in slow and rapid acetylators, that represent 50 % of Caucasian populations. 
Izoniazid is a substrate of NAT2 and slow acetylators have higher blood concentrations and 
adverse effects than the rapid acetylators [44].  
1.4 Liver cell models in in vitro toxicology 
Drugs are deeply involved in liver damage, but establishing causality has been a major hurdle 
in understanding most of the toxicity mechanisms [40]. The effect that xenobiotics can exert 
on induction or inhibition of detoxifying enzymes, namely from CYP450 family, hepatic 
transporters, repair enzymes and induction of tolerance of cellular receptors is especially 
difficult to predict with the currently existing in vitro and in vivo drug testing models, mainly 
due to interspecies and inter-individual differences. 40-50 % of drug candidates showing 
hepatotoxicity in humans did not present the same in animal models, which shows the 
importance of an improvement of in vitro models using human cells [45]. On the other hand, 
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relevant drugs might be excluded from development when toxicity is observed in animal 
models while those molecules might present no relevant human toxicity. Pantoprazol (5-
(difluormethoxy)-2-[3,4-demethoxy-2-pyridyl)methylsulfinyl]-benzimidazole) is an example of 
a drug with relevant toxicity in rodent and canine models due to the hepatic formation of 
benzimidazo-2-thiol. However, this metabolite is not detected in humans and pantoprazol is 
today widely-used in human pharmacology as a proton pump inhibitor [46]. 
According to the United States National Research Council (NRC) report on “Toxicity Testing 
in the 21st century: A vision and a strategy” (US Tox21), the existing concepts and testing 
procedures are not sufficiently adequate for extrapolation to human beings, lacking 
physiological as well as representative assay conditions [47]. The improvement of in vitro 
testing using more relevant models for accurate assessment and prediction of adverse drug 
reactions will eventually reduce animal experimentation, following the 3R principles, it is a key 
to increase success in drug development and would avoid non-reasonable costs during clinical 
introduction of a new drug candidate [48].  
The 3R principles comprise Reduction, by decreasing animal number required for a test 
method using integrated approaches consistent with scientific practices necessary to obtain 
valid results; Refinement, by improving animal well-being and reducing or eliminating pain or 
distress; and Replacing, by using systems alternative to animals, or using a phylogenetically 
lower species than the current test [49]. The development and implementation of alternative 
in vitro models is thus in line with the current 3R view, namely the replacement principle.  
Currently, in vitro hepatotoxicity models are based on the use of liver slices, genetically 
engineered cells, monolayer (2D) or suspension cultures of human hepatoma cell lines or 
primary hepatocytes. The advantages and limitations of each tissue/cell source for in vitro 
testing are described in Table 1.3.  
Table 1.3 Advantages and limitations of in vitro liver preparations.  
Model Advantages Limitations 
Isolated 
perfused liver 
Maintenance of functions close to the in vivo organ  
Lobular structure preserved 
Functional bile canaliculi and possibility of 
bile collection 
Short-term kinetic studies  
Viability: 2-3 h 
Study of one or a few compounds 
only 
Suitable only for liver of small 
animals 
No reduction in the number of 
animals used 
Liver slices Lobular structure preserved 
Detection of selective intra-lobular effects 
Viability: 6 h to 2 days 
No possibility of bile collection 
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Possibility to use human tissue 
Studies on several compounds at different 
concentrations 
Inter-assay variability 
Human tissue availability / 
Interspecies differences 
Isolated 
hepatocytes 
Obtained from whole livers or wedge biopsies 
Functions close to those of in vivo hepatocytes 
Studies on several compounds at different 
concentrations 
Interspecies and Pharmacogenomics studies 
Representative of different lobular subpopulations 
Cryopreservation 
Viability: 2-4 h 
No bile canaliculus 
Human tissue availability / 
Interspecies differences  
Primary 
hepatocyte 
cultures 
(pHep) 
Longer viability than isolated tissue 
Induction/inhibition of drug metabolizing enzymes 
Interspecies and Pharmacogenomic studies 
Viability: 2-4 days 
Early phenotypic changes 
Altered bile canaliculi 
Difficult recovery of cells and 
maintenance of function upon 
cryopreservation 
Human tissue availability / 
Interspecies differences 
Hepatoma cell 
lines (HepG2, 
Huh7) 
High proliferation activity and good availability 
Stable metabolic performance 
Well characterized and abundant data available 
Decreased drug enzyme activities 
Genotype instability 
HepaRG Retains many liver-specific functions (CYP450) 
Stable karyotype 
Differentiation into both hepatocyte or biliary 
lineages 
Derived from one donor 
Distinct profile of phase II and III 
enzymes expression relative to 
hpHep 
Less available than other cell lines 
Stem cell 
derived 
hepatocyte-
like cells 
(HLC) 
Good availability 
Analysis of genetic polymorphisms 
Drug testing with patient-specific cell lines for 
personalized medicine 
Characterization of differentiation/maturation 
processes for potential 
in vitro or clinical use  
Establishment of disease models 
Costly differentiation protocols  
Incomplete hepatic differentiation 
with current protocols  
Lack of standardized methods for 
cell differentiation and 
characterization  
 
Subcellular 
fractions 
Drug enzyme activities preserved 
Production of metabolites for structural analysis 
Short-term studies 
No cytosolic phase II enzyme 
reactions 
Cofactors required for activity 
Genetically 
engineered 
cells 
One or more human enzymes expressed 
Available mainly for CYPs 
Unlimited cell number 
Use for specific purposes only 
No physiologic levels of enzymes 
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The cell culture models are advantageous relative to the use of perfused livers or liver slices 
since they allow longer cell culture time; and relative to subcellular fractions due to the 
possibility of a more complete biotransformation phenotype, including phase I, II and III. 
Distinct cellular models present also major drawbacks [48, 50]. Primary cultures of 
hepatocytes present important interspecies differences when isolated from rat. Human 
primary hepatocytes are scarce and present high donor variability. Furthermore, liver-isolated 
hepatocytes although originating representative phenotypic and functional profiles, soon lose 
those properties in vitro [7], thus compromising long-term metabolic studies. Human hepatoma 
cell lines, such as HepG2, Huh7 and HepaRG have low metabolizing activity and poor 
phenotype and functional match to the hepatocytes in vivo [51]. HepG2, have low levels of 
CYP450 enzymes but normal levels of phase II enzymes except for UGTs [52, 53], which 
make them appropriate for testing the toxicity of the parent compound but less suited for 
metabolite toxicity testing. More recently, HepaRG cells, a human hepatocellular carcinoma 
cell line composed of a mixture of both hepatocyte-like and biliary-like cells, has been reported 
to maintain hepatic functions and expression of liver-specific genes comparable to that of 
human primary hepatocytes (hpHep) without inter-donor variability and functional instability 
[54]. Nevertheless, Gerets et al. [55] have characterized primary human hepatocytes, HepG2 
cells, and HepaRG cells at the level of mRNA/gene expression and CYP activity in response 
to inducers and their prediction capacity for the detection of human hepatotoxins and 
hepatotoxic drugs and observed that although HepaRG cells seem to be a suitable model for 
the induction studies, these cells were not as predictive as hpHep and were quite comparable 
to HepG2 cells for the prediction of human hepatotoxic drugs [55]. Lübberstedt et al. [56] also 
showed that HepaRG present comparable or even higher CYP2C9, CYP2D6 and CYP3A4 
enzyme activity than that of hpHep [56] and present relevant UGT1A1 and GST activity levels 
[57]. However, when cultured using a three-dimensional (3D) bioreactor, HepaRG cells were 
not able to retain OATP1B1 activity and its detection at protein level was also significantly 
decreased when compared to 3D hpHep over 9 days in culture [58], being the function of 
hepatic transporters the NTCP and BSEP also reported to be less functional in HepaRG cells 
[59]. Therefore, due to the unsatisfactory phenotype of the currently available cell sources, the 
use of stem cell-derived hepatocyte-like cells has been proposed as an alternative cell source 
for in vitro hepatotoxicity studies and will be further explored in the Section 1.6 of this Chapter. 
1.4.1 3D culture systems in in vitro toxicology 
The major drawback of the currently available in vitro liver preparations lays on insufficient 
hepatocyte-like functions and metabolic competence. A valid alternative for in vitro toxicology 
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testing comprise more predictive cell cultures closer to the in vivo environment. 3D cell culture 
systems apply tissue bioengineering approaches to obtain physiologically relevant in vitro liver 
cellular models. Those cell culture systems have been shown to improve the biotransformation 
capacities in both primary hepatocytes [48, 60-65] and hepatoma cell lines [66-68] over time 
in culture. In fact, by mimicking cell-to-cell and cell-to-matrix interactions such models can be 
of enormous impact for testing drug susceptibility effects in vitro. These systems have the 
potential of enabling the validation of molecules as therapeutic targets, to assess their safety, 
with higher accuracy and decreasing the number of sacrificed animals [66, 69].  
3D cell cultures can be achieved using either dynamic or static systems. Dynamic systems 
might be stirred or perfused, depending on the cell culture system complexity; whereas a 
stirred system might be perfused [70] or not [71]. Stirred system allow for a better medium 
oxygenation, since the mechanic stirring facilitates oxygen diffusion as well as medium 
homogenization, further resembling the physiological blood flow. Mechanic stirring also 
creates a hydrodynamic shear stress that shall be balanced between causing cellular stress 
and death and improving cell performance [72]. It has been reported that some CYP450 genes 
are induced through blood flow-mediated shear stress [72, 73]. An in vitro study performed by 
Vinci et al. [74] showed that flow positively affects the expression and activity of detoxification 
genes of phase I, II and III, in primary human hepatocytes [74]. Stirred and/or perfused 
systems also promote a liver-like mass transfer which might induce the liver zonation 
phenomenon in vitro. A continuously perfused system further creates a more physiological 
culture condition since it has the advantages of a stirred system but further avoids fluctuations 
of basic cell culture parameters such as pH, oxygen, glucose and lactate concentration and 
accumulation of other cell culture products that are present in discontinuous renewal of fresh 
culture media [62-64, 70]. Mimicking the blood flow is particularly interesting in hepatocyte cell 
culture and in xenobiotic metabolism studies, by avoiding the accumulation of metabolites that 
influence the pharmacokinetics of a specific compound [75] .  
3D culture systems are ease of high throughput adaptation and of up scaling, but vary in 
complexity and on remote monitoring of cell culture parameters. Three-dimensional systems 
can comprise spheroids formation (Table 1.4), cells adherent to a scaffold [76, 77], or more 
complex cellular systems such as HμREL® biochip [78], hollow-fiber bioeactor [64], multi-well 
perfused bioreactor [79], bioartificial livers [80] and more recently the microfluidic devices [75, 
78, 81, 82] and the bioprinted systems [75] (Table 1.5).  
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Table 1.4 Advantages and limitations of spheroid cell cultures for in vitro toxicity testing applications. 
Spheroid forming techniques Advantages Limitations 
Non-adhesive surface 
Ultra-low attachment plate  
Low cost  
Easy to perform 
Co-culture of different cell types 
Variation in size/cell 
number/shape  
Stirred Bioreactors 
 
Low complexity 
Massive production 
Long-term culture  
Dynamic control of culture conditions 
Co-culture of different cell types 
Adaptable to perfusion 
Adaptable to online monitoring 
Easy to scale up 
Require specialized 
equipment  
 
NASA rotary system Low complexity 
Massive production 
Long-term culture 
Dynamic control of culture conditions 
Better cell differentiation 
Co-culture of different cell types 
Require specialized 
equipment  
Variation in size/cell number 
Cell sampling not possible 
 
 
Hanging drop Inexpensive  
Easy to perform 
Well-controlled spheroid size 
Fast spheroid formation 
Co-culture of different cell types 
Easy to trace spheroid assembly 
Labor intensive  
Massive production difficult 
 
Micro-molding Well-controlled spheroid size 
Co-culture of different cell types 
Designed aggregate geometry 
High complexity 
Requires specialized facilities  
Adapted from [83, 84]  
The multicellular spheroid is a 3D system that takes advantage of the self-assembling capacity 
of cells to form aggregates and maintain cell viability, over an extended time in culture while 
keeping a better hepatocyte-like functional phenotype when compared with 2D cultures [61, 
68, 70, 85-87]. Non-adhesive surfaces allow the formation of multicellular spheroids usually 
under a static system. Herein, spheroid size is controlled by the cell density at inoculation and 
fetal bovine serum (FBS) concentration. This approach is less complex and easier to perform 
than other spheroid systems that require specialized training (e.g., hanging drop technique), 
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or the use of a scaffold or matrix, or bioreaction systems. Thus, non-adhesive surfaces are 
especially advantageous to optimize culture medium supplementation and to test a diversity 
of toxic compounds using fewer cells (this system is available from a 384-well plate format to 
large cell culture flasks up to 636 cm2). Non-adhesive surfaces have been previously used in 
small-scale 3D cell culture systems, applied either to stem cell [88, 89] or hepatic cell lines in 
culture [90].  
The spinner flask suspension culture (SFSC) is a simple and effective stirred system that has 
been previously described for culturing primary hepatocytes where cells maintained their 
functions up to 3 weeks, namely albumin and urea secretion and biotransformation activity of 
phase I and phase II enzymes [61, 70, 71, 85]. Herein, the spheroid dimensions can be 
controlled by the agitation rate that further promotes a high homogeneity of the medium and 
quick dilution of toxic metabolites, while allowing a greater distribution of nutrients and oxygen, 
therefore reducing cell death [71]. This system has the possibility for up-scaling (125 mL to 36 
L of working volume) and can be adapted to a perfusion system. It is also possible to monitor 
the culture online [70] or to sample and collect cells or cell culture medium for several analyses 
[91], which is particularly interesting for drug pharmacokinetic studies.  
Another example of a perfused system is the hollow-fiber bioreactor [92-95]. This system was 
originally developed to function as extracorporeal liver support system. It was firstly designed 
to accommodate a 3D perfusion, high-density culture of human liver cells with a cell 
compartment volume of 800 mL [96]. This system consists on a complex capillary network, 
based on three independent interwoven capillary systems for arterio-venous medium 
perfusion, oxygen supply, and carbon dioxide removal, with an electronically controlled 
perfusion device with pumps for medium feed and recirculation, temperature control and a 
valve regulated by a gas mixing unit. There are several capillary layers, their number 
depending on the bioreactor size, that serve for counter-current medium perfusion through 
two independent capillary systems and direct membrane oxygenation of the cells located 
between the capillaries [62-64]. Later, the hollow-fiber bioreactor was also miniaturized to cell 
compartment volumes of 8, 2 and 0.5 mL for drug testing applications [63, 64, 95] and 
presented impressive results at a physiological [62] and biotransformation level using human 
primary hepatocytes in culture up to 2 weeks [64, 95]. The large number of cells that is needed 
and the challenging setup make this system applicable for medium throughput. In addition, 
cell sampling during culture time is also not feasible. Nevertheless, as with the spinner vessels 
this system enables online measurements and medium sample collection making it still 
particularly interesting for long-term studies, namely pharmacokinetic/toxicokinetic and 
mechanistic studies [92-95]. 
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Table 1.5 Advantages and limitations of complex in vitro hepatotoxicity cell model systems.  
Cell models Advantages Disadvantages 
HμREL® biochip  Moderate throughput 
Allows for multiple cell types and interaction 
between cell types 
Preservation of cell viability and metabolic 
competency 
Microscopic imaging and oxygen sensing  
Physiologically relevant ratios of liquid : cells and 
shear stress 
Requires less media and cells than traditional 
culture 
Good correlation with in vivo clearance rates 
A complex system to establish 
and maintain 
Sample removal difficult  
No 3D tissue constructs 
 
Hollow-fibre Reactor 
 
Moderate throughput 
Counter-directional flow  
Scalable  
Long-term culture 
Possibility of PBPK studies 
Real-time monitoring of metabolic function 
A complex system  
Microscopic evaluation is only 
possible in the end of the 
experiment 
High number of cells 
Cell sampling not possible 
 
Multi-well perfused 
bioreactor 
High throughput 
Cells form 3D tissue constructs 
Sustained liver-like cell functionality  
Physiological shear stress  
Good correlation with in vivo clearance rates 
Ability for microscopic examination 
Uses greater cell numbers and 
larger media volumes  
 
Bioartificial livers Low throughput 
Microenvironment most similar to in vivo tissue  
Allows for studies of functional heterogeneity  
Ability to evaluate hepatotoxicity using human 
blood 
Does not maintain viability or 
functionality of hepatocytes 
longer  
Requires large number of cells 
Currently not in use with other 
cell types 
Complex membranes needed 
for proper use 
Cell sampling not possible 
Microfluidic devices Long-term culture 
Laminar flow of cell culture media mimics the 
blood flow hemodynamics 
Stable low shear pressure 
Possibility to study multiple organs interaction 
Possibility of PBPK studies 
Real-time monitoring of metabolic function 
A complex system to develop 
and establish 
Very low-sample and cell 
amounts 
General Introduction 
 23 
Liver bioprinting Allows to build specific structures including 
endothelial and other cell types 
A complex system to establish  
The printing process induces 
stress on cells 
Adapted from [75, 81, 82, 97]. 
There is a wide variety of studies using 3D culture systems, comprising distinct cell sources 
such as primary rat and human hepatocytes, HepG2 cell line and HepaRG showing 
encouraging results as in vitro hepatotoxicity models. 
Miranda et al. [71] showed that freshly isolated rat hepatocyte spheroid cultures could be 
maintained up to 21 days in culture using a stirred culture vessel (3D) bioreactor system. 
During this time, liver-specific functions, such as albumin and urea secretion, phase I (ECOD 
and testosterone hydroxylation) and phase II (UGTs) enzyme activities, and the capacity to 
metabolize diphenhydramine and troglitazone, were observed [71]. Using a similar cell culture 
system, Pinheiro et al. [91] also demonstrated the maintenance of the hepatic phenotype in 
culture by the detection of the specific hepatocyte markers ALB, CK-18, HNF-4α, MRP-2, 
and OATP-C, by the stable activity levels of phase I (ECOD and EROD) and phase II 
(SULT1A1) activities, which were modulated by nevirapine and its metabolites. Remarkably, 
a complete in vitro study of biotransformation mechanisms of NVP and its metabolites, 
including induction of enzymatic activity of phase I and II metabolites was only possible in vitro 
when resorting to in vitro 3D cultures [91, 98]. Resorting to co-culture systems using fibroblasts 
[99] or NPC [85] further improved hepatocyte functions in vitro. 
Due to its lower availability studies with human hepatocytes are scarcer, though impressive 
results have also been reported. Tostões et al. [100] evaluated the feasibility of using human 
primary hepatocyte spheroids for repeated drug dose testing. The 3D spheroids were cultured 
in an automated perfusion bioreactor for 3-4 weeks in serum-free conditions [100]. These cell 
culture conditions allowed the maintenance of phase I enzyme expression and activity, as well 
as responding to induction as well of phase II enzyme expression and activity, of hepatic 
markers (HNF-4a, CK-18, CYP3A and ALB) presence, and of albumin and urea synthesis 
rates. In this study, polarity markers and bile canaliculi function were observed in human 
hepatocyte spheroids after two weeks of bioreactor culture [100]. Human primary hepatocytes 
cultured in a small-scale hollow-fiber bioreactor, with a cell compartment volume of 0.5 mL 
showed the preservation of CYP1A2, CYP2D6, and CYP3A4/5 activities between 40 % and 
100 %, whereas CYP2B6 and CYP2C9 activities were preserved to a lesser extent up to 10 
days in culture [94]. Moreover, immunofluorescence characterization also showed the 
presence of CYP2C9 and CYP3A4 and the drug transporters BCRP, MDR1 and MRP-2 in the 
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bioreactor up to 2 weeks in culture [63, 94]. These systems also displayed relevant 
biotransformation and toxicity profiles for several drugs including paracetamol and diclofenac 
[94, 95]. The use of human cryopreserved hepatocytes is also reported for 3D cultures. Bell 
and co-workers [87] provided a proof-of-principle that cryopreserved human primary 
hepatocytes spheroids could reflect liver pathologies such as cholestasis, steatosis and viral 
hepatitis. In this study, bile acid accumulation was mimicked upon chlorpromazine exposure, 
since MRP-2 and BSEP presented relevant activity and BSEP gene expression was 
decreased by drug exposure [87]. Moreover, these primary hepatocyte spheroids closely 
resembled intact liver tissues at the proteome level, whereas 2D monolayer cultures originated 
from the same liver tissues presented a multitude of deregulated important metabolic 
pathways [87]. Tsamandouras et al. [82] also used human cryopreserved hepatocytes to study 
the population variability in hepatic drug metabolism using hepatocytes from five different 
donors cultured in a perfused 3D human liver microphysiological system. Within this system, 
the metabolic depletion profile and metabolite formation of six compounds (phenacetin, 
diclofenac, lidocaine, ibuprofen, propranolol and prednisolone) were measured [82]. mRNA 
levels of 90 metabolism-related genes, and markers of functional viability (LDH release, 
albumin and urea production), for each donor, were identified as significant predictors of in 
vitro metabolic clearance. This data allowed to develop a population physiologically-based 
pharmacokinetic (PBPK) model for lidocaine to illustrate the translation of the in vitro output 
to the observed pharmacokinetic variability in vivo, being this the first study of population 
variability in drug metabolism in the context of an in vitro microphysiological system [82]. 
The study from Leite et al. [86] presents impressive results on a 3D-bioreactor with self-
assembled spheroids of HepaRG, showing the induction of CYP1A2, 2B6, 2C9, and 3A4 and 
UGT enzymes [86]. Long-term functionality was shown by 7-week stable profiles of albumin 
secretion and the formation of tissue-like arrangements including bile canaliculi-like structures 
and polar distribution of transporters [86]. Herein, the system biocompetency was evaluated 
by the study of paracetamol cytotoxicity as evaluated by LDH activity quantification, showing 
the same profile over 1 month in culture [86].  
Despite several interesting in vitro liver models are reported in the literature [5, 7, 17, 46, 61, 
63-65, 70, 71, 74, 82, 83, 85, 90, 95, 99, 101], a comprehensive and systematic comparison 
between distinct cell culture systems that would allow its wide adoption for pharmacological 
and toxicological applications is still scarce. It should also be noted that the added value of a 
specific cell culture system for the prediction of drug action and toxicity in human liver, 
depends on the specific study goals.  
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In fact, the comparison of cell culture systems and cell sources is a challenging task. Cell 
viability and stability, morphological and architectural features, phase I and phase II metabolic 
capacity, response to a large panel of well-accepted reference drugs, as well as the 
physiological preservation of key metabolic and signalling pathways under long-term cultures 
shall be taken into consideration. Thus, several hepatotoxicity studies that evaluated 
diclofenac (Table 1.6) and troglitazone (Table 1.7) considering distinct cell sources and 
culture conditions were collected from the literature for a comprehensive review of the 
differences on the obtained IC50 values in different models.  
Table 1.6 Diclofenac cytotoxicity endpoints observed in different cell types and cell culture systems. 
Cell Type Cell Culture System 
Exposure 
Time 
IC50 [µM] or [µM] with 
Observed Toxicity* Endpoints References 
HepG2 
2D 24 h 
392 
MTT [104] 
rpHep 331 
hpHep 763 
FaO 682 
rpHep 
2D 24 h 
222 
ATP quantification [105] 
hpHep 138 
hHep 
2D 24 h 
1413 
Almar Blue [106] Huh7 686 
HCCT-T 104 
rpHep 
2D 24 h 
393 
LDH and MTT [107] FaO 700 
HepG2 750 
rpHep 
2D 24 h 
263 tetrazolium salt 
WST-1 [108] HepG2 399 
HepG2 2D 24 h 1700 ATP quantification [90] 
cryo hpHep 2D 24 h 375 
live cell protease 
caspase-3/7 
[109] 
HepG2 
3D 
Spheroids 
with matrigel 
24 h after 
21 days in 
culture 
1000 ATP quantification [90] 
HepG2 3D 7 days 
after 21 
400 ATP quantification [90] 
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Spheroids 
with matrigel 
days in 
culture 
rpHep 3D 
Spheroids in 
dynamic 
culture 
24 h 
*100 LDH, Glucose 
secretion, gGT 
leakage 
[103] 
HepH2 *500 
cryo hpHep 3D Spheroids 
48 h 
7days 
28 days 
190 
57 
46 
ATP quantification [87] 
hpHep Hollow-fibre bioreactor 10 days 
*300 Decrease of 
Lactate secretion, 
increase in 
ammonia 
secretion and 
Lower cell density 
and organization 
in 1000 µM vs 300 
µM 
[95] 
*1000 
 
 Diclofenac and troglitazone were selected in this General Introduction due to the importance 
of the drug metabolism for its hepatotoxicity, and thus it is expected to observe a higher toxicity 
in more competent systems. Diclofenac is one of the most prescribed NSAID worldwide [102]. 
Diclofenac causes rare albeit significant cases of serious hepatotoxicity with a fatality rate of 
10 % [102]. As such, diclofenac was herein selected as a hepatotoxicant dependent on 
bioactivation. Diclofenac toxicity may be attributed to its reactive metabolites 4-OH-diclofenac, 
diclofenac-acyl-glucuronide and 4-OH-diclofenac-acyl-glucuronide [102]. 4-OH-diclofenac is 
its main metabolite, metabolized by CYP2C9; whereas 5-OH-diclofenac is formed in a lower 
extent, by CYP3A4. Diclofenac and both OH-diclofenac can suffer glucuronic acid conjugation, 
by UGT2B7, and be eliminated across the canalicular plasma membrane into the bile by MRP-
2 [102]. Therefore, diclofenac metabolism comprises phase I, II and III enzyme activities. 
Diclofenac toxicity studies are scarce in comparing monolayer and 3D cell cultures. In a recent 
study diclofenac metabolism and toxicity was investigated in perfused 3D bioreactors using 
primary human hepatocytes [95]. However, no data for its comparison with monolayer cell 
culture is reported. Although no IC50 value was calculated, Xu et al. [103] observed toxicity for 
concentrations higher than 0.5 µM [103]. Moreover, it was observed that diclofenac 
significantly increased LDH release in liver spheroids but not in HepG2 spheroids [103], 
suggesting that a higher bioconversion of diclofenac and its metabolites in 3D may be 
occurring, resulting in its more toxic sub-products and consequently in higher cytotoxicity. 
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Table 1.7 Troglitazone cytotoxicity endpoints observed in different cell types and cell culture systems. 
Cell Type Cell Culture System 
Exposure 
Time 
IC50 [µM] or [µM] with 
Observed Toxicity* Endpoints References 
co-culture 
of rpHep 
and NPC 
2D 48 h 
*from 10 µM in LDH 
*from 50 µM in ATP 
LDH release and 
ATP 
quantification 
[99] 
co-culture 
of hpHep 
and NPC 
2D 48 h 
*from 100 µM in LDH 
*from 100 µM in ATP 
LDH release and 
ATP 
quantification 
[99] 
cryo hpHep 2D 24 h 100 µM live cell protease and caspase-3/7 [109] 
HepG2 2D 24 h 200 µM ATP quantification [90] 
HepaRG 2D 
24 h after 5 
days in 
culture 
40 µM ATP quantification [101] 
HepaRG 2D 
24 h after 
22 days in 
culture 
300 µM ATP quantification [101] 
rpHep and 
NPC 
co-culture 
3D Scaffold 1 to 8 days 
*from 50 µM in LDH 
*from 50 µM in ATP 
LDH release and 
ATP 
quantification 
[99] 
co-culture 
of hpHep 
and NPC 
3D Scaffold 1 to 8 days 
*from 10 µM in LDH 
*from 1 µM in ATP 
LDH release and 
ATP 
quantification 
[99] 
hpHep 3D Spheroids 
8 days 
14 days 
9 µM 
7 µM 
ATP 
quantification [116] 
HepaRG 3D Spheroids 
8 days 
14 days 
10 µM 
1 µM 
ATP 
quantification [116] 
HepaRG 3D Spheroids 
24 h after 5 
days in 
culture 
400 µM ATP quantification [101] 
HepaRG 3D Spheroids 
24 h after 
22 days in 
culture 
>500 µM ATP quantification [101] 
HepG2 3D Spheroids with matrigel 
24 h after 
21 days in 
culture 
200 µM ATP quantification [90] 
HepG2 3D Spheroids with matrigel 
7 days 
after 21 
days in 
culture 
55 µM ATP quantification [90] 
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HepG2/ 
C3A 
3D spheroids 
in a micro-
physiological 
chip 
24 h *285 µM 
oxygen uptake 
mitocondrial 
demage 
[81] 
  
Troglitazone (TGZ) is a thiazolidinedione derivative developed for the treatment of type II 
diabetes that was withdrawn due to non-immune idiosyncratic toxicity, with 100 liver failure 
cases in 1.9 million patients [110]. TGZ is extensively metabolized by CYP3A4 and GST, it is 
a CYP3A and 2B6 inducer and is able, as well as its sulfate conjugate, to inhibit BSEP [111, 
112]. This leads to an increased formation of troglitazone metabolites as well as to its 
intracellular accumulation, resulting in intrahepatic cholestasis, mitochondria dysfunction, 
covalent binding to proteins, macromolecular damage ultimately leading to apoptosis [113]. 
TGZ is more toxic in humans than in rodent models [99, 114]. In 3D human liver models 
increased sensitivity to TGZ toxicity was observed (Table 1.7), which may be related to higher 
formation of metabolites due to higher induction. Nonetheless, Gunness et al. [101] obtained 
discrepant results, with a 3D model of HepaRG cells being 10 times less sensitive to 
troglitazone than the monolayer model after 24h of exposure and 5 days in culture [101]. This 
decreased sensitivity might reflect a higher clearance, commonly increased in 3D cultures due 
to the cellular architecture. In fact, HepaRG cells present an unproportioned [101] activity of 
phase I, II and III that might interfere with drug and metabolite clearances. These latter 
observations may possibly explain the differences between rats and humans, since rats have 
a higher TGZ clearance comparing with humans [115]. 
In sum, Tables 1.6 and 1.7 show that hepatic cell lines still present relevant differences 
showing in general a lower sensitivity to drugs whose toxicity depends on drug 
biotransformation, even when more physiologically relevant cell culture systems are adopted. 
Thus, besides their disadvantages, primary hepatocytes are still the gold standard for in vitro 
studies since these are currently the cells presenting the more representative phenotype of 
the liver in vivo, particularly when cultured using 3D cell culture approaches.  
1.5 Development, validation and regulatory acceptance of alternative in vitro 
toxicology approaches for hepatic systems 
The main aim of all hazard and risk assessment strategies is to assess human health effects. 
According to OECD (Organisation for Economic Cooperation and Development) TG 417 [117], 
toxicokinetics should be evaluated in vivo using the rat as test system [117]. Ideally, in silico 
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and in vitro methods should model human toxicokinetic processes and use human cells and/or 
tissues. However, as already mentioned, there is a limited availability of human hepatic cells 
and tissues, and several ethical concerns are often raised in obtaining/using them. Moreover, 
given the well described species differences hepatic phase I and phase II biotransformation 
pathways studies are difficult to extrapolate from other species to humans [118]. Thus, other 
approaches are being developed since a stronger scientific foundation offers the prospect of 
improved risk-based regulatory decisions [119, 120]. 
Regulatory authorities and related agencies namely, ICH (International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use), European Commission, OECD, EURL-ECVAM (European Union Reference Laboratory 
- European Centre For Validation of Alternative Methods), ICCVAM (Interagency Coordinating 
Committee on the Validation of Alternative Methods), REACH (Registration, Evaluation, 
Authorization and Restriction of Chemicals) and US Tox21 collaborative program, expect to 
generate more robust data on the potential risks of environmental agents and pharmaceuticals 
to humans and to expand capabilities to test target molecules more efficiently [120]. They are 
also prepared to face alternative testing approaches that reduce animal testing and increase 
drug development efficiency and prediction level of adverse drug reactions and the path for 
this includes improving in vitro testing and using new in vitro technologies [48, 121-128]. EU-
ToxRisk is an example of an integrated project, funded by Horizon 2020 (€ 30 million) 
involving 38 European partners and one from the USA. This project will integrate advances in 
in vitro and in silico toxicology, read-across methods, and adverse outcome pathways, 
continuing the strategy of SEURAT-1, a projected integrated in the FP7 initiative that was the 
first EU-funded project addressing the issue of alternatives to animal testing for prediction of 
repeated dose systemic toxicity [120]. 
The specific objectives of EU-ToxRisk are the “development of a new way of risk assessment” 
comprising the development of new non-animal methods with special emphasis on their 
acceptance and implementation in regulatory contexts [120]. Several alternative methods, in 
other fields of toxicology than toxicokinetics and hepatotoxicity, are already scientifically 
validated, accepted by competent regulatory bodies including OECD, FDA (Food and Drug 
Administration) and EPA (Environmental Protection Agency), and are in use for regulatory 
toxicology purposes, thus reducing or fully replacing living animals in toxicology 
experimentation [129]. However, no hepatic metabolism studies are yet validated and 
accepted by the regulatory authorities as alternative methods [130]. The ECVAM Status 
Report on the Development, Validation and Regulatory Acceptance of Alternative Methods 
and Approaches from 2016 reports only two alternative in vitro toxicokinetic models under 
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evaluation: (i) In vitro hepatic biotransformation – CYP induction: HepaRG and cryopreserved 
human hepatocytes and (ii) In vitro Fish Hepatic Metabolism, to avoid the use of fish bio-
concentration tests [130]. Currently, EURL ECVAM coordinates the “Multi-study Validation 
Trial for cytochrome P450 (CYP) induction providing a reliable human-metabolic competent 
standard model or method using the human cryopreserved HepaRG cell line and 
cryopreserved human hepatocytes”. 
Overall, this fully supports the European policy and world-wide interest in developing and 
implementing alternative in vitro toxicology methods for the risk assessment in hepatic 
systems. As reviewed in Section 1.4, the use of 3D systems improved the quality of data and 
allowed to produce more relevant results. However, the data present high variability that might 
result from distinct cell sources, experimental endpoints and inter-laboratory differences. This 
highlights the need of alternative robust cell sources, able to recreate physiologically relevant 
phenotypes and to represent specific genotypes of interest, which are pertinent such as 
genetic variations in metabolizing enzymes with importance in drug response. Stem cell 
derived hepatocyte-like cells and their adaptation to more physiologically relevant cell culture 
systems have been recently proposed for filling this gap [131]. 
1.6 Stem cell application on in vitro toxicology 
Stem cells (SC) are an ubiquitous presence in the living organisms being essential in every 
moment of development and maintenance of life. Since the development of the first stem cell 
line, in 1981 [132], the scientific interest in SCs has been growing exponentially [51]. SCs are 
considered a very valuable and promising cell source for their potential application in cell 
therapy, and more recently in drug discovery. SCs enable more robust human hazard 
identification and optimized drug development strategies [125].  
SCs are designated as embryonic, extra-embryonic, neonatal or adult SCs according to their 
role in development and origin. More recently, other cells designated as induced pluripotent 
stem cells (hiPSC) that re-programed to a pluripotent state from mature cell populations, 
presenting embryonic stem cell-like characteristics, have been identified [133]. Stem cells are 
considered as such by presenting indefinite self-renewal, plasticity and the ability of multi-
lineage differentiation. Different SC sources present different potentialities and drawbacks for 
each particular application. Human embryonic stem cells (hESC) and hiPSC are pluripotent 
cells, presenting a higher differentiation potential than adult stem cells. hESC offer 
considerable advantages for clinical applications when compared  to immortalized cells or 
primary cell cultures, as they are genetically normal (diploid) and do not exhibit the extend of 
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donor-dependent variability, characteristic of primary cells [134]. However, their utilization 
drives many ethical, technical, and legal concerns [135-137]. Alternative sources of SC, such 
as hiPSCs and adult stem cells do not present such ethical concerns. Several laboratories 
established protocols for differentiation of hiPSCs into hepatocytes [138], which can restore 
liver function in animal models of liver failure [139]. However, hiPSCs are not yet ready for 
transplanting into patients. Most iPSCs have been generated with integrating vectors, which 
may not get silenced efficiently or could disrupt endogenous genes [140]. Furthermore, there 
is evidence that iPSC therapy can lead to tumor formation and before clinical use, researchers 
need to focus on safety of hiPSC therapy in light of the potential for tumor formation [137]. 
Both hiPSC and hESC, present a high teratoma forming potential in vivo [141] as well as high 
genomic instability, namely by accumulating of mutations [142], which is not observed in adult 
stem cells such as mesenchymal stromal cells (MSC). Adult stem cells are part of tissue 
homeostasis and responsible for regenerating damaged tissues. These cells can be 
distinguished per origin of tissue, stage of development, genes expressed and differentiation 
ability [143, 144].  
1.6.1 Mesenchymal stromal cells (MSC) 
MSC classification is still controversial, being commonly defined as adult SC, fetal or neonatal 
SCs depending on its origin. Independently of their origin, MSC are characterized in vitro 
according to international standards, namely the ones defined by the International Society for 
Cell Therapy (ISCT) [145]. The three ISCT criteria are plastic adherence, the tri-lineage 
differentiation capacity (adipocyte, chondrocyte and osteoblast) and a specific surface marker 
profile, as evaluated by flow cytometry, consisting on a population where at least 95 % cells 
express CD105, CD73 and CD90; and less than 2 % cells express CD45, CD34, CD14 or 
CD11b, CD79α or CD19 and HLA-DR. MSCs can be isolated from a number of neonatal 
tissues, such as: fetal blood, liver and bone marrow [146], amniotic sac and fluid, placenta 
[146-148], umbilical cord blood [149], umbilical cord matrix [150-154]; and from adult tissues, 
such as adipose tissue, brain, spleen, liver, kidney, lung, bone marrow, muscle, thymus and 
pancreas [155].  
For toxicological and regenerative medicine applications, MSC present many advantages as 
the ease of isolation from non-controversial sources at a relatively low-cost, in contrast with 
hESC. Additionally, MSC do not require feeder layers or high serum conditions comparing to 
ESC [156] and, although they are not an infinite cell source, these cells do show a satisfactory 
proliferative capacity in vitro [157]. The most studied MSC are derived from bone marrow (BM-
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MSC), the tissue from which MSC were firstly identified and harvested, and from the adipose 
tissue (AT-MSC). More recently, cells derived from extra-embryonic tissues such as placenta 
and umbilical cord matrix (UCM-MSC) or blood became a more interesting cell source due to 
the non-invasive access and to its more primitive origin. These neonatal MSC sources show 
less of the donor variability seen with other sources of MSC due to donor age, health 
conditions, clinical history or lifestyle. Moreover, MSC derived from the umbilical cord tissue, 
in particular, maintain high chromosomal stability upon expansion in vitro in opposition to ESC 
[151] and iPSC [144, 149, 156-158], which is of special interest for clinical applications and to 
produce homogeneous populations of differentiated cells. Furthermore, MSC from the 
umbilical cord tissue are obtained in reproducible conditions and have been demonstrated to 
have a quite high differentiation capacity into cells of mesodermal origin such as myoblasts 
and cardiomyocytes [159], ectodermal as neurons, and endodermal origin as insulin-
producing cells and hepatocyte-like cells (HLC). Human neonatal MSC (hnMSC) have 
demonstrated, along with the potential of differentiation into the hepatic lineage [160], other 
advantages relative to other MSC sources. Namely, hnMSC are isolated from a highly 
available source, do not suffer transformation and present lower epigenetic marks related with 
the donor life style [161, 162]. Nevertheless, hnMSC might be obtained from donors with 
distinct pharmacogenetic profiles and, thus, being particularly interesting for inter-individual 
pharmacogenomic studies. Thus, hnMSC present a very promising, and still scarcely explored 
cell source for in vitro toxicology studies.  
1.6.2 Deriving human hepatocyte-like cells (HLC) from stem cells by mimicking liver 
embryogenesis 
An efficient production of differentiated hepatocytes from SC has been sought by researchers 
and pharmaceutical industry. The aim is to improve reliability and accuracy of drug screening 
[163] by the possibility of using human cells and of building physiologically representative cell 
culture models. The differentiation of stem cells into HLCs have been attempted from hiPSC, 
hESC [138, 164-167] and also from adult stem cells, mainly from MSC such as human BM-
MSC [168, 169], human AT-MSC [170, 171] or human UCM-MSC [172-179]. However, it is 
agreed that a completely mature HLC population has not yet been achieved.  
Differentiation strategies to derive HLC from SC can include: (i) the addition of soluble medium 
factors, including growth factors, cytokines and hormones; (ii) rebuilding the in vivo cell-to-
matrix and cell-to-cell interactions; and (iii) determining cell fate via genetic or epigenetic 
modification [180]. All these strategies aim at mimicking the development of hepatocytes in 
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vivo. Liver development is described in models of mouse, chicken and zebra fish and scarcely 
in human embryos. The major events in early mammalian endoderm development are 
described in Figure 1.6.  
To clarify the gene regulation and the signalling events of liver development four main steps 
are considered: (i) Endoderm induction; (ii) Foregut and hepatic competence induction; (iii) 
Hepatoblast and liver bud formation; and (iv) Differentiation of hepatoblast into hepatocyte.  
(i) Endoderm induction, in vivo, occurs during gastrulation. The endodermal germ layer is 
established and emerges as a sheet of cells from the anterior end of the primitive streak [181]. 
Signalling by the growth factor Nodal initiates endoderm and mesoderm formation in a 
concentration-dependent manner. Low concentrations of Nodal originate mesoderm formation 
while high concentrations originate endoderm formation. The transcription factors induced by 
Nodal are Sox17 and Foxa1-3, which regulate a cascade of genes responsible for the 
endoderm specification [114]. The endoderm induction step in vitro has been tested on 
embryonic stem cells and iPSCs through cell exposure to Activin A, a growth factor from the 
same family as Nodal, TGF-β family [114, 182-184]. 
(ii) The next step on development is foregut and hepatic competence induction that occurs 
when the endoderm forms a primitive gut tube that is subdivided into foregut, midgut and 
hindgut. Each domain expresses a specific transcription factor: Hhex in foregut, Pdx1 in the 
midgut and Cdx in the hindgut (Figure 1.6 c). The embryonic liver originates from the ventral 
foregut endoderm. Herein, gradients of fibroblast growth factor (FGF), Wnt, bone 
morphogenetic protein (BMP) and retinoic acid secreted from the adjacent mesoderm are 
responsible for this patterning of endoderm [185-187]. FGF and Wnts/β-catenin are secreted 
from the posterior mesoderm, repress foregut fate and promote hindgut development by 
inhibiting the expression of the Hhex gene, which is essential for liver development. The 
absence of Wnt/β-catenin by its inhibition initiates liver development [186]. Only the foregut 
endoderm is competent to develop into the liver possibly due to the expression of transcription 
factors like Foxa2, Gata-4, Gata-6 and Hhex [188]. In vitro, this step is mimicked by exposing 
cells to growth factors such as FGFs and EGF once they activate the Hhex gene expression 
[114, 185].  
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Figure 1.6 Major events in early mammalian endoderm development. (a) Gastrulation. (left) The embryonic 
epiblast (blue) viewed from above. Epiblast cells (solid black) migrate down through the primitive streak, becoming 
mesoderm (dashed red) or endoderm (dashed yellow) cells. (right) Oblique view of migrating epiblast cells, in which 
formation of the new mesoderm and endoderm is visible. (b) Tube formation and patterning. (left) The mesoderm 
and ectoderm have been pulled back to reveal the endoderm below. At this stage, the anterior endoderm is 
adjacent to the cardiac mesoderm and septum transversum (which mediate liver induction) whereas more dorsal 
portions of the endoderm are in contact with the notochord (which mediates pancreas induction). The folds of the 
anterior intestinal portal (AIP) and caudal intestinal portal (CIP) form the gut tube as they migrate towards each 
other at the midline. Blue arrows indicate the process of turning, by which the embryo switches from a convex to a 
concave shape, with the endoderm on the “inside”. The roman numeral designations are derived from fate-mapping 
studies and indicate the prospective regions of endoderm that will give rise to later endoderm derivatives. (right) 
The relative position of endoderm domains changes with the completion of gut tube folding; the region that 
previously constituted the most anterior portion of endoderm (I) shifts to the ventral midline and gives rise to lung 
(Lu), liver (Li), and ventral pancreas (VP). (c) Budding and morphogenesis. Budding of endoderm derivatives 
begins shortly after the gut tube is formed and involves many transcription factors. DP, dorsal pancreas; E, 
embryonic day; St, stomach. From [189]. 
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(iii) Afterwards, hepatoblast and liver bud formation takes place once the foregut receives 
signals from the developing heart and septum transversum mesenchyme (STM), which 
releases FGF and BMP respectively. These signals induce hepatic fate in the ventral foregut 
endoderm [190, 191]. After hepatic specification, cells start to express hepatic markers such 
as Albumin (ALB), α-fetoprotein (AFP), transcription factors as c/EBPa and HNF-4a and 
change their morphology from cuboidal to pseudostratified columnar epithelium, forming the 
liver bud. Then, the layer involving hepatic endoderm breaks down and the hepatoblasts 
migrate into STM. Hhex, Gata-4, Gata-6, Prox1, Onecut-1 and Onecut-2 are crucial for the 
delamination process [55]. At this stage the liver bud undergoes exponential growth and 
becomes the major site of fetal haematopoiesis. STM and hepatic mesenchyme secrete FGF, 
BMP, Wnt, Retinoic Acid and HGF, which promote hepatoblast proliferation and survival [181, 
185, 191, 192]. This step is generally mimicked in vitro using FGF and BMP to mimic signals 
sent by the developing heart and STM, which induce a transformation in cell disposal and 
morphology [190, 191]. Herein, hepatocyte growth factor (HGF) is also commonly used to 
promote hepatoblast formation as well as cell culture supplements like insulin–transferrin–
sodium selenite (ITS) and nicotinamide, that synergistically affect the hepatic driving pathway 
[181].  
(iv) Finally, hepatoblasts, that are bipotent cells, can differentiate into hepatocytes or biliary 
epithelial cells. Initially, hepatoblasts express genes associated with both adult hepatocytes 
(HNF4A, ALB, CK18) and biliary epithelial cells (CK19), as well as fetal liver genes such as 
AFP. Hepatoblasts in contact with the portal vein form a monolayer followed by a bilayer of 
cuboidal biliary precursors, increasing the expression of biliary genes and the down-regulation 
of hepatic genes. One factor responsible for the induction of hepatoblast differentiation into 
hepatocytes is oncostatin M (OSM) secreted by haematopoietic cells in the liver [193]. It 
induces metabolic maturation through gp130 and JAK/Stat3 signaling pathways [194]. These 
secreted factors regulate several liver-enriched transcription factors including C/EBPa, HNF-
1a, Foxa1-3, nuclear hormone receptors and HNF-4a which control hepatocyte gene 
expression [181, 195]. In addition to conventional protocols using growth factors Takayama et 
al. [166] sequential transduced of Sox17, Hhex, and HNF-4α on hESC and hiPSC, which 
induced further HLC maturation [166]. In fact, the transcription factor HNF-4a, plays a critical 
role in liver development and function as lipid and glucose metabolism. The maturation of 
hepatocytes and formation of extrahepatic bile ducts are gradual. This process continues even 
after birth [181] and is mimicked in vitro by the use factors such as OSM, and dexamethasone 
[193, 196]. 
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Stem cell-derived HLCs may be characterized in vitro at four levels such as morphological, 
RNA, protein and enzymatic activity levels [180]. Since MSC and hepatocytes derive from 
different germ layers, the process of differentiation of MSC into HLC must involve a successful 
transdifferentiation, which is a still poorly understood process [180]. This issue and the lack of 
homogeneity between MSC populations, due to cell origin, isolation, purifying and expanding 
methods render HLCs differentiation a more challenging task. In fact, Takayama et al. [166] 
identified that differentiation efficacies differed between human iPSC lines, possibly due to the 
difference of epigenetic memory of original cells or to the difference of the inserted position of 
the foreign genes for the reprogramming [166]. This observation is reinforced also by several 
authors [140, 197] and highlights the advantages of a neonatal MSC source. 
1.6.3 hMSC differentiation into HLC  
MSCs have been reported as presenting important differences in their transcriptomes with 
respect to their source. De Kock et al. [160] suggested that the neonatal, the umbilical cord 
tissue cells WJ-MSCs presented a favourable transcriptome regarding hepatocyte 
differentiation in comparison with the gold standards of mesoderm-derived stem cells: hAT-
MSC, BM-MSC and human skin derived precursors (hSKP) [160]. Interestingly, hUCM derived 
MSCs have been reported to express early endoderm markers, such as GATA-4 [151], GATA-
5, GATA-6, SOX9 and SOX17 and liver progenitor markers such as DKK1, DPP4, DSG2, 
CX43 and CK19 [150, 160]. Lee et al. [198] study highlighted the importance of MSC cell 
source accordingly to its potential applications [160, 161]. This study evaluated neonatal 
MSCs such as chorionic-villi MSC, amnion MSC, chorionic plate MSC and WJ-MSC and adult 
MSC (BM- and AT-MSCs) and showed that the more primordial MSC sources, neonatal 
MSCs, presented a better hepatocyte differentiation phenotype [198].  
Despite the advantages of hnMSC, few differentiation studies are available regarding these 
cells [172, 174, 176, 179, 199]. Anzalone et al. [161] extensively characterized hnMSCs and 
its differentiation potential into HLCs in comparison with other MSCs sources, highlighting their 
advantages relative to BM-MSC and AT-MSC. A comparison of placenta derived stem cells 
(PDSC) and BM-MSC also showed the superiority of the neonatal stem cells for in vitro 
hepatotoxicity studies, since PDSCs-derived HLCs showed higher sensitivity to toxicants 
exposure [200]. One example is the report by Campard et al. [172], where the potential of 
hUCM-MSC to differentiate into HLCs using a three-step protocol that mimic the in vivo liver 
embryogenesis was evaluated, comprising a more complete analysis of cell phenotype, 
including biotransformation activity. Using this protocol, a population of differentiated cells with 
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hepatocyte-like characteristics was obtained. Differentiated HLCs expressed the hepatic 
markers ALB, Glucose-6-phosphatase (G6P), Tryptophan-2,3-dioxygenase (TDO), α1-
Antitrypsin (AT), Tyrosine aminotransferase (TAT) and exhibited CYP3A4 activity as well as 
glycogen accumulation, and urea production. However, other crucial hepatic markers were 
still not present such as HepPar1, HNF-4α and CYP2B6, neither CYP3A4 induction after 
exposure to phenobarbital, and AFP, which implies that a mature phenotype was not achieved 
[172]. More recently, Zhang et al. [174] and Zhou et al. [177], differentiated hUCM-MSC into 
HLC using two-step protocols, achieving positive staining for CK-18, ALB and AFP; whereas 
HLCs were negative for CK-19, LDL uptake capacity and glycogen storage and presented a 
fibroblastic morphology [174, 177]. Therefore, presenting less mature phenotype than the one 
reported by Campard et al. [172].  
Considering that the transcription of genes governing cell-fate during development critically 
depends on the chromatin accessibility, epigenetic modifiers (EM) have also been suggested 
for improving HLC phenotype. Those have been considered to modulate the intricate interplay 
between chromatin modulation, including histone (de)acetylation and DNA (de)methylation, 
and liver-enriched transcription factors that occur during embryonic development [201]. Their 
use was extensively reviewed by Snykers et al. [201] for the differentiation of stem cells into 
HLCs as well as for the maintenance of a hepatic phenotype in cultures of primary hepatocytes 
[201]. The more commonly used EM are histone deacetylase inhibitors (HDACi) namely 
trichostatin A (TSA), sodium butyrate and valproic acid, and DNA methyltransferase inhibitors 
(DNMTi), namely 5-azacytidine (5-AZA). The general mechanism of action of these agents is 
represented in Figure 1.7. 
An et al. [202] tested the effect of valproic acid prior to subjecting cells to the differentiation 
protocol and observed albumin presence (though not its production in cell culture 
supernatant), improved LDL uptake, urea production and glycogen storage [202]. More 
recently, Mortezaee et al. [203] observed an improved HLC phenotype by differentiating 
hnMSC isolated from the umbilical cord matrix and introducing 1 mM sodium butyrate and 1 
μM retinoic acid in a two-step differentiation of a 28 days protocol. Cells characterization 
consisted only on AFP and HNF1A gene expression, PAS staining and albumin production 
[203]. Raout et al. [204] evaluated the effect of valproic acid and miR-122-5p on the hepatic 
differentiation of hnMSC isolated from the umbilical cord matrix and observed gene expression 
of some hepatic markers, glycogen storage, albumin and urea production, presence of 
albumin and CYP3A4 [204]. 
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Figure 1.7. Epigenetic control of gene transcription. Inhibition of gene transcription typically corresponds to 
hypermethylated CpG islands in gene promoter regions and deacetylated histone tails at local chromatin domains. 
The indirect mechanism of gene silencing may involve binding of methyl-binding proteins (MeCp) to methylated 
cytosine and subsequent recruitment of HDAC-corepressor (CoR) complexes, resulting in a non-permissive 
heterochromatin status that blocks binding of transcription factors (TF) and polymerase II RNA complexes (PolII) 
to target promoter sequences. The direct mechanism may involve the direct interference of TF with HDAC or 
methylated CpG sites within the promoter. HDAC inhibitors (HDACi) and DNMT inhibitors (DNMTi) modulate the 
chromatin structure, creating an open, transcriptionally active euchromatin configuration at gene coding and 
regulatory regions, accessible for TF, thereby facilitating gene transcription. Abbreviations: 5-AzaC, decitabine; M, 
5-methyl cytosine at CpGs; SB, sodium butyrate; TSA, trichostatin A; VPA, valproic acid. From [201]. 
5-AZA has been applied for promoting the differentiation of stem cells into various cell types 
[205-207]. 5-AZA is a competitive inhibitor of DNA cytosine methyltransferases [208]. 
However, it can also exert its epigenetic modifying activity directly or indirectly through 
different mechanisms [209] including interference with RNA methylation and modulation of 
nonsense-mediated mRNA decay efficiency in a MYC-dependent manner [210, 211]. 
Regarding hepatocyte differentiation, 5-AZA was administered in vivo to 20 days gestational 
age rat foetuses resulting in a quick maturation of hepatocyte morphology 18h after treatment 
as well as higher expression of genes such as TAT and ALB, reflecting a temporal advance 
of changes that would occur later in liver development [212]. On hepatocyte differentiation 
protocols in vitro, 5-AZA has only been attempted on hAT-MSCs by Seeliger et al. [213], and 
on umbilical blood derived MSCs by Yoshida et al. [214] being applied 24h prior the 
differentiation induction since proliferation is needed for the incorporation of 5-AZA into cellular 
DNA. 5-AZA at 20 μM [213] improved glucose secretion, and CYP1A1/2 and CYP2B6 activity. 
Urea production was similar in both freshly isolated hepatocytes and cells not exposed to 5-
AZA [213]. On the other hand, Yoshida et al. [214] achieved a significantly higher ALB, c/EBP-
α, CYP1A1/2 and PAS positive cells, as well as higher urea production and ALB gene 
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expression after 21 days of differentiation than in non-treated cells [214]. However, a less 
mature phenotype than the one observed by Seeliger et al. [213] was obtained. 
DMSO has also been proposed as an epigenetic modifier that induces hepatic differentiation 
though its mechanisms are still poorly understood. In fact, DMSO has been extensively 
reported a as differentiation inducer for several cell lines such as HepaRG [54] and HL-60 
[215] and more recently for progenitor cells [216-219] and stem cells differentiation [183, 217, 
220-224]. The effect of DMSO on stem cell differentiation was thoroughly studied by Cheety 
et al. [225] that observed an activation of the retinoblastoma protein in DMSO treated cells. 
DMSO is further responsible for a higher proportion of cells in early G1 phase [225]. This cell 
cycle phase is of high importance for cell differentiation and a prolonged G1 phase has been 
reported as an indication of a differentiated status by reflecting loss of pluripotency and gain 
of lineage specific markers [226]. Thus, the DMSO treatment may increase the 
responsiveness of the stem cells differentiation signals, enhancing differentiation across all 
germ layers, and improving terminal differentiation into functional derivatives [225]. During 
spontaneous differentiation of hESCs, DMSO treatment resulted in a selective downregulation 
of key markers associated with stemness (Oct-4, Sox-2, Nanog and Rex-1); ectoderm (Nestin, 
TuJ1, NEFH and Keratin-15); mesoderm (HAND-1, MEF-2C, GATA-4 and cardiac-actin); and 
endoderm (SOX-17, GATA-6) [222]. DMSO has been also reported to promote hypo- and 
hypper phosphorylation of several cellular proteins [227, 228], on phosphatidiylinositol 
signaling [229] as well as to increase membranes permeability and floppiness [230], namely 
by transiently opening water pores and facilitating Ca2+ entrance into the cells [231]. Su et al. 
[232] reported that in cultures of primary rat hepatocytes, DMSO at a concentration of 2 % 
was able to maintain normal transcription factors pattern on cultured cells, thus reflecting more 
relevant CYP450 enzyme activities, namely by restoring HNF-4α and c/EBP-α levels that 
rapidly decreased in cultures without DMSO [232].  
1.6.4 Stem cell derived HLC resorting to 3D culture strategies  
3D culture systems have been shown to increase the functions of hepatocytes in vitro. 
Therefore, some authors have attempted to mimic the ontogenic environment of liver by using 
3D cell cultures, to promote the hepatogenic differentiation and hepatocyte maturation [97, 
122, 180]. 3D cell cultures have also been applied to SCs, although scarce in number, with 
great success to study the maintenance of their undifferentiated phenotype for long culturing 
periods [233, 234] and to promote cellular differentiation and maturation [235-237]. 
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The use of 3D cell culture systems on HLCs derived from hnMSCs has to our best knowledge 
only been reported by our group [173]. It had been described for other sources of MSCs [238-
242], and in a higher number using hiPSCs and hESCs [122, 184, 236, 243, 244]. The 3D 
strategies used for the purpose of hepatic differentiation include the use of scaffolds [122, 238, 
240-242, 245], clustering into natural or synthetic matrix [244], self-assembled spheroids [122, 
173, 236, 239] or hollow-fiber bioreactors [173, 184, 243]. 
Gieseck et al. [244] showed the ability of hiPSCs to differentiate into HLCs detecting the 
presence of ALB, AFP, AT, as well as CYP3A4 activity under 2D and 3D cell cultures, the last 
consisting of cell clustering onto collagen matrix. However, the presence of the hepatic 
transporter MRP-2 was only detected under the 3D cell culture system [244]. Moreover, 2D 
culture maintained CYP3A4 activity for 20 days after the achievement of a differentiated 
phenotype, whereas the 3D culture could maintain not only a stable CYP3A4 activity but also 
albumin production, with a simultaneous decrease of AFP production, until day 50 after 
differentiation [244].  
Nano-scaffold structures were used to culture human BM-MSC-derived HLCs. Herein, the 
expression of ALB, AFP, CK18, CK19 and CYP3A4 was observed as well as an increased 
ability to produce urea and transferrin relative to 2D and to undifferentiated cells [245]. 
Baharvand et al. [122] also observed higher albumin, AFP and urea production in a 28-day 
long protocol, when comparing 2D and 3D cultures of human embryonic stem cell derived-
HLCs, using embryoid bodies cultured in 24-well tissue culture dishes containing a 3D scaffold 
as 3D strategy [122]. 
By resorting to self-assembled spheroid strategies, Subramanian et al. [236] showed an 
improved hepatic phenotype of hESC derived HLC when cultured on spheroid static cultures, 
namely regarding albumin secretion and decrease of AFP expression that was maintained for 
2 weeks in culture [236]. Considering HLC derived from MSCs, Okura et al. [239] observed 
hepatocyte characteristics on HLC clusters derived from adipose tissue hMSC as ALB and AT 
presence, urea production and glycogen storage capacity but the comparison with 2D cell 
cultures is scarce [239]. Stem cell differentiation using the hollow-fiber bioreactor was 
attempted using hESC and resulted in an upregulation of pathways related to steroid hormone 
biosynthesis, ABC transporters and CYP-dependent metabolism of xenobiotics in comparison 
to 2D cultures, also revealing maturation of the HLCs in this environment [243]. Freyer et al. 
[184] also showed that this 3D bioreactor improved hiPSC-derived HLCs differentiation with 
increased albumin secretion, CYP2B6 activity, and allowing the formation of tissue-like 
structures with cell-to-cell contacts, in comparison with 2D cultures. However, some aspects 
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of hepatic functionality such as AFP expression, and the absence of CYP2C9 activity and 
expression of the biliary transporter MRP-2 protein presence could not be detected [184]. This 
cell culture system was also studied for the maturation of hnMSC-derived HLCs and compared 
with a self-assembled spheroid under a static culture and a respective monolayer control. 
HLCs displayed a more mature hepatocyte-like phenotype under both 3D cultures than in the 
2D culture, namely at biotransformation level and the differences between both systems were 
subtle. The spheroids revealed higher bupropion conversion whereas bioreactor showed 
increased albumin production and capacity to biotransform diclofenac [173]. This highlights 
the potential of 3D systems for cell maturation and maintenance of specific cell functions. In 
fact, as showed in Section 1.4. toxicological studies using a human hepatocyte cell line in 3D 
conditions have shown different sensitivity to molecules when compared to 2D cultures [66], 
probably due to a more complete biotransformation phenotype. 
1.6.5 Stem cell based in vitro hepatotoxicity models 
The reports of hepatotoxicity studies using HLCs are still scarce and despite the demonstrated 
advantage of 3D culture for cell differentiation and maturation, the latter are even scarcer.  
Some studies describe and compare the potential of HLCs for toxicological applications with 
each other and with the industry gold standard cellular models: HepG2 and cryopreserved 
human primary hepatocytes. The toxicological advantage of hiPSC-derived HLCs was 
observed by Sjogren et al. [246] study, where HLCs better predicted drug induced apoptosis 
than Huh7 and HepaRG [246]. Another study, from Holmgren et al. [247], evaluated the 
response of hiPSC derived HLCs to specific hepatotoxic drugs over 14-days exposure [247]. 
The hiPSC-derived hepatocytes revealed to be more sensitive to the toxic compounds after 
extended exposures. In addition to conventional cytotoxicity, evidence of steatosis was also 
observed in the cells exposed to troglitazone [247]. Moreover, the IC50 value is of 20 µM, 60 
µM and 100 µM after 14, 7 or 2 days of exposure [247], falling into the range of human primary 
hepatocytes (Table 1.7). The use of hESC and hiPSC-derived HLCs was also compared in a 
study by Medine and co-workers [248]. Both HLCs showed a hepatocyte-like phenotype with 
positive staining of albumin and HNF-4a, E-CAD, AT and CYP3A4 as well as displaying 
CYP3A4, 2C9 and 1A2 activity. However, only hESC-derived HLCs displayed CYP2C9-
dependent cytotoxicity similarly to human cryopreserved primary hepatocytes [248]. Recently, 
it was also demonstrated that hiPSC and hESC-derived HLCs presented cytotoxicity, cellular 
multi-functional parameters, CYP450 enzyme activity profiles closer to hpHeps than HepG2 
[249]. Once again, hESC-derived HLCs revealed improved hepatic function with higher 
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correlation with hpHep than hiPSC derived-HLCs. Remarkably, in this study it was possible to 
demonstrate that the hepatotoxic mechanism of aflatoxin B1, a well-known mycotoxine, was 
mediated by CYP3A4 using a stem cell-derived hepatocyte model [249]. 
Tasnim et al. [197] also performed a complete comparative study of 2D and 3D cultures of 
HLCs, resorting to spheroid formation into a matrix of galactosylated cellulosic sponges, 
focusing on its in vitro hepatotoxicity potential applications. Two hiPSC lines and one hESC 
line were used to derive HLC [197]. The better performance of hESC-derived HLCs as well as 
a high variability of different hiPSC lines were reinforced, which is in accordance with other 
studies [140, 250]. In this study, the cells were differentiated under 2D cultures for 20 days 
and seeded into 3D culture or 2D control cultures for an extended period of 12 days. 3D culture 
did not change albumin production. However, hepatic markers expression, urea secretion, and 
CYP3A4, 1A2 and 2B6 activities and induction were significantly higher in 3D comparing with 
2D. The HLC CYP450 activity reached 30-150 % higher than human cryopreserved 
hepatocytes activity in one hiPSC cell line and in hESC-derived HLC [197]. Upon paracetamol, 
troglitazone, and methotrexate exposure, hESC-HLCs predicted better paracetamol 
cytotoxicity regardless of the cell culture systems, and 3D hESC-HLCs predicted better 
methotrexate cytotoxicity than 3D hiPSC-HLC. Both stem cell-derived HLC 3D cultures were 
more sensitive than primary hepatocytes to troglitazone exposure, conversely to 2D HLCs 
[197]. 
The exploitation of MSC-derived HLCs as an in vitro cell model for hepatotoxicity studies is 
less reported than of hiPSC or hESC. Rodrigues and co-workers [251] derived HLC from 
human neonatal skin precursors (hSKP) expressing ALB, as well as biotransformation 
enzymes such as CYP1B1, FMO1, GSTA4, GSTM3, and the drug transporters ABCC4, 
ABCA1 and SLC2A5 [251]. This hSKP-HLC responded to paracetamol exposure as primary 
human hepatocytes concerning the toxicogenomic evaluation of "liver damage", "liver 
proliferation", "liver necrosis" and "liver steatosis" [251]. More recently, Rodrigues et al. [162] 
showed that, similarly to in vitro primary hepatocytes, hSKP-HLC were also able to display a 
steatosis phenotype upon VPA induction with some features in common with in vivo 
observations of mild steatosis, whereas advanced steatosis was not possible to mimic [162]. 
Both studies are, to our knowledge, the first report in which human postnatal stem cells are 
described as a potentially relevant cell source for in vitro hepatotoxicity drug testing, namely 
steatogenic compounds and compounds interfering with lipid metabolism. 
In summary, major challenges to be overcome for the relevant application of SC-derived 
hepatocytes in toxicology still exist: (i) the immature phenotype since only hepatocyte-like cells 
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expressing low levels of liver-specific markers, especially drug metabolizing and detoxifying 
enzymes, are usually obtained [166, 252, 253]; (ii) the lack of defined and validated endpoints 
of hepatic differentiation and maturation; (iii) the lack of standardization and data using 
relevant positive controls; and (iv) the generation and maintenance of functional hepatocytes 
in high numbers [253]. Once these questions are solved, in vitro toxicogenomics, 
transcriptomics, proteomics and metabolomics technologies as well as progress in high 
throughput screening can be applied to hepatocytes of human origin derived from stem cells 
[163]. In fact, the emergence of mechanistic models for toxicity testing, including in vitro 
disease models, and its introduction at the timeframe of lead selection and optimization, in 
parallel with in vitro pharmacokinetic studies, will significantly reduce compound attrition rate 
by selection of safer and more efficacious lead molecules. The upcoming stem cell-based 
toxicity testing models might have an important future role on addressing safety gaps of 
present drug discovery and development. 
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UCX® is a highly homogeneous, extensively characterized and therapy-driven population of 
human neonatal mesenchymal stromal/stem cells (hnMSC), registered as a trademark and 
resulting from a patented generation method [154]. UCX® are obtained in high numbers and 
are already in pre-clinical trials for several cardio-vascular and auto-immune disorders. The 
consistent and controlled fabrication process of UCX® [154, 254] and its neonatal source that 
proved to be relevant for MSCs hepatic differentiation [160, 200] makes this cell population a 
privileged candidate to use for hepatic differentiation procedures to obtain models for in vitro 
toxicology. The aim of this work was to derive hepatocyte-like cells (HLC) from UCX® to 
address and solve the following problems: 
(i) The difficult task of obtaining and maintaining functional hepatocytes in vitro, in quality 
and numbers that would be compatible to high throughput drug screening (important for the 
pharmaceutical industry); 
(ii) The development of a 3D culture system for UCX® cell expansion and/or maintenance 
and improvement of the hepatic differentiation or the differentiated phenotype.  
The main goal of this thesis was to obtain differentiated HLC of human origin with a mature 
phenotype, showing high and persistent levels of biotransformation activity in a scalable 3D 
culture condition that could be routinely used by pharmaceutical industry in drug screening. 
To achieve this general aim the following specific objectives were proposed: 
- Use the 3D culture strategies for maintaining and expanding UCX® cells focusing on 
the development of 3D cultures to support, maintain and expand UCX® cells for further HLC 
differentiation. For this, the 3D UCX® cells structures will be cultured in suspension using 
stirred tank vessels (spinner vessels) and static cultures using ultra-low attachment plates; 
- Develop a differentiation protocol to derive HLC from UCX®, taking into consideration 
the cytokines and growth factors present during liver embryogenesis; 
- Improve UCX®-derived hepatocyte phenotype by resorting to 3D culture technology, 
applying the previously optimized differentiation protocol to the 3D culture conditions: self-
assembled spheroids and a multi-compartment 3D perfusion bioreactor. Such environment 
provides more physiologic conditions essential to the developmental process, such as cell-to-
-cell interactions allowing a higher biological activity to be achieved in terms of liver-specific 
markers levels and drug detoxifying enzymes and further fulfilling the toxicological/cell therapy 
applications herein proposed; 
- Evaluate UCX®-derived hepatocytes, namely their hepatocyte-like character in both 
2D and 3D cell culture by their morphological and phenotypic characteristics, including 
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metabolic/biotransformation ability, when exposed to drugs as a proof-of-concept of HLCs 
culture in terms of their potential interest for in vitro toxicology applications. 
My thesis is that 3D culture conditions in the presence of cytokines and growth factors involved 
in liver embryogenesis would result in a hMSC-based in vitro model more representative of 
the liver physiological conditions, which could be standardized and therefore routinely used 
for toxicology screening. This could meet the most pressing pharmaceutical industry needs 
and give a step forward in predictive toxicology, with possible applications in cell therapy. 
Chapter 3 describes the development of a differentiation strategy to derive hepatocyte-like 
cells from UCX® cells. Previous stem cell hepatocyte differentiation studies were considered, 
namely, the one by Campard et al. [172] to our knowledge, the only work reporting hepatocyte 
differentiation from hUCM-MSC. Campard et al. [172] describes a differentiation protocol, 
however a more complicated MSC isolation method was employed and some inconsistency 
in hepatic markers expression was revealed, which perhaps demonstrates a less than mature 
HLC output. Nevertheless, such protocol was the starting point for the differentiation protocol 
herein developed through an intensive characterization of HLC under 8 distinct differentiation 
protocols, using 2D cultures for practical reasons. The generated HLC were evaluated for the 
chemical optimization of the differentiation protocol, were tested under extended cell culture 
times, up to day 34, and characterized for its transcriptome in comparison with human primary 
hepatocytes. 
Besides, the obtained HLC presented relevant hepatocyte-like characteristics, the hypothesis 
of further improving its phenotype in 3D culture was evaluated. Therefore, Chapter 4 describes 
the optimization and characterization of UCX® under 3D cultures for maintaining and 
expanding UCX® cells.  
In Chapter 5, HLC culture was adapted to two distinct 3D cultures: self-assembled spheroids 
and the hollow-fiber bioreactor to optimize the cell culture environment for HLC maturation. 
The obtained functional HLC were once again deeply characterized at gene expression, 
protein, enzymatic activity and capacity to biotransform reference drugs under these cell 
culture systems.  
Finally, Chapter 6 describes the proof-of-concept study of the 3D spheroids as model for in 
vitro study of drugs that undergo hepatic biotransformation, by mimicking the human 
nevirapine biotransformation and induction profile. 
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3 Chapter 3. The role of epigenetic modifiers on extended cultures 
of functional hepatocyte-like cells derived from human neonatal 
mesenchymal stem cells 
 
The scientific content of the present chapter has been included in the following publication: 
Cipriano M, Correia JC, Camões SP, Oliveira NG, Cruz P, Cruz H, Castro M, Ruas JL, Santos 
JM, Miranda JP. The role of epigenetic modifiers on extended cultures of functional 
hepatocyte-like cells derived from human neonatal mesenchymal stem cells. Arch Toxicol. 
2017;91:2469-89. DOI 10.1007/s00204-016-1838-0 
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3.1 Abstract 
The development of predictive in vitro stem cell-derived hepatic models for toxicological drug 
screening is an increasingly important topic. Herein, umbilical cord tissue-derived 
mesenchymal stromal cells (hnMSCs) underwent hepatic differentiation using an optimized 
three-step core protocol of 24 days that mimicked liver embryogenesis with further exposure 
to epigenetic markers, namely the histone deacetylase inhibitor trichostatin A (TSA), the 
cytidine analogue 5-azacytidine (5-AZA) and dimethyl sulfoxide (DMSO). FGF-2 and FGF-4 
were also tested to improve endoderm commitment and foregut induction during Step 1 of the 
differentiation protocol, being HHEX expression increased with FGF-2 (4 ng/mL). DMSO (1 
%, v/v) when added at day 10 enhanced cell morphology, glycogen storage ability, enzymatic 
activity and induction capacity. Moreover, the stability of the hepatic phenotype under the 
optimized differentiation conditions was examined up to day 34. Our findings showed that 
hepatocyte-like cells (HLCs) acquired the ability to metabolise glucose, produce albumin and 
detoxify ammonia. Global transcriptional analyses of the HLCs showed a partial hepatic 
differentiation degree. Global analysis of gene expression in the different cells revealed shared 
expression of gene groups between HLCs and hpHeps (human primary hepatocytes) that 
were not observed between HepG2 and hpHeps. In addition, bioinformatics analysis of gene 
expression data placed HLCs between the HepG2 cell line and hpHeps and distant from 
hnMSCs. The enhanced hepatic differentiation observed was supported by the presence of 
the hepatic drug transporters OATP-C and MRP-2 and gene expression of the hepatic 
markers CK18, TAT, AFP, ALB, HNF4A and CEBPA; and by their ability to display stable 
UGTs, EROD, ECOD, CYP1A1, CYP2C9 and CYP3A4-dependent activities at levels either 
comparable with or even higher than those observed in primary hepatocytes and HepG2 cells. 
Overall, an improvement of the hepatocyte-like phenotype was achieved for an extended 
culture time suggesting a role of the epigenetic modifiers in hepatic differentiation and 
maturation and presenting hnMSC-HLCs as an advantageous alternative for drug discovery 
and in vitro toxicology testing. 
Keywords: 
hnMSC; Hepatocyte-like cells; CYP metabolism; Drug transporters; Epigenetic modifiers. 
  
The role of EM on extended cultures of functional HLCs derived from hnMSC 
 51 
3.2 Introduction 
The pharmaceutical industry faces considerable challenges regarding political and social 
pressure to reduce the cost of medicines. The drug development process is expensive, lasts 
on average 10-15 years and shows a success rate of only 11 % for all therapeutic areas. The 
majority of drug attrition is due to lack of efficacy or safety that occurs essentially in the clinical 
phases IIb and III of drug development [2]. Liver damage is also an important cause of new 
drug failures, post-marketing withdrawals or relabeling with black box warnings, of which 21 
% accounts for hepatotoxicity [3]. This is mostly due to the fact that hepatotoxicity is difficult 
to predict in early stages of drug development, making the improvement of pre-clinical models, 
namely human cellular models, particularly relevant concerning human safety. The need of an 
available source of human hepatocytes is therefore of major importance for in vitro toxicology 
applications [255]. 
Human primary hepatocytes (hpHeps) are not easily available and they are not much 
proliferative in healthy conditions or in vitro given their highly-differentiated cell type [7]. 
Additionally, these cells quickly lose their normal functions, namely metabolism of xenobiotics, 
when isolated and maintained in culture. Human cell lines as HepG2, Huh7, and more recently 
HepaRG, have also been used to study hepatic metabolism of new molecules and toxicants. 
However, these immortalized cell models still present crucial drawbacks for predictive 
hepatotoxicity such as an incomplete metabolic profile regarding phase I, phase II and hepatic 
transporters [7], resulting in distinct toxicity profiles for the same compounds, when compared 
to primary hepatocytes [50, 246].  
Differentiation of stem cells (SC) has been suggested as an alternative approach for obtaining 
functional hepatocyte-like cells (HLC). Sjogren et al. [246] showed that induced pluripotent 
stem cell (iPSC)-derived hepatocytes are better toxicity predictors than Huh7 and HepaRG for 
drugs that cause apoptosis via mitochondrial-driven mechanisms. However, although the 
scientific community has already achieved impressive results, a completely mature HLC 
population derived from SCs has not yet been achieved [255, 256]. MSC, in particular, are a 
promising SC type, regarding availability, expandability, ethical and safety concerns [154, 257-
259], when compared to iPSC or ESC. Despite its mesenchymal nature, MSCs derived from 
human bone marrow [168], human adipose tissue [171] or human umbilical cord tissue [172, 
174, 179] have been described as able to undergo hepatocyte differentiation. In a comparative 
study, Lee et al. [198] showed that neonatal MSC, namely placenta-derived MSCs (including 
chorionic-villi MSCs, amnion MSCs, chorionic plate MSCs and WJ-MSCs) presented a better 
hepatocyte-like phenotype after differentiation than adult MSCs, such as human AT-MSC and 
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BM-MSC, reinforcing that each MSC type has a different differentiation potential and the 
importance of the choice of the primary MSC source [160].   
The few papers reporting hepatic differentiation of human neonatal umbilical cord tissue-
derived MSCs (hnMSC-UCM) [172, 179] characterize the obtained HLCs in terms of urea and 
albumin production, positive glycogen storage, acetylated low-density lipoprotein (Ac-LDL) 
uptake and the presence of hepatic markers as CK-18, albumin (ALB) and α-fetoprotein (AFP) 
through immunohistological or gene expression analyses. These studies did not contemplate 
a deeper evaluation of the metabolic potential of these cells regarding phase I, II and III 
metabolic activities. Most importantly, the maintenance of cell functionality in culture was not 
evaluated. Some publications do evaluate CYP and hepatic transporter presence in iPSC or 
human ESC-derived HLCs [260, 261], but this analysis using MSCs has still not been 
thoroughly explored. Considering hnMSC-UCM, Campard et al. [172] investigated the activity 
of CYP3A4 only and tested if hnMSC-UCM-derived HLCs would respond to the phenobarbital 
induction stimuli, which was not observed. Additionally, essential hepatic markers such as 
HNF-4α and CYP2B6 were not detected, as well as HepPar1, a highly sensitive marker of 
hepatocyte’s mitochondria. More recently, Zhang et al. [174] and Zhou et al. [177] published 
on differentiation of hnMSC-UCM into HLCs, using a two-step protocol but the achieved 
phenotype is less mature than the reported by Campard et al. [172], presenting positive 
staining for CK-18, ALB and AFP. Nevertheless, the cells presented a fibroblast-like 
morphology and did not present glycogen storage and Ac-LDL uptake capacities [174, 177].  
Considering that the transcription of genes governing cell-fate during development critically 
depends on the chromatin accessibility, epigenetic modifiers (EM) have also been suggested 
for improving HLC phenotype. In this study, a total of eight protocols were used to test the 
differentiation capacity of a specific population of hnMSC-UCM, UCX® [257-259], isolated 
using a method which was fully adapted in compliance with advanced therapy medicinal 
product (ATMP) regulatory requirements [254]. This differentiation procedure was performed 
using a combination of different cytokines in order to mimic liver embryogenesis and the 
addition of EM. The EM tested in this work are small molecules that have been previously 
described and applied in vitro as promoters of hepatic differentiation, namely trichostatin A 
(TSA), dimethyl sulfoxide (DMSO), and 5-azacytidine (5-AZA). TSA is a histone deacetylase 
inhibitor (HDAC-I) [168], DMSO exerts an epigenetic modulation through less described 
mechanisms [222] and the cytidine analogue 5-AZA is a small molecule that inhibits DNA 
methylation [213, 214]. hnMSCs showed the ability to commit with the endoderm lineage and 
to differentiate into mature HLCs. Moreover, the addition of EM and the optimized 
differentiation protocol resulted in an improved cell phenotype and a remarkable maintenance 
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of HLC hepatic functions in culture was achieved, locating HLCs closer to hpHeps as shown 
by global gene expression. 
3.3 Material and Methods 
3.3.1 Reagents 
Cell culture supplements were purchased from Lonza (Basel, Switzerland), unless otherwise 
stated. Trypsin-EDTA, fetal bovine serum (FBS), insulin-transferrin-selenium solution (ITS) 
and non-essential amino acids supplement (NEAA) were purchased from Gibco®/Life 
Technologies (Madrid, Spain). 7-ethoxyresorufin and 7-ethoxycoumarin were purchase from 
Alfa Aesar (Karlsruhe, Germany). Hepatocyte growth factor (HGF), fibroblast growth factors 
(FGF-2 and FGF-4) and oncostatin-M (OSM) were purchased from Peprotech (Rocky Hill, NJ, 
USA). Finally, Iscove's modified Dulbecco's medium (IMDM), alpha modified Eagle's medium 
(α-MEM), epidermal growth factor (EGF), dexamethasone, DMSO, nicotinamide, 5-AZA, 
trypan blue, periodic acid, Schiff’s reagent Mayer’s hematoxylin, amylase, Hank’s balanced 
salt solution (HBSS), 4-methylumbelliferone (4-MU), β-glucuronidase/arylsulfatase, resorufin, 
3-methylcholantherene (3-MC), omeprazole and rifampicin were acquired from Sigma-Aldrich 
(Madrid, Spain).  
3.3.2 Rat-tail collagen extraction and plate coating  
Rat-tail collagen extraction was performed based on Rajan et al. [262]. Briefly, rat-tails were 
washed twice in 70 % ethanol prior to skin removal using sirurgical material. Tendon fibres 
were pulled out, separated from bone and cartilaginous tissue and suspended in PBS. Fibres 
were then washed three times and immersed for 1 hour in 70 % EtOH before being transferred 
into 0.1 % acetic acid and stirred during 48 hours at 4°C, for fibre acid digestion. The solution 
was centrifuged at 16000 x g for 90 minutes at 4 ºC. The supernatant was collected, lyophilized 
and the resultant solid stored at -80 °C until further use. 
For collagen plate coating, lyophilized collagen was dissolved in a final concentration of 1 
mg/mL in 0.1 % acetic acid and diluted to 0.2 mg/mL in PBS. A volume of this solution covering 
with excess the whole area of cell culture was added to cell culture surfaces and kept for 30 
minutes at 37 ºC. After incubation cell culture surfaces were left to dry under UV light for 30 
minutes and washed in PBS prior to use.  
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3.3.3 Cell cultures 
hnMSCs were isolated as described in [257-259] and expanded as undifferentiated cells in α-
MEM supplemented with 10 % of FBS (v/v) (growing medium). HepG2 cells were cultured in 
α-MEM supplemented with 10 % FBS (v/v), 1 mM of sodium pyruvate and 1 % NEAA (v/v). 
Cryopreserved human primary hepatocytes (hpHep; pool of 10 donors) were purchased from 
Invitrogen™ (Carlsbad, CA, USA; HEP10, A12176), thawed on cryopreserved hepatocyte 
recovery medium (CHRM; CM7000, Invitrogen™) and manipulated according to manufacturer 
instructions. Rat primary hepatocytes (rpHep) were isolated from Wistar rats 3- to 6-month 
old, weighting 200 to 400 g, obtained from Charles River Laboratories (Barcelona, Spain) and 
cultured according to our previous reports [61, 71, 85]. Prior to each experiment, the animals 
were kept in a separate cage for at least 24 hours, with ad libitum access to food and water. 
All applicable institutional and governmental regulations concerning the ethical use of animals 
were followed, according to the European guidelines for the protection of animals used for 
scientific purposes (European Union Directive 2010/63/EU) and the Portuguese Law nº 
113/2013. Briefly, the animals were anesthetized with an intraperitoneal injection of ketamine 
(90 mg/kg body weight) and xylazine (10 mg/kg body weight) solution, for surgery. The liver 
was perfused in situ, via portal vein, for 7 minutes with a Perfusion Buffer I (0.14 M NaCl, 6.7 
mM KCl, and 10 mM HEPES with pH 7.5 adjusted with 2.4 M EGTA) at 39 ºC. Subsequently, 
perfusion was continued with a collagenase (10 mg/100 g body weight) containing buffer (67 
mM NaCl, 6.7 mM KCl, 100 mM HEPES, albumin (0.5 % m/v), and 4.8 mM CaCl2, adjusted to 
pH 7.6) at 39 ºC for 4 min. The flow rate for the perfusion buffers was 10 mL/min. After 
perfusion the liver was removed from the animal and dissociated in cold Perfusion Buffer I 
with 10 g/L of albumin. The resultant cell suspension was filtered through gauze, centrifuged 
for 10 min at 50 x g, washed once with the medium, centrifuged again, and resuspended in 
the cold medium for a final concentration less than 3.5 x 106 cell/mL. For the enrichment of the 
final hepatocyte population, an additional Percoll-step was included. Five milliliters of cell 
suspension was layered over a 25 % Percoll solution and centrifuged at 1300 x g at 4 ºC for 
20 min, and the hepatocytes were obtained as a pellet. The cell pellet was diluted in 
phosphate-buffered saline (PBS), centrifuged for 10 min at 50 x g, and washed twice with PBS 
for removing the Percoll solution. Finally, the cells were harvested in supplemented Williams’E 
medium for culturing. Cell viability was assessed by the trypan blue exclusion test and was, 
routinely, within an 85–95 %. Cells were seeded at a density of 1.6 x 105 cells/cm2 on collagen 
pre-coated 24-well plates. The cells were cultured on Williams’ E cell culture media 
supplemented with 10 % FBS (v/v), 1 mM sodium pyruvate (v/v), 1 % NEAA (v/v), 40 µg/mL 
gentamicin, 100 U/mL penicillin, 100 µg/mL streptomycin, 100 µg/mL amphotericin B, 1.4 µM 
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hydrocortisone and 32 U/mL human insulin. 6h after cell inoculation, medium and non-
adherent cells were removed.  
All cell cultures were maintained at 37 °C in a humidified atmosphere with 5 % CO2 in air. Cell 
viability was assessed through trypan blue exclusion. Cell passage (hnMSC and HepG2) was 
performed every 72h or when cells reached 70-80 % confluence. 
3.3.4 Hepatocyte differentiation of hnMSC 
hnMSCs were seeded in 24-well plates (Nunc™, Wiesbaden, Germany) at a density of 1.5 x 
105 cells/cm2 in rat-tail collagen coated surface. Cells were allowed to proliferate for 24 hours 
in hnMSC growing medium. A three-step differentiation protocol was applied using as basal 
medium (BM) IMDM with 1 % penicillin-streptomycin-fungizone (P/S/A). Briefly, in the first step 
(Step 1), consisting of 48 hours, 4 different combination of growth factors were tested: BM 
supplemented with 2 % FBS, 10 ng/mL of EGF and (i) 10 ng/mL of FGF-2; (ii) 4 ng/mL of FGF-
2; (iii) 4 ng/mL of FGF-2 and 10 ng/mL of FGF-4 or (iv) 10 ng/mL of FGF-2 and 10 ng/mL of 
FGF-4. In the second step (Step 2), cells were maintained for 10 days with BM supplemented 
with 20 ng/mL of HGF, 4 ng/mL of FGF-2, 10 ng/mL of FGF-4, 0.61 g/L of nicotinamide and 1 
% ITS. In the third step (Step 3), at day 13 of differentiation, cells were supplemented with BM 
containing 8 ng/mL of OSM, 1 µM of dexamethasone and 1 % ITS. This culture medium was 
maintained up to day 34 of culture. The medium was renewed every 3-4 days in all protocols. 
DMSO (1 %, v/v), 5-AZA (20 µM) and TSA (500 nM) supplementation was performed and a 
total of 8 protocols evaluated, as summarized in Table 3.1. 
Table 3.1. Summary of the DMSO, TSA and 5-AZA supplementation times in the hepatic differentiation 
protocols. 
Protocol 1 2 3 4 5 6 7 8 
DMSO - D13 D13  D13 D10 D10 D10 
TSA - - D13 D6 D6 - D10 - 
5-AZA§ - - - - - - - D0 
§ 24 hours of exposure time. 
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3.3.5 Gene expression 
3.3.5.1 RNA isolation 
Total RNA was isolated from samples with 0.5-1.0 million of cells using Trizol® (Life 
Technologies) and extraction was performed according to manufacturer instructions.  
For microarray analysis of gene expression, RNA was further purified using a NZY Total RNA 
Isolation kit (NZYTech, Lisbon, Portugal), and quantified by measuring absorbance at 260 nm 
using LVis Plate mode (SPECTROstar Omega, BMG Labtech, Ortengerg, Germany). RNA 
integrity and sample purity were also measured using a 2100 Bioanalyzer (Agilent 
Technologies; Palo Alto, CA), assuring a RIN score higher than 8. Microarray analysis of 
hpHeps and HLC gene expression was performed using Affymetrix Human Genome U133 
Plus 2.0 Gene Arrays at the Bioinformatics and Expression Analysis core facility at Karolinska 
Institutet (Sweden). For quantitative real time-PCR (qRT-PCR), RNA concentration was 
determined as above, prior to cDNA synthesis. 
3.3.5.2 Microarray 
Microarray data from undifferentiated hnMSCs (UCX®) and HepG2 cells, performed using the 
same array platform, were obtained from Gene Expression Omnibus (GSE51869 and 
GSE40117) (PMID: 24438697; PMID: 23393228). Subsequent analysis of differential gene 
expression and Principal Component Analysis (PCA) were performed using AltAnalyze (PMID: 
20513647). Gene expression levels in HLCs, hnMSCs, and HepG2 cells were compared to 
the gene expression levels in hpHeps. Gplots heatmap.2 R package [263] was used to 
generate a gene expression heatmap of the 2000 genes with highest variance across the 
samples. Bioinformatic pathway analysis was conducted using the Ingenuity Pathways 
Analysis (IPA) software for genes with a fold change greater than 2 compared to the 
expression levels in hpHeps (Benjamini-Hochberg-corrected p < 0.05). The network biology-
based computational platform CellNet (PMID: 25126793) was used to assess cell identity 
based on gene expression profiles. Venn diagrams were generated using Venny [264]. 
3.3.5.3 qRT-PCR 
cDNA was synthesized from 1 µg RNA using NZY First-Strand cDNA Synthesis kit (NZYTech) 
according to the manufacturer instructions. Quantitative real time PCR was performed using 
SensiFAST™ SYBR® Hi-ROX kit (Bioline®, Luckenwalde, Germany). Master mix was 
prepared for a final reaction volume of 25 µL, using 1 µL of template cDNA and 0.1 µM of 
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forward and reverse primers. Table 3.2 presents the specific human primers used for 
endoderm markers, progenitor hepatocytes and hepatocytes. The reaction was performed on 
StepOneTM Real-Time PCR System (Applied Biosystems®/ Life Technologies) consisting of a 
denaturation step at 95 °C for 10 minutes, 40 cycles of denaturation at 95 °C for 15 seconds, 
annealing at 60 °C for 1 minute and extension at 72 °C for 30 seconds. A dissociation stage 
was added to determine the melting temperature (Tm) of a single nucleic acid target sequence 
as a quality and specificity measure. The comparative Ct method (2-ΔΔCt) was used to quantify 
the amount of target genes which were normalized to a reference gene GADPH and relative 
to undifferentiated cells, hnMSCs. The efficiency of each reaction was estimated from a 
serially diluted cDNA from a cell type expressing the target gene in order to construct a 
standard curve (1, 10-1 and 10-2) for each gene.  
Table 3.2 Primers used for qRT-PCR characterization of differentiated and undifferentiated hnMSCs, HepG2 
and hpHeps. 
 Primers Melting 
temperature (Tm) 
Reference 
HHEX_F GCTTCAGAACCCATCCATGT 
80.10 [190] 
HHEX_R TTCCCCTCACGAAGAAGTTG  
CK18_F TGGTACTCTCCTCAATCTGCTG 
83.61 
[265] 
CK18_R CTCTGGATTGACTGTGGAAGT  
CK19_F ATGGCCGAGCAGAACCGGAA  
88.58 
CK19_R CCATGAGCCGCTGGTACTCC  
HNF4A_F ATTGACAACCTGTTGCAGGA  
71.83 
[266] 
HNF4A_R CGTTGGTTCCCATATGTTCC  
AFP_F TGCAGCCAAAGTGAAGAGGGAAGA 
80.46 
AFP_R CATAGCGAGCAGCCCAAAGAAGAA  
ALB_F TGCTTGAATGTGCTGATGACAGGG  
81.90 
ALB_R AAGGCAAGTCAGCAGGCATCTCATC 
TAT_F TGCTGAGCAGTCTATCCACT  
84.31 
TAT_R CTGCTCACAGAACTCCTGGAT  
CEBPA_F CAACACTTGTATCTGGCCTCTG 
82.17 
CEBPA_R CGAGCAAAACCAAAACAAAAC  
CYP1A1_F TGGATGAGAACGCCAATGTC  86.42 
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CYP1A1_R TGGGTTGACCCATAGCTTCT  
CYP3A4_F ATTCAGCAAGAAGAACAAGGACA  
81.84 [267] 
CYP3A4_R TGGTGTTCTCAGGCACAGAT  
GAPDH_F GAAGGTGAAGGTCGGAG  
83.63 [170] 
GAPDH_R GAAGATGGTGATGGGATTTC 
3.3.6 Histology 
3.3.6.1 Immunocytochemistry 
Cells cultured on collagen coated glass slides (Nunc™, Lab-Tek™ II Chamber Slide™) were 
fixed with 4 % paraformaldehyde (PFA; Sigma-Aldrich) in PBS with 4 % sucrose for 15 minutes 
and permeabilized with 0.3 % Triton™ X-100 (Sigma-Aldrich) in phosphate buffer saline (PBS) 
for 15 minutes at room temperature (RT). Blocking and incubation with antibodies was 
performed using a solution of 0.2 % fish skin gelatin/ 2 % bovine serum albumin (BSA) in PBS 
for 30 minutes at RT. Incubation with primary antibodies was performed overnight at 4 ºC: 
mouse anti-human CK-18 (Santa Cruz Biotechnology®, Inc, Heidelberg, Germany) diluted at 
1:200; rabbit anti-human CK-19 diluted at 1:50, rabbit anti-human albumin diluted at 1:500; 
rabbit anti-human multidrug resistance protein-2 (MRP-2) diluted at 1:50; mouse anti-human 
organic anion-transporting polypeptide C (OATP-C); mouse anti-human CYP1A2 diluted at 
1:100 (Santa Cruz Biotechnology®, Inc); mouse anti-human HNF-4α (R&D Systems, 
Minneapolis, MI, USA) diluted at 1:500; and rabbit anti-human CYP3A4 (Nosan Corporation, 
Yokohama, Japan) diluted at 1:500. Secondary antibody incubation with donkey anti-mouse 
Alexa Fluor 488 and/or goat anti-rabbit Alexa Fluor 594 (Molecular Probes®/ Life 
Technologies) diluted in 1:500 was performed for 1 hour at RT. ProLong® Gold Antifade 
Mountant with DAPI (Molecular Probes®/ Life Technologies) was used as mounting medium. 
Sample fluorescence was examined in fluorescence Microscope Axio Scope.A1 coupled with 
AxioCam HR (Carl Zeiss, Oberkochen, Germany) and images collected using AxioVision Rel. 
4.7 software. Cryopreserved hpHeps, freshly isolated rpHeps cultured for one day and HepG2 
were used as positive controls while undifferentiated hnMSCs were used as negative control. 
3.3.6.2 Periodic acid Schiff’s (PAS) staining 
Cells cultured in 24-well plates were fixed with 4 % PFA in PBS. The staining was performed 
by incubation with 1 % periodic acid in PBS for 10 minutes, Schiff’s reagent for 15 minutes 
and Mayer’s hematoxylin counterstaining for 30 seconds. The preparations were washed with 
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H2O between each step. Inner control consisted of differentiated HLCs and primary 
hepatocytes treated with 1 g/L of amylase in CaCl2 at 30 mM, for 15 minutes at 37 °C after 
fixation, in order to digest the existent glycogen and assure that the pink stain corresponds to 
glycogen. Positive and negative controls consisted of cryopreserved hpHeps, freshly isolated 
rpHeps, cultured for 2 days, and HepG2 cells, and undifferentiated hnMSCs when at 70 % 
confluence, respectively. Staining was visualized in an inverted microscope (Olympus, Tokyo, 
Japan) and data images were recorded using Moticam 2500 and collected using Motic Images 
Plus V2.0 software (Motic, Xiamen, China). 
3.3.7 Albumin and urea production 
Albumin and urea quantification were determined on cell culture supernatant using an albumin 
ELISA kit (Bethyl Laboratories, Montgomery, TX, USA) and a quantitative colorimetric urea kit 
(QuantiChrom™ Urea Assay Kit, BioAssay Systems, Hayward, CA, USA), respectively. Both 
procedures were performed according to the manufacturer instructions. Data acquisition was 
done using a microplate reader (SPECTROstar Omega, BMG Labtech). The data refers to the 
production rate and is expressed as pg/106 cells.h and µg/106 cells.h, respectively. 
3.3.8 Biotransformation activity 
3.3.8.1 Phase I enzyme metabolism 
CYP enzyme activity was measured by means of 7-ethoxyresorufin-O-deethylase (EROD) 
activity, 7-ethoxycoumarin-O-deethylase (ECOD) activity and P450-GloTM assays (Promega, 
Madison, WI, USA). EROD assay mainly reflects the activity of the human isozymes CYP1A2 
and CYP1A1 [268]. The procedure consisted of cell incubation with 8 mM of 7-ethoxyresorufin 
in non-supplemented BM for 90 minutes. The product concentration, 7-hydroxyresorufin, was 
measured in supernatants after 2 hours of enzymatic digestion with β-
glucuronidase/arylsulfatase. The quantification was calculated using a calibration curve of 
resorufin in culture medium. Fluorescence was measured (Ex: 530 nm/ Em: 590 nm). ECOD 
assay measures human CYP2B6, CYP1A2 and CYP2E1 activities [61, 268]. The procedure 
consists of 90 minutes incubation with 7-ethoxycoumarin at 0.8 mM in non supplemented BM. 
7-hydroxycoumarin concentration was determined after the same digestion procedure as used 
for EROD assay, followed by a liquid-liquid extraction step with chloroform and back-extraction 
of the organic phase with a solution of 5.84 % of NaCl in 0.1 M of NaOH. Fluorescence was 
measured (Ex: 340 nm/ Em: 460 nm). Induction of ECOD and EROD activities was performed 
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by 48 hour incubation with 2.5 μM of 3-MC or 100 μM of omeprazole. CYP3A4, CYP2C9 and 
CYP1A1 activities were assessed using the luminescent P450-Glo™ assay with the 
respective substrates Luciferin-PPXE, Luciferin-H and Luciferin-CEE. Each assay was 
performed with a final volume of 60 μL and luminescent intensity measured according to 
manufacturer instructions. Induction was performed by 48 hour incubation with 2.5 μM of 3-
MC for CYP1A1 or 25 μM of rifampicin for CYP2C9 and CYP3A4. Luminescence and 
fluorescence measurements were done using a microplate reader (SPECTROstar Omega, 
BMG Labtech). The data is expressed as pmol/106 cells.h, except for CYP3A4 activity that is 
expressed as nmol/106 cells.h. 
3.3.8.2 Phase II metabolism 
Uridine 5’-diphosphate glucuronosyltransferases’ (UGTs) activity was determined by 
quantification of the substrate 4-MU before and after cell incubation. The procedure was 
performed according to Miranda et al. [61] with slight modifications. Briefly, a 100 μM of 4-MU 
in HBSS was incubated with cells for 1 hour. The supernatants were freshly transferred into a 
black 96-well plate, 4 μL of NaOH at 0.1 M added per well in order to achieve pH = 11 and 
fluorescence was measured (Ex: 340 nm/ Em: 460 nm). UGTs activity was measured at day 
1 on the cells used as negative (hnMSCs) and positive (HepG2, hpHeps and rpHeps) controls. 
The data is expressed as nmol/106 cells.h. 
3.3.9 Protein quantification 
For protein quantification, cells were lysed with 0.1 M of NaOH and incubated overnight at 37 
ºC. Protein concentration was determined using the bicinchoninic acid (BCA) protein assay kit 
(Novagen, Madison, WI, USA) according to manufacturer instructions and also measured by 
absorbance at 280 nm using LVis Plate mode (SPECTROstar Omega, BMG Labtech). A linear 
calibration curve to relate total protein with cell number was generated to estimate cell number, 
from each cell type and for both methods of quantification.  
3.3.10 Statistical analysis 
The results are given as the mean ± SEM. Statistical data analysis was performed using 
GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). The effects on 
metabolic activity were evaluated by two-way ANOVA with Holm-Sidak method in order to 
determine whether the metabolic activity of each compound was significantly altered by the 
protocol, the induction of specific CYP450 enzyme inducers, over the time of culture, and to 
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evaluate differences between groups and controls. In all cases, p < 0.05 was considered 
statistically significant. 
3.4 Results 
3.4.1 The endoderm marker HHEX is expressed in hnMSC and induced by FGF-2 
The three-step protocol developed for hepatocyte differentiation was optimized based on 
previously described methodologies [168, 172, 269] and considering the liver development 
stages: commitment, differentiation and maturation. Since hnMSCs are of mesodermal origin, 
particular attention was given to the endoderm commitment by testing the effect of FGF-2 at 
4 ng/mL and 10 ng/mL, in the presence or absence of FGF-4 on HHEX gene expression 
(Figure 3.1). 
 
Figure 3.1 Gene expression of HHEX on hnMSCs after exposure to different FGF cocktails in the 
differentiation Step 1 (D3). qRT-PCR shows HHEX higher expression with 4 ng/mL of FGF-2 when compared to 
10 ng/mL of FGF-2, or 4 ng/mL of FGF-2 and 10 ng/mL of FGF-4, or 10 ng/mL of FGF-2 and 10 ng/mL of FGF-4 
(black bars). Positive controls (white bars) are cryopreserved hpHeps and HepG2 cell line. Data is normalized to 
the reference gene GAPDH and expressed in Log10 relative to hnMSCs (n = 3). 
HHEX is an endoderm marker essential in liver development [270]. A basal expression of the 
HHEX gene was detected on hnMSCs. The addition of FGF-2 at 4 ng/mL produced a 200-fold 
increase in HHEX expression, whereas it only produced an 85-fold increase when cells were 
exposed to a combination of FGF-2 at 4 ng/mL and FGF-4 (10 ng/mL). Moreover, HHEX gene 
expression in the presence of FGF-2 (10 ng/mL) resulted in an 8- and 17-fold increase in the 
absence or presence of FGF-4, respectively. Thus, FGF-2 only was added to Step 1 of all 
differentiation protocols to a final concentration of 4 ng/mL. 
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3.4.2 Epigenetic modifiers improve hepatocyte phenotype on HLC 
The epigenetic modifiers (EM) tested in this work consist of small molecules that have been 
previously described and applied as promoters of hepatic differentiation, namely TSA, DMSO 
and 5-AZA. Previously, we have evaluated TSA at concentrations ranging from 100 nM to 
1000 nM being 500 nM the best tested condition (data not shown), and therefore the 
concentration used in this work. As for DMSO and 5-AZA, 1 % and 20 μM, respectively, were 
adopted according to literature [54, 213]. Furthermore, DMSO was tested alone, from days 10 
and 13 onwards, or in combination with TSA or 5-AZA in a total of 8 different differentiation 
protocols (Table 3.1). During the differentiation protocol, cells in culture were maintained 
confluent and in serum-free conditions in order to prompt differentiation rather than 
proliferation. The fibroblastic morphology of hnMSC was kept during the first two steps of the 
differentiation protocol except for protocols 4 and 5, where TSA was added at day 6. This 
resulted in cell detachment (Figure 3.2) and therefore protocols 4 and 5 were not further 
pursued. From day 13 onwards, after the addition of OSM and dexamethasone, cell 
morphology started to change to a more epithelial-like shape with granular cytoplasm in all 
other protocols, i.e., protocols 1-3 and 6-8 (Figure 3.2). At day 24, an epithelial polygonal 
hepatocyte-like morphology, with some binucleated cells, and glycogen storage ability were 
observed in HLCs obtained with protocols 1, 2, 6 and 8, where TSA was absent and DMSO 
was present (Figure 3.2). Accordingly, ALB and CK-18 were detected by 
immunocytochemistry. Overexpression of HHEX (data not shown), CK18, TAT, CEBPA, 
HNF4A and CYP3A4 was observed at day 24 in all protocols (Figure 3.3). CK19, a biliary cell 
marker, showed low expression in all protocols. ALB and AFP overexpression was observed 
on protocols 1, 6 and 8 (Figure 3.3). In parallel, the HLC enzymatic competence, namely 
phase I and II activities were analysed (Figure 3.4a). Similar EROD activity was obtained with 
all protocols. However, the protocols including DMSO at day 10 (protocols 6-8) presented 
significant induction of EROD activity (p < 0.01) whereas protocols with TSA only revealed 
induction when concomitantly added with DMSO (protocols 3 and 7; p < 0.05). In particular, 
protocol 6 resulted in higher CYP3A4 activity when compared to the positive controls (p < 
0.05). CYP3A4 induction was also observed with this protocol (p < 0.05). Regarding phase II 
enzymatic activity, an increased UGTs activity was observed in differentiation protocols where 
DMSO was added at day 10 (protocols 6, 7 and 8) when compared to its supplementation at 
day 13 (protocols 2 and 3), independently of TSA presence (p < 0.001; Figure 3.4a). A positive 
effect of 5-AZA (protocol 8) was also observed with improved UGTs activity (p < 0.01) when 
compared to the protocol where it was absent (protocol 6), as previously observed by Seeliger 
et al. [213]. Finally, the protocols without TSA, but supplemented with DMSO at day 10 
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(protocols 6 and 8) presented higher urea production (Figure 3.4b), especially protocol 6 (p < 
0.05) where the achieved urea production was comparable to HepG2. All protocols also 
presented a significant increase in albumin production ability when compared to the negative 
control (Figure 3.4c).  
 
Figure 3.2 Comparative characterization of hnMSC-derived HLC obtained with the differentiation protocols 
1-8 (D24). Phase contrast, PAS staining and immunocytochemical representative images reveal an epithelial 
morphology, glycogen storage ability and the presence of CK-18 and ALB, respectively, in HLCs from protocols 1-
3, 6 and 8. In immunocytochemical analysis, cell nuclei were counterstained with DAPI. Scale bar = 50 μm.  
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Figure 3.3 Gene expression analyses of HLC-derived from hnMSCs upon exposure to protocols 1-3 and 6-
8 (D24). qRT-PCR shows over expression of the hepatic markers ALB, AFP, CK18, HNF4A, CYP3A4, TAT and 
CEBPA and underexpression of the biliary marker CK19 (grey bars and black bar for protocol 6). Positive controls 
(white bars) are HepG2 cell line and cryopreserved hpHeps. Data is normalized to the reference gene GAPDH and 
expressed in Log10 relative to hnMSCs (n= 3). 
Overall, TSA supplementation resulted in a more heterogeneous cell phenotype considering 
morphology and expression of hepatocyte-specific proteins (protocols 3 and 7); whereas 
DMSO supplementation resulted in HLCs expressing hepatocyte markers, epithelial cell 
morphology, homogeneous glycogen storage and improved HLC biotransformation activity 
(protocols 2, 6 and 8). The later was more evident when DMSO was added at day 10 (protocol 
6) rather than at day 13 (protocol 2).  
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Figure 3.4 Functional capacity of HLC-derived from hnMSCs upon exposure to protocols 1-3 and 6-8 (D24). 
(a) Phase I (EROD and CYP3A4 activities) and phase II (UGTs activity) enzymatic activities. Induction studies 
(striped bars) were performed for 48 hours with 25μM of rifampicin (CYP3A4) or 2.5 μM of 3-MC (EROD). rpHeps 
and hpHeps were cultured for 72 hours and 24 hours for phase I and phase II assays, respectively; (b) Urea 
secretion; and (c) Albumin production. Grey bars correspond to HLCs differentiated using protocols 1-3 and 7-8 
and black bars to protocol 6. Controls (white bars) are hnMSCs (negative control) and HepG2 cell line, rpHeps and 
hpHeps (positive controls). Data is represented as mean ± SEM (n = 4-6). *, **, *** Significantly differs among the 
controls with p < 0.05, p < 0.01 and p < 0.001, respectively. $, $$, $$$ Significantly differs from protocol 6 with p < 
0.05, p < 0.01 and p < 0.001, respectively. #, ## Significantly induced activity with p < 0.05 and p < 0.01, respectively. 
3.4.3 hnMSC-derived HLC present a partial hepatic differentiation at the 
transcriptional and functional levels at day 34 
The need for a competent alternative model for drug metabolism studies encouraged us to 
examine the stability of hepatic phenotype in culture. Overall, protocol 6 provided the best 
condition where HLCs showed results that are comparable to the positive controls. Thus, 
hnMSC-derived HLCs were kept in culture until day 34, revealing an epithelial morphology 
and the presence of binucleated cells and maintaining confluence throughout the cell culture 
period (Figure 3.5). Differentiation efficiency and phenotype maintenance was further 
evaluated at the transcriptional and functional levels. PAS straining demonstrated glycogen 
storage ability of HLCs up to day 34 in culture (Figure 3.5). Albumin and urea secretion was 
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also stable during the full culture period, showing levels higher than hnMSCs (p < 0.05; Figure 
3.6).  
 
Figure 3.5 hnMSCs-HLC morphology and glycogen storage ability upon sequential exposure to liver-
specific factors and DMSO supplementation from day 10 onwards. (a) Cell morphology of hnMSCs during the 
differentiation process at days 4, 13, 17, 24, 27 and 34 and of undifferentiated hnMSCs (negative control), HepG2 
cell line and rpHeps (positive controls); (b) PAS staining of HLCs at days 27 and 34 of undifferentiated hnMSCs 
(negative control) and rpHeps (positive controls). HLCs and rpHeps stained after digestion with amylase in order 
to access the specificity of the observed staining are also presented. Controls are hnMSCs (negative control) and 
rpHeps (positive controls). Representative images were acquired with phase-contrast microscopy. Scale bar = 50 
μm. 
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Figure 3.6 Effect of culture time on albumin and urea production in HLC-derived from hnMSCs up to day 
34 in culture upon sequential exposure to liver-specific factors and DMSO supplementation from day 10 
onwards (black bars). Undifferentiated hnMSCs and HepG2 cell line, rpHeps and hpHeps are negative and 
positive controls, respectively (white bars). Data is represented as mean ± SEM (n = 4-6). *, **, *** Significantly 
differs among the controls with p < 0.05, p < 0.01 and p < 0.001, respectively.  
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Figure 3.7 Genome wide analyses of HLC-derived from hnMSCs at day 34 of differentiation. (a) Volcano plot 
of differently expressed genes in HLC vs hpHep (fold change > 2, p < 0.05); (b) Heatmap representation of the 
2000 genes with highest variance across samples in hpHeps, HLCs, hnMSCs and HepG2; (c) Principal component 
analysis (PCA) of gene expression profiles in hpHeps, HLCs, hnMSCs and HepG2; (d) Expression profile-based 
prediction of biological function activation performed with IPA for HLCs, hnMSCs, and HepG2 cells compared to 
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hpHeps. Positive Z-scores indicate activation whereas negative z-scores indicate repression; (e) Relative 
expression levels of genes involved in drug metabolism comprehending phase I, II and drug transporters in HepG2, 
hpHeps, HLCs and hnMSCs, compared to hpHeps. 
 
Figure 3.8 Genome wide analyses of HLC-derived from hnMSCs at day 34 of differentiation. (a) Venn 
diagram representing the number of differentially expressed genes in HLCs, hnMSCs and HepG2 compared to 
hpHeps (fold change > 2, p < 0.05). The diagram shows how many differentially expressed genes are common or 
unique to the various cell types analysed. (b-c) CellNet analysis of cell identity depicting the gene regulatory 
network (GRN) score (b) and network influence score for liver (c). The GNR score indicates to which level specific 
tissue/cell GRN are established. The network influence score indicates how the expression of each transcriptional 
regulator within a GRN compares to the expression levels in the target tissue/cell (in this case liver). Orange 
indicates higher expression and blue indicates lower expression. (d) IPA analysis of canonical pathways associated 
with differentially expressed genes in HLCs, hnMSCs and HepG2, compared to hpHeps. 
To compare gene expression signatures between our HLCs (D34) and hpHeps, an unbiased 
whole genome analysis was performed. To get a better understanding on how hnMSC-derived 
HLCs compared to other cells we then compared our data with previously published gene 
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array data from undifferentiated hnMSCs and HepG2 cell line available at Gene Expression 
Omnibus. Interestingly, global gene expression analysis (Figure 3.7a), comparing 
differentially expressed genes in HLCs and hpHeps, estimated that ~70 % of transcripts 
remain the same between HLCs and hpHeps (n = 17152), using a combined criterion of p < 
0.05 and fold change > 2. The heatmap representation and unsupervised clustering of the 
2000 genes with highest variance (Figure 3.7b) showed that in some clusters the 
differentiation protocol approximates the HLC’s gene expression profile to that of hpHeps, 
when compared to the undifferentiated hnMSCs. It also revealed similar gene expression 
clustering between HLCs and hpHeps, which was not observed between HepG2 and hpHeps. 
In HLCs, the expression of some genes involved in drug transport, amino acid metabolism 
and proliferation of hepatocytes was comparable to hpHeps, whereas others involved in 
xenobiotic metabolism remained poorly expressed (Figure 3.7b and 3.7d). Accordingly, a 
PCA plot (Figure 3.7c) evidenced a partial gain of mature hepatic features of the HLCs 
revealing that HLCs did not reach the hpHep global gene expression profile, but are closer 
than the HepG2 cell line and distant from hnMSCs. In fact, a Venn diagram representing the 
number of differentially expressed genes in HLCs, hnMSCs and HepG2 compared to hpHeps 
(fold change > 2, p < 0.05) shows that HLCs have less differentially expressed genes than 
hnMSC or HepG2, when these cells are compared to hpHeps (Figure 3.8a). Additionally, 
CellNet analysis for assessing cell type identity, plotted as GRN (gene regulatory networks; 
Figure 3.8b) and network influence scores (Figure 3.8c), demonstrated that HLCs consist of 
a mixed cell type with both “fibroblast” and “ovary” features. CellNet is a platform that estimates 
how closely cell populations resemble their target cell/tissue type [271]. The rational is that by 
measuring the establishment of cell- and tissue- (C/T) specific GRNs in a cell population would 
serve both as a robust metric of cellular identity and a tool to identify aberrant regulatory 
nodes. Thus, as expected, undifferentiated hnMSCs and liver cells (hpHeps and HepG2) had 
a maximum GRN status score for “fibroblast” and “liver”, respectively. Moreover, from the total 
of 16 cell/tissue types listed, no significant changes in GRN scores were observed between 
HLCs and hpHeps for “esc”, “neuron”, “skin”, “hspc”, “macrophage”, “bcell”, “tcell”, “heart”, “sk. 
muscle” and “lung”.  Regarding the “fibroblast” GRN status, the HLCs showed a decrease 
relative to the hnMSCs revealing some degree of differentiation, but still some features of 
MSCs from where they were derived. The network influence profile, on the other hand, was 
similar in HLCs and hnMSCs, whereas hpHeps presented high influence on transcription 
factors such as NR1H4 (FXR), NR1/3 (CAR), NR1/2 (PXR), HNF4A (Figure 3.8c). The GRN 
score is based on the expression levels of a limited number of transcriptional regulators 
(Figure 3.8c). Therefore, to get a better assessment of the activation status of biological 
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pathways and functions in HLCs, we performed a bioinformatics pathway analysis herein 
plotted within three categories: metabolism, cell death and survival, and cell growth, 
proliferation and cancer in all groups relative to hpHeps (Figure 3.7d). All groups (HLC, 
HepG2 and hnMSC) presented a negative z-score indicating repression of the expression 
profile for drug transport, xenobiotic metabolism, and amino acid metabolism though HLCs 
presented a higher activation than hnMSCs and HepG2 cell line for the later two 
subcategories. In contrast to HepG2 or hnMSCs, cell death and survival and cell growth, 
proliferation and cancer categories presented the same activation in HLCs as in hpHeps 
(Figure 3.7d), suggesting that HLCs are closer to hpHeps regarding these particular bio-
functions. Most importantly, Figure 3.7d further indicates that, unlike HepG2, HLCs display a 
less “cancer cell”-like profile as shown by normalized gene expression signatures associated 
with cell death, apoptosis, proliferation of hepatoma cell lines, proliferation of tumor cells, 
colony formation and liver cancer. Finally, canonical pathways representation from the IPA 
analysis showed an approximation of HLCs to hpHeps in glucose and lipid metabolism and in 
signalling pathways such as PI3K/AKT, PKA, oncostatin M and Wnt/β-catenin (Figure 3.8d); 
and major differences in the PXR/RXR and FXR/RXR activation pathways followed by 
xenobiotic metabolism signalling and glutathione-mediated detoxification. 
In order to have a deeper insight on gene expression profile, genes were also grouped 
considering genes coding for key enzymes in phase I, II and II of drug metabolism (Figure 
3.7e). High expression of the phase I enzymes CYP1B1, CYP3A7 and MAO was observed in 
HLCs but not in the other groups relative to hpHeps. Moreover, there was a higher expression 
of CYP3A5 and CYP3A7 relative to HepG2 and hnMSCs; whereas the expression of relevant 
CYPs such as CYP2D6, CYP2C9 and CYP3A4 was similar in HLCs, HepG2 and hnMSCs, 
being considerably lower than hpHeps. Remarkably, some aldehyde dehydrogenase 
isoforms, namely from ALDH1, ALDH3, ALDH7, ALDH9, ALDH18 subfamilies, were induced 
in HLCs to levels comparable to hpHeps. Phase II metabolism analysis showed a high 
expression of GST family genes and a low expression of UGT transcripts. In the “drug 
transporters” group, similar expression of some transcripts was observed in both ABC and 
SLC transporters, namely ABCA, ABCC, SLC5, SLC7, SLC28, SLC29 and SLCO subfamilies.  
To support global transcriptomic characterization, further gene and protein expression of 
selected mature hepatocyte markers was evaluated by qRT-PCR and immunofluorescence. 
Confirming qRT-PCR gene expression data (Figure 3.9), and despite low expression relative 
to hpHeps (Figure 3.7e), the hepatic transporters OATP-C and MRP-2 and the 
biotransformation enzymes CYP1A2 and CYP3A4 were detected by immunofluorescence, 
along with the presence of CK-18, ALB and HNF-4α and the absence of CK-19 (Figure 3.10). 
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In fact, the transcription factors HNF4A and CEBPA, the biotransformation enzymes CYP1A1 
and CYP3A4, the genes encoding for ALB, AFP and the enzyme involved on amino acid 
metabolism TAT, all presented increased expression from day 24 up to day 34, being TAT, 
CK18 and CYP3A4 higher than HepG2 (Figure 3.9), suggesting some level of maturation. 
The observed CK18 expression level is comparable with hpHeps and higher than HepG2 cell 
line. CK19 was under expressed as expected.  
 
Figure 3.9 Gene expression analyses during hnMSC differentiation into HLCs upon sequential exposure to 
liver-specific factors and DMSO supplementation from day 10 onwards. qRT-PCR shows increased gene 
expression over time of the hepatic markers ALB, AFP, CK18, HNF4A, CYP3A4, TAT and CEBPA and decreased 
expression of the biliary marker CK19 in HLCs (black bars).  Positive controls (white bars) are HepG2 cell line and 
cryopreserved hpHeps. Data is normalized to the reference gene GAPDH and expressed in Log10 relative to 
hnMSCs (n = 3). 
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Figure 3.10 Immunocytochemical analysis of HLC-derived from hnMSCs upon sequential exposure to liver-
specific factors and DMSO supplementation from day 10 onwards (D27). Representative images show the 
presence of the hepatic markers ALB, CK-18, HNF-4α, MRP-2, OATP-C, CYP1A2, CYP3A4 and the absence of 
the biliary marker CK-19. hnMSCs and HepG2 cell line were used as negative and positive controls, respectively. 
Cell nuclei are stained with DAPI. Scale bar = 50 μm. 
The functional characterization of HLCs further supported the gain of hepatic features, namely 
by examining the effect of culture time on CYP and UGTs activities (Figure 3.11). ECOD and 
CYP1A1 activities were maintained with time in culture. Conversely, EROD, CYP2C9 and 
CYP3A4 activities and induction abilities were greatly improved by day 34, reaching levels 
higher than HepG2 for CYP3A4 and CYP2C9. At day 34, CYP3A4, CYP1A1 and EROD 
activities are also enhanced when compared to rpHeps. A 2.5-fold and ~3-fold activity increase 
was even observed for CYP3A4 when compared to hpHep basal and induced activities, 
respectively. Accordingly, UGTs activity was maintained during 13 days counting from the last 
day of the differentiation protocol, revealing a 2.2-fold and 2.7-fold increase in UGTs activity 
by day 27, when compared to HepG2 (p < 0.01) and rpHeps (p < 0.001), respectively.  
In summary, the differentiation process herein developed evidenced a partial hepatic 
differentiation of the HLCs with relevant improvements regarding the HepG2 cell line. 
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Figure 3.11 Effect of culture time on phase I and phase II activities in HLC-derived from hnMSCs up to day 
34 in culture upon sequential exposure to liver-specific factors and DMSO supplementation from day 10 
onwards. Phase I and phase II activity was assessed by measuring EROD, ECOD, CYP1A1, CYP2C9 and 
CYP3A4 and UGTs activities, respectively, at days 21, 27 and 34 (black bars). Induction assays (stripped bars) 
were performed with 48 hour incubation with 2.5 µM of 3-MC (CYP1A1 activity), 100 µM of omeprazole (ECOD 
and EROD activities) and 25 µM of rifampicin (CYP3A4 and CYP2C9 activities). Controls (white bars) are hnMSCs 
(negative control) and HepG2 cell line, hpHeps and rpHeps (positive controls). rpHeps and hpHeps were cultured 
for 72 hours and 24 hours for phase I and phase II assays, respectively. Data is represented as mean ± SEM (n = 
3). *, **, *** Significantly differs among the controls with p < 0.05, p < 0.01 and p < 0.001, respectively.  #, ##, ### 
Significantly induced activity with p < 0.05, p < 0.01 and p < 0.001, respectively.  
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3.5 Discussion 
Hepatotoxicity studies are usually limited in duration, and results may not provide a complete 
understanding of drug’s cumulative and long-term in vivo effects. The inability to culture, 
characterize and challenge cells over longer periods of time is a relevant drawback of primary 
hepatocyte cell culture. Maintaining metabolic competence for longer periods of time is thus 
of foremost importance to investigate enzyme induction and inhibition, drug metabolism and 
drug chronic toxicity and it is the main reason why alternative in vitro models have not yet 
been fully achieved [17]. The differentiation of stem cells, MSCs in particular, into HLCs has 
been attempted to provide qualified model systems to study hepatic drug metabolism in vitro 
[168, 171, 172, 174, 179]. Many reports have shown distinct hepatic differentiation abilities 
among different MSCs. Although the differentiation efficiency has been greatly improved by 
modifying the culture conditions, the obtained HLCs are still insufficient for either toxicological 
or clinical applications [168]. In this work, we have demonstrated that a specific population of 
human neonatal MSCs isolated from the umbilical cord tissue, UCX®, [154, 258] is actually a 
promising cell source for deriving functional HLCs. The use of epigenetic modifiers on hepatic 
differentiation, especially DMSO, enabled the achievement of highly efficient hnMSC-derived 
HLCs, and most importantly, metabolic competence could be enhanced up to day 34 in 
culture. Whole genome analysis further confirmed the gain of hepatic features of HLCs and 
improvement regarding HepG2 cell line.  
We firstly investigated the in vitro endoderm commitment potential of hnMSCs. Different MSCs 
have been reported to present important differences in their transcriptomes depending on their 
tissue source. De Kock et al. [160] suggested that WJ-MSCs presented a more favourable 
transcriptome regarding hepatocyte differentiation when compared to other types of stem 
cells, namely AD-MSCs, BM-MSCs and human skin-derived precursor cells. In fact, hnMSC-
UCM have been described as expressing early liver specific markers, endoderm genes such 
as GATA4 [151], GATA5, GATA6, SOX9 and SOX17 and liver progenitor markers as DKK1, 
DPP4, DSG2, CX43 and CK19 [150, 160]. GATA4 has been reported to be a transactivator of 
HHEX expression [272] required for definitive endoderm tissues for normal liver development. 
Conversely, GATA6 gene deletion impairs HHEX up-regulation needed for liver bud formation 
and a normal hepatic developmental program, showing that GATA6 is essential for the earliest 
stages of hepatic development [273]. In liver development, the FGF family of cytokines is 
secreted by cardiogenic mesoderm and is required for the hepatic commitment of endoderm. 
Kang et al. [274], using mouse embryos, showed that FGF-4 is important for cell distribution 
in primitive endoderm but not for its formation, being later required for lineage restriction. On 
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the other hand, FGF-2 is a powerful inducer of foregut-derived cell lineages [275]. FGF-2 
concentration determines cell differentiation fate as Ameri et al. [190] observed in studies of 
embryo development, showing that low concentrations of FGF-2 (4 ng/mL) triggers hepatic 
fate, whereas higher concentrations promote pancreatic and pulmonary differentiation. Thus, 
the effect of FGF-2 at 4 ng/mL and 10 ng/mL, alone or in combination with FGF-4, on 
endoderm commitment/foregut induction was evaluated by means of HHEX gene expression. 
Our data showed a basal HHEX expression in undifferentiated hnMSCs that was further 
induced by FGF-2 in a concentration-specific manner, reinforcing the differentiation potential 
of these cells into endoderm-derived lineages. The observed up-regulation of HHEX gene 
expression by FGF-2 at 4 ng/mL on differentiating cells is in accordance with Zhang et al. 
[275] that showed that 5 ng/mL of FGF-2 increased HHEX expression. Ameri et al. [190] also 
showed that higher concentrations of FGF-2 would reduce HHEX expression and inhibit 
further ALB expression, determining 4 ng/mL as the optimal concentration to direct hepatic 
cell fate. On the other hand, FGF-4 was reported to down regulate HHEX expression [276], 
which is also in agreement with our findings. The importance of HHEX for hepatic lineage 
commitment was also shown in vitro by differentiating human ESCs [270]. 
In this work, the differentiation strategy adopted consisted in a three-step sequential induction 
of hnMSC differentiation rather than through cell exposure to a cocktail. As previously 
reported, a sequential differentiation procedure better mimics the in vivo liver development 
[269]. In spite of the advantages of hnMSCs, few studies on hepatic differentiation are 
available on this cell type [172, 174, 179]. As aforementioned, one example is the report by 
Campard et al. [172], where the potential of hnMSC-UCM to derive HLCs was evaluated 
although not reaching a mature phenotype. Later, Zhang et al. [174] and Zhou et al. [177] 
published the differentiation of hnMSC-UCM into HLCs, using two-step protocols but the 
achieved phenotype is less mature than that reported by Campard et al. [172]. Therefore, the 
later procedure was applied to hnMSCs as our starting point (protocol 1) for the differentiation 
protocols developed herein.  
The effect of the epigenetic modifiers TSA, 5-AZA or DMSO, with different exposure times, 
was tested in hepatic differentiation or maturation. DMSO is routinely used for HepaRG cell 
line maturation [54] and more recently for progenitor cells [217] and SC differentiation [183, 
221-223]. HepaRG cell line is an important reference in cell-based assays due to its relevant 
phase I, phase II and phase III activities that are not usually observed on other cell lines such 
as HepG2 [277]. Herein, DMSO was used at 1 % as reported in literature for the maturation 
of foetal hepatocytes [217] and was tested alone, from days 10 and 13 onwards, and in 
combination with TSA or 5-AZA. TSA is an HDAC-I that presented promising differentiation-
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inducing properties in human and rodent primary cultures of adult hepatocytes, hepatoma cell 
lines and that was also tested for hepatocyte differentiation of BM-MSCs [168]. In contrast, to 
our knowledge, 5-AZA effect on hepatocyte differentiation protocols in vitro has only been 
attempted on AD-MSCs by Seeliger et al. [213], and on umbilical blood-derived MSCs by 
Yoshida et al. [214], being applied 24 hours prior to the differentiation induction since 
proliferation is needed for the incorporation 5-AZA on cellular DNA.  
Our findings indicate that a sequential differentiation protocol gradually induced cellular 
modifications from spindle fibroblast-like to hexagonal epithelial-like shaped binucleated cells 
with glycogen storage ability. These morphological changes were particularly evident upon 
DMSO treatment without TSA co-treatment. Accordingly, by the end of Step 3, HLCs exposed 
to DMSO from day 10 onwards also had increased expression of the liver-specific markers 
CK18, ALB, CEBPA, TAT, HHEX, AFP, HNF4A, CYP1A1 and CYP3A4. The mechanisms 
through which DMSO induces hepatic differentiation are still poorly understood. However, 
studies by Cheety et al. [225] showed an activation of the retinoblastoma protein in DMSO-
induced cells. Furthermore, a high proportion of cells in early G1 phase was also observed. 
G1 is of high importance for cell differentiation and a prolonged G1 phase has been reported 
as an indication of a differentiated status by reflecting loss of pluripotency and gain of lineage 
specific markers [226]. Thus, DMSO treatment increases the responsiveness of SC 
differentiation signals, enhancing differentiation across all germ layers, and improving terminal 
differentiation into functional derivatives [225]. DMSO has also been associated to hypo- and 
hipper-phosphorylation of several cellular proteins [227, 228] and on phosphatidylinositol 
signalling [229]. Finally, DMSO at 2 % (v/v) on rpHeps resulted on more relevant CYP enzyme 
activity by restoring HNF-4α and CEBPA levels that rapidly decreased in culture without 
DMSO [232] corroborating the observed gene expression data that showed increased 
expression of these factors up to day 34 in culture.  
Nevertheless, the presence and expression of hepatic markers by SC-derived hepatocytes 
does not make them mature hepatocytes [278]. Moreover, besides obtaining a mature HLC 
population, a major aim of this study was to obtain functional HLCs that do not dedifferentiate 
with time in culture. Therefore, we further tested the functional capacity of the HLCs cultured 
up to day 34. During this period, the HLCs kept on exhibiting a hepatocyte phenotype by 
possessing liver-specific markers at the mRNA and protein levels. Additionally, functional 
aspects such as albumin secretion, ammonia detoxification, glycogen storage, inducible CYP 
activity and phase II activity were also validated against undifferentiated hnMSCs. The 
increase in CK18, CEBPA, HNF4A, TAT, AFP and ALB expression indicate that cells 
developed into more mature hepatocytes with time in culture.  
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Biotransformation capacity was also of particular interest in these extended cultures being the 
use of hepatocyte cultures hampered mostly by the rapid loss of CYP enzyme expression and 
activity in vitro. Therefore, regarding phase I metabolism, CYP3A4, CYP2C9 and CYP1A1 
were evaluated due to their relevance in drug metabolism [50]. EROD and ECOD activities 
were also investigated covering CYP1A1/2 and CYP2B6/1A2/2E1, respectively. HLCs 
showed CYP activity, which was either maintained or increased with time, and responded to 
rifampicin and omeprazole/3-MC induction in CYP3A4/CYP2C9 and ECOD/EROD/CYP1A1, 
respectively. Not only CYP3A4 and CYP1A1 were overexpressed in HLCs (qRT-PCR 
analysis), but also they could convert substrates more efficiently than rpHeps, as shown by 
the P450-GloTM and EROD activity assays. In addition, the P450-GloTM substrate (PPXE) for 
CYP3A4 activity may also detect some activity of other CYP3A enzymes such as CYP3A5 
and CYP3A7, being the later overexpressed in our transcriptomic analysis. CYP3A7 is present 
in liver, though it is more expressed in fetal liver, which may indicate that HLCs are following 
the liver fate despite presenting a less mature phenotype. Moreover, evidence supporting the 
shift between CYP3A7 and CYP3A4 immediately after birth has been reported [279]. This shift 
is apparently triggered by HNF-4α [279], herein detected by qRT-PCR at the mRNA 
expression and protein levels, although at a much lower extent than in hpHeps and showing 
a network influence negative score. Most importantly, although transcriptomic analysis points 
out to CYP3A4 and CYP2C9 underexpression on HLCs, their enzimatic activities reached 
higher levels than positive controls (D34), hence with positive implications for the use of these 
HLCs as an in vitro model for drug development. To note that primary hepatocytes, used as 
controls in functional assays, were obtained under their optimal culture conditions, i.e., up to 
day 3 of culture, otherwise cell dedifferentiation would have been observed; and consisted of 
a pool of 10 donors to avoid inter-individual differences. Moreover, since cultivation of primary 
hepatocytes is known to induce cells dedifferentiation the whole genome analyses of hpHeps 
was performed in non-cultivated cells, which may justify part of the transcriptome profile 
distance observed between HLCs and hpHeps. In fact, previous results described that overall 
gene expression profiles of hpHeps approached SC-derived HLCs after an extended 
cultivation period [256]. 
Phase II enzymes and the hepatic transporters are also important determinants of 
pharmacological and toxicological activity of xenobiotics [255]. Glucuronidation is a major 
metabolic pathway by which the parent compound is converted in water-soluble derivatives 
and therefore more readily excreted [50, 246, 255]. Despite the low expression of UGTs 
observed in the hpHep transcriptome profile, the HLC’s UGTs activity was observed up to day 
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34 in culture, being 1.7-fold and 2.1-fold higher than HepG2 or rpHeps, respectively, and 
similar to hpHeps, further suggesting a relevant HLC maturation level.  
The hepatic transporters are essential for xenobiotic metabolism and elimination through 
blood or bile. SLC transporters are involved in pathways as transport of glucose and other 
sugars, bile salts and organic acids, metal ions and amine compounds as well as transport of 
vitamins nucleosides, and related molecules [176]. In particular, SLCO1A and SLCO3A, which 
have drug and organic anion transporter activity, presented an expression level similar to 
hpHeps in transcriptomic analysis. Moreover, transporters involved in amino acid transport 
such as SLC7 subfamily were also detected. OATP-C (SLC21A6) is a liver specific influx 
transporter, located in the sinusoidal membrane of hepatocytes and MRP-2 (ABCC2) is an 
efflux transporter, also highly expressed in liver, and located on the basolateral membrane [7]. 
The presence of both transporters at the protein level was detected suggesting phase III cell 
phenotype. Gene expression and protein presence of OATP-C have been reported on human 
ESC-derived HLCs [260]. MRP-2 activity has been previously published by Li et al. [171] on 
human AD-derived HLCs and gene expression of sinusoidal and basolateral drug 
transporters, but none of those two were reported on HLCs derived from hnMSCs. To our 
knowledge, the presence of MRP-2 and of OATP-C was herein shown for the first time on 
hnMSC-derived HLCs. Moreover, an overexpression of the ABCA1 hepatic transporter was 
detected in the microarray analysis, relative to hpHeps, hnMSCs and HepG2 cell line despite 
the low activation, the nuclear receptor canonical pathways LXR/RXR FXR/RXR and 
PXR/RXR. LXR is activated by cholesterol and its metabolites and consequently activates 
ABCA1 expression. Bile acids activate FXR and PXR responds to fatty acids by increasing its 
uptake in hepatocytes [280]. This may suggest that the focus of HLC differentiation on phase 
I and II metabolism may be neglecting other essential features of the hepatocyte functions 
such as bile acids and lipid metabolism. Thus, this observation suggests that a further 
optimization of differentiation medium composition, namely by increasing its lipid content, 
should be taken into consideration in future studies, together with a broader characterization 
of HLCs at lipid and glucose metabolism levels. In fact, the bile salts supplementation, not 
commonly used in primary hepatocyte cultures, was recently reported to induce mature liver 
functions namely BSEP, MRP-2 and CYP7A1 [281]. In the present report, the results of a total 
of 8 conditions that differed in the combination and time of supplementation of three EMs are 
presented. Our data show that hnMSCs are capable of differentiating into HLCs upon 
mimicking the in vivo development micro-environment of hepatocytes by the addition of the 
epigenetic modifier DMSO from day 10 onwards. Furthermore, a genome-wide analysis 
increased the perception of the level of HLC maturation, indicating a partial hepatic phenotype. 
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Remarkably, some features were enhanced along the differentiation protocol, namely in terms 
of drug transporter and phase I and phase II metabolism expression and function, taking the 
HLCs in the direction of a mature phenotype. The acquisition of such a stable and active 
biotransformation capacity will be determinant for the potential applicability of liver-like in vitro 
models for longer-term toxicity testing.  
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4 Chapter 4. Three-dimensional spheroid cultures of human 
neonatal mesenchymal stem cells 
 
This chapter includes Madalena Cipriano’s work that is part of the scientific content of the 
following publication: 
Santos JM, Camões SP, Filipe E, Cipriano M, Barcia R, Filipe M, Teixeira M, Mosqueira D, 
Nascimento DS, Simões S, Gaspar M, Pinto-do-Ó P, Cruz P, Cruz H, Castro M, Miranda JP. 
2015. 3D spheroid cell culture of umbilical cord tissue-derived MSCs (UCX®) leads to 
enhanced paracrine induction of wound healing. Stem Cell Res Ther. 6(1): 90-109; DOI: 
10.1186/s13287-015-0082-5 
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4.1 Abstract 
3D cell culture models continue proving to be better models than the traditional 2D monolayer 
culture due to improved cell-to-cell interactions, cell-to-matrix interactions, and the formation 
of structures that better resemble the in vivo tissue architecture. Thus, 3D culture systems 
hold great promise for clinical applications by priming to a more physiologically relevant cell 
phenotype. Herein, a 3D culture model of human neonatal mesenchymal stem cells (hnMSC) 
was developed and characterized with respect to spheroid formation, cell phenotype and 
viability. We aimed at testing the hypothesis that the natural self-aggregation of hnMSC 
isolated from the umbilical cord stroma, is an effective system for establishing a robust 3D cell 
culture spheroid-based system to be further applied to the hepatic differentiation. To obtain 
hnMSC spheroids, two approaches were adopted: (i) dynamic cultures using spinner flask 
suspension cultures (SFSC); and (ii) static cultures using ultra-low attachment (ULA) plates. 
Both systems enabled hnMSC spheroid formation, resulting in a viable long-term culture up 
to 11 days, with a homogeneous spheroid size and without the presence of necrotic centres 
observed by H&E staining. Immunofluorescence detection of Ki-67 revealed < 5 % of 
proliferating cells showing a limited capacity of cell expansion under SFSC conditions, which 
was further confirmed by total protein quantification in both cell culture systems. In dynamic 
cultures, hnMSC spheroids successfully mimicked the native cell microenvironment, with 
sustained production of extracellular matrix (ECM) components like collagen I and fibronectin, 
as well as, of the basement membrane proteins laminin and collagen IV. The ULA system 
showed to be a robust tool for the implementation and validation of hepatic differentiation 
strategies whereas the scalability of SFSC system further represents a new approach for the 
maintenance of high cell numbers meeting the needs for clinical, pharmacological and 
toxicological applications. 
 
Keywords: 
Human neonatal mesenchymal stromal cells; 3D culture; Spheroids; Spinner flask suspension 
cultures; Ultra-low attachment plates; Extracellular matrix 
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4.2 Introduction 
Mesenchymal stromal cells are a subset of stem cells that may be isolated from a number of 
adult and neonatal tissues, such as adult bone marrow [155] and adipose tissue [282], fetal 
blood [146], amniotic fluid, placenta [147, 148], umbilical cord blood [149] and umbilical cord 
stroma (Wharton’s jelly – WJ-MSC) [283]. MSC present several unique characteristics that 
make these cells an ever-increasing subject not only for clinical research but also for in vitro 
toxicology applications. MSC have also been shown to display immune-modulatory properties, 
capacity to home to sites of inflammation and have demonstrated a quite high differentiation 
capacity, yielding not only osteoblasts [284], chondrocytes [285] and adipocytes [286] but also 
other cells of mesodermal, endodermal and ectodermal origin, such as myoblasts [287], 
cardiomyocytes [288], hepatocytes [172] insulin-producing cells [289] and neurons [290], 
amongst others. 
Most of data on MSC properties has been obtained with bone marrow-derived MSC (BM-
MSC) or adipose tissue-derived MSC (AT-MSC) [291, 292], while increasing evidence show 
that MSC from other sources could have distinct characteristics with regards to differentiation, 
expansion potential with concomitant genomic stability, and tissue regeneration capabilities 
[150, 160, 258, 292, 293]. Cells derived from extra-embryonic tissues such as placenta and 
umbilical cord tissue or blood became a more interesting cell source due to the non-invasive 
access and its more primitive origin. Indeed, neonatal MSC sources show less of the donor 
variability seen with other sources of MSC due to donor age, health conditions, clinical history 
or lifestyle [150, 160]. These cells are also obtained in more reproducible conditions, making 
them ideal for medium/high throughput screening, and maintain high chromosomal stability in 
vitro allowing for a stable expansion, which is of special interest for clinical applications [254]. 
A subset of human MSCs derived from the umbilical cord tissue, UCX®, have shown promising 
results in several non-clinical trials [257, 294]. These cells are isolated, expanded and 
cryopreserved according to a patented method (INPI PAT20081000083882; 
PCT/IB2008/054067; WO2009044379) [154]. The UCX® isolation method was particularly 
designed to produce a highly homogeneous population of cells, compliant with the MSC 
standards as defined by the International Society for Cellular Therapy (ISCT) [145]. In addition, 
UCX® are obtained in high numbers and have been characterized with respect to safety and 
potency and their isolation method has been fully adapted to the requirements to produce an 
advanced therapy medicinal product (ATMP), as defined by EMA guidelines [254, 258]. 
Recently, the UCX® tissue regeneration capacity has been functionally demonstrated in 
several animal models for myocardial infarction and rheumatoid arthritis [258, 294, 295], and 
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are already under pre-clinical trials for several auto-immune disorders [257, 258, 296]. 
Furthermore, in vitro and in vivo studies, performed with conditioned medium produced by 
UCX®, have demonstrated the potential for promoting cutaneous wound healing [257, 259].  
The expansion and maintenance of MSCs is currently performed using traditional monolayer 
(2D) cultures where cells migrate and proliferate while adhering to the plastic surface of static 
culture flasks. In fact, these cell culture conditions are far from the in vivo physiological 
environment, as they lack the cell-to-cell and cell-to-ECM interactions. To overcome the lack 
of a physiologically relevant cell culture conditions, three-dimensional (3D) cell cultures have 
been developed, providing a more matrix-like environment. Thus, the use of MSC 3D culture 
systems has gained increasing attention [61, 70, 71, 297-299], being applied to enhance 
chondrogenic differentiation [300] or to improve the cells’ therapeutic potential [298, 299]. In 
fact, the 3D environment showed the capacity of priming WJ-MSC to a more therapy-driven 
phenotype regarding wound-healing by resorting to decellularized amniotic membrane 
scaffolds as support for cell culture [301]. Alternatively, a less complex 3D model is the cells’ 
self-assembling into spheroid-like structures, that enables greater cell-to-cell and cell-to-
matrix interactions [61, 70, 71, 299, 302-304]. Several techniques allow for the spheroid 
formation, such as spinner flask suspension cultures (SFSC) and the use of non-adhesive 
surfaces, among others. The SFSC are amenable for both cell expansion and differentiation 
[305], as well as for up-scaling processes avoiding some regulatory constraints related to 
adhering supports and scaffolds.  
The ultra-low attachment (ULA) plates consist on a non-adhesive surface enabling simple and 
low cost spheroid formation. ULA are advantageous for the optimization of culture medium 
supplementation and to test a diversity of toxic compounds using lower amounts of cells, since 
this system is available in 384, 96, 24 or 6-well formats. ULA plates have also been commonly 
used as smaller-scale cell culture systems to evaluate mesenchymal stem cell proliferation 
and differentiation potential [88, 89], as well as to improve the liver-like properties of the 
hepatic cell line HepG2 in repeated dose, high-throughput, toxicity studies [66, 90]. 
In this work, we aimed at testing the hypothesis that the natural self-aggregation of UCX® is 
an effective system for priming these cells towards a more physiological environment and, 
consequently, differentiation ability. For this purpose, a reproducible and scalable 3D culture 
system for extended maintenance of multipotent UCX® spheroids was developed, devoid of 
supporting matrices or the use of complex scaffolds. Two distinct 3D spheroid systems, (i) 
ULA plates and (ii) SFSC, were developed. In both systems, spheroids were maintained in 
culture for up to 11 days, showing low proliferative capacity and absence of necrotic centres. 
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In the SFSC, the environment within hnMSCs spheroids successfully mimicked the native cell 
microenvironment as seen by the sustained production of ECM components like collagen I 
and fibronectin, as well as of basement membrane proteins like laminin and collagen IV.  
4.3 Material and Methods 
4.3.1 Ethics and regulations 
This study was approved by the Ethics Committee of the Hospital Dr. José de Almeida 
(Cascais, Portugal), in the scope of a research protocol between ECBio – Research & 
Development in Biotechnology, S.A. and HPP Saúde – Parcerias Cascais, S.A.. Umbilical 
cord donations, with written informed consents; as well as umbilical cord procurement, were 
made per Directive 2004/23/EC of the European Parliament and of the Council of 31 March 
2004 on setting standards of quality and safety for the donation, procurements, testing, 
processing, preservation, storage and distribution of human tissues and cells. All animal 
experiments were carried out with the permission of the local animal ethical committee in 
accordance with the EU Directive (2010/63/UE), Portuguese law (DR 129/92, Portaria 
1005/92) and all relevant legislations. The experimental protocol was approved by Direcção 
Geral de Alimentação e Veterinária (DGAV). 
4.3.2 Cell culture reagents 
Cell culture media and supplements used in this work were all purchased from Sigma-Aldrich®, 
unless stated otherwise. Foetal bovine serum (FBS) and Trypsin/EDTA were obtained from 
Gibco®. 
4.3.3 hnMSC isolation and culture 
4.3.3.1 hnMSC characterization 
In this work, UCX® were the used hnMSC and were isolated at ECBio, S.A. according to the 
procedure described in the patent (INPI PAT20081000083882; PCT/IB2008/054067; 
WO2009044379) [154]. hnMSC cryopreserved up to P12 were thawed and used for cell 
culture as described below. In 2D cultures (static monolayer cultures) cells were seeded at a 
density of 7.0x103 cells/cm2 in hnMSC medium (α-MEM with 2 mM glutamine, 1 g/L D-(+)-
Glucose and 2.2 g/L sodium bicarbonate) supplemented with 10 % FBS (v/v) and incubated 
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at 37°C in a humidified atmosphere with 5 % CO2. Cell passage was performed every 72h or 
when cells reached 70-80 % confluence.  
3D spheroid cultures were performed in SFSC and ULA plates. In SFSC, 125 mL spinner 
vessels with ball impeller containing hnMSC medium supplemented with 10 % FBS were 
inoculated with single-cell suspensions obtained from 2D cultures at a concentration of 1 x 106 
cells/mL. To promote cell aggregation, the spinner vessels were agitated at 80 rpm and kept 
at 37 ºC in a humidified atmosphere of 5 % CO2. After 24 h, 50 % of cell culture supernatant 
was changed with fresh hnMSC medium supplemented with 10 % FBS (v/v). The stirring rate 
was adjusted to keep spheroid size below 350 µm. FBS was reduced to 5 % (v/v) at day 2 of 
culture and completely removed at day 5.  
In ULA plates 3D cultures, 1.2 x 105, 2.4 x 105 and 3.6 x 105 cells/mL were inoculated on 24-
well plates with 0.5 mL of UCX® medium per well, containing 10 % or 20 % of FBS (v/v). FBS 
was reduced to 5 % at day 1 of culture and completely removed at day 4.  
In 3D cultures medium was changed every 3-4 days to guarantee nutrient availability and to 
decrease the accumulation of toxic by-products.  
For plating back spheroids into to 2D cultures, a 5 mL cell suspension from 3D cultures was 
collected at day 7. Spheroids were digested with 0.25 % Trypsin/EDTA resulting in smaller 
spheroids that were inoculated in a 6-well plate. Cells adhered and proliferated for 1 passage, 
being afterwards collected for flow cytometry analysis of cell surface marker expression, and 
assessment of tri-lineage differentiation potential as described below.  
4.3.3.2 Flow cytometry 
Cell surface marker expression was analyzed by flow cytometry. For the characterization of 
hnMSC in both 2D and 3D cultures, cell detachment from culture flasks and dissociation from 
spheroids were achieved by using 0.25 % Trypsin/EDTA and the resulting single-cell 
suspension washed with 2 % BSA in PBS. Detection of cell surface markers was performed 
with the following antibodies and their respective isotypes after incubation for 1h at 4 ºC (all 
from BioLegend® unless stated otherwise): PE anti-human CD105 (eBioScience®); APC anti-
human CD73; PE anti-human CD90; APC anti-human CD44; PerCP/Cy5.5 anti-human CD45; 
FITC anti-human CD34; FITC anti-human CD31; PerCP/Cy5.5 anti-human CD14; Pacific Blue 
anti-human CD19 and pacific-blue anti-human HLA-DR. All samples were acquired on a 
Gallios (Beckman Coulter) and the results analyzed with Kaluza software (Beckman Coulter). 
A minimum of 1.0 x 104 events was acquired per surface marker. 
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4.3.3.3 Tri-lineage differentiation  
Tri-lineage differentiation was performed in hnMSC 2D and 3D cultures. Spheroids were 
dissociated into a single-cell suspension with 0.25 % Trypsin/EDTA and transferred to the 
appropriate culture plates for cell proliferation and expansion. Adipogenic and osteogenic 
differentiation was initiated when cultures reached 80-100 % confluence. For the 
chondrogenic differentiation, non-dissociated spheroids were also used for differentiation. To 
induce adipogenic differentiation, cultured cells were incubated in adipogenic differentiation 
medium, for 3 days, consisting of α-MEM supplemented with 20 % FBS, 2 mM L-glutamine, 
10 μg/mL insulin, 200 μM indomethacin, 0.5 mM isobutylmetylxantine, and 1 μM 
dexamethasone; and subsequently 1 day in adipogenic maintenance medium, consisting of 
α-MEM supplemented with 20 % FBS, 2 mM L-glutamine and 10 μg/mL insulin. Medium 
replacement cycles were repeated during 21 days after which histochemical staining was 
performed. To induce osteogenic differentiation, cells were incubated in osteogenic 
differentiation medium consisting of α-MEM, 10 % FBS, 1 g/L glucose, 2 mM glutamine, 10 
mM β-glycerol phosphate, 50μg/mL ascorbate-2-phosphate and 100 nM dexamethasone. The 
medium was changed every 3 days during 21 days. Finally, for chondrogenic differentiation, 
cells (both dissociated cells and spheroids) were maintained in suspension as pellets, 
incubated in differentiation medium consisting on DMEM-LG, 1 % FBS, 2 mM L-glutamine, 
6.25μg/mL insulin, 10 ng/mL TGF-β1 (Tebubio) and 50μM ascorbate-2-phosphate. The 
medium was replaced every 3 days during 21 days and histochemical staining was performed. 
For cytochemical staining cells were fixed with paraformaldehyde 4 % for 20 minutes. In 
adipogenic and osteogenic differentiation protocols, cells were stained with Oil Red O and 
alkaline phosphatase, respectively. For chondrogenic differentiation, spheroids were cut into 
sections and stained with alcian blue. The presence of stained cells was confirmed by inverted 
microscopy with phase contrast (Leica, DMIL HC).  
4.3.4 hnMSC viability evaluation 
4.3.4.1 Cell membrane integrity assay  
The qualitative assessment of the cell plasma membrane integrity during culture was 
performed using the enzyme substrate fluorescein diacetate (FDA) and the DNA-dye 
propidium iodide (PI). Briefly, cell aggregates were incubated with 20 µg/mL FDA and 1 µg/mL 
PI in PBS for 2–5 minutes and then observed using an inverted fluorescence microscope 
(Nikon Eclipse Ti-U). 
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4.3.4.2 hnMSC spheroid visualization and measurement  
hnMSC spheroids were observed by bright field microscopy (Olympus CK30), and their 
average diameter determined by measuring at least 30 spheroids per condition. Spheroid 
diameters were measured using Motic Images Version 2.0 software.  
4.3.4.3 Haematoxylin and eosin staining  
hnMSC spheroids were resuspended in Tissue Tek® O.C.T.™ (Sakura®) for preparing 
cryosections of 10 μm. Slides were first stained with Harris's haematoxylin (Sigma-Aldrich®) 
for 10 min, followed by an incubation step with HCl 1 % (v/v) in 70 % EtOH, and by Eosin Y 
(Sigma-Aldrich®) staining for 2 min. Slides were then submitted to increasing concentrations 
of ethanol and finally incubated in xylene (EMD Chemicals). Samples were mounted with 
Entellan® (Merck). Images were acquired on an Olympus CK30 inverted microscope and 
processed using Motic Images Version 2.0 software. 
4.3.5 Immunofluorescence microscopy 
Cryosections from hnMSC spheroids were prepared as described above. Tissue sections 
were fixed with cold acetone for 10 minutes and blocked for 1 h with 4 % FBS (v/v) and 1 % 
bovine serum albumin (BSA) (v/v) in PBS. Incubation with primary antibody was performed in 
a humidified chamber for 2 h at RT or overnight at 4 ºC. The primary antibodies used were: 
Ki-67 (Rabbit IgG, AB16667, Abcam®) diluted 1:100; Collagen IV (Goat, AB769, Millipore) 
diluted 1:10; Fibronectin (Rabbit, F-3648, Sigma-Aldrich®) diluted 1:400; Laminin (Rabbit IgG, 
L9393, Sigma-Aldrich®) diluted 1:50; collagen I (Rabbit IgG, AB21285, Abcam®) diluted 1:200. 
All primary antibodies were diluted in 1 % BSA (v/v) in PBS. The incubation with secondary 
antibodies was carried out for 1 h at RT. The secondary antibodies used were as follows: goat 
anti-rabbit 594 (1:500) for Ki-67 staining; rabbit anti-goat-biotin (1:400) followed by streptavidin 
555 (1:500) for Collagen IV staining; donkey anti-rabbit IgG 568 (1:1000) for Laminin staining; 
donkey anti-rabbit IgG 647 (1:1000) for Collagen I staining and goat anti-rabbit 488 (1:1000) 
for Fibronectin staining. All secondary antibodies were purchased from Invitrogen™. Sections 
were mounted using ProLong gold antifade with DAPI (Invitrogen™), and observed on an 
inverted fluorescence microscope (Axiovert 200M, Carl Zeiss) coupled with a monochrome 
camera (AxioCam MNC, Carl Zeiss).  
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4.3.6 Protein quantification 
Protein concentration was determined as described in Chapter 3.  
4.3.7 Statistical analysis 
Data analysis and graphs were plotted using GraphPad Prism® software (GraphPad Software, 
San Diego, CA, USA). Values presented in the text and figures are as average ± standard 
deviations of at least three independent experiments, except otherwise specified.  
4.4 Results 
4.4.1 Isolation and characterization of hnMSC cells 
The hnMSC have been isolated as described in Santos, J. M. et al. [154] (2009) “Optimized 
and defined method for isolation and preservation of precursor cells from human umbilical 
cord” (INPI PAT20081000083882; PCT/IB2008/054067; WO2009044379) [154]. From the 
time the patent has been submitted, the method has been further optimized at ECBio, S.A., to 
be GMP compliant. The optimization process, which was not in the scope of this thesis, 
resulted in further robustness and essentially can produce a homogeneous population of > 95 
% MSCs (according to the International Society of Cell Therapy - ISCT) without the need to 
use cell sorting. Thus, with the ECBio, S.A., methodology, which is reproducible, the cells 
obtained are consistently 1) adherent to plastic, 2) > 95 % positive for CD105, CD90 and CD73 
and < 2 % positive for CD14, CD19, CD34, CD45 and HLA-DR, and 3) capable of 
differentiating into osteoblasts, chondrocytes and adipocytes when adequately stimulated with 
the correct differentiation factors in vitro. In addition, ECBio, S.A. showed that these 3 ISCT 
criteria for defining MSC are preserved along cell expansion enabling at least 55 cumulative 
population doublings (P22) before reaching the first signs of senescence (data not shown). 
Cells isolated as to the abovementioned protocol, were cultured in monolayer (2D) and 
expanded for further use in this Chapter and in the Chapters 3, 5 and 6. 
4.4.2 hnMSC form viable spheroids in spinner flask suspension cultures (SFSC) and 
ultra-low attachment (ULA) plates 
For the development of static spheroid cultures, using 6-well ULA plates, cell density (1.2 x 
105, 2.4 x 105 and 3.6 x 105 cells/mL) and FBS initial concentration (10 and 20 %, v/v) were 
evaluated. Within ULA plates, compact hnMSC spheroids could be observed during the first 
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24 h after cell inoculation in all conditions, reaching an average spheroid size above 300 μm 
(Figure 4.1b) at day 3. The lower inoculum presented less than 2.5 % of aggregates bigger 
than 300 μm whereas this value was of 10 % to 2.4 x 105 cells/mL and of 25 % to 0.36 x 105 
cells/mL inocula. In contrast, the FBS concentrations tested showed no differences on 
aggregate formation and consequently, 10 % FBS (v/v) was preferred to 20 % (v/v) for allowing 
a quicker reduction of FBS concentration to 0 %. Thus, the optimized conditions for hnMSC 
spheroid formation under static culture conditions consisted in an inoculum of 1.2 x 105 
cells/mL, with 10 % FBS (v/v). FBS concentration was afterwards reduced to 5 % (v/v), at day 
1, and removed at day 4 without causing changes on achievable aggregate sizes (spheroid 
diameters of 105 ± 6 μm (Average + SEM) (Figure 4.1b) or on spheroid compact morphology. 
In parallel, a SFSC system was developed and optimized to obtain hnMSC 3D spheroids 
(Figure 4.1). For this purpose, different culture parameters such as inoculum concentration, 
impeller type and agitation rate were evaluated. Two impeller types (ball and paddle) were 
tested and two cell densities (1.0 x 106 cells/mL and 0.5 x 106 cells/mL) were chosen as 
starting points according to previous observations [306]. hnMSC were cultured in 125 mL 
spinner flasks for 11 days in a perfusion mode consisting of 50 % culture medium replacement 
at days 2, 6 and 9. 
Compact multicellular spheroids of hnMSC could be obtained when using the ball impeller, 
but not with the paddle impeller, due to lower cell viability and lower size and shape 
homogeneity (data not shown). Consequently, only the ball impeller cultures were further 
maintained and monitored. Herein, the agitation rate was set to 80 rpm for the first 2 days of 
culture and increased to 100-120 rpm once the aggregates were formed to control the 
aggregate size. Phase contrast microscopy shows that hnMSC first form small low-density cell 
aggregates of approximately 50-100 µm diameter (Days 1-2, Figure 4.1b). Compact 
spheroids could only be obtained when a higher cell density was used as inoculum (1x106 
cells/mL) that, once assembled, did not increase in size. Measurements of spheroids were 
based on phase-contrast images throughout the whole culture period (days 2, 4, 6, 9 and 11 
of culture) yielding a size-distribution plot (Figure 4.1b). On average, spheroid diameters were 
143 µm + 9.78 µm (Average + SEM) after 2 days and 308 µm + 9 µm (Average + SEM) from 
day 4 to day 11 of culture (Figure 4.1b). The formation of necrotic centers on spheroids was 
circumvented by maintaining the average spheroid size under 350 µm, which was achieved 
by optimizing the inoculum (Figure 4.1 and 4.2), FBS concentration and by controlling the 
stirring rate. Thus, FBS reduction was also attempted since several potential applications of 
3D MSC cultures, either in vitro pharmacology or in regenerative medicine, require serum free 
conditions. Cells were inoculated with 10 % of FBS (v/v) that was then reduced to 5 % (v/v) at 
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day 2 of culture and completely removed at day 5. The complete FBS removal was achieved 
without compromising spheroids structure or/and cell viability (data not shown).  
The results showed that our optimized culture conditions, namely an inoculum of 1 x 106 
cells/mL inoculum and ball impeller, enabled the formation and maintenance of hnMSC 
spheroids for at least 11 days. 
 
Figure 4.1 hnMSC form spheroid structures. a) Phase contrast microscopy representative of the time course of 
the aggregation of hnMSC into spheroids cultured in ULA plates with an inoculum of 1.2 x 105 cells/mL. Scale bar 
100 μm. b) Sizes of hnMSC spheroids generated in ULA plates at day 3, when optimizing inocula and serum 
concentration, and in both systems evaluated at days 2, 4, 6, 9 and 11, when seeded at 1.2 x 105 cells/mL and 
10 % FBS (v/v) (ULA) or at 1 x 106 cells/mL (SFSC). Aggregates diameters were measured from captured images 
of spheroids (n=3). Data is shown in Average ± SEM. 
Cells within spheroids may have less access to nutrients, thus the evaluation of cellular 
viability under the optimized 3D culture conditions is critical. To assess cell proliferation and 
viability within hnMSC spheroids, samples were collected for H&E, FDA/PI and Ki-67 staining 
and biomass quantification at various time points (Figure 4.2) To follow spheroid morphology, 
histological analysis of spheroid sections was performed at days 3, 9 and 11 (Figure 4.2a). 
H&E staining of sections revealed that spheroids were solid with evenly distributed cells, 
embedded in extracellular matrix, presenting no evidence of necrotic cores (Figure 4.2a). The 
surface of the spheroid had a layer of epithelium-like cells that were flatter and more elongated 
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in appearance. Ki-67 staining of spheroid cryo-sections showed the presence of only < 5 % of 
cells were actively proliferating at day 3 and less at day 11 (Figure 4.2b). These results are 
in accordance with biomass quantification values that did not significantly change during 
culture time; whereas the decrease in biomass values are associated to cultures reefed 
(Figure 4.2c). Moreover, no significant cell lysis occurred as assessed by quantification of 
LDH (data not shown) and the live/dead (FDA/PI) assay showed high cell viability (> 70 %) in 
the spheroids (Figure 4.2a). It demonstrates that spheroids size range was not critical 
regarding cell viability and the formation of necrotic centres. The results showed that both 3D 
culture conditions enabled the formation and maintenance of UCX® spheroids comprising 
viable cells for at least 11 days.  
 
Figure 4.2 3D spheroid cultures allow the extended maintenance of viable hnMSC without necrotic cores. 
a) Phase contrast and fluorescence images representatives of spheroids at days 3, and 11. From left to right: H&E 
staining of hnMSC spheroid sections; Immunofluorescence images representatives of hnMSC spheroid 
cryossections labelled with Ki-67 (red) and DAPI (blue); and, Viability of hnMSC spheroids in culture as assessed 
by staining with FDA (live cells, green) and PI (dead cells, red). b) Biomass quantification at days 2, 4, 6, 9 and 11 
on hnMSC spheroids cultured on SFSC (Left) and ULA plates (Right). Data is shown in Average ± SEM (n=3). 
Scale bar 100 μm. 
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4.4.3 hnMSC grown in 3D culture conditions maintain MSC antigen expression 
phenotype 
hnMSC cell-surface marker expression was analyzed by flow cytometry (data not shown). The 
surface epitopes of hnMSC dissociated from spheroids were like the surface epitopes of 
hnMSC obtained from adherent monolayers (2D) dissociated under the same conditions. 
From day 4 onwards, the population of 3D-spheroid-dissociated cells showed a decrease in 
CD105 and CD90 expression levels, most likely due to the smaller cell size while in spheroids 
than in 2D which, by resulting in a lower yield of fluorescence emission, shifted the signal to 
the negative region of the histograms. In fact, flow cytometry side scatter results indicate that 
cells grown in 3D spheroids were approximately 30 % smaller in size when compared to cells 
grown in 2D monolayer cultures (data not shown). The expression of CD105 and CD90 
surface epitopes increased again to high levels once hnMSC grown in 3D spheroids were 
plated back (culture day 7) in 2D monolayer conditions (replated cells, data not shown), 
supporting the hypothesis that the observed lowered expression was due to smaller cell size 
when cells grow in aggregates. 
To assess if 3D culture conditions altered hallmark properties of hnMSC, namely their 
differentiation potential, cells in 3D culture were dissociated from spheroids at days 3, 6 and 
9, plated onto culture flasks and grown as monolayers. Plated cells retained the ability to 
adhere and proliferate on a plastic surface. Cell multipotency was then assessed and 
confirmed by the ability of hnMSCto differentiate in vitro into adipocyte-, osteoblast- and 
chondrocyte-like cells (data not shown). Adipogenic and osteogenic biochemical 
differentiation, evidenced by lipid vacuole formation and matrix mineralization, respectively, 
could be confirmed at all time points. In turn, chondrogenic differentiation was attempted using 
both, 3D-spheroid dissociated cells and intact 3D-spheroids directly. Chondrocyte 
differentiation was obtained with dissociated cells, but was greatly enhanced by cells in 
aggregates already embedded in their own chondrogenic-type extracellular matrix. Overall, 
cells obtained from 3D cultures and plated back under 2D conditions show a similar 
differentiation capacity as cells grown in conventional 2D cultures at similar passages. 
4.4.4 hnMSC spheroid structures mimic the native environment ex vivo 
A crucial component of the stem/progenitor cell niche is the extracellular matrix, by modulating 
cell-fate, making available a large array of biochemical and biophysical cues. To evaluate 
whether the hnMSC spheroids replicate the native tissue environment ex vivo by producing 
the Wharton’s jelly ECM, the expression of major ECM proteins was analyzed (Figure 4.3). 
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Immunohistochemical evaluation of cells in spheroids showed sustained expression of the 
ECM components collagen I, fibronectin, as well as of the basement membrane proteins 
laminin and collagen IV, between days 3 and 11 in vitro (Figure 4.3), suggesting that an 
environment resembling that of the native tissue was formed within the aggregates. Moreover, 
no differences in terms of ECM distribution/composition between the aggregate inner core and 
outer layer in any of the different-sized aggregates were observed. A uniform distribution of 
laminin, collagen IV and fibronectin expression, with interspersed regions of collagen I 
deposition generically characterized the hnMSC spheroids.  
 
Figure 4.3 Expression of extracellular matrix proteins by hnMSC spheroids. Immunostaining of representative 
cryosections of hnMSC grown in 3D culture demonstrate the expression of relevant ECM molecules. Within the 
spheroid, laminin and collagen IV define the basal lamina surrounding hnMSC which is in close association with 
the ECM proteins fibronectin and collagen I. A similar ECM composition was observed irrespectively of the culture 
duration when considering the analyzed time-points of day 3 and 11. Scale bar, 100 µm.  
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4.5 Discussion 
MSCs are commonly cultured and expanded under conventional adherent monolayer (2D) 
culture conditions. However, cells replicative ability, colony-forming efficiency and 
differentiation capacity might decrease over time in culture [307]. In fact, cells change their 
shape and influence tissue mechanic properties during development and tissue healing in 
response to morphogens, cell-to-cell contact, adhesion to extracellular matrix, among other 
factors [308]. 2D systems fail to mimic the in vivo physiological environment of MSCs, which 
might limit their potential applications. In an attempt to recreate the complex microenvironment 
of living systems, the use of MSCs three-dimensional (3D) culture models has gained 
increasing attention [61, 70, 71, 85, 297-299], namely as a procedure for enhancing the 
differentiation of the cells [300, 309] or for increasing their therapeutic potential [298, 299, 
310]. Self-assembled spheroids are a 3D strategy that enables a greater cell-to–cell and cell-
-to-matrix interactions [61, 70, 71, 85, 297-299] and is amenable for both cell expansion and 
differentiation [305]. Thus, the work presented here was designed to obtain a 3D culture of 
hnMSC, using spheroids as strategy, and discuss how the cells phenotype under this 3D 
culture might be advantageous for its potential applications. The spheroid formation and 
culturing techniques, SFSC and ULA, were selected due to the possibility of up-scaling 
processes (SFSC), and by being devoid of supporting matrices or complex scaffolds that might 
result in some regulatory constraints when applying the cells for therapeutic proposes. 
Furthermore ULA plates allow for high throughput screening, important for the optimization of 
cell differentiation strategies and further use for in vitro toxicology studies. 
The development of a viable homogenous long-term 3D culture of hnMSC spheroids required 
the optimization of several factors, namely the initial inoculum, the FBS concentration and, in 
SFSC the use of an appropriate impeller and the optimization of the agitation rate. 
Mechanically stirred culture conditions, as in SFSC, creates a hydro-dynamic shear stress that 
must be optimized in order to balanced cellular stress and death with cell performance [72]. 
Mechanical forces may ultimately compromise cell viability, morphology, gene expression and 
differentiation potential [311]. Therefore, the obtained 3D hnMSC structures were fully 
characterized and monitored throughout the whole culture period, not only in terms of cell 
viability, proliferation and morphology, but also regarding cell surface protein expression and 
cell plasticity. Firstly, both a ball and paddle impeller were tested for our 3D spheroid culture 
in the SFSC. Compact multicellular spheroids of hnMSC could be obtained when using the 
ball impeller, but not with the paddle impeller (data not shown), which is in accordance with 
Yirme et al. [312] that observed higher viability, cell growth, size and shape homogeneity on 
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hESC cultured on SFSC with ball impeller rather than using paddle impeller [312]. The ULA 
plates, under a static cell culture condition, also resulted in compact viable multicellular 
spheroids of hnMSC observed by H&E analysis, with a low aggregate size distribution. A 
homogeneous cell culture regarding spheroid size is of major importance to achieve a 
homogeneous population of differentiated cells for in vitro toxicology studies, namely to 
achieve reproducible induction of a specific lineage commitment. The awareness of necrotic 
centers formation is also an important feature on the 3D spheroid culture implementation. 
Necrotic centers may be formed in aggregates larger than 350 µm [313]. Moreover, higher 
spheroid size might contain cells in various stages, usually including proliferating, quiescent, 
apoptotic, hypoxic, and necrotic cells, since in large size spheroids, the core cells receive less 
oxygen, growth factors, and nutrients from the medium, and tend to be in a quiescent or 
hypoxic state [314]. This may be particularly relevant in tumor cell cultures, but our study 
aimed at creating a viable 3D culture of hnMSC that might enhance its differentiation and 
tissue regeneration properties. Thus, the average spheroid size, in both static and stirred 3D 
hnMSC cultures, was maintained under 350 µm. In fact, necrotic centers were not present in 
our 3D cultures as observed in the H&E analysis and LDH assay.  
Serum-free conditions were also successfully applied to our cell culture systems without 
compromising the cell culture viability or spheroid morphology. This was also reported on 
bovine umbilical cord derived-MSC 2D and 3D cultures [306] as well as on human BM-MSC 
[88]. Alimperti et al. [88] used static cultures (ULA plates) to screen the media mixtures and 
the components based on cell proliferation potential to obtain a prototype serum-free medium 
that was characterized in both static (ULA plates) and dynamic culture (SFSC) by examining 
the proliferation and differentiation potential of BM-MSC spheroids produced [88]. In fact, 
serum free culturing is of high interest for MSC clinical and in vitro applications. Serum 
composition has a high variability, being a mixture rich of growth factors, proteins, vitamins, 
trace elements and hormones, among others [315], which has profound effects on cells 
proliferation and differentiation and causes phenotypical differences, resulting in reduced 
reproducibility of experimental results [316]. Although FBS composition favours cell growth, it 
is well recognized that use of FBS is not desirable for clinical applications due to the lack of a 
well-defined composition, the high batch-to-batch variability [315] and the risk of contamination 
agents that might induce immunogenic reactions when transfused into patients [88]. For this 
reason, UCX® isolation and culture was adapted towards the production of an advanced 
therapy medicinal products (ATMP) by Martins et al. [254]. ATMP adaptation included the use 
of human serum, tested for virus and endotoxin presence, and assured the maintenance of 
UCX®’s immunomodulatory properties [254]. Nevertheless, serum-free conditions are also 
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required to evaluate the cells’ conditioned medium composition and how cells secretome may 
exert a biological effect devoid of serum contribution. The UCX® secretome, produced in low 
serum (2 %, v/v) [257] and serum-free conditions, demonstrated a relevant biologic effect in 
vitro [257, 259] and in vivo on wound healing [259]. The paracrine effect of UCX® secretome, 
was further improved by 3D culturing that resulted in an increased production of MMP-2, MMP-
9, VEGF, G-CSF, HGF, FGF-2, TGF-ß1 and IL-6, and revealed its direct involvement in all 
phases of wound healing, i.e. homeostasis, inflammation, proliferation and remodelling [259]. 
In fact, Santos et al. [259] showed that the cells conditioned medium is an important alternative 
to the use of cells in the final formulation of ATMP by providing a proof-of-concept that a 
reproducible system to produce UCX®-conditioned medium, the 3D UCX® spheroids cultured 
on SFSC, can be used to prime a secretome for eventual clinical applications [259]. In fact, 
several studies showed that MSC cultured in serum-free formulations resulted in enhanced 
anti-inflammatory, angiogenic and immunomodulatory properties [88, 259, 306, 317, 318]. The 
adaptation of MSC spheroids to serum free conditions is also of major importance for in vitro 
applications such as the induction of cell differentiation into a specific lineage. The lack of a 
well-defined composition may also interfere with the effect of the cytokines and growth factors 
used to induce cell differentiation. Moreover, it may also mask the toxicity of several chemicals. 
For this reason, the use of serum-free is recommended in the guidelines for good cell culture 
practice as well as by the ECVAM Advisory Committee that strongly recommends the use of 
serum-free substitutes for both current and future in vitro methods [319]. 
In our study, 3D culturing showed an effect on cell morphology, proliferation, differentiation 
and ECM production capacity. MSC morphology is spherical when cultured in spheroids and 
becomes more elongated in 2D conditions. The size of MSC in spheroids is also drastically 
smaller than cells in 2D monolayer as seen by microscopy and evaluated by flow-cytometry. 
This has also been reported in literature, with 3D culturing resulting in 75 % reduction in 
individual cell volume [31, 57-59]. Proliferation and differentiation in culture are mainly 
regulated by cell density via increased juxtracrine (contact-dependent) and paracrine signaling 
[308]. In fact, contact-dependent signaling is one of the major differences between 2D and 3D 
culture conditions, differentially regulating cell signaling and fate. The proliferation rates of 
cells in spheroids is generally lower than in 2D and are cell line and matrix dependent [233, 
320-322]. Under our optimized conditions, spheroid cell viability could be maintained up to 11 
days, whereas cell proliferation greatly decreased (< 5 %) when compared to monolayer 
cultures. However, as reported by other authors [297-299], when spheroids are cultured back 
to monolayer conditions, similar proliferation rates and multilineage differentiation were 
observed as in cells maintained in 2D, reinforcing the effect of contact-dependent signaling.  
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The contact-dependent signaling has also been correlated to cell differentiation, since hMSC 
differentiation depends not only on cytokines and growth factors but also on mechanical 
gradients [307, 308, 323]. Ruiz et al. [323] observed that changing the shape of the 
multicellular sheet surface from convex to concave surfaces modulates the differentiation of 
BM-MSC into osteogenic or adipogenic, respectively [323]. The degree of cell spreading also 
showed to be able to switch BM-MSC commitment between lineage fates, in which well spread 
cells undergo osteogenesis while less spread cells undergo adipogenesis [324]. In fact, our 
3D cell culture conditions enhanced chondrogenic differentiation, resulting in increased alcian 
blue stained chondrospheres, which is in accordance to previous observations that suggested 
that 3D cultures of MSC yield more homogeneous differentiated populations [300, 325]. 
ECM is also a crucial component of the stem cell niche which, by making available a large 
array of biochemical and biophysical cues, modulates cell fate. In fact, Wharton’s jelly is a 
connective tissue layer very rich in ECM fibrous proteins, interstitial proteins and signaling 
molecules, whereas the WJ-ECM is mainly composed of collagens such as collagen type I, II, 
III, IV and VI, laminin and fibronectin [326, 327]. Immunostaining of the hnMSC spheroids 
showed that cells were embedded in a rich ECM composed of collagen I, fibronectin, laminin 
and collagen IV, suggesting that an environment resembling that of the native tissue was 
formed within the aggregates. Besides, it has been demonstrated that the preservation of an 
endogenous ECM in human MSC aggregates improves multilineage potential, while cells 
preserve its MSCs properties [327]. Previous studies using mRNA/cDNA microarrays 
demonstrated marked differences between transcriptome profiles of MSCs maintained in 
spheroids versus MSCs cultured in monolayers, including those confirming widespread 
changes to the cellular architecture and ECM [299, 328, 329]. The fact that the cell 
proliferation/metabolism is rather different between the two systems may also have an 
important effect upon the overall cellular activity. Thus, the production of ECM within the 
aggregate may have also increased the overall cell homeostasis, preserving cells from 
entering anoikis, the apoptotic process induced by the loss of interaction between the cell and 
the ECM [330]. 
In conclusion, by resorting to scalable commercially available systems, the 3D culture of 
hnMSC spheroids was successfully developed. Both 3D cell culture systems enabled the long-
term maintenance of viable, multipotent hnMSC within self-assembled spheroids. The ULA 
system showed to be a robust tool for the implementation and validation of cell differentiation 
strategies whereas the scalability of SFSC system further represents a new approach for cell 
culturing and differentiation with potential for both, clinical and pharmacology/toxicology 
applications.
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5 Chapter 5. Self-assembled 3D spheroids and hollow-fiber 
bioreactors improve MSC-derived hepatocyte-like cell 
maturation in vitro  
 
The scientific content of the present chapter has been included in the following publication: 
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K, Miranda JP. 2016. Self-Assembled 3D Spheroids and Hollow-fibre Bioreactors improve 
MSC-Derived Hepatocyte-Like Cell Maturation In Vitro. Arch Toxicol. 2017;91:1815-32. DOI 
10.1007/s00204-016-1838-0  
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5.1 Abstract 
3D cultures of human stem cell-derived hepatocyte-like cells (HLCs) have emerged as 
promising models for maintaining hepatocyte phenotype in short and long-term in vitro cultures 
by better resembling the in vivo environment of the liver and consequently increase the 
translational value of the resulting data.  
In this study, the first stage of hepatic differentiation of human neonatal mesenchymal stem 
cells (hnMSCs) was performed in 2D monolayer cultures for 17 days. The second stage was 
performed by either maintaining cells in 2D cultures for an extra 10 days as control, or 
alternatively cultured in 3D as self-assembled spheroids or in multi-compartment membrane 
bioreactor system. All systems enabled hnMSC differentiation into HLCs as shown by positive 
immune-staining of hepatic markers CK-18, HNF-4α, albumin, the hepatic transporters OATP-
C and MRP-2 as well as drug metabolizing enzymes as CYP1A2 and CYP3A4. Similarly, all 
models also displayed relevant glucose, phase I and phase II metabolism, the ability to 
produce albumin and to convert ammonia into urea. However, EROD activity and urea 
production were increased in both 3D systems. Moreover, the spheroids revealed higher 
bupropion conversion whereas bioreactor showed increased albumin production and capacity 
to biotransform diclofenac. Additionally, diclofenac resulted in an IC50 value of 1.51 ± 0.05 and 
0.98 ± 0.03 in 2D and spheroid cultures, respectively. This data suggests that the 3D models 
tested improved HLC maturation showing a relevant biotransformation capacity and thus 
provide more appropriate reliable models for mechanistic studies and more predictive systems 
for in vitro toxicology applications 
Keywords: 
Spheroids; Hollow-fiber bioreactor; Hepatocyte-like cells; Human neonatal mesenchymal 
stem cells; In vitro toxicology 
  
3D Spheroids and hollow-fiber bioreactors improve MSC-derived HLC maturation in vitro 
 101 
5.2 Introduction 
Drug development suffers from a lack of predictive toxicity identification at early stages, 
leading to an unacceptable high number of new compounds failing into progress toward 
clinical use. Clearly, current non-clinical models and approaches in drug discovery poorly 
predict toxic events: cellular models often lack the complexity to cover key mechanisms driving 
adverse events, animal models lack translational confidence to humans and genetic variability 
of susceptible human subpopulations is not adequately addressed. Stem cell (SC)-derived 
hepatocyte-like cells (HLCs) can present relevant clinical and toxicology testing applications 
as soon as a satisfactory hepatocyte-like functional phenotype can be achieved. In toxicology, 
HLCs can be used as a platform for in vitro liver disease modeling [199], toxicological 
screening or for mechanistic hepatotoxicity studies [331] whereas within the clinical field, 
HLCs can contribute to the recovery of injured liver tissues, not only by cell replacement but 
also by delivering trophic factors that support endogenous liver regeneration [332].  
In vitro hepatotoxicity studies are still mostly performed using liver slices, genetically 
engineered cells, two-dimensional (2D) monolayer cultures, or suspension cultures of either 
human hepatoma cell lines or primary hepatocytes. These culture models present major 
challenges like cell availability and/or maintenance of a functional phenotype in vitro [7, 50], 
which sustains the need for alternative cellular models.  
SC-derived HLCs have been reported as a relevant alternative due to their ability to maintain 
a mature HLC phenotype such as the expression of liver-specific markers as well as a 
satisfactory activity of drug metabolizing and detoxifying enzymes, including phase I, phase II 
and hepatic transporters [252]. However, SC-derived HLCs show in some aspects a reduced 
hepatic functionality when compared to human hepatocytes. Several factors contribute to this 
immature phenotype, namely the SC nature/source, SC isolation technology and the culture 
system applied. We have recently demonstrated that a specific subset of human neonatal 
MSCs (hnMSCs) derived from the umbilical cord tissue, termed UCX®, have a strong ability to 
differentiate into highly functional and durable HLCs [333].  
Three-dimensional (3D) culture systems have been implemented in order to overcome the 
immature phenotype observed in long-term primary hepatocyte cultures. Primary hepatocytes 
grown in 3D cultures showed increased functionality in vitro, such as the role of many 
transporter proteins [62] and the activities of some drug metabolizing enzymes [61, 85] when 
compared to cells grown and maintained in traditional 2D monolayer cultures. 3D cell cultures 
allow high cell-to-cell and cell-to-extracellular matrix (ECM) contacts that are essential for the 
acquisition of cell polarity during development [7, 259]. In fact, hepatoblasts are essentially 
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non-polarized cells that present little cell-to-cell contacts whereas hepatocytes present a 
highly polar epithelial morphology that depends on the ECM composition and stiffness to 
maintain their functions [7]. Some authors have attempted to mimic the ontogenic environment 
of liver by using 3D cell cultures in order to promote hepatogenic differentiation. As an 
example, 3D culturing proved to be successful in improving the hepatocyte-like phenotype in 
terms of biotransformation activity, as shown by spheroid-based cultures of either hESCs-
derived or iPSC-derived HLCs [236, 237, 334, 335]. In particular, the differentiation of hESCs 
in a hollow-fiber bioreactor resulted in an upregulation of pathways related to steroid hormone 
biosynthesis, ABC transporters and cytochrome P-450 (CYP)-dependent metabolism of 
xenobiotics in comparison to 2D cultures, also revealing maturation of the HLCs in this 
environment [243]. Apart from hESCs and iPSCs, MSCs have also been effectively used to 
derive HLCs in 3D culture conditions [239]. By resorting to nano-scaffold structures, human 
bone marrow-MSC-derived HLCs showed increased ability to produce urea and transferrin 
[245]. However, although evidence suggests that 3D culture systems offer advantages over 
2D culture systems in terms of HLC derivation, it is still not clear which system provides the 
best differentiation and maintenance conditions.  
3D cultures can be achieved using either dynamic or static systems, comprehending spheroid 
formation [85], cell adherence to a scaffold or more complex cellular systems such as hollow-
fiber bioreactors [63]. The multicellular spheroid technique, a 3D system that uses the capacity 
of cells to self-assemble, has been shown to improve primary hepatocyte phenotype over 
extended periods in culture when compared to 2D cultures [61, 70, 85]. Non-adherent surfaces 
are especially advantageous for spheroid formation and culturing due to the ease of culture 
set up and scale-up, and likely adaptable to high-throughput screening. More complex 
systems, such as hollow-fiber cartridge bioreactors, originally developed to function as 
extracorporeal liver support systems, have also been designed to accommodate dynamic 3D 
high-density culture of human liver cells [63, 64, 94, 95].  
Herein an HLC differentiation protocol from a specific subset of human neonatal MSCs (UCX®) 
was developed and applied two different 3D cell culture systems: a spheroid-based 3D static 
culture system and in a bioreactor consisting on three independent interwoven capillary 
systems for arterio-venous medium perfusion, oxygen supply, and carbon dioxide removal 
[63]. The results were compared to HLC differentiation in a traditional 2D monolayer culture 
system in order to identify specific relevant differences and define the best cell culture 
conditions for HLC maturation and maintenance. We present evidence that deriving HLCs 
using 3D approaches result in a cell population with considerably higher liver functional 
features, namely phase I and phase II metabolizing capacity, but also higher urea and albumin 
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production. Moreover, we have defined a differentiation protocol for obtaining mature and 
homogeneous hepatocyte-like cell populations of human origin that can be used in the future 
as an alternative for biotransformation studies in vitro. 
5.3 Material and Methods 
5.3.1 Reagents 
Trypsin-EDTA, fetal bovine serum (FBS) and insulin-transferrin-selenium solution (ITS) were 
purchased from Gibco®/Life Technologies (Madrid, Spain). Penicillin-Streptomycin-
Amphotericin B (P/S/A), non-essential amino acids supplement (NEAA) and sodium pyruvate 
(NaP) were purchased from Lonza (Basel, Switzerland). 7-ethoxyresorufin was purchased 
from Alfa Aesar (Karlsruhe, Germany). Hepatocyte growth factor (HGF), fibroblast growth 
factors (FGF-2 and FGF-4) and oncostatin-M (OSM) were purchased from Peprotech (Rocky 
Hill, NJ, USA). Iscove's modified Dulbecco's medium (IMDM), alpha modified Eagle's 
minimum essential medium (α-MEM), epidermal growth factor (EGF), dexamethasone, 
dimethyl sulfoxide (DMSO), nicotinamide, 5-azacytidine (5-AZA), periodic acid, Schiff’s 
reagent Mayer’s hematoxylin, Harris's haematoxylin, Eosin Y Eosin, α-amylase, β-
glucuronidase/arylsulfatase, resorufin, 3-methylcholanthrene (3-MC), omeprazole and 
rifampicin were acquired from Sigma-Aldrich (Madrid, Spain). 
5.3.2 Cell cultures 
Rat primary hepatocytes (rpHep) were isolated and cultured as described in Chapter 3. 
HepG2 cells and cryopreserved human primary hepatocytes were cultured as described in 
Chapter 3.  
5.3.3 Human neonatal MSC cultivation and differentiation into HLCs 
This study was approved by the Ethics Committee of the Hospital Dr. José de Almeida 
(Cascais, Portugal), in scope of a research protocol between ECBio (Research & 
Development in Biotechnology, S.A.) and HPP Saúde (Parcerias Cascais, S.A.). Umbilical 
cord donations, with written informed consents, as well as umbilical cord procurement, were 
made according to Directive 2004/23/EC of the European Parliament and of the Council of 31 
March 2004 on setting standards of quality and safety for the donation, procurements, testing, 
processing, preservation, storage and distribution of human tissues and cells. hnMSCs 
(UCX®) were isolated and fully characterized as described previously [257, 259] and expanded 
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as undifferentiated cells in α-MEM supplemented with 10 % of FBS (v/v). A three-step 
differentiation protocol was used for generating HLCs. Briefly, hnMSCs were seeded at a 
density of 1.5 x 105 cells/cm2 in a rat-tail collagen coated surface, as described in Chapter 3. 
In the first step, cells were maintained in IMDM with 1 % P/S/A supplemented with 2 % FBS, 
10 ng/mL of EGF and 4 ng/mL of FGF-2, for 48 hours. In the second step, cells were 
maintained for 10 days with BM supplemented with 20 ng/mL of HGF, 4 ng/mL of FGF-2, 10 
ng/mL of FGF-4, 0.61 g/L of nicotinamide, 1 % ITS and 1 % DMSO. From day 13 onwards 
(third step), cells were supplemented with BM containing 8 ng/mL of OSM, 1 µM of 
dexamethasone, 1 % ITS and 1 % DMSO. Culture medium was changed every 3 days. At day 
17, cells were trypsinized and reinoculated in medium containing 20 µM of 5-azacytidine (5-
AZA) and 5 % of FBS into (i) 2D culture plates pre-coated with collagen (2 x 104 cells/cm2); (ii) 
ultra-low attachment plates (2.5 x 104 cells/mL) in order to obtain a 3D spheroid culture; and 
(iii) 3D miniaturized hollow-fiber bioreactors with a cell compartment volume of 0.5 mL pre-
coated with collagen (40 x 106 cells/bioreactor). Medium was changed 24 h after inoculation 
to remove 5-AZA and FBS. Cells were maintained in third step differentiation medium, with 
medium replacement every 3 days.  
5.3.3.1 Bioreactor technology 
The hollow-fiber multi-compartment bioreactor system consists of an electronically controlled 
perfusion device with pumps for medium recirculation and feed, temperature control and a 
valve-regulated gas mixing unit. The miniaturized bioreactor is made of capillary layers that 
serve for counter-current medium perfusion through two independent capillary systems and 
direct membrane oxygenation of the cells located between the capillaries as represented in 
Figure 5.1 [62-64]. Medium was recirculated at a rate of 3.0 mL/h through the bioreactor and 
fresh medium was added with 0.2 mL/h, at a constant total volume of the recirculation circuit 
of 12 mL. In the recirculating medium, oxygen, glucose and lactate concentrations and pH 
values were measured daily with a blood gas analyser (ABL 700, Radiometer, Copenhagen, 
Denmark); the release of lactate dehydrogenase (LDH), that can be correlated with cell 
viability, was measured with an automated clinical chemistry analyzer (Modular P800, Roche 
Diagnostics, Heidelberg, Germany).  
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Figure 5.1 Miniaturized 3D multi-compartment bioreactor for high-density liver cell perfusion (a). The 
bioreactor has two capillary layers (see upper right insert) that serve for counter-current medium perfusion through 
two independent capillary systems (red and blue) and direct membrane oxygenation (yellow) of the cells located 
between the capillaries. The lower inserts show microscopic pictures (30-fold magnification) of (1) the capillary bed 
before inoculation and (2) immediately after cell inoculation, revealing a homogenous distribution of the inoculated 
cell suspension between the capillaries. Bioreactor operation in an electronically controlled perfusion device (b) 
equipped with pumps for medium recirculation and medium feed, temperature control and with a valve-regulated 
gas mixing unit. Perfusion parameters are automatically monitored and can be regulated via an integrated touch 
screen. Adapted from [64] 
5.3.4 Cell viability assays 
Diclofenac cytotoxicity was evaluated in both 2D monolayer and 3D spheroid cultures using 
the MTS reduction assay and by the determination of LDH activity. Briefly, cells were seeded 
in 100 μl of culture medium at a density of 6,400 and 16,000 cells per well in 96-well collagen 
coated and ultra-low attachment (ULA) plates, in 2D and 3D cultures, respectively. Cultures 
were then incubated and exposed to concentrations of diclofenac of 4.0, 3.0, 2.0, 1.6, 1.0, 0.8, 
0.2, 0.1, 0.05 or 0.0 mM. After 24 h incubation, the cell culture supernatants were collected 
for LDH activity measurement using TOX-7 kit (Sigma-Aldrich, St. Louis, MO) as a measure 
of cell lysis and cells were incubated with MTS (Promega, Madison, WI, USA) in IMDM to 
measure mitochondrial activity. Both methods were applied according to the manufacturer’s 
1
ba
2
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instructions. IC50 was calculated using a non-linear regression fit for the Log10 transformation 
of the concentration values using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, 
CA, USA). Five independent experiments were performed. 
5.3.5 Determination of albumin secretion and urea synthesis 
Albumin and urea secretion were quantified in the cell culture supernatants as described in 
Chapter 3. 
5.3.6 Biotransformation activity 
Cytochrome P-450 (CYP) activity was measured by means of 7-ethoxyresorufin-O-deethylase 
(EROD) activity and luminescent CYP-GloTM assays (Promega, Madison, WI, USA) for 
CYP3A4, CYP2C9 and CYP1A1. Uridine 5’-diphosphate glucuronosyltransferases (UGTs) 
activity was measured by means of 4-methylumbelliferone (4-MU) conjugation by several 
UGTs. CYP450 and UGTs activities were measure as described in Chapter 3. 
5.3.6.1 Substrate Conversion 
The HLCs competence to convert the substrates bupropion (100 μM) and diclofenac (9 μM) 
was evaluated. The functional enzyme activity test for drug specific CYP activity comprised 
CYP2B6 and CYP2C9 and was based on probe reactions, by quantification of the substrates 
1-OH-bupropion and 4-OH-diclofenac, respectively. Methanol as the initial solvent of CYP 
substrates was removed by evaporation (40 min) and substrates were dissolved in culture 
medium before application. Samples from cell culture medium were taken at 0, 0.5, 1, 3, 5 
and 6 h after substrate injection. For the bioreactor, the system was kept in recirculation mode 
without feeding during the CYP activity assays. Samples were snap-frozen and stored at -80 
ºC until analysis. Quantification of metabolites was performed in medium by a LC–MS/MS 
method as described previously [62, 64, 94]. 
5.3.7 Gene (transcript) expression 
RNA isolation and extraction, cDNA synthesis and quantitative real-time PCR (qPCR) was 
performed as described in Chapter 3. 
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5.3.8 Histology 
5.3.8.1 Sample preparation 
Histological analyses were performed in 3D spheroid or bioreactor sections or in 2D 
monolayer cultures. After culture termination, bioreactors were disassembled and the 
capillaries were perfused with a 4% formalin solution for 1 h, followed by dehydration and 
paraffin embedding using standard procedures. Sections (2.5-3.5 µm thick) were 
deparaffinized in Paraclear® and rehydrated in solutions with decreasing ethanol 
concentrations. 3D spheroids were resuspended in Tissue Tek® O.C.T.™ (Sakura®) for 
preparing cryosections of 5-7 µm and fixed with cooled acetone for 10 min. In monolayer 
cultures, cells were cultured on collagen coated glass slides (Nunc™, Lab-Tek™ II Chamber 
Slide™) and fixed with a 4% formalin solution for 10 min. 
5.3.8.2 Immunocytochemistry 
Samples from the bioreactor were pre-treated with 0.1 M citrate buffer in a pressure cooker at 
120 ºC for 15 min in order to unmask antigens. Blocking was performed with 3% bovine serum 
albumin and 2% FBS (both from Sigma-Aldrich, Munich, Germany) for 1 h. Primary and 
secondary antibodies were diluted in blocking buffer for the staining procedure. Incubation 
with primary antibodies was performed overnight at 4 ºC, using the following dilutions: mouse 
anti-human CK-18 (Chemicon, International, Temecula, CA) at 1:200; rabbit anti-human CK-
19 at 1:50, rabbit anti-human albumin at 1:500; rabbit anti-human MRP-2 at 1:50; mouse anti-
human OATP-C at 1:50; mouse anti-human CYP1A2 at 1:100 (all Santa Cruz Biotechnology®, 
Heidelberg, Germany); mouse anti-human HNF-4α (R&D Systems, Minneapolis, MI, USA) at 
1:500; and rabbit anti-human CYP3A4 (Nosan Corporation, Yokohama, Japan) at 1:500. 
Incubations with secondary antibodies were performed for 1 h at RT, using goat anti-mouse 
Alexa Fluor 488 (green staining) and goat anti-rabbit Alexa Fluor 594 (red staining) (Invitrogen, 
Carlsbad, CA). Staining of nuclei was performed using 4’,6-diamidino-2-phenylindole (DAPI; 
Molecular Probes, Eugene, USA). Slides were mounted with Aqua-Poly/Mount cover slipping 
medium (Polyscience Europe, Eppenheim, Germany). 
Microphotographs were taken using a Zeiss Axiovert 200M microscope (Carl Zeiss, Göttingen, 
Germany) with a Retiga 2000R digital camera (QImaging, Surrey BC, Canada) and Image Pro 
Plus software (Media Cybernetics, Silver Spring, MD, USA). 
HepG2 were used as positive controls while undifferentiated hnMSCs cultured as spheroids 
were used as negative control. 
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5.3.8.3 Periodic acid Schiff’s (PAS) staining 
PAS staining was performed to detect glycogen stored in HLCs after differentiation. Cultures 
were incubated with 1 % periodic acid in PBS for 10 minutes, Schiff’s reagent for 15 minutes 
and Mayer’s hematoxylin counterstaining for 30 seconds. The preparations were washed with 
H2O between each step. For negative control differentiated HLCs and human liver histological 
sections were treated with 1 g/L of amylase in 30 mM CaCl2 for 15 minutes at 37 °C before 
staining, in order to digest the existent glycogen. Anonymized liver tissue samples were 
obtained from tissue remained from partial liver resection with informed consent of the patients 
and approval by the Ethical Committee of the Charité - Universitätsklinikum Berlin. 
5.3.8.4 Haematoxylin and Eosin (H&E) staining 
Slides were stained with Harris's haematoxylin for 10 min, followed by an incubation step with 
HCl 1% (v/v) in 70% EtOH, and by Eosin Y staining for 2 min. Slides were then submitted to 
increasing concentrations of ethanol and finally incubated in Paraclear® (EMD Chemicals). 
Samples were mounted with Entellan® (Merck).  
5.3.9 Statistical analysis 
The results are given as the mean ± SEM. Statistical data analysis was performed using 
GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). To estimate the 
significance of the differences of the obtained data a two-way ANOVA with Holm-Sidak 
method was used with p < 0.05 considered as statistically significant. 
5.4 Results 
5.4.1 5-AZA triggers HLCs maturation 
In an attempt to promote hepatic differentiation and maturation of hnMSC the effect of 5-AZA 
was tested under 2D culture conditions. 5-AZA was added to the culture medium at day 17, 
after cell detachment and re-inoculation, and compared with non-5-AZA-supplemented cells. 
A cell passage was introduced at this point since cell proliferation is required for 5-AZA activity 
as a DNA methylation inhibitor. Also at day 17 a change in cell morphology from fibroblastic 
to epithelial appearance was observed and the hepatoblast/early hepatocyte markers, such 
as CK18, ALB and AFP (Figure 5.2a), were overexpressed. Therefore, we classified the pre-
differentiated cells at day 17 as hepatoblast-like cells (HbLCs). 
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At day 27, cells exhibited an epithelial polygonal hepatocyte-like morphology with some bi-
nucleated cells and stained positive for PAS (data not shown). Overexpression of hepatocyte-
specific genes such as ALB, HNF4A, CEBPA, HHEX, TAT and the CYP genes (CYP1A1, 
CYP3A4, CYP1B1), as confirmed by qPCR analysis, was also observed (Figure 5.2a). In fact, 
no significant differences were detected in albumin production with both protocols (Figure 
5.2b). However, in the presence of 5-AZA, a significant increase in urea production (2-fold) 
and in EROD activity (1.2-fold) was observed at day 27 when compared to non-treated cells 
(Figure 5.2c and 5.2d). In addition, UGTs activity remained at a high level both in the presence 
and in the absence of 5-AZA (days 21 and 27) (Figure 5.2e). These data suggest that 5-AZA 
supplementation promoted HLC maturation obtaining phenotypically and functionally 
competent HLCs at day 27. 
5.4.2 3D cultures allow the formation of viable tissue-like structures of HLCs 
To test whether 3D culturing improves HLC metabolic functions, cells were cultured in 3D 
miniaturized multi-compartment hollow-fiber membrane bioreactors, or as self-assembled 
spheroid-based suspension cultures in ULA plates after the re-inoculation step (day 17). In 
parallel, cells were maintained under 2D monolayer (2D) static conditions as control. The 
viability of trypsinized cells was always above 95% (data not shown). In ULA plates, cells 
formed clusters after 24 h that progressively compacted in smooth spheroids with relatively 
small diameters of 109.5 ± 27.6 µm (Mean ± SD) (Figure 5.3e), thus avoiding the formation 
of necrotic centers (Figure 5.3a). In the bioreactor, after cell inoculation, the cells remained 
viable as daily assessed by LDH determination (Figure 5.3f). No evidence of cell proliferation 
was observed in either 2D or 3D confluent cultures. Moreover, both 3D cell culture systems 
allowed for the formation of tissue-like structures (Figure 5.3a and 5.3b), while a 
homogeneous population of polygonal shaped cells presenting some binucleated cells was 
observed in 2D cultures (Figure 5.3c). 
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Figure 5.2 5-AZA triggers HLCs maturation. Gene expression analyses (a) of the hepatic markers on 
hepatoblast-like cells (day 17, light grey bars) and on HLCs (day 27) cultured in 2D culture, with and without 5-AZA 
treatment (grey and black bars, respectively). qPCR shows over expression of the hepatic markers ALB, AFP, 
CK18, HNF4A, CEBPA, CYP1A1, CYP1B1, CYP3A4, TAT and HHEX and under expression of the biliary marker 
CK19 (black and grey bars) for both conditions. 5-AZA supplemented HLCs present higher expression of all genes 
except for CK18 and CK19. Data is normalized to the reference gene GAPDH and expressed in Log10 relative to 
hnMSCs (n= 3). Metabolic capacity of HLCs in 2D cultures until day 27, with and without 5-AZA treatment 
differentiation (grey and black bars, respectively) and on the controls: undifferentiated cells (hnMSCs) HepG2 cell 
line, and primary hepatocytes, human (hpHep) and rat (rpHep) (white bars), is shown by albumin production (b), 
urea secretion (c), EROD activity (phase I) (c) and UGTs activity (phase II) (e), (n=3 Mean ± SEM).  
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Figure 5.3 HLCs cell culture characterization in spheroids, bioreactors and in 2D cultures. Cell morphology 
and glycogen storage capacity demonstrated on (a) HLCs in 3D spheroids; (b) HLCs in the hollow-fiber (hf) 
bioreactor; (c) HLCs in 2D cultures and compared with (d) human liver sections; (a) and (c) are representative 
images of living cells and (b) is H&E stained, showing cells tightly adhered to the hollow-fiber membrane (hf). (a1), 
(b1) (c1) and (d1) are representative images of PAS stained cells whereas c2 and d2 were treated with 5 g/L of 
amylase before PAS staining as glycogen specificity control. Representative images were acquired at day 27 with 
phase-contrast microscopy.  Scale bar = 50 µm. (e) Represents the homogeneity of spheroids size from day 19 to 
day 27 and (f) shows LDH release to the recirculation medium in the BR indicating some cell lyses after inoculation 
(day18) and remains constantly low from day 20 onwards, reflecting the viability of culture.  
5.4.3 Hepatic-specific markers are upregulated in HLC 3D cultures 
Along with the HLC morphology the presence of hepatocyte-specific markers further 
sustaining a hepatocyte-like phenotype was obtained in all culture systems at day 27. The 
cytoskeleton protein CK-18, present in hepatocytes, was highly detected in HLCs both at 
transcript (Figure 5.4) and protein levels (Figure 5.5), whereas CK-19, present in biliary cells, 
bi-potent progenitor cells (oval cells) or hepatocarcinoma cells, was under-expressed in HLCs. 
In fact, CK19 expression (Figure 5.4) was ~3-fold, 2.5-fold and 4.5-fold lower in HLCs (day 
27) in spheroids, bioreactor and 2D cultures, respectively, when compared to hepatoblast-like 
cells (day 17) (Figure 5.2a). Moreover, the same profile of CK19/CK18 gene expression was 
observed in HLCs and in primary hepatocytes in contrast to HepG2 cells (Figure 5.4). The 
expression levels of AFP and CYP3A4 in HLCs were higher in cells grown and maintained in 
3D systems, when compared to 2D cultures (Figure 5.4); whereas the transcript levels of 
HNF4A, a liver enriched transcription factor, CYP1A1 and CEBPA was similar between 
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bioreactor and 2D and ALB mRNA levels were higher in the bioreactor than in spheroids and 
2D culture. Nevertheless, at day 27 the mature hepatocyte marker genes (ALB, CEBPA, 
HNF4A, CYP1A1, CYP1B1) were unregulated relative to undifferentiated cells and to cells at 
day 17 of differentiation (Figure 5.2a). 
 
 
Figure 5.4 Gene expression analyses of the hepatic markers on HLCs (day 27) cultured in 2D culture, in 
spheroids and in bioreactors. qPCR shows over expression of the hepatic markers ALB, AFP, CK18, HNF4A, 
CEBPA, CYP1A1, CYP1B1 and CYP3A4 and under expression of the biliary marker CK19 for all samples, except 
for HepG2 cell line that presented overexpression of CK19. Positive controls are HepG2 cell line and cryopreserved 
hpHep. Data is normalized to the reference gene GAPDH and expressed in Log10 relative to hnMSCs (n= 3). 
The relative expression of ALB, HNF4A and CYP3A4 was confirmed by immunofluorescence 
with HNF-4α showing a clear nuclear localization (Figure 5.5). In turn, the uptake transporter 
protein OATP-C and the efflux hepatic transporter MRP-2 revealed a different localization in 
the 3D culture systems when compared to 2D (Figure 5.5), showing a certain degree of 
cellular polarization, an important characteristic of differentiated hepatocytes. The presence 
of phase I enzyme CYP1A2 was also observed (Figure 5.5), further demonstrating the 
presence and upregulation of hepatic-specific markers in HLC 3D cultures. 
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5.4.4 3D culturing improves cell metabolic activity 
The glucose metabolism, ammonia conversion and albumin production were evaluated in the 
hnMSC-derived HLCs maintained as spheroids or in bioreactors and compared to the cells 
maintained as 2D monolayer. The metabolic activity of HLCs was examined in cell culture 
supernatants and in the bioreactor-circulating medium during the differentiation period.  
The lactate production levels and profiles in 2D, spheroids and bioreactor culture were similar 
(Figure 5.6b). All systems presented glucose metabolism as shown by glycogen storage data 
(Figure 5.3) and glucose release to the medium, shown as negative glucose consumption 
(Figure 5.6a). The latter could be observed in 2D cultures from day 24, consistently showing 
higher levels than 3D cultures (p < 0.01). Conversely, the 3D cell culture systems presented 
an improved metabolic profile regarding urea production, a specific metabolic function of 
hepatocytes. In fact, at the end of cultivation (day 27) ammonia conversion into urea was 5.8- 
and 8.3-fold higher in the bioreactor and in the spheroid-based culture, respectively, when 
compared to 2D cultures (p < 0.05) (Figure 5.6c). The urea production levels observed in the 
bioreactor and in the spheroid-based culture were also respectively similar and higher to levels 
observed in HepG2 and primary hepatocyte spheroids (Supplementary Material, Table 5.1). 
In turn, albumin production was improved in HLCs cultured in the bioreactor, which resulted 
in a 2.9-fold induction relative to 2D (p < 0.001). Spheroid culture albumin production was 
similar to 2D (Figure 5.6d). Overall, 3D culturing improved cells’ metabolic activity, particularly 
for urea production in the spheroids and for albumin production in the bioreactor. 
 
Chapter 5 
 114 
 
Figure 5.5 Immunohistochemical analysis of HLC-derived hnMSCs cultured in spheroids, in bioreactors 
and in 2D cultures (day 27). Representative images show the presence of the hepatic markers CK-18, the plasma 
protein ALB, the transcription factor HNF-4α, the efflux transporter MRP-2, the uptake transporter protein OATP-
C, the biotransformation enzymes CYP1A2 and CYP3A4 and slight presence of the biliary marker CK-19. hnMSCs 
and HepG2 cell line cultured in 3D spheroids were used as negative and positive controls, respectively. Cell nuclei 
are stained with DAPI. Scale bar: 50 μm. 
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Figure 5.6 Metabolic capacity of HLCs cultured in 3D cultures, bioreactor and spheroids, and in 2D cultures 
as a control from day 18 until day 27 is shown by (a) Glucose consumption as well as (b) Lactate (c) Albumin 
and (d) Urea production. * p < 0.05, **p < 0.01 and *** p <  0.001 relative to 2D (n=3 Mean ± SEM).  
5.4.5 HLC Phase I and II enzyme activity is improved in 3D culture conditions 
HLC potential applications in drug metabolism studies imply their biotransformation 
competence. HLC metabolic capacity was monitored regarding phase I and II enzymes at 
different time points. The activity levels of CYP enzymes were measured by EROD, 
CYP1A1/2, CYP2C9 and CYP3A4 activity (Figure 5.7a, 5.7b, 5.7c and 5.8). Phase II 
metabolism was evaluated by UGTs activity (Figure 5.7d). EROD (CYP1A1/2) was performed 
in all culture systems on day 27 (Figure 5.8). However, enzymatic activities could be 
monitored in spheroid-based and 2D-culture distinct time points (days 21 and 27). These two 
cell culture systems are more amenable to screen a higher number of features, including 
induction studies, and therefore CYP1A1, CYP3A4, CYP2C9 activities and their ability to be 
induced by 3-MC (CYP1A1) or rifampicin (CYP3A4 and CYP2C9) were also evaluated (Figure 
5.7).  
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Figure 5.7 Phase I and Phase II metabolism on HLCs. CYP2C9 (a), CYP3A4 (b), CYP1A1 (c) and UGTs (d) 
activity is shown in 2D cultures (grey bars) and spheroids (dark grey bars) as well as the ability to be induced 
(striped bars) by rifampicin (CYP3A4 and CYP2C9) or by 3-MC (CYP1A1) at days 21 and 27 of cell culture. 
Undifferentiated cells (hnMSCs), HepG2 cell line, and primary hepatocytes, human (hpHep) and rat (rpHep) were 
used as controls. All controls were performed in 2D (white bars) and in spheroids culture (SP, light grey bars) 
except for hpHep. All HLCs activities were superior to hnMSCs (*). * p < 0.05, ** p < 0.01, *** p < 0.001 (n=3 Mean 
± SEM).  
Phase I and II enzyme activity increased along the differentiation protocol, in both spheroid 
and 2D conditions. HLCs cultured in both 3D systems presented EROD activity higher than 
that of HepG2 cell line and rpHep (p < 0.01) (Figure 5.8). In fact, a 4.8- and 3.8- fold increase 
was observed in the bioreactor and spheroid-based cultures, respectively, when compared to 
2D monolayer cultures.  
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Figure 5.8 EROD activity on HLCs cultured in bioreactors, spheroids and 2D cultures at day 27 of the 
differentiation (black and grey bars) and on the controls undifferentiated cells (hnMSCS), HepG2 cell line, and 
primary hepatocytes, human (hpHep) and rat (rpHep) (white bars). ** p < 0.01 and *** p <  0.01 relative to 2D (n=3 
Mean ± SEM). 
3D spheroids showed a significant increase in CYP3A4, CYP2C9 and CYP1A1 enzymes 
activity from day 21 to day 27 (p < 0.05). CYP1A1 and CYP3A4 activity in HLCs culture in 3D 
and 2D conditions were similar to those observed in HepG2 cell line. Moreover, HLCs in 3D 
and 2D culture surpassed the activity level of CYP2C9 in HepG2 cells in both monolayer and 
spheroid cultures. In addition, CYP1A1, CYP2C9 and CYP3A4 were consistently induced in 
spheroid HLCs, in contrast to 2D cultures where no induction of CYP3A4 was observed. Most 
importantly, CYP3A4 activity was induced by ~2.5-fold in spheroid HLCs whereas the hpHep 
were only induced by 1.5-fold (Figure 5.7b) at day 27. The same trend was observed for 
CYP1A1 (1.7-fold induction) and CYP2C9 (6-fold induction) activities in HLC spheroids and in 
hpHep. Moreover, CYP2C9 induction was detected in HLC spheroids and hpHep cultures but 
not in HepG2 cell line in both monolayer or spheroids culture.  
Phase II metabolism (Figure 5.7d), observed by the ability to convert 4-MU by several UGTs, 
increased in both cultures throughout time, being similar to primary hepatocytes (cultured for 
24h) and statistically higher than in HepG2 spheroid cultures (p < 0.01).  
HLCs obtained and maintained in the three culture systems showed to be metabolic 
competent as quantified by both phase I and phase II enzyme activities. CYP activity levels of 
HLCs were higher than those obtained with the HepG2 cell line for CYP2C9, CYP3A4, EROD 
and UGT activity. Moreover, CYP activity and induction capacity was either maintained or 
increased over time in spheroid-based cultures, further sustaining that the 3D cultures 
improved HLC maturation. 
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5.4.6 hnMSC-derived HLCs metabolize diclofenac and bupropion 
Considering the maintenance of enzyme activity of the HLCs between day 21 and 27, and the 
better performance in albumin and urea production, glucose metabolism and CYP activity on 
day 27, the ability to convert drugs, namely diclofenac and bupropion, to their specific 
metabolites was evaluated in all systems at this time point. HLCs showed the capacity to 
biotransform diclofenac and bupropion whereas undifferentiated hnMSCs revealed the 
presence of residual metabolites in significantly lower amounts (Figure 5.9). The spheroids 
showed a higher capacity to metabolize bupropion (CYP2B6), followed by the bioreactor and 
the 2D cultures (Figure 5.9b). On the other hand, the bioreactor presented the higher 
metabolic conversion rate for diclofenac (Figure 5.9a) into 4-OH-diclofenac. 
5.4.7 HLCs show higher toxicity to diclofenac in spheroid suspension cultures 
To examine the applicability of hnMSC-derived HLCs to be used for predicting drug induced 
cytotoxicity, treatment with a drug that causes hepatotoxicity was performed. Diclofenac at 
concentrations ranging from 0.05 to 4 mM was used for testing HLC suitability for drug 
screening. In addition, cell viability was evaluated by MTS reduction assay and by the 
determination of LDH activity in both the spheroid and the 2D models in order to identify the 
most relevant culture system. Our results show that both assays have a dose-response profile 
after a 24 h-period of incubation with cells maintained in spheroid-based cultures being 
significantly more sensitive to diclofenac exposure than HLCs in 2D cultures (p < 0.001) 
(Figure 5.10). The calculated IC50 values for 3D spheroid and 2D monolayer cultures exposed 
to diclofenac were 0.98 ± 0.03 mM and 1.51 ± 0.05 mM, respectively, for the MTS assay 
(Figure 5.10). For the LDH release assay a significant increase was only observed for 
concentrations above 2mM in both culture systems (data not shown). Therefore, the results 
herein observed may suggest that a higher bioconversion of diclofenac and its metabolites 
may be occurring in the spheroid-based system. 
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Figure 5.9 Metabolic competence of HLCs evaluated by exposure to (a) diclofenac and (b) bupropion. Time 
course of product formation over 6 h and formation rates (calculated over 3 h) of CYP specific metabolites (OH-
diclofenac for CYP2C9 and OH-bupropion for CYP2B6) in undifferentiated cells (hnMSCs) and HLCs in spheroid 
and bioreactor cultures (3D, black marks) and HLCs in 2D cultures (white marks) at day 27 of cell culture. * p < 
0.05 and ** p <  0.01 relative to 2D (n=3 Mean ± SEM).  
 
Figure 5.10 Comparison of diclofenac cytotoxicity in 3D spheroids and 2D monolayer cultures evaluated 
by MTS mitochondrial activity assay. The HLCs were incubated with 4.0, 3.0, 2.0, 1.6, 1.0, 0.8, 0.2, 0.1, 0.05 
and 0.0 mM of diclofenac. The relative amount of live cells is calculated to non-treated HLCs (Mean ± SEM).  
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5.5 Discussion 
The liver function is partially ensured by the hepatocytes. A function that is dependent on the 
establishment of relevant cell-to-cell and cell-to-matrix interactions as well as on maintenance 
of gradients of oxygen, nutrients, endobiotics and xenobiotics and their metabolites. 3D 
cultures provide environmental characteristics that mimic the liver physiology in vivo better 
than traditional monolayer cultures [7].  Thus, by applying 3D cell culture systems to HbLC 
maturation, we hypothesized that the HLC phenotype and functionality could be improved. 
Our hypothesis rests on our previously reported efficient differentiation protocol for deriving 
HLCs from a specific population of umbilical cord tissue derived-hnMSCs. This protocol was 
developed in monolayer culture conditions that resulted in HLCs with drug metabolizing 
capacity lower than primary hepatocytes (Chapter 3). Herein, such protocol was improved 
and successfully adapted to highly reproducible 3D cell culture systems that improved HLC 
maturation. Most importantly, the HLCs derived from our hnMSC population showed 
significant drug metabolizing capacity comparable to primary hepatocytes, which is crucial for 
in vitro toxicology applications.  
For a more efficient HLC differentiation, some further improvements were introduced to our 
previously developed protocol [333]. Hepatoblasts are characterized by their bi-potency and 
represent a highly proliferative stage of hepatogenesis [336]. Thus, a cell passage step was 
applied to HbLC at differentiation day 17, in order to allow for cell proliferation which is 
otherwise not occurring in a confluent monolayer cell culture. A proliferative stage is also 
necessary for 5-AZA incorporation into the DNA, since it is a cytidine analogue that inhibits 
DNA methylation [209]. To our knowledge, 5-AZA effects on hepatocyte differentiation 
protocols in vitro has only been attempted on human adipose-derived stem cells by Seeliger 
et al. [213], and on umbilical cord blood derived MSCs by Yoshida et al. [214] being applied 
24 h prior to the differentiation induction. Seeliger et al. tested the DNA methylation effect of 
5-AZA (5 to 20 μM). The best result was observed with 5-AZA at 20 μM [213] with improved 
glucose secretion, and CYP1A1/2 and CYP2B6 activity. Urea production was similar to both 
freshly isolated hepatocytes and cells not exposed to 5-AZA [213]. On the other hand, Yoshida 
et al. achieved a significantly higher proportion of ALB, c/EBP-α, CYP1A1/2 and PAS positive 
cells, as well as higher urea production and ALB gene expression after 21 days of 
differentiation than on non-5-AZA-treated cells [214]. However, a less mature phenotype than 
that observed by Seeliger et al. [213]. 5-AZA was previously tested on HLC differentiation at 
day 0, using our hnMSC source [333] but no significant HLC functionality improvement was 
observed. Therefore, 5-AZA was herein tested on day 17 after a cell passage step. This should 
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inhibit DNA methylation by 5-AZA as well as increase the expression of genes in a presence 
of a chemical cocktail that is inducing the hepatic differentiation and maturation. In fact, this 
approach resulted in increased urea production, EROD activity and the expression of hepatic-
specific marker genes, namely ALB, CEBP, HNF4A, CYP1A1, CYP1B1 (day 27) when 
compared to non-differentiated cells.  
Several reports on the generation of functional HLCs from human SC have been described. 
The majority of these studies use direct developmental signaling of embryonic and induced 
SC for deriving HLCs in monolayer cultures. However, fully functional hepatocytes have not 
been obtained so far. Some reports describe the differentiation of hnMSCs into HLCs [172, 
174, 179], but only two of them resort to 3D cell culturing, one using a collagen scaffold [337] 
and another culturing HLCs as spheroids [338]. 3D culture conditions promote a structural 
organization which is important for the maintenance of liver cell characteristics [7], as shown 
by the higher albumin secretion, ammonia detoxification, amino acid metabolism, 
glycogenolysis, bile secretion, enzymatic activity related to biotransformation and the polar 
distribution of transporters observed in primary hepatocyte cultures performed in several 
different 3D culture settings [61, 64, 70, 71, 85]. 3D culturing also proved successful in 
improving the hepatocyte-like phenotype in terms of biotransformation activity, as shown by 
spheroid-based cultures of either hESCs-derived or iPSC-derived HLCs [236, 237, 334, 335]. 
In particular, the differentiation of hESCs in a hollow-fiber bioreactor resulted in an 
upregulation of pathways related to steroid hormone biosynthesis, ABC transporters and CYP-
dependent metabolism of xenobiotics in comparison to 2D cultures, also revealing maturation 
of the HLCs in this environment [243]. Apart from hESCs and iPSCs, MSCs have also been 
effectively used to derive HLCs in 3D culture conditions [239]. By resorting to nano-scaffold 
structures, human bone marrow-MSC-derived HLCs showed increased ability to produce urea 
and transferrin [245]. Although evidence is clear about the advantages of 3D culture systems 
over 2D culture systems in terms of HLCs derivation, it is still not clear which system provides 
better differentiation and maintenance conditions. In this work, a static spheroid cell culture 
model and a perfused bioreactor system were applied and compared to traditional monolayer 
cultures in terms of promotion of HLCs phenotype and function.   
In this study, cells were adapted to 3D cell culture systems at the trypsinization step (day 17) 
and their hepatocyte specific features were evaluated up to differentiation day 27. It has been 
described that cells cultured in three-dimensional systems are able to form ECM, thus 
providing high cell-to-cell and cell-to-matrix interactions. This effect was previously observed 
in primary hepatocytes either cultured in spheroids [61, 71] or in a perfused bioreactor [94]. In 
fact, a compact cell organization with distinct localization of hepatic transports among cell 
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membrane could be observed in HLC 3D cultures, which resulted in higher phase I metabolic 
activity. However, when developing an HLC-based in vitro system other hepatocyte specific 
features such as urea or albumin production, herein improved, should not be disregarded. 
The 3D configuration creates a gradient with higher oxygen, glucose and nutrients presence 
in the outer layer of the spheroid and in cells closer to the capillaries in the bioreactor, which 
may mimic the liver periportal environment characterized by higher xenobiotic metabolism and 
glycogen synthesis from glucose as well as lower urea production [7, 50]. Therefore, a more 
heterogeneous cell population is expected in 3D cultures than in monolayer cultures. Indeed, 
CYP1A2 and CYP3A4 are detected in the tissue-structure, whereas the hepatic transporters 
OATP-C and MRP-2 are predominantly located near the hollow-fiber capillary suggesting 
some phenotype zonation in the bioreactor. The same could be observed in the spheroids, 
although at a lesser extent. Conversely, a homogeneous distribution of phase I enzymes and 
the hepatic transporters is observed in monolayer cultures. 
In the present study, cells maintained in both 2D or 3D culture systems revealed a gene 
expression profile closer to hpHep, particularly in terms of CK19 and AFP gene expression 
when compared to HepG2 cell line. In turn, CK19 gene and protein expression were lowered 
in 3D culture conditions reflecting a higher maturity of the HLCs in those environments. In fact, 
CK19 is present in progenitor cells of the developing liver, hepatoblasts and later in the 
development in ductal plates. In normal mature liver, CK19 is exclusively expressed in biliary 
duct cells and in oval cells, a type of bi-potent cells involved in hepatocyte and cholangiocyte 
differentiation [339, 340]. Thus, the isolated CK19 positive cells observed in 2D cultures reflect 
the presence of less differentiated cells whereas the presence of CK19 clusters, more evident 
in the spheroid-based cultures, can reveal some differentiation into biliary-like cells.  
Furthermore, by providing a perfused cell culture system with a bioreactor, characterized by 
higher cell-to-cell contacts, we achieved improved albumin production by HLCs, as observed 
by increased ALB gene expression, intracellular presence and secretion. This has not been 
observed in spheroid-based cultures. However, cells kept in the spheroid-based culture were 
able to show higher albumin secretion than cells kept in the 2D system, from day 27 to day 34 
(Figure 5.11), suggesting that long-term cultivation may indeed allow cell maturation.  
On the other hand, HLC spheroids showed CYP induction capacity and UGT activity. UGT 
activity is associated with later hepatocyte maturity [341] and it is scarcely reported on stem 
cell-derived HLCs. Herein, we can observe a higher glucuronidation capacity in the spheroids, 
showing a 2-fold increase from day 21 to day 27, to levels comparable to cryopreserved hpHep 
cultured for 24h. In agreement with previous studies by Hamilton et al. [342] showing that the 
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induction of CYP enzymes is dependent on cell density and cell-to-cell contacts in hpHep 
cultures, the induction of CYP activity was consistently observed in the spheroid-based 
cultures but not in the monolayer system. Finally, the expression of CYP3A4 was higher in 
HLCs from 3D cultures, which is reflected by CYP activity on day 27 when compared to cells 
in 2D cultures. 
 
Figure 5.11 Phase I and II metabolism on HLCs up to day 34. CYP2C9 (a), CYP3A4 (b), CYP1A1 (c) and UGTs 
(d) activity is shown in 2D cultures (grey bars) and spheroids (dark grey bars) as well as the ability to be induced 
(striped bars) by rifampicin (CYP3A4 and CYP2C9) or by 3-MC (CYP1A1) at days 27 and 34 of cell culture. 
Undifferentiated cells (hnMSCs), HepG2 cell line, and primary hepatocytes, human (hpHep) and rat (rpHep) were 
used as controls. All controls were performed in 2D (white bars) and in spheroids culture (SP, light grey bars) 
except for hpHep. All HLCs activities were superior to hnMSCs (*). * p < 0.05, ** p < 0.01, *** p < 0.001 (n=3 Mean 
± SEM). 
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The presence of hepatic transporters and CYP metabolism is particularly relevant for in vitro 
toxicology applications. Gieseck et al. [244] compared iPSC-derived HLCs in 2D conditions 
with iPSC-derived HLCs in 3D conditions and observed that the expression of the MRP-2, an 
efflux transporter protein, occurred only in the HLCs obtained from 3D cultures consisting of 
cells clustered onto a collagen matrix. Additionally, a stable CYP3A4 activity and albumin 
production was maintained, while AFP production decreased [244]. Subramanian et al. [236] 
also showed a phenotype improvement of HLCs derived from hESCs when cultured on 
spheroid static cultures, namely the decrease of AFP expression and an increase of albumin 
production and expression. Finally, Okura et al. [239] observed hepatocyte-like characteristics 
on HLCs clusters derived from adipose tissue hMSCs as indicated by ALB and antithrombin 
presence, urea production and glycogen storage capacity, but the comparison with 2D cell 
cultures is scarce. In the present study, we could observe not only MRP-2 presence, but also 
an influx transporter with great impact in pharmacokinetics, OATP-C. 
Notably, HLCs cultured in any of the three systems presented a relevant biotransformation 
capacity by converting bupropion and diclofenac into their corresponding metabolites, 1-OH- 
bupropion and 4-OH-diclofenac. Moreover, CYP3A4 is present in all cell cultures systems at 
protein level and its activity was confirmed in spheroids and 2D culture by the luminescent 
assay and in bioreactor by midazolam conversion into 1-OH-midazolam (data not shown). 
Diclofenac is mainly metabolized by CYP2C9 into 4-OH-diclofenac and also, in a lower extent, 
converted into 5-OH-diclofenac by CYP3A4. Diclofenac and OH-diclofenac are glucuronidized 
by UGT2B7 and excreted across the canalicular plasma membrane into the bile via MRP-2 
[102]. Therefore, diclofenac metabolism comprises phase I, II and III enzyme activities and its 
toxic effects can be associated to its reactive metabolites 4-OH-diclofenac, diclofenac-acyl-
glucuronide and 4-OH-diclofenac-acyl-glucuronide [102]. In addition, diclofenac is one of the 
most prescribed nonsteroidal anti-inflammatory drug (NSAID) worldwide [102]. There are 
several lines of evidence demonstrating drug induced liver injury (DILI) by diclofenac including 
in vitro, in vivo and epidemiological data. Diclofenac causes rare albeit significant cases of 
serious hepatotoxicity. Due to the large number of patients treated the absolute number of 
reported cases of hepatotoxic adverse drug reaction by diclofenac is still impressive with 
fatality rate of 10 % [102]. As such, diclofenac was herein selected as a hepatotoxicant 
dependent of bioactivation. Herein, the cells kept in spheroids showed lower IC50 values for 
diclofenac than cells cultured in monolayer conditions, which can be a result of a higher 
CYP2C9 activity in spheroids. The IC50 values for diclofenac among the literature are highly 
variable. For conditions of 24 h of diclofenac exposure to hpHep monolayer cultures IC50 
values of  0.76 mM [104] and 1.41 mM [106]  have been reported. The value calculated for our 
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spheroid culture of 0.98 ± 0.03 mM falls within this range. The 2D culture, in turn, showed a 
higher IC50 value (1.51 ± 0.05 mM) similar to what has previously been reported for iPSC-
derived HLCs (IC50 of 1.85 mM and 1.92 mM) [343]. Diclofenac toxicity studies are scarce in 
comparing monolayer and 3D cell cultures. To our knowledge, the study of Xu et al. [103] is 
the only one reporting the effects of diclofenac in rat primary hepatocyte and HepG2 spheroids 
[103]. In a recent study diclofenac metabolism and toxicity was investigated in perfused 3D 
bioreactors using primary human hepatocytes [95]. However, no data for its comparison with 
monolayer cell culture is reported. Although no IC50 value was calculated, these authors 
observed toxicity for concentrations higher than 0.5 µM. Moreover, it was observed that 
diclofenac significantly decreased LDH release in liver spheroids but not in HepG2 spheroids 
[103], pointing out the importance of using metabolic competent cells to assess the toxicity of 
this drug. Herein, higher levels of 4-OH diclofenac are observed in monolayer, but an 
increased phase I (CYP2C9 and CYP3A4) and II (UGTs) activities is shown for spheroid 
cultures. Therefore, the results herein observed may suggest that a higher bioconversion of 
diclofenac and its metabolites in spheroids may be occurring, resulting in its more toxic sub-
products and consequently in higher cytotoxicity. 
An important achievement of this study is a thorough characterization of HLCs derived from 
MSCs in distinct culture conditions. The findings herein described support the potential of 
hnMSC-derived HLCs as an alternative cell type for human biotransformation studies, thus 
reinforcing the importance of the cell culture environment as a key factor for the maintenance 
of the hepatocyte-like phenotype [61, 70, 71, 85]. Overall, the 3D culture systems tested 
clearly improved a liver specific phenotype, with biotransformation capacity of the resulting 
HLCs, with no major differences between the spheroid-based culture system and the hollow-
fiber bioreactor. However, the subtle differences between phenotypic impacts promoted by 
each of the 3D models adopted are enough to entail that optimal culture systems should be 
selected depending on the scientific applications. Furthermore, our study supports the viability 
of the abundant and ethically safe hnMSCs (UCX®) to serve as precursors to achieve a mature 
HLC phenotype. Differentiated UCX® presented high and persistent levels of 
biotransformation activity in vitro that meet the pharmaceutical industry needs in terms of high-
throughput drug screening. 
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5.6 Supplementary Material 
Table 5.1 Albumin Production on the controls: undifferentiated cells (hnMSCS), HepG2 cell line, and 
primary hepatocytes, human (hpHep) and rat (rpHep) in 2D and in spheroids culture 
Albumin Production (pg/106cells.h) 
Mean ± SD 
 2D 3D 
(Spheroids) 
hnMSCs 35.47 ± 7.75 44.17 ± 9.63 
HepG2 8472.47 ± 33.97 14807.09 ± 1125.66 
rpHep 331.69 ± 13.32 469.56 ± 59.77 
hpHep 26318.39 ± 4478.80 - 
 
Table 5.2 Urea Production on the controls: undifferentiated cells (hnMSCS), HepG2 cell line, and primary 
hepatocytes, human (hpHep) and rat (rpHep) in 2D and in spheroids culture 
Urea Production (µg/106cells.h) 
Mean ± SD 
 2D 3D 
(Spheroids) 
hnMSCs 0.31 ± 0.11 1.20 ± 0.22 
HepG2 13.97 ± 3.37 35.47 ± 2.83 
rpHep 21.32 ± 10.06 71.47 ± 7.24 
hpHep 57.96 ± 1,89 - 
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6 Chapter 6. The integrated assessment of nevirapine 
biotransformation unveils the biocompetence of a 3D in vitro 
model of human hepatocyte-like cells for liver function studies 
 
The scientific content of the present chapter has been included in the following publication: 
Cipriano M, Pinheiro PFP, Sequeira C, Santos JM, Oliveira NG, Marques MM, Castro M, 
Pereira AS, Miranda JP. The integrated assessment of nevirapine biotransformation unveils 
the biocompetence of a 3D in vitro model of human hepatocyte-like cells for liver function 
studies (submitted for publication) 
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6.1 Abstract 
Three-dimensional (3D) cultures have been demonstrated to better mimic the in vivo hepatic 
tissues and maintain metabolic functions in primary hepatocyte and hepatocyte-like cell (HLC) 
cultures. Herein, we used NVP as a model drug for to assess the adequacy of human neonatal 
mesenchymal stem cell (hnMSC)-derived HLCs as a hepatic model for drug biotransformation 
studies. Nevirapine (NVP) is an antiretroviral drug with associated hepatotoxicity, partially 
related to its extensive hepatic metabolism and its auto-induction capacity. Studies on NVP 
bioactivation/toxicity are still needed and challenging, due to unclear reactivity of its 
metabolites and impaired detection of reliable biomarkers of toxicity. Since the toxic effects of 
NVP appear to be strongly associated with the generation of reactive metabolites that form 
covalent adducts with biomacromolecules, determining the cells’ thiolomic profile could 
represent a relevant strategy for the early detection of electrophilic/oxidative stress. HLCs 
cultured as 3D self-assembled spheroids or as a monolayer were exposed to 300 µM of NVP 
for 3 and 10 days. Both 3D and 2D HLC cultures yielded all known phase I NVP metabolites, 
i.e., 2-OH-NVP>12-OH-NVP>3-OH-NVP>8-OH-NVP. Induced ECOD and SULT1A1 activities 
and increased gene expression of CYP3A4 and CYP2D6 were also observed upon NVP 
exposure. In addition, 3D cultures presented upregulated CYP2B6 (phase I), UGT1A1, 
SULT1A1 and GSTA1-A2 (phase II) and MRP7 (phase III), which resulted in higher amounts 
of NVP phase I and II metabolites. Regarding the thiolomic profile analyses, in contrast to the 
2D system, the HLC 3D model responded to NVP exposure at all evaluated levels, namely by 
showing an increased total free GSH amount in the supernatant and maintenance of the 
intercellular levels of its precursors, CYS and GLU-CYS. Moreover, regarding the glutathione 
oxidation status, only 3D-HLC presented an increased intracellular GSSG/GSH ratio. Our 
results demonstrate the adequacy of hnMSC-derived HLC 3D model as a metabolic 
competent system comprising phase I, II and III regulation at gene expression and enzymatic 
activity levels, namely presenting auto-induction of its own metabolism. These data highlight 
the relevance of human hepatocyte-like cells derived from stem cell as alternative in vitro 
models to study drug metabolism and unveil toxicity alerts associated with drug metabolism 
and bioactivation. 
Keywords: 
In vitro alternative models; Nevirapine biotransformation; Human mesenchymal stem cells; 
Hepatocyte-like cells; 3D culture  
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6.2 Introduction 
Alternative in vitro hepatotoxicity studies have been explored due to the well-known 
drawbacks of primary hepatocytes and hepatic cell lines, such as availability and long-term 
metabolic stability, and metabolic competence, respectively [7]. Stem cells constitute a source 
of human cells which differentiation into hepatocytes has already been attempted. The 
differentiation of human induced pluripotent stem cells (hiPSC), human embryonic stem cells 
(hESC) and human mesenchymal stem cells (MSC) into hepatocyte-like cells (HLC) have 
been extensively reported [75], but none has been yet validated for routine hepatotoxicity 
testing.  
3D cultures of primary hepatocytes have shown to display an enhanced phenotype than 
traditional monolayer cultures concerning cell biotransformation and functional ability over 
time in culture [61, 63, 64, 70, 71, 85, 91, 95, 98]. It allows higher cell-to-cell and cell-to-matrix 
contact, the presence of gradients of nutrients and oxygen and cell polarization. This is 
essential for hepatocyte functional specialization, which can be of enormous impact when 
studying drugs susceptibility in vitro [7]. Therefore, promising for an early assessment of 
molecules as therapeutic targets or detecting its potential toxic effects, with higher accuracy 
and decreased number of sacrificed animals. 3D cell cultures comprise cells adherent to a 
scaffold [76, 77], multicellular spheroids [61, 70, 71, 85], or more complex cellular systems 
such as hollow-fiber bioreactors [64, 173]. The last two conditions have been previously 
explored by our group for deriving HLC from human neonatal MSC [173]. In such work, the 
phenotype of hnMSC-derived HLC was improved by resorting to more physiologically relevant 
cell culture systems, namely, self-assembled spheroids formed in non-adhesive surfaces 
(ULA static system) and perfused hollow-fiber bioreactors (perfused system) [173]. Ultra-low 
attachment multi-well plate presents itself as a simpler non-adhesive surface format for 
multicellular spheroids formation. It is particularly advantageous for the optimization culture 
media supplementation or to test compounds’ toxicological effects and has been used in 
smaller-scale cell culture systems, applied either to stem cell [88, 89] or hepatic cell lines [90].  
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved by the 
US Food and Drug Administration and by the European Medicines Agency for the treatment 
of HIV type-1 infection, being the most prescribed NNRTI in the world, and the most prescribed 
antiretroviral in countries with limited economic resources [91]. NVP is mostly used in mother-
to-child transmission HIV infection prophylaxis. It is also the most tolerated NNRTI though it 
presents skin and hepatic toxicity [344, 345], which conferred NVP a black box warning for 
hepatotoxicity that occurs in 6 % of patients within the first six weeks of treatment and can be 
Chapter 6 
 130 
life threatening if resulting in fulminant liver failure [345]. NVP is extensively metabolized, 
being only 2.7 % of NVP excreted in urine in human as parent compound [346]. Its half-life is 
reduced from 45 h after first dose to 30 h after two weeks of dosing [347], corresponding to 
the NVP auto-induction period. NVP is biotransformed by phase I and II enzymes, whereas 
both NVP and its metabolites can regulate their own metabolism. Indeed, NVP induces 
CYP2B6 and CYP3A4 [348], whereas 2-OH-NVP induces SULT1A1 [91]. NVP phase I 
metabolites 2-OH-NVP, 12-OH-NVP, 3-OH-NVP and 8-OH-NVP present increasing plasma 
concentrations during the first 4 weeks of treatment [349], but may also suffer secondary 
oxidation, such as the conversion of 12-OH-NVP into 4-COOH-NVP that is only detected in 
plasma after 1 month of treatment [349]. On the other hand, 12-OH-NVP may suffer 
glucuronidation or sulfonation. 12-sulfoxy-NVP is a more reactive product able to form adducts 
with proteins and DNA with consequent toxic effects [350, 351] that may be detoxified trough 
glutathione conjugation, namely by GSTA1-1, GSTM1-1 and GSTA3-1 [352]. Due to its 
bioactivation, detoxification and toxicity mechanisms, NVP in vitro studies require a functional 
cellular model, namely regarding phase I, II and III enzymes activity. Therefore, NVP has 
shown to be a relevant tool for the evaluation of in vitro cellular models of biotransformation 
particularly when resorting to physiologically relevant cell culture systems as the 3D spheroids 
[91, 348]. As such, the aim of this study was to evaluate hnMSC-derived HLCs cultured in 2D 
and 3D as a human based-alternative in vitro tool for toxicology studies. The formation of NVP 
metabolites over long-term culture was analysed together with its effect on gene expression 
and activity of phase I, II and hepatic transporters, NVP metabolite quantification and on cell 
thiolomic profile.  
6.3 Material and Methods 
6.3.1 Reagents 
Trypsin-EDTA, fetal bovine serum (FBS) and insulin-transferrin-selenium solution (ITS) were 
purchased from Gibco®/Life Technologies (Madrid, Spain). Penicillin-Streptomycin-
Amphotericin B (P/S/A), non-essential amino acids supplement (NEAA) and sodium pyruvate 
(NaP) were obtained from Lonza (Basel, Switzerland) and 7-ethoxycoumarin from Alfa Aesar 
(Karlsruhe, Germany). Hepatocyte growth factor (HGF), fibroblast growth factors (FGF-2 and 
FGF-4) and oncostatin-M (OSM) were purchased from Peprotech (Rocky Hill, NJ, USA). 
Iscove's modified Dulbecco's medium (IMDM), alpha modified Eagle's minimum essential 
medium (α-MEM), epidermal growth factor (EGF), dexamethasone, dimethyl sulfoxide 
(DMSO), nicotinamide, 5-azacytidine (5-AZA), trypan blue, Hank’s balanced salt solution 
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(HBSS), 4-methylumbelliferone (4-MU), β-glucuronidase/arylsulfatase and reagents used for 
SULT1A1 activity and thiolomic profile determination were acquired from Sigma-Aldrich 
(Madrid, Spain). Nevirapine (NVP) was a gift from Dr. F. A. Beland (National Center for 
Toxicological Research, Jefferson, AR, USA). NVP stock solution was prepared in tissue 
culture grade DMSO at a concentration of 150 mM. Finally, high-performance liquid 
chromatography (HPLC)-grade solvents that were used in the extraction and mobile phases 
of the chromatography experiments were purchased from VWR (Leuven, Belgium). 
6.3.2 Cell culture  
hnMSC (UCX®) were isolated and fully characterized as described previously [257, 259] and 
expanded as undifferentiated cells in α-MEM supplemented with 10 % of FBS. HepG2 cell line 
was cultured as described in Chapter 3. A three-step differentiation protocol was used for 
generating HLCs as described in Chapter 5. Briefly, hnMSC were seeded at a density of 1.5 
x 105 cells/cm2 in a rat-tail collagen coated surface, used at a concentration of 0.2 mg/mL. At 
day 17 of differentiation, cells were trypsinized and reinoculated in differentiation medium 
(IMDM containing 8 ng/mL of OSM, 1 µM of dexamethasone, 1 % of DMSO and 1 % ITS) 
containing 20 µM of 5-azacytidine (5-AZA) and 5 % of FBS into (i) ultra-low attachment plates 
(2.5x104 cells/mL) to obtain a 3D spheroid culture or (ii) 2D culture plates pre-coated with 
collagen (2 x 104 cells/cm2) as control. Cells were maintained for 24h and then the medium 
was replaced by third step differentiation medium. Medium replacement occurred every 3 
days.  
At day 24 of the differentiation cells were incubated with 300 µM of Nevirapine [91, 98] and 
exposed for 3 and 10 days. HepG2 and hnMSC were treated for 72h. DMSO concentration 
was 1 % DMSO (v/v) in both NVP-treated cells and non-treated cells since this is the DMSO 
concentration used in the differentiation media.  
Cell culture was monitored microscopically using phase contrast microscopy (Olympus CK30 
inverted microscope). Images were acquired using Moticam 5.0 (Motic) and recorded with 
Motic Images Plus 2.0 software. The spheroid diameter was evaluated every 3 days according 
to Chapter 4.  
6.3.3 Biotransformation activity 
CYP enzyme activity was measured by means of 7-ethoxycoumarin-O-deethylase (ECOD) 
activity and P450-GloTM assays (Promega, Madison, WI, USA) and UGTs activity by means 
of 4-MU conjugation as described in Chapter 3. 
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The thermostable SULT1A1 activity was assessed in cell homogenates from both 2D and 3D 
cultures. Cell homogenates were obtained by sonication of cell pellets, containing ~0.07 x 106 
cells, suspended in 200 µL of sonication buffer (10 mM triethanolamine at pH 7.4 with 0.25 M 
sucrose and 5 mM β-mercaptoethanol). Sonication procedures were performed on ice. 
SULT1A1 activity was assessed using the 2-naphthol sulfonation assay in cell homogenates 
as previously described [91]. A reaction mixture containing 50 mM phosphate buffer (pH 7.5), 
5 mM MgCl2, 0.5 mM EDTA, 20 µM of adenosine 3′-phosphate 5′-phosphosulfate (PAPS), 5 
mM of potassium p-nitrophenol sulfate (KNPS) and 100 µM of 2-Nafthol (2-NAF) 5 mM 4-
nitrophenyl sulfate. An effective PAPS-regenerating system results from the the addition of p-
nitrophenyl sulfate. SULT1A1 catalyzes the synthesis of 2-naphthylsulfate from 2-NAF and 
PAPS, producing p-nitrophenol. The measurement of p-nitrophenol absorbance at 405 nm is 
therefore an indirect measure of sulfotransferase activity. A calibration curve was built with p-
nitrophenol and absorbance registered at 405 nm (SPECTROstar Omega, BMG Labtech) 
after 5 hours incubation at 37 ºC in a humidified atmosphere. 
The ECOD, CYP3A4/5, UGTs and SULT1A1 activities were normalized to incubation time and 
cell number as described in Chapter 3. Data is expressed as fold induction of NVP treated 
cultures relative to non-treated cultures. 
6.3.4 Gene expression 
RNA isolation was performed using Trizol® (Life Technologies, Madrid, Spain). RNA was 
quantified prior to cDNA synthesis as previously described [173, 353]. cDNA synthesis was 
performed from 0.5 µg of RNA using a commercially available kit (NZYTech, Lisbon, Portugal) 
and quantitative real-time PCR (qPCR) performed using PowerUp™ SYBR® Green Master 
Mix (Applied Biosystems, Thermo Fisher Scientific, USA), according to the manufacturer’s 
instructions. A final reaction volume of 15 µL, with 1 µL of template cDNA and 0.1 µM of 
forward and reverse primers (Table 6.1) was used and the reaction was performed in the 
Real-time PCR system (ABI7300; Applied Biosystems®/ Life Technologies, Madrid, Spain). 
The amplification of cDNA consisted on a denaturation step at 95 °C for 10 minutes, 40 cycles 
of denaturation at 95 °C for 15 seconds, annealing at 60 °C for 1 minute and extension at 72 
°C for 30 seconds. As a quality and specificity measure, a dissociation stage was added to 
determine the melting temperature in all runs. The comparative Ct method (2-ΔΔCT) was used 
to quantify the amount of target genes, normalized to a reference gene BACTIN and relative 
to NVP non-treated cells unless otherwise stated. The efficiency of each PCR reaction was 
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estimated from a serially diluted cDNA from HepG2 non-treated cells in order to construct a 
standard curve (1, 10-1, 10-2) for each gene, considering efficiencies between 1.8-2.2.  
Table 6.1 Primers used for qRT-PCR characterization of differentiated HLCs,  undifferentiated hnMSCs and 
HepG2 cell line 
6.3.5 Quantification of nevirapine metabolites  
Supernatants from 3D and 2D cell cultures were collected (triplicates) on days 27 and 34 of 
the differentiation, and treated separately. For the quantification of phase I and phase II NVP 
metabolites, 15 mL of cell culture supernatants were incubated for 24 hours at 37 °C in the 
absence (free metabolites) or presence of sulfatase (type H-1 from Helix pomatia, E.C. 
3.1.6.1, 100 U/mL) and saccharic acid 1,4-lactone (4 mg/mL) for the detection of free 
metabolites plus sulfate conjugates [356] or β-glucuronidase (type VII-A from E.coli, E.C. 
3.2.1.31, 100 U/mL) for the detection of free metabolites plus glucuronic acid conjugates [357]. 
The pH of all samples was readjusted to 7.0 before the double extraction with dichloromethane 
(2 x 15 mL). The residues obtained from the organic extracts, upon evaporation, were 
 Primers Melting temperature (Tm) Reference 
BACTN_F CATGTACGTTGCTATCCAGGC 87,6 PrimerBank ID 
4501885a1[354] 
BACTN_R CTCCTTAATGTCACGCACGAT 
CYP3A4_F ATTCAGCAAGAAGAACAAGGACA  81.84 [267] 
CYP3A4_R TGGTGTTCTCAGGCACAGAT  
CYP2B6_F TTCCTACTGCTTCCGTCTATCAAA 79.7 [355] 
CYP2B6_R GTGCAGAATCCCACAGCTCA 
CYP2D6_F TGGCAAGGTCCTACGCTTC 86.3 [355] 
CYP2D6_R GCCACCACTATGCACAGGTT 
SULT1A1_F CGGCACTACCTGGGTAAGC 81.9 PrimerBank ID: 
29540539a1[354] 
SULT1A1_R CACCCGCATGAAGATGGGAG 
UGT1A1_F TGACGCCTCGTTGTACATCAG 78.8 [355] 
UGT1A1_R CCTCCCTTTGGAATGGCAC 
GSTA1-A2_F TGCAACAATTAAGTGCTTTACCTAAGTG 74 [355] 
GSTA1-A2_R TTAACTAAGTGGGTGAATAGGAGTTGTATT 
MRP7_F TGGCACATTCCCCTCATGG 82.2 [355] 
MRP7_R CCACAACACGGTCAGCACTA 
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dissolved in 150 µL of H2O/MeOH (1/1) and analyzed on an Agilent 1100 Series HPLC-UV 
system (Agilent Technologies Inc.) as detailed in Marinho et al. [358]. The metabolite levels 
were normalized with the cell numbers and expressed as ng/106 cells. 
6.3.6 Determination of the thiolomic profile 
For the determination of the thiolomic profile of the cultures, both cells (intracellular fraction) 
and cell supernatants (extracellular fraction) were collected from 3D and 2D cultures in the 
absence or presence of NVP.  
The extracellular thiolomic profile studied herein included glutathione and its catabolism 
product cysteinylglycine (CYS-GLY) in their total non-protein-bound (free) forms, designated 
as low molecular weight thiols (LMWT). The intracellular thiolomic profile study included 
glutathione and its precursors cysteine (CYS) and glutamylcysteine (GLU-CYS). These three 
moieties were analyzed in their S-thiolated protein (RSSP) forms [S-glutathionylated (GSSP), 
S-cysteinylated (CysSSP), and S- glutamylcysteinylated (GluCysSSP) proteins, respectively] 
and in their LMWT forms. The latter were composed by the reduced (RSH) fractions, including 
the reduced glutathione (GSH), CysSH and GlyCysSH, and the respective oxidized disulfides 
(RSSR).  
Cell culture supernatants (extracellular fraction) and cell lysates (intracellular fraction) were 
collected at days 27 and 34 of the differentiation and treated as described below. The thiolomic 
profile was measured as detailed previously [359]. Briefly, the cells were collected and 
immediately sonicated in 200 µL of ice-cold phosphate-buffered saline with 1 % Triton. The 
amount of total thiols (RSSP+RSH+RSSR) was obtained by reducing the sulphydryl groups 
with tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (100 g/L). After a 30 min incubation 
at room temperature, the samples were treated with trichloroacetic acid (TCA; 100 g/L) 
containing EDTA (1 mM), for protein precipitation. After centrifugation (13000 x g, 10 min, 
4°C), the supernatant was collected for derivatization of the free sulphydryl groups. 
Derivatization was performed with 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid ammonium 
salt (SBD-F) at 1 g/L in buffer, 125 mM sodium tetraborate, 4 mM EDTA and 1.55 M NaOH) 
at 60 ºC for 1 h, protected from light. Finally, a volume of 30 µL was analyzed by HLPC.  
The quantification of the free forms was performed in cells and in cell culture supernatants. 
The latter were collected on ice and centrifuged for 5 min at 10000 x g at 4º C for cell debris 
removal, whereas cell samples were prepared as mentioned above. Samples were then 
submitted to protein precipitation with TCA, with subsequent centrifugation (13000 x g, 10 min, 
at 4ºC) [360] and reduced with TCEP for R LMWT quantification or incubated with reverse 
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osmosis water to obtain the naturally reduced RSH fraction. After 30 min incubation at room 
temperature, the previously described derivatization protocol was followed. HPLC analysis 
was performed on a Shimadzu LC-10AD VP system (Shimadzu Scientific Instruments Inc) 
using a reversed-phase C18 LiChroCART 250-4 column (LiChrospher 100 RP-18, 5 µm, 
VWR, USA), at 29 ºC with a fluorescence detector (lEx: 385 nm/ lEm: 515 nm). The mobile 
phase consisted of 100 mM ammonium acetate buffer (pH 4.5) and methanol [98:2 (v/v)]. The 
analytes were separated in isocratic elution mode for 22 min, at a flow rate of 0.6 mL/min.  
The data, expressed as average ± SD, was normalized with cell number and was represented 
as nmol/106 cells for non-treated cells and as fold induction in NVP-treated cultures relative 
to non-treated cultures. 
6.3.7 Statistical analysis 
Statistical data analysis was performed using GraphPad Prism version 6.0 (GraphPad 
Software, La Jolla, CA, USA). The data were compared by the two-way ANOVA with Holm-
Sidak method, with differences considered statistically significant for p < 0.05.  
6.4 Results 
6.4.1 NVP modulates key biotransformation enzymes in 2D and 3D cultures 
NVP metabolism comprises phase I, II and III enzyme players. It is primarily metabolized into 
its phase I metabolites 2-OH-NVP, by CYP3A4/5, 12-OH-NVP by CYP3A4/5, CYP2D6 and 
CYP2C9, 3-OH-NVP by CYP2B6 and 8-OH-NVP by CYP3A4/5, CYP2B6 and CYP2D6 [91, 
348]. These may undergo further phase II biotransformation through glucuronic acid 
conjugation or sulfate conjugations [91], the later involved in NVP bioactivation. Within NVP 
bioactivation the quinone methide from NVP, 12-OH-NVP and 12-sulfoxy-NVP are particularly 
reactive being associated to NVP-induced hepatotoxicity. Thus, to evaluate the 
biotransformation competence of this in vitro model the gene expression levels of CYP3A4, 
CYP2B6, CYP2D6, UGT1A1, SULT1A1, GSTA1-A2 and MRP7 (Figure 6.1) were assessed. 
The same genes were evaluated in undifferentiated cells (hnMSC) and in HepG2 cell line 
cultured as monolayer exposed to NVP for 3 days. ECOD, CYP3A4/5, UGTs and SULT1A1 
activities as well as the formation of NVP phase I (2-OH-NVP, 3-OH-NVP, 8-OH-NVP and 12-
OH-NVP) and II (respective sulfate and glucuronic acid conjugates) metabolites were also 
studied upon NVP treatment for 3 (D27) and 10 (D34) days in both 3D (3D-HLC) and 
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monolayer HLC (2D-HLC) cultures (Figure 6.2). NVP non-treated cells and hnMSCs were 
used as controls. Results are summarized in Table 6.2. 
Upon NVP treatment the total cell number remained similar to non-treated cultures during the 
whole culture time, indicating no cell loss due to possible cytotoxic effect of NVP or its 
metabolites in HLC, HepG2 and hnMSC cultures (data not shown).  
Gene expression analysis showed that all evaluated genes were more upregulated by NVP in 
3D HLC than in 2D HLCs or HepG2 (Figure 6.1a, 6.1b and 6.1c). Remarkably, when exposed 
to NVP all the studied genes were also upregulated in 3D-HLC relative to 2D-HLCs (Figure 
6.1d). This difference was further increased from day 27 to day 34, except for CYP3A4, 
CYP2D6 and GSTA1-A2 (Figure 6.1d).  
Accordingly, CYP3A4/5 activity was induced 5-fold and 1.5-fold, at D27, in 3D- and 2D-HLC 
cultures, respectively (Figure 6.2); whereas after 10 days of NVP exposure (D34) both 3D- 
and 2D-HLC cultures showed ~1.5-fold induction of CYP3A4/5 activity relative to non-treated 
cultures (Figure 6.2). CYP3A4 participates in 2-OH-NVP, 12-OH-NVP and 8-OH-NVP 
formation. However, it is particularly relevant for 2-OH-NVP production, given that CYP3A4/5 
is the only CYP450 enzyme known to be involved on its formation. The conversion of NVP 
into 2-OH-NVP (total fraction) was decreased in both 2D and 3D cultures from day 27 to day 
34. In contrast, in both systems 12-OH-NVP was enhanced or maintained from D27 to D34. 
12-OH-NVP is associated to CYP3A4/5 but also CYP2D6, whose expression at the gene level 
was slightly increased upon NVP treatment.  
Finally, 8-OH-NVP metabolite was barely detected within our model. 8-OH-NVP is also 
produced via CYP2B6 and its detection increased only in 3D-HLCs from day 27 to day 34. 
Herein, ECOD, which reflects CYP2B6, 1A1 and 1A2 activities, was induced 1.3-fold and 3.7-
fold on 3D-HLC after 3 and 10 days of treatment with NVP in comparison with non-treated 
cultures, respectively; whereas in monolayer its induction was only observed after 3 days 
treatment (2.5-fold) (Figure 6.2). CYP2B6 is also involved in 3-OH-NVP metabolism and, in 
fact, in 3D cultures, a ~2-fold induction from D27 (~35 ng/106 cells) to D34 (~76 ng/106 cells) 
was observed. In 2D cultures, the amount of 3-OH-NVP (~10 ng/106 cells) was unaltered 
throughout culture time (Figure 6.3). Some NVP biotransformation activity was also displayed 
by hnMSC (Figure 6.3a). However, in accordance to phase I and II activities measurements 
(Figure 6.2) the level of NVP metabolites is also low (Figure 6.3a). 
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Figure 6.1 Gene expression analyses of 3D- and 2D-HLCs after 3 (day 27) and 10 days (day 34) of NVP 
treatment. (a) Gene expression of phase I enzymes comprising CYP3A4, CYP2B6 and CYP2D6 in NVP-treated 
cells relative to non-treated cells. (b) Gene expression of phase II enzymes comprising SULT1A1, UGT1A1 and 
GSTA1-A2 in NVP-treated cells relative to non-treated cells. (c) Gene expression of the MRP7 transporter in NVP-
treated cells relative to non-treated cells. (d) Combined phase I, II and III gene expression in 3D-HLCs relative to 
2D-HLCs in NVP-treated and non-treated cells at day 34. Data for HepG2 cells and hnMSC exposed to NVP for 3 
days and used as positive and negative controls, respectively, are also shown (a, b and c). The data (AVG ± SD, 
n=3) is normalized to the reference gene BACTIN and expressed as the Log10 of the ratios, except for CYP3A4 
and CYP2D6. 
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Phase II biotransformation enzyme activity and transcript levels within 3D and 2D-HLC 
incubated with NVP were also monitored. Upon exposure to NVP, and in comparison to non-
treated cultures, UGT1A1, SULT1A1 and GSTA1-A2 overexpression was only observed in 
3D-HLC (Figure 6.1), being UGT1A1 and SULT1A1 expression higher at D34. Accordingly, 
at D34 both UGT (p < 0.05) and SULT1A1 activities were increased in 3D-HLC, whereas in 
2D-HLC only SULT1A1 was enhanced (Figure 6.2). In non-treated HLCs, UGT [173] and 
SULT1A1 (data not shown) activities are maintained in 2D-HLC and increase in 3D-HLC from 
D27 to D34 (p < 0.01).  
 
Figure 6.2. Enzymatic induction in 3D- and 2D-HLCs after 3 (day 27) and 10 days (day 34) of NVP treatment. 
The data for hnMSC, cultured in monolayer and exposed to NVP for 3 days, are presented as negative control. * 
p < 0.05, ** p < 0.01 and *** p < 0.001 relative to 2D-HLCs or relative to non-treated cells according to the scheme, 
# p < 0.05 and ### p < 0.001 relative to day 27 of culture. The data (AVG ± SD, n=3) is represented as fold induction 
in NVP-treated cells relative to control cells. 
When measuring phase II metabolites it was observed that 2-OH-NVP and 12-OH-NVP 
sulfonation decreased over the time in both cultures, being absent in 2D-HLCs at D34. In 
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contrast, the amount of 3-OH-NVP sulfate conjugates was increased at day 34 in both cultures 
and ~8-fold higher in 3D relative to 2D cultures. 3-OH-NVP was the metabolite showing higher 
sulfate conjugation, representing 95 % and 60 % of the total 3-OH-NVP detected in 3D- and 
2D-HLCs, respectively.  
  
Figure 6.3 Levels of NVP phase I and II metabolites in 3D- and 2D-HLCs after 3 (day 27) and 10 days (day 
34) of NVP treatment. (a) Quantification of phase I and II NVP metabolites in HLCs and in hnMSC, cultured in 
monolayer and exposed to NVP for 3 days and (b) relative proportions of total NVP metabolites (free metabolites 
+ sulfate conjugates + glucuronic acid conjugates) at days 27 and 34. The data (AVG ± SD, n=3) is normalized to 
total cell number. 
Glucuronic acid conjugates were mainly detected in 3D cultures as well. Most glucuronic acid 
conjugated metabolites are 2-OH-NVP and 12-OH-NVP, but also 8-OH-NVP, and all 
increased from day 27 to day 34 in 3D-HLC. In fact, in 3D cultures the amount of 12-OH-NVP 
and 2-OH-NVP conjugates increased from ~13 % (D27) to ~40 % (D34) and to ~32 % (D34), 
respectively. Conversely, in 2D-HLCs the level of 12-OH-NVP and 2-OH-NVP conjugates 
decreased from ~8 % and ~17 % to undetected, respectively, which is in accordance with both 
UGT1A1 expression and UGTs activity. Overall, NVP induced gene expression and the 
activity of the enzymes responsible for its own metabolism, particularly in 3D culture conditions 
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(Table 6.2). Most importantly, such increase was further observed when increasing NVP 
treatment time, covering the induction period of NVP.  
6.4.2 3D cultures thiolomic profile is altered upon NVP exposure  
To test how NVP altered the thiolomic profile of HLCs, thiols quantification was primarily 
performed in NVP non-treated 3D and 2D-HLC cultures (Figure 6.4), followed by its 
quantification in treated cells (Figure 6.5 and Figure 6.6).  
Firstly, the total CYS, GLU-CYS and GSH intracellular content was compared in NVP non-
treated cultures. CYS is the first substrate for GSH formation and GLU-CYS, an intermediate 
element of GSH formation. CYS was detected in higher amounts in 3D-HLCs than 2D-HLCs 
at day 27 (p < 0.01) and similar in both cultures at day 34. GLU-CYS amounts were higher in 
3D-HLC relative to 2D-HLC, being both higher than in hnMSC (data not shown). In addition, 
GSH was increased from day 27 to day 34, although only significantly in 3D-HLCs (p < 0.05) 
(Figure 6.4a, Table 6.2).  
The same approach was performed in extracellular fractions. Herein, CYS-GLY and GSH 
were evaluated on its free form. CYS-GLY is a product of GSH degradation by the action of 
gGT membrane enzyme. CYS-GLY and GSH amount were statistically higher in HLCs relative 
to hnMSC at days 27 and 34 (p < 0.01, data not shown). Moreover, at day 27 both CYS-GLY 
and GSH levels were higher in 2D-HLC than in 3D-HLC (p < 0.05), which was inverted at day 
34 (Figure 6.4a). The free low molecular (R LMWT) and protein bond (RSSP) fractions of the 
evaluated thiols was similar in both cultures at day 27. However, the fraction of GSSP is 
significantly higher in 3D-HLC than in 2D HLC (p < 0.01) (Figure 6.4b). 
The thiolomic profile was then accessed upon NVP treatment. The intracellular thiolomic 
profile remained unchanged in 2D-HLCs, whilst a significant decrease on GLU-CYS and GSH 
was observed in 3D-HLC (p < 0.01) after 10 days of NVP treatment (Figure 6.5a and Table 
6.2). On the other hand, extracellular thiol levels increased similarly from D27 to D34 in both 
3D and 2D-HLCs (Figure 6.5a) (p < 0.05). As for the free low molecular and protein bond 
fractions differences between 2D and 3D-HLCs were only observed at 34. Herein, we 
observed an increase of intracellular protein-S-cysteinylation in 3D-HLC and an increase of 
intracellular free CYS and GLU-CYS in 2D-HLC (p < 0.001) (Figure 6.5b). Moreover, S-
glutathionylation of proteins and the amounts of free GSH were particularly decreased in 3D-
HLCs (p < 0.001) (Figure 6.5b) indicating that its oxidized fraction (GSSG) is increased. In 
fact, a higher GSSG/GSH ratio (p < 0.05) (Figure 6.6 and Table 6.2) was observed in 3D-
HLCs suggesting increased oxidative/electrophilic stress in 3D-HLC upon NVP exposure.  
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Figure 6.4. Intracellular and extracellular thiolomic profile in non-NVP-treated 3D- and 2D-HLCs at day 27 
and day 34. (a) Intracellular levels of total CYS, GLU-CYS and GSH and extracellular levels of total CYS-GLY and 
GSH. (b) Intracellular levels of protein-bound (RSSP) and free low molecular weight (R LMWT) CYS, GLU-CYS 
and GSH. * p < 0.05, ** p < 0.01 and *** p < 0.001 relative to 2D-HLCs; # p < 0.05, ## p < 0.01 and ### p < 0.001 
relative to day 27 of culture. The data is represented as AVG ± SD, n=3 
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Figure 6.5. Intracellular and extracellular thiolomic profile in 3D- and 2D-HLCs after 3 (day 27) and 10 (day 
34) days of NVP treatment. (a) NVP effect on intracellular levels of total CYS, GLU-CYS and GSH and on 
extracellular levels of total CYS-GLY and GSH. (b) NVP effect on intracellular levels of protein-bound (RSSP) and 
free low molecular weight (R LMWT) CYS, GLU-CYS and GSH measured at days 27 and 34 of the differentiation 
(3 and 10 days of exposure, respectively). * p < 0.05, ** p < 0.01 and *** p < 0.001 relative to non-treated cells (a) 
and to 2D-HLCs (b). The data is represented as AVG ± SD, n=3. 
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Figure 6.6 NVP effect on glutathione oxidation (intracellular GSSG/GSH ratio) in 3D- and 2D-HLCs after 10 
days of NVP treatment (day 34). * p < 0.05 relative to non-treated cells. The data is represented as AVG ± SD, 
n=3. 
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Table 6.2 Comparative summary of 3D- and 2D-HLC metabolic capacity upon 10 days of NVP treatment 
(day 34) 
Endpointa 
3D-HLC 
(NVP treated / non-
treated) 
2D-HLC 
(NVP treated / non-
treated) 
3D-HLC / 2-HLC 
(NVP treated) 
Gene 
expression 
Phase I 
CYP3A4 
CYP2B6 
CYP2D6 
+ 
+++ 
+ 
+ 
unchanged 
+ 
+ 
+++ 
+ 
Phase II 
SULT1A1 
UGT1A1 
GSTA1-A2 
+ 
+ 
+ 
unchanged 
unchanged 
unchanged 
++ 
+++ 
++ 
Phase III MRP7 + unchanged ++ 
Enzymatic 
activity 
Phase I 
ECOD (CYP2B6) 
CYP3A4 
++ 
unchanged 
unchanged 
unchanged 
+ 
unchanged 
Phase II 
UGTs 
SULT1A1 
unchanged 
unchanged 
unchanged 
unchanged 
+ 
unchanged 
NVP 
metabolite
s 
 
Phase I 
2-OH-NVP     
(CYP3A4) 
12-OH-NVP 
(CYP3A4/2D6/2C9) 
3-OH-NVP     
(CYP2B6) 
8-OH-NVP 
(CYP3A4/2D6/2C9) 
            detected     2-
OH-NVP           A4)  
            detected 2-OH-
NVP(CYP3A/2D6/2C9) 
            detected 3-OH-
NVP         (CYP2B6) 
            detected 
            detected     2-
OH-NVP           A4)  
            detected 2-OH-
NVP(CYP3A/2D6/2C9) 
            detected 3-OH-
NVP         (CYP2B6) 
            detected 
                 + 2-OH-NVP           
(CYP3A4)  
                 + 12-OH-
NVP(CYP3A/2D6/2C9) 
                ++ 3-OH-
NVP         (CYP2B6) 
         unchanged 
Phase II 
Sulfate conjugates 
Glucuronic acid 
conjugates 
detected 
detected 
detected 
not detected 
++  
+++  
Glutathione content 
extracellular GSH  
intracellular GSH  
GSSG 
+ 
- 
+ 
unchanged  
+ 
unchanged 
- 
+ 
+ 
aGene expression: (+) 1-20 fold increase, (++) 20-250 fold increase, (+++) >250-fold increase;  
Enzymatic activity, NVP metabolites and glutathione content: (-) <1-fold decrease; (+) 1-4-fold increase; (++) 4-
10fold increase; (+++) >10-fold increase. 
b detected/not detected: production of nevirapine metabolites in nevirapine-treated cultures 
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6.5 Discussion 
The effect of NVP on CYP450 activity was previously shown in microsomal preparations [348] 
and on an ex vivo placenta pharmacokinetic model [361]. However, a complete study of 
biotransformation mechanisms of NVP and its metabolites, including induction of enzymatic 
activity of phase I and II metabolites has only been achieved recently, when resorting to an in 
vitro 3D hepatocyte culture [91, 98]. Pinheiro et al. study [91] integrated information about 
NVP phase I and II biotransformation, regulation of biotransformation enzymes by the parent 
drug and its metabolites and detoxification and bioactivation/toxicity pathways of reactive 
metabolites was provided, further enabling a thorough in vitro study of xenobiotics 
bioactivation and the identification of NVP specific biomarkers [91, 98]. The modulation of 
SULT1A1 activity by NVP and 2-OH-NVP was also observed, in first hand, pointing out to a 
synergistic effect of the parent drug and its main phenolic metabolite as a key factor in the 
formation of the toxic NVP metabolite [91, 98]. In the present study, due to its complex 
metabolic profile, NVP was selected as a model drug to substantiate the applicability of our 
HLC-based 3D culture system as an in vitro toxicology model. Herein, the NVP effects on 
gene expression and enzymatic activity resulted in its bioactivation by our system along with 
the production of all the known NVP metabolites (phase I and II). In addition, an effect on 
HLCs’ thiolomic profile was also shown. 
The information available on the literature on the steady state relative proportions of 
nevirapine metabolites differ greatly. It further depends on the type of study, i.e., in vivo animal 
studies, in vitro studies or clinical trials (Table 6.3).  
As shown in Table 6.3 clinical studies report that 2-OH-NVP and 12-OH-NVP are the major 
NVP metabolites whereas 3-OH-NVP relative amounts vary in the literature. The decrease of 
2-OH-NVP and increase of 12-NVP-OH from single dose to steady state is also reported in 
clinical studies [362], indicating that our data might refer to the NVP induction period, that lasts 
about two weeks in vivo [349]. Our data showed that even though there were an increase of 
12-OH-NVP of 3-fold from day 27 to day 34, 2-OH-NVP was always the major metabolite, in 
both cell culture systems (60 % and 57 % for 3D- and 2D-HLCs at day 34, respectively), 
followed by 12-OH-NVP (28 % and 26 % for 3D- and 2D-HLCs, respectively). Erickson et al. 
[348] also showed that the formation rate of 2-OH-NVP is ~2-fold higher than of 12-OH-NVP 
by human CYP3A4/5 microsomal preparations [348].  
3-OH-NVP turned to be the third most abundant metabolite at day 34 (10 % and 15 % for 3D- 
and 2D-HLCs, respectively), followed by 8-OH-NVP with a proportion of less than 2 % for all 
conditions. 8-OH is consensually a minor metabolite only detected in samples derived from 
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human systems such as human plasma [349, 363], human urine [346], human microsomal 
preparations [348] and is not detected after single dose [362]. Herein, it increased from day 
27 to day 34 only in 3D-HLC reflecting the high CYP2B6 activity and its induction in HLCs, 
and the clinical studies observations, as a result of NVP auto-induction of CYP2B6 activity.  
Table 6.3 Comparison of relative levels (expressed as percentage) of NVP metabolites in clinical, pre-
clinical and in vitro studies. 
Study type Sample 2-OH-NVP * 
12-OH-
NVP * 
3-OH-
NVP * 
8-OH-
NVP * Refs 
Clinical, 2 weeks of NVP treatment plasma 13 43 39 2.0 [349] 
Clinical, 4 weeks of NVP treatment plasma 15 43 42 2.0 [349] 
Clinical, Steady state NVP treatment urine 23 33 33 1.0 [346] 
Clinical, Steady state NVP treatment plasma 13 80 6.0 0.0 [358] 
Clinical, Steady state NVP treatment plasma 16 75 7.0 2.0 [363] 
Clinical, Single Dose NVP treatment plasma 32 52 16 0.0 [362] 
Clinical, Steady state NVP treatment plasma 5 51 9 35 [362] 
Non-clinical (chimpanzee) urine 68 19 13 0.0 [364] 
In vitro, spheroids of freshly isolated 
rat primary hepatocytes, exposed to 
NVP for 11 days 
Cell culture 
supernatant 25 57 18 0.0 [91] 
In vitro, human cryopreserved 
microssomal preparations 
Microssomes 
reaction buffer 39 27 27 7.0 [348] 
In vitro, HLC spheroids exposed to 
NVP for 10 days 
Cell culture 
supernatant 60 28 10 2.0  
* the relative amounts of NVP metabolites were collected from the literature considering total amounts of 
metabolites, including phase II metabolites that were also incorporated in its phase I form 
Glutathione conjugation might result from either spontaneously or enzymatic reactions 
catalyzed by GST. GSTs (GSH-S-transferase) are of major importance in liver as a cellular 
defence mechanism. GSTA1 and GSTA2 account for 3 % of total hepatocyte cytoplasmic 
proteins and is a particularly important GST family in the liver. In cultured human hepatocytes, 
GSTA gene expression drops quickly to 10 % of freshly isolated cells [20]. GSTA1 and GSTA2 
present common expression, regulation mechanisms and substrates [365] and catalyze the 
glutathione conjugation with a wide range of electrophiles, possess glutathione-dependent 
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steroid isomerase activity, and glutathione-dependent (selenium-independent) peroxidase 
(GPx) activity [366]. Herein, GSTA1-A2 gene expression was induced upon NVP exposure in 
3D- but not in 2D-HLCs. The induction of GSTA1-A2 is an adaptive response that protects 
against oxidative stress, resulting from the activation of the transcription factors regulated by 
a different signaling pathway for chemoprotective agents and electrophilic toxicants response 
[367]. Cytoprotective agents induce GSTA2 and concomitantly activate the PI3K-Akt/ERK-
RSK1-mTOR pathways that activate the transcription factors favoring cell viability [367]. NVP 
metabolites 3-OH-NVP and 12-sulfoxy-NVP were the only metabolites that have been shown 
to form glutathione conjugates [352]. 3-OH-NVP glutathione derivatives are reported to be 
non-enzymatic or mediated by GSTP1-1, whereas 12-sulfoxy-NVP glutathione derivatives are 
mediated by GSTA1-1, GSTM1-1 and GSTA3-1 [352]. Thus, we evaluated GSTA1-A2 
expression levels upon NVP treatment as well as quantified GSH, its precursors and its 
degradation productions in intracellular and extracellular fractions. To clarify the effect of NVP 
biotransformation on HLCs redox homeostasis and glutathione biosynthesis regulation HLCs’ 
thiolomic profile was also evaluated.  
GSH may undergo extracellular γ-glutamyltranspeptidase (γGT)-mediated cleavage of the γ-
glutamyl moiety, leaving a cysteinyl-glycine (CYS-GLY) conjugate that is further cleaved by 
dipeptidase, resulting in a cysteinyl conjugate [368]. Physiologically, γGT provides CYS from 
GSH to the cells to be used in de novo biosynthesis of GSH [369]. In our HLC cultures, CYS-
GLY was significantly increased in NVP treated cells, at day 34, in both 3D- and 2D-HLCs, 
revealing the above mentioned response to the presence of NVP and of its metabolites. In 
fact, GSH degradation to CYS-GLY is only performed extracellularly by cells with γGT, such 
as the hepatocyte [368].  
The rate of GSH synthesis is determined by cysteine availability and glutamate cysteine ligase 
(GCL) activity. In our cell culture context, cysteine was highly available in cell culture medium. 
Thus, the higher GSH in 3D cultures at day 34 in cells (p < 0.01) and in cell culture 
supernatants (p < 0.01) probably reflected a higher GCL activity in the 3D-HLC. Interestingly, 
it is reported that the gene expression of GCL catalytic subunit (GCLC) is upregulated where 
increased cellular defence is necessary [368], namely as a mechanism of defence against 
oxidative stress mediated by the transcription factors Nrf2 and HNF1β [370]. GLU-CYS is 
formed by the action of GCL and is the limiting substrate for GSH synthesis by glutathione 
synthethase (GS). Total GLU-CYS amounts were similar in 3D- and 2D-HLCs and slightly 
increased over the time in culture. However, intracellular CYS levels were significantly 
increased in the 3D-HLCs at day 27 resulting in higher GSH levels in non-treated cultures at 
days 27 and 34. This might indicate that GSH synthesis is occurring at a higher rate in the 3D 
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cultures, which is corroborated by the unchanged levels of glutathione synthesis precursors 
in 3D and not in 2D cultures upon NVP exposure.  
An increased S-glutathionylation of proteins was proposed by MaGarry et al. [371] as an 
adaptive response determinant to paracetamol toxicity [371]. Our data showed that S-
glutathionylation of proteins is slightly increased at day 27 in both NVP-treated cultures. On 
the other hand, at day 34, besides total GSH is increased in 3D-HLCs up on NVP treatment, 
its free and protein bond forms are decreased suggesting a higher exposure to oxidative harm. 
This was observed by the higher GSSG/GSH ratio, the induction of GSTA1-A2 expression 
and increased gluthathione biosynthesis, which is possibly reflecting an adaptation to the 
oxidative harm caused by reactive species such as 12-sulfoxy-NVP.  
3D spheroids of rat primary hepatocytes previously showed to be superior on mimicking the 
in vivo metabolism of NVP, providing integrated information on its biotransformation regulation 
as well as on detoxification and bioactivation/toxicity pathways [91]. HLCs, in both 2D and 3D 
cultures, showed a response to NVP exposure, but intracellular GSSG was only significantly 
increased in 3D HLC.  
 
In conclusion, the biotransformation competence of our 3D-HLC model was herein reinforced 
by the correct profiling of NVP biotransformation, as well as by mimicking the NVP auto-
induction processes as observed in man. Moreover, the thiolomic analysis reflected the higher 
glutathione production in 3D cultures, which together with a more effective glucuronic acid 
conjugation also suggests a higher protection in the 3D HLCs. In sum, 3D-HLC showed to be 
advantageous relative to the traditional monolayer cell culture by displaying a more complete 
phenotype comprising phase I, II and III of drug metabolism that was maintained or increased 
over the time in culture, being suitable to be applied in mechanistic models for hepatotoxicity 
testing.  
In a near future, the introduction of such human stem cell derived physiologically relevant 
hepatic 3D models might take part in in vitro pharmacokinetic studies and may indeed 
significantly contribute to the reduction of compound attritions’ rate by the selection of safer 
lead molecules, and have an important role in drug discovery and development. 
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The enormous development of cell and tissue engineering approaches over the last decade 
resulted in a growing interest on improving in vitro testing and on using new in vitro 
technologies to generate more robust data on the potential risks to humans brought by 
environmental agents and pharmaceuticals. Major interest scopes expanding capabilities to 
test target molecules more efficiently, reducing animal testing, increasing drug development 
efficiency and improving prediction of adverse drug reactions [48, 121-128]. Alternative 
approaches are already scientifically validated, accepted by competent regulatory bodies and 
in use for regulatory toxicology purposes in several areas, namely in dermatology and 
immunology [129]. However, no toxicokinetic or hepatic metabolism studies have been 
validated and accepted yet by the regulatory authorities as alternative methods [130]. Those 
are essentially performed in animal models despite the evidence for relevant interspecies 
differences [118]. 
The liver is one of the main targets for toxicity caused by pharmaceuticals, reason why the 
evaluation of potential hepatotoxicity represents a critical step in the development of new 
drugs. Given that the liver is the main organ responsible for xenobiotic metabolism, it is also 
the first tissue contacting with the majority of toxicants and their metabolic products. Although 
biotransformation reactions generally parallel detoxification processes, the formation of 
reactive metabolites is relatively frequent. Indeed, drug induced hepatotoxicity accounts for 
more than 50 % of the cases of acute liver failure [372].  
Currently, in vitro hepatotoxicity testing is performed using monolayer (2D) cell cultures or 
suspensions of human hepatoma cell lines or primary hepatocytes, having both major 
drawbacks [48, 50]. Primary cultures of hepatocytes originate the more representative 
phenotypic and functional profile. However, this phenotype is lost within the first days in 
culture, there are important interspecies differences when cells are isolated from rats or have 
limited availability when isolated from human donors. Hepatoma cell lines have poor 
metabolizing capacity [51]. Therefore, the short-term functional culture of primary hepatocytes 
and the low biotransformation capacity of hepatoma cell lines make it difficult for the detection 
of the toxicity that compounds exert through metabolism and restricts repeat dosing studies. 
3D controlled culture conditions have allowed the maintenance and further improvement of 
some hepatocyte functional features for longer periods in culture [61, 62, 64, 71, 95]. On the 
other hand, to overcame the low availability of human functional cells as well as to improve 
the reliability and accuracy of drug screening, an efficient production of differentiated 
hepatocytes from stem cells has also been sought by researchers, upon request from 
regulatory bodies and the pharmaceutical industry [163]. Merging 3D culture techniques and 
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stem cells as cell source might offer an important potential alternative for the development of 
an alternative in vitro hepatic model for toxicology applications, including long-term studies.  
Derivation of hepatocyte-like cell populations have been attempted from hESCs [48, 51, 122, 
134, 140, 164-167, 180, 183], MSCs [150, 161, 168, 170, 172, 174, 176-179, 200, 202-204, 
239, 240, 242, 265], bipotent liver progenitor cells [180] and iPSCs [138, 184, 235, 244, 246, 
373] although no study has reported a fully satisfactory HLC functional phenotype. Several 
strategies have been followed to derive HLC from SC by in vitro mimicking the in vivo liver 
development. This has been performed by the addition of soluble factors, including growth 
factors, cytokines and hormones to the cell culture media, reproducing the in vivo cell-to-matrix 
and cell-to-cell interactions using alternative cell culture strategies, and determining cell fate 
via genetic modification or epigenetic modulation [180]. The original work presented in this 
thesis focused on deriving hepatocyte-like cells from human neonatal mesenchymal stromal 
cells for potential drug screening applications. The developed strategy enclosed the 
importance of the chemical cocktail and of the tissue architecture needed to mimic the tissue 
development in vivo. The major challenges of the application of SC-derived hepatocytes in 
toxicology were considered, namely the immature phenotype of the HLC reported in literature 
at the time [166, 252, 253], the lack of defined and validated endpoints for hepatic 
differentiation and maturation, the lack of standardization and use of relevant positive controls 
for differentiation, and the need of generating significant numbers of HLC [253]. In this 
Chapter, we integrate our new findings on human neonatal MSC differentiation potential with 
the current state of the art and conclude on how close we might be from presenting a real in 
vitro alternative for biotransformation and hepatotoxicity studies. 
 
Firstly, UCX® were selected as the stem cell source because of their genotypic and phenotypic 
characteristics. UCX® is a highly homogeneous, extensively characterized and therapy-driven 
population of human neonatal MSCs, registered as a trademark and resulting from a patented 
method [154]. These hnMSCs are obtained in high numbers and present high genomic 
stability upon expansion, enabling at least 55 cumulative population doublings (up to passage 
22) before reaching senescence, preserving the ISCT criteria for defining MSC along cell 
expansion, including differentiation capacity into osteoblasts, chondrocytes and adipocytes 
[154]. Hence, UCX® are a great candidate to use as an alternative cell source for the hepatic 
differentiation to obtain models for in vitro toxicology. Neonatal MSC sources are 
advantageous over other MSCs sources given their neonatal nature which makes them 
independent of health condition, clinical history or lifestyle. Furthermore, neonatal MSCs 
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maintain high chromosomal stability upon in vitro expansion as opposed to ESCs [151] and 
iPSCs [144, 149, 156-158]. Neonatal MSC have also demonstrated high differentiation 
capacity namely into cells of mesodermal origin such as myoblasts and cardiomyocytes [159], 
ectodermal as neurons, and endodermal origin. The relevance of a human neonatal source of 
stem cells for hepatic differentiation has also been shown by several studies [198] that 
compared different sources of MSCs, where neonatal stem cells presented better hepatocyte 
differentiation phenotype, reinforcing the importance of a primordial MSC source and most 
importantly, revealing that each MSC type have different differentiation capabilities and 
potential applications [160, 161]. Despite the advantages of hnMSC, few studies are available 
on these cells [172, 174, 176, 179, 199].  
 
The first main objective of this work was to establish an optimized hepatic differentiated 
protocol for obtaining fully competent hepatic cells. The hepatic differentiation is usually 
implemented by mimicking the in vivo ontogenic development of the liver. The translation of 
these stages to the in vitro differentiation of stem cells is particularly challenging on defining 
the timing and composition of the differentiation cocktails. Indeed, a sequential exposure to 
cytokines and growth factors has been shown of utmost importance to achieve a more 
homogeneous population of HLC [269, 374], which is further corroborated by the finding that 
there is a strict control of growth factor secretion during development [375, 376]. Moreover, 
the best combination of timing and differentiation cocktail composition for deriving stem cells 
into hepatocytes is far from being consensual and may vary according to the type of stem cell 
[168, 180, 201, 269, 374, 377, 378]. In this work, we first optimized a protocol under traditional 
monolayer cell culture conditions using sequential exposure of cytokines and growth factors 
in a three-step protocol. The hepatic differentiation protocol aimed, at first, at promoting the 
endoderm commitment, the first step in liver development. Endoderm commitment is 
controlled by a time and concentration-dependent secretion of growth factors, namely FGFs 
[185-187]. In fact, FGF-2 concentrations are a key factor on tissue development signalling, as 
previously reported [190], being also a powerful inducer of foregut-derived cell lineages [275]. 
This was observed in our cells in Chapter 3 by a FGF-2 concentration dependent effect on 
HHEX gene expression. The second step of the hepatic differentiation is hepatic commitment 
(D3-D13), which is mimicked by HGF supplementation. To further mimic the liver development 
in vivo, a third step for hepatoblast maturation and differentiation into hepatocytes was 
introduced by dexamethasone and oncostatin M from day 13 onwards.  
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Epigenetic modifiers have been described as having a role on hepatic differentiation [201]. 
Therefore, with the aim of optimizing the best differentiation strategy; an extensive/exhaustive 
comparison of several differentiation protocols was performed by further adding epigenetic 
modifiers [201] to the core differentiation protocol. To our knowledge, this is the first work that 
compares three distinct epigenetic modifiers TSA, 5-AZA and DMSO, separately or in 
combination, and at different time-points (Chapter 3). We first, attempted to reproduce the 
most promising protocols in the literature applied to MSCs [168, 172]. Snykers et al. [377] 
tested 100-1000 nM of TSA on hepatic differentiation of bone marrow MSCs showing that the 
concentration of 1000 nM improved HLC phenotype when added at day 6 of the differentiation 
protocol [168, 377]. We also tested the effect of 100, 500 and 1000 nM of TSA on UCX® 
differentiation (data not shown). On deriving UCX® under these conditions [377], we observed 
that an epithelial morphology could only be achieved with 500 nM TSA, whereas CK-18 
presence and glycogen storage ability was only observed when using 100 and 500 nM of TSA. 
The concentration of 500 nM of TSA resulted on the higher EROD and UGT activities, of 17.5 
± 2.6 (Average ± SEM) and 173.7 ± 12.5 (Average ± SEM) (unpublished data), respectively. 
For this reason, 500 nM of TSA was tested at days 6, 10 and 13 of the differentiation using a 
protocol adapted from Campard et al. [172]. By the time this thesis was initiated (Chapter 3) 
the work by Campard et al. [172] was the only one using WJ-MSC, the same hnMSC source 
as UCX®, where the derived HLCs displayed relevant biotransformation activity [172]. More 
recently, other studies have been published on hnMSC-derived HLCs [161, 174, 177, 200, 
202-204]. However, the study from Campard et al. [172] is still the only one showing 
biotransformation activity and the incapacity of CYP3A4 induction by phenobarbital [172]. 
Interestingly, in our battery of protocols the use of DMSO alone resulted in a better HLC 
phenotype (Chapter 3) and for this reason, the use of TSA was not further explored. DMSO 
has been described for the differentiation of HepaRG cells [54] and as improving the hepatic 
differentiation [183, 217, 220-224]. To our knowledge, DMSO has only been used on the 
differentiation of MSCs from the adipose tissue and at the concentration of 0.1 % [220, 221, 
239]. Banas et al. [221] and Okura et al. [239] included DMSO at 0.1 % in their sequential 
protocols hindering the possibility of specifically evaluating its effect; whereas Alizadeh et al. 
[220] tested HGF and HGF+DMSO using a cocktail-based protocol. In the work by Alizadeh 
et al. [220], cells morphology was fibroblast-like, but DMSO resulted in an upregulation of AFP, 
CK18, ALB and HNF4A relative to non-treated cells [220]. On the other hand, the 
differentiation protocol described by Banas et al. [221] resulted in epithelial-like morphology, 
positive PAS staining and LDL uptake as well as ALB presence. The weakness of both studies 
is the absence of positive controls, such as primary hepatocytes or hepatic cell lines [220, 
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221]. DMSO was also evaluated in other stem cells than MSCs. Pal et al. [222] tested 0.01, 
0.1 and 1 % of DMSO on embryoid bodies of hESC after spontaneous differentiation [222]. 
Hay et al. [183, 379] used 1 % of DMSO on hESC, before differentiation [379] and after 
endoderm partening induction [183], and the last conditions increased the proportion of 
hepatocytes in the end population to approximately 70 % [183]. The DMSO effect on 
endoderm commitment in the first days of the in vitro differentiation is still controversial and 
was only reported for hESC [183, 223, 225]. MSC are from the mesenchymal origin whereas 
hepatocytes derive from the endodermal layer. Thus, the process of differentiation of MSC 
into HLC must involve a successful transdifferentiation. This is a still poorly understood 
process [180], and distinguishes the hepatic differentiation of pluripotent stem cells (ESC and 
ipSC) from MSC. In this study, one of the most remarkable achievements (Chapter 3) was 
the introduction of DMSO at day 10 of the protocol, which resulted in a significant improvement 
of the HLC phenotype and its maintenance during an extended period, i.e. for 13 days. The 
transcriptomic analyses of the obtained HLCs was also a remarkable achievement that better 
clarified how close we were from the in vitro hepatic golden standards, the human 
hepatocytes, normally used for drug metabolism and hepatotoxicity studies [256, 281]. This 
analysis revealed a partial hepatic differentiation degree, by the shared expression of gene 
groups between HLC and human primary hepatocytes that were not observed between 
HepG2 and hpHep. In addition, bioinformatic analysis of gene expression data placed our 
HLC between the HepG2 cell line and hpHep and distant from hnMSC. This fact, together with 
the noteworthy activity of CYP3A4 and the presence of hepatic transporters were the most 
important features of our achieved HLC at this point of this thesis (Chapter 3).  
The major difficulty in comparing stem cell-derived HLC studies is the lack of proper controls 
and the inclusion of enzymatic activity evaluation. The absence of appropriate controls 
enables the comparison of the achieved HLC with other protocols [122, 236, 238, 242, 243]. 
Most importantly it also impairs the evaluation of how close or how far might the achieved 
phenotype be from the hepatocyte. It is surprising the number of studies claiming a successful 
differentiation of stem cells into HLC that do not perform or do not show results on a gold-
standard subject to the same experimental conditions, e.g. a primary hepatocyte or, at least, 
a hepatoma cell line. Particularly with hnMSC-derived HLC and to our best knowledge, only 
the work presented in this thesis, Zhang et al. [174] and Raut et al. [204] presented data on 
human cryopreserved primary hepatocytes, human primary hepatocytes or adult liver, 
respectively, as positive controls. The later, however, only presented the control for gene 
expression studies but not for albumin and urea secretion. Nevertheless, the evaluation of 
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those characteristics is of utmost importance for the validation of a differentiated and functional 
cell type.  
 
The control of proliferation is also of utmost importance during liver development. There are 
two main stages of higher cell proliferation within the liver development, a first stage, such as 
the outgrowing bud of proliferating endodermal cells present in the ventral floor of the foregut, 
and afterwards, a second proliferation stage is triggered by the septum transversum 
mesenchyme, which is required for expansion and complete differentiation of the hepatocytes 
[380]. For designing a hepatic differentiation protocol, we intended to create an initial step 
where endoderm commitment was favoured and where proliferation signals were slowly 
silenced, triggering differentiation signalling pathways in a synchronous way in all cells to 
produce a homogenous population of HLC. In fact, the homogeneity of the differentiated HLCs 
have been reported as a problem for pluripotent stem cells, hESC and hiPSC, differentiation 
with 60 to 80 % of albumin positive cells [381]. However, the second-high proliferation stage 
of hepatic commitment had not been yet considered in our differentiation protocol obtained in 
Chapter 3. As such, the second-high proliferation stage of hepatic development was recreated 
by introducing a cell passage step at day 17, when cells were considered to be hepatoblast-
like at the gene expression level (Chapter 5). The cell passage step (day 17) was tested with 
and without the presence of 5-AZA. To our knowledge, 5-AZA effect on hepatocyte MSC-
differentiation protocols in vitro had only been attempted by Seeliger et al. [213] and Yoshida 
et al. [214]. In these works, 5-AZA was applied 24h prior the differentiation induction since 
proliferation is needed for the incorporation 5-AZA on cellular DNA. Herein, the cell passage 
step brought up the opportunity to test the effect of 5-AZA later in the differentiation protocol, 
and this approach was the innovative feature that resulted in the best tested protocol.  
 
The significant results achieved with this optimized hepatic procedure led us to step up into 
the 3D cultures as a strategy to improve hepatic differentiation by rebuilding the in vivo cell-
to-matrix and cell-to-cell interaction, going into the direction of the second main objective of 
this work. In this context, undifferentiated hnMSC cultures under three-dimensional conditions 
were firstly established in parallel, using a self-assembled spheroid approach (Chapter 4). 
This approach aimed at evaluating if our hnMSC 3D cultures would maintain an 
undifferentiated phenotype and differentiation capacity. Indeed, hnMSC spheroids fully 
retained a mesenchymal phenotype as defined by ISCT up to day 3 of culture, which 
represented a safer window for initiating differentiation. As expected, 3D spheroid structures 
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also primed cells to produce a rich ECM (Chapter 4) as well as a distinct cytokine and growth 
factor profile [259]. A reduction of the cells proliferation rate was another observation of our 
work, presenting itself as an advantage given that low cell proliferation is required for triggering 
cell differentiation. 
The hepatic differentiation in 3D cultures, both as spheroids or in a hollow-fiber bioreactor, 
was attempted starting at day 0 of the differentiation (unpublished data). In 3D spheroids 
histological analysis showed absence of necrotic cores and positive cells for glycogen, CK18, 
HNF-4α and ALB. Urea production was also observed. However, there was high loss in cell 
number over the time in culture and ECOD and CYP3A4 activities were not detected, possibly 
indicating that a mature phenotype was not achieved (unpublished data). In the hollow-fiber 
bioreactor, the long-term culturing also lead to cell loss, as observed by LDH release and by 
low lactate production. Histological analysis showed a non-compact tissue structure, and 
although the cells were positive for glycogen ALB, CK-18, CK-19, HNF-4α, MRP-2, OATPC, 
CYP1A2 and CYP3A4, and able to secrete urea, no EROD activity was observed (unpublished 
data). Elevated cell loss in long-term HLC spheroid differentiation was also reported by Okura 
et al. [239] that observed up to 50 % of cell loss, evaluated by DNA quantification [239]. Still, 
it is interestingly to note that most 3D HLC cultures are inoculated into the 3D system at day 
0 of the differentiation [122, 184, 238-242, 245], but few report on using a differentiation step 
in 2D prior to 3D culturing [236, 243, 244]. The last present longer cell culture times, up to day 
32 [236] and 45 of the differentiation [244], and higher hepatocyte-like phenotype, namely 
regarding maintenance of albumin production and CYP3A4 activity [173, 244]. This raised the 
question of whether long differentiation time under 3D conditions, i.e. from day 0, do enable 
MSC derivation and maintenance of the achieved hepatocyte-like phenotype. In fact, the cell 
passage step at the hepatoblast-like stage, represented an opportunity to perform the first 17 
days of differentiation in monolayer, followed by a final maturation step in 3D (Chapters 5). In 
Chapter 5, this integrated culturing/differentiation strategy was approached and cells hepatic-
specific features evaluated up to differentiation day 27, in the bioreactor, and up to day 34, in 
spheroids. HLC cultured in both three-dimensional systems formed ECM (Chapter 5), which 
provided high cell-to-cell and cell-to-matrix interactions, as previously observed in primary 
hepatocytes either cultured in spheroids [61, 71] or in a perfused bioreactor [94]. In fact, the 
ECM composition in the developing liver is dynamic and distinct from the adult [7]. Fibronectin 
and type IV collagen increase during development whereas types I and III collagen and laminin 
decrease [382, 383]. In the adult liver parenchyma, ECM is constituted by fibronectin and type 
I and III collagen [7]. Moreover, the hepatoblast expansion and growth of primitive liver bud is 
a step in the liver development that requires ECM remodelling [384] highlighting the 
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importance of studying the ECM composition of our 3D-HLC to evaluate if this would better 
mimic the developing liver microenvironment or the adult liver ECM.  
Importantly, our integrated system showed that overall 3D HLC present a better behaviour 
regarding key features of drug metabolism, comprising phase I and phase II enzymatic 
activities and drug transporters (Chapter 5). The formation of definitive endoderm in the 
developing embryo occurs in a monolayer of cells [385]. Sivertsson et al. [243] tested the 
inoculation of differentiating hESC in a hollow-fiber bioreactor at the definitive endoderm stage 
and at the hepatic progenitor stage; and evaluated the transcriptional patterns and 
mechanistic pathways that were affected by the 3D culturing system relative to 2D and by the 
time of inoculation in 3D. High transcriptional differences were observed between the 2D and 
3D cultured cells [243]. Another feature that may have positively contributed to the success of 
our integrated approach is the fact that OSM (included from days 13 onwards) has a 
proliferative effect on the hepatoblasts [193, 194]; and despite the fact that the cell culture 
remains completely confluent, during the 2D culture period, some cell loss was observed 
which might have been compensated by cell proliferation further leading to cell selection. 
The 3D configuration also creates a gradient that led us to discuss the possible hepatic 
zonation that these cell culture systems might generate. Hepatic zonation is defined as the 
distinct functions exerted by the hepatocytes according to its localization in the hepatic lobule 
and occurs, physiologically, as a response to the gradient that results from the different 
composition of periportal and perivenous blood. It is expected to have higher oxygen, glucose 
and nutrients in the outer side of the spheroid or in cells near to the medium in capillaries in 
the bioreactor, which may better mimic the liver periportal environment rather than the 
perivenous. The perivenous hepatocytes are characterized by a higher xenobiotic metabolism, 
important regarding our objective, by glycogen synthesis from glucose and have less access 
to oxygen, and thus closer to physiologic conditions of the inner cells [7, 50]. 
The differentiation medium established in this work contains high amounts of insulin (1.72 µM) 
and glucose (25 mM), being insulin a signalling molecule present in higher concentrations in 
the periportal hepatocytes [386, 387]. A more periportal-like phenotype was observed in the 
2D cultures, regarding urea secretion capacity and glucose metabolism behaviour. In the 2D 
culture we observed lower glycogen stain, and higher glucose release into the cell culture 
medium than in both 3D cultures (Chapter 5). Nevertheless, preliminary work of our group 
demonstrated that HLCs exposed to low concentrations of glucose (5mM), no insulin and no 
dexamethasone overexpressed genes involved in glycolysis and lipogenesis (PDK4 and 
GLUT1), gluconeogenesis (PEPCK and G6P), bile acid metabolism (FXR) and mitochondrial 
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function and biogenesis (PGC1A) [388]. This was in accordance with our ingenuity pathway 
analysis of HLC canonical pathways showing that HLCs are closer to hpHep than HepG2 cell 
line regarding Gluconeogenesis (Chapter 4). Bell and co-workers [87] showed that the long-
term maintenance of regulated metabolic pathways such as glycolysis, gluconeogenesis and 
the γ-glutamyl cycle, a key pathway in maintaining redox homeostasis [389], was only 
observed in human cryopreserved hepatocyte spheroids, resembling intact liver tissues, 
whereas 2D monolayer cultures originating from the same livers presented relevant 
deregulation of these pathways [87]. This fact reinforces the importance of the relevant 
expression of such pathways on our hnMSC-derived HLCs.  
Interestingly, the spheroids presented a higher glycogen stain in the outer cells of the spheroid 
whereas the bioreactor presented a homogeneous glycogen stain (Chapter 5). This may 
suggest that the HLCs in the bioreactor are using both glucose and lactate to synthetize 
glycogen, depending on the cell’s localization within the 3D structure. Therefore, the bioreactor 
might present a more balanced presence of periportal-like and perivenous-like cells whereas 
perivenous-like phenotype might be scarcer in the spheroid culture, sustaining also the higher 
urea production observed on the 3D cultures, and particularly in the spheroids culture. In turn, 
albumin production, which is more associated with the perivenous phenotype [6] and is also 
stimulated by blood flow-mediated shear stress [390], was improved in HLC cultured in the 
bioreactor. The effect of medium flow on inducing albumin secretion was demonstrated by 
Prodanov et al. [390] using a human primary hepatocyte 3D microfluidic system [390]. 
Additionally, McCarty et al. [387] demonstrated the creation of spatially-controlled zonation 
across multiple hepatocyte metabolism levels through the application of precise concentration 
gradients of exogenous hormone (insulin and glucagon) and chemical (3-methylcholanthrene) 
induction agents in a microfluidic device, using a monolayer rat primary hepatocytes [387]. In 
the same study, a high concentration of insulin was directly correlated with a gradient in 
glycogen storage via periodic acid-Schiff staining and urea production via carbamoyl 
phosphatase synthetase I staining [387]. This is in accordance with our observations for HLC 
glycogen storage and urea production in relation to high insulin concentrations, mimicking the 
in vivo hepatic zonation. The effect of the gradient and blood flow-mediated shear stress have 
also been reported on the expression and activity of biotransformation proteins [72-74, 387, 
390]. McCarty et al. [387] observed a gradient on cell viability upon the exposure to allyl 
alcohol and paracetamol reflecting the in vitro creation of hepatocyte carbohydrate, nitrogen, 
alcohol degradation, and drug conjugation metabolic zonation staining [387].  
Our immunofluorescence data (Chapter 5) may also suggest some phenotype zonation in the 
bioreactor since CYP1A2 and CYP3A4 are present within the tissue and not near the 
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capillaries whereas the hepatic transporters OATP-C and MRP-2 are predominantly located. 
This was also observed with the spheroids to a lower extent. Herein, MRP-2 is predominant 
in the spheroid outer layer, whereas OATP-C is widespread within the spheroid. Therefore, a 
more organized cell culture system as within both 3D models, may present an overall higher 
level of both periportal-like and perivenous-like cells than the 2D culture.  
Overall, the findings described in Chapter 5 reinforce the importance of the cell culture 
environment as a key factor for the maintenance of the hepatocyte-like phenotype as initially 
hypothesised. It further supported that the subtle differences between phenotypic impacts 
promoted by each of the 3D models adopted are enough to entail that optimal culture systems 
should be selected depending on the scientific applications.  
 
This work intended to build a physiologically relevant alternative method using human cells 
for studying xenobiotic biotransformation as well as its mechanisms of action. This has been 
demonstrated in Chapter 6 where HLCs displayed relevant biotransformation and 
detoxification responses regarding the model drug nevirapine. Both 2D and 3D models 
presented the 4 main metabolites of NVP as well as its phase II metabolites. The later were 
detected in much higher amounts in 3D HLC than in 2D HLC as a consequence of the auto-
induction of NVP and its metabolites. Moreover, only 3D HLCs presented an overexpression 
of GSTA1-A2, which is induced by oxidative stress, and of the MRP7 transporter. A complete 
response to NVP and its metabolites on the thilomic profile was also only observed in 3D HLC, 
by showing GSH synthesis (Chapter 6). Additionally, only 3D-HLC showed increased 
intracellular GSSG levels, probably as a result of a higher synthesis of the toxic metabolite 12-
sulphoxy-NVP. Thus, the work described in Chapter 6 supports that our 3D HLCs are a 
competent system amenable to be applied to the study of hepatotoxicity of xenobiotics.  
 
A better understanding of the mechanisms contributing to de-differentiation or loss of 
phenotype of primary hepatocytes would also be interesting to develop better strategies to 
improve stem cell derived HLC phenotype in culture. As reported by Godoy et al. [281], 
cultured human primary hepatocytes gene regulatory network alterations resemble those of 
inflammatory liver diseases [281]. The same group, in a previous gene networks study 
identified, by cluster analysis, highly correlated groups of genes associated with mature liver 
functions [256]. Interestingly, one of the 3 clusters that fail to reach the expression levels of 
hepatocytes is controlled by the transcription factors HNF1, CAR, FXR and PXR. This cluster 
strongly overlaps with genes repressed in cultivated hepatocytes compared to freshly isolated 
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hepatocytes, suggesting that current in vitro conditions lack stimuli required to maintain 
hepatocyte-like gene expression. This explains the resulting deficient HLC-like phenotype 
[256]. Indeed, the 3D cell culture systems had proven a lot in the field of improving cell function 
and would be interesting to further compare freshly isolated hepatocytes with cultured 
hepatocytes and stem cell-derived hepatocytes also under 3D culture systems. Considering 
the cellular complexity of the liver and the functional sophistication of the hepatocyte, together 
with the fact that it exhibits more individual functions (>500) than any of the other ~200 
terminally differentiated cell types in the human body [4], it is not surprising that the 
maintenance of a fully functional hepatocyte in culture is difficult to achieve. Therefore, this 
makes hepatocytes amongst the most challenging cell types to mature artificially.  
 
Final Remarks 
This thesis was that 3D culture conditions in the presence of cytokines and growth factors 
involved in liver embryogenesis would result in a hMSC-based in vitro model more 
representative of the liver physiological conditions. Moreover, we intended to develop a 
system that could be standardized and therefore routinely used for toxicology screening, with 
possible applications in cell therapy. Altogether, the results here presented support the viability 
of abundant and ethically safe hnMSC to serve as precursors to achieve a mature HLC 
phenotype. Indeed, a more mature HLC phenotype was achieved by resorting to 3D 
spheroids, particularly regarding biotransformation capacity. We also demonstrate that HLC 
and particularly 3D HLC as a long-term tool to access drug induced alterations on 
biotransformation, considering phase I, II and hepatic transport, as well as on the regulation 
of detoxification pathways, such as glutathione synthesis. It is agreed that there are still many 
challenges on improving stem cell derived HLC. The international community strongly 
supports new in vitro alternatives to animal testing as long as methods were correctly 
validated. SC based technologies, integrating testing systems, can be a valuable tool to 
reduce, and possibly replace, the current ethical-problematic animal experimentation in drug 
discovery, safety pharmacology and toxicology. We may still be away from the day that stem 
cell-derived HLC are used for regulatory proposes in the drug development process, but we 
believe that the work here presented is a step forward on the establishment of a human in 
vitro hepatic model, suitable for in vitro toxicology applications. 
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Future Perspectives 
Although the present work showed noteworthy achievements, it also raised several questions, 
namely on how to optimize the cell culture conditions for providing the best environment for 
HLCs’ function. In general, the hepatocyte culture medium composition studies were 
performed with the focus of maintaining hepatocyte biotransformation capacity and this might 
explain the high concentrations of dexamethasone usually applied. Dexamethasone is a 
glucocorticoid that induces hepatocyte maturation, namely phase I metabolic activity [196, 
391]. The transcriptome analysis of the canonical pathways activation showed a similar 
activation in HLC and hpHep (Chapter 4) for glucocorticoid receptor signalling. 
Glucocorticoids may also cause insulin resistance and therefore, interfere with cell energy 
metabolism [392]. Thus, medium composition could be optimized to increase cell sensitivity 
to such insults. Specifically, a medium that would better mimic the composition of blood in the 
human body would be extremely relevant, containing additional biomolecules such as bile 
acids and cholesterol, thus allowing the possibility of using HLC to develop relevant 
hepatotoxicity mechanisms rather than hepatic cytotoxicity [281]. In fact, our transcriptome 
analysis data identified that the canonical pathways of Bile acids biosynthesis, Triacylgrlicerol 
biosynthesis and the Superpathway of cholesterol biosysntesis were downregulated relative 
to HepG2 and hpHep (Chapter 4). One relevant mechanism of DILI is the development of a 
cholestasis phenotype upon drug exposure that represents 20-50 % of the DILI cases and is 
associated with drugs with hepatic elimination [40]. Cholestatic liver injury results from 
dysfunction of the mechanisms of bile formation [40]. In vitro mimicking of cholestatic-like 
phenotype depends on the presence of functional bile canaliculi. This structure formation has 
been reported on primary hepatocyte cultures, only under 3D conditions [87, 281, 393] and its 
function implies also the maintenance of efflux transporters over the time in culture. Sandwich 
culture of primary hepatocyte showed that long-term culturing led to leaking and damaged bile 
canaliculi [393]. It has been suggested that the in vitro formation of such structures depends 
not only on the 3D culture conditions but also on the chemical composition of the surrounding 
medium [394]. Bile secretion can only occur when bile formation is observed. Bile is formed 
by water, bile salts, lipids namely phosphatidylcholine and cholesterol, proteins, vitamins and 
several organic and inorganic solutes of considerable complexity and its formation is regulated 
by a multitude of post transcriptional regulatory pathways and cytokine and hormone signals 
[394]. In fact, HLC culture medium is commonly serum-free and not supplemented with lipids 
or bile salts, whereas human primary hepatocyte cultures carry at least intracellularly some 
components needed for bile formation. The hypothesis of improving primary hepatocyte 
cultures by bile acid supplementation was also suggested by Godoy et al. [281] that observed 
Chapter 7 
 162 
that cultured hepatocytes presented a cluster of downregulated genes involved in bile salt 
metabolism, when compared with non-cultured hepatocytes [281]. In addition, bile salts have 
been reported to induce mature liver functions in pluripotent and foetal liver cells [395] and in 
hepatocyte-like cells derived from MSC [396], although those are not routinely used in 
hepatocyte culture media [281].  
 
The work developed here focused mainly on HLC capacity to metabolize drugs and for this 
reason much effort was made on characterizing CYP enzymes, phase II enzymes and hepatic 
transporters. Nevertheless, it would be also interesting to further improve medium composition 
considering the HLC lipid metabolism and bioenergetic profile, also resorting to 3D cultures. 
Finally, in the toxicology field, a HLC spheroid culture in the SFSC system equipped with a 
perfused set-up would allow to perform pharmacokinetic studies and allow further validation 
HLC biotransformation capacities.  
 
  163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 Bibliography 
 
Bibliography 
 164 
1. European Commission Staff Working Document. Pharmaceutical Industry: A Strategic Sector for the European Economy. 
[Internet] Brussels (BE) 26 p. SWD 216 final/2, Aug 2014. Available from: 
http://ec.europa.eu/DocsRoom/documents/7649/attachments/1/translations/en/renditions/native. 
2. Kola, I., Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5. 
3. Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D., Zineh, I., et al. Identifying genetic risk factors for 
serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904-16. 
4. Goldring, C., Antoine, D. J., Bonner, F., Crozier, J., Denning, C., Fontana, R. J., et al. Stem cell-derived models to improve 
mechanistic understanding and prediction of human drug-induced liver injury. Hepatology. 2017;65(2):710-721. 
5. Bhatia, S. N., Underhill, G. H., Zaret, K. S., Fox, I. J. Cell and tissue engineering for liver disease. Sci Transl Med. 
2014;6(245):245sr2. 
6. Jungermann, K., Kietzmann, T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr. 
1996;16:179-203. 
7. Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., et al. Recent advances in 2D and 
3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their 
use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87(8):1315-530. 
8. Ramadori, G., Moriconi, F., Malik, I., Dudas, J. Physiology and pathophysiology of liver inflammation, damage and repair. 
J Physiol Pharmacol. 2008;59 Suppl 1:107-17. 
9. Gregus Z., Parkinson A., Ogilivie B.W., Buckley D.B., Kazmi F., Czerwinski M., Parkinson O., Jaeschke H., 2013. 
Chapters: Mechanisms of toxicity, Biotransformation of xenobiotics and Toxic responses of the liver. In: Casarett & Doull's 
Toxicology: The basic science of poisons. Eighth Edition ed. San Francisco: McGraw-Hill, Medical Publishing Division. 
49-122 p., 185-366 p. and 669-664 p.  
10. Wienkers, L. C., Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 
2005;4(10):825-33. 
11. Hilal-Dandan R, Brunton L.L., Goodman and Gilman's Manual of Pharmacology and Therapeutics [Internet], Second 
Edition ed. New York, NY: McGraw-Hill, Chapter 6, Drug Metabolism. Available from: 
http://accesspharmacy.mhmedical.com/content.aspx?bookid=1810&Sectionid=124489935. Nov, 2016. 
12. Pascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., Vilarem, M. J. The expression of CYP2B6, CYP2C9 and 
CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619(3):243-53. 
13. Watkins, P. B. Basic mechanisms of normal and abnormal gastrointestinal function: Drug metabolism and transport in 
the liver and intestine (Part 1: Section 26). In: Yamada, T., editor. Textbook of Gastroenterology. 1. Fifth Edition ed. West 
Sussex, PO19 8SQ, UK: Blackwell Publishing/John Wiley & Sons; 2009. p. 1744. 
14. Strassburg, C. P., Oldhafer, K., Manns, M. P., Tukey, R. H. Differential expression of the UGT1A locus in human liver, 
biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol. 
1997;52(2):212-20. 
15. Kiang, T. K., Ensom, M. H., Chang, T. K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol 
Ther. 2005;106(1):97-132. 
16. Gamage, N., Barnett, A., Hempel, N., Duggleby, R. G., Windmill, K. F., Martin, J. L., et al. Human sulfotransferases and 
their role in chemical metabolism. Toxicol Sci. 2006;90(1):5-22. 
17. Hewitt, N. J., Lechon, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., et al. Primary hepatocytes: current 
understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use 
of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 
2007;39(1):159-234. 
18. Zanger U.M. and Schwab M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme 
activities, and impact of genetic variation. Pharmacol Ther. 2013. 138(1):103-41 
19. Jancova, P., Anzenbacher, P., Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ 
Palacky Olomouc Czech Repub. 2010;154(2):103-16. 
20. Morel, F., Fardel, O., Meyer, D. J., Langouet, S., Gilmore, K. S., Meunier, B., et al. Preferential increase of glutathione 
S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and 
dithiolethiones. Cancer Res. 1993;53(2):231-4. 
21. Mulder, T. P., Court, D. A., Peters, W. H. Variability of glutathione S-transferase alpha in human liver and plasma. Clin 
Chem. 1999;45(3):355-9. 
22. Kalliokoski, A., Niemi, M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705. 
23. Kullak-Ublick, G. A., Becker, M. B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev. 
2003;35(4):305-17. 
24. Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., Peters, J. M. Xenobiotic metabolism, disposition, and regulation 
by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci. 2011;120 Suppl 1:S49-75. 
25. Pascussi, J. M., Gerbal-Chaloin, S., Duret, C., Daujat-Chavanieu, M., Vilarem, M. J., Maurel, P. The tangle of nuclear 
Bibliography 
 165 
receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol. 
2008;48:1-32. 
26. Handschin, C., Meyer, U. A. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev. 2003;55(4):649-
73. 
27. Faber, K. N., Muller, M., Jansen, P. L. Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003;55(1):107-24. 
28. Tolson, A. H., Wang, H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug 
Deliv Rev. 2010;62(13):1238-49. 
29. Duanmu, Z., Locke, D., Smigelski, J., Wu, W., Dahn, M. S., Falany, C. N., et al. Effects of dexamethasone on aryl 
(SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. 
Drug Metab Dispos. 2002;30(9):997-1004. 
30. Bell, L. N., Chalasani, N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29(4):337-47. 
31. Ju, C. Immunological mechanisms of drug-induced liver injury. Curr Opin Drug Discov Devel. 2005;8(1):38-43. 
32. European Medicies Agency, Viramune -EMEA/H/C/000183 -IB/0123. 12/02/2016. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000183/WC50005 
1481 .pdf 
33. Larson, A. M. Diagnosis and management of acute liver failure. Curr Opin Gastroenterol. 2010;26(3):214-21. 
34. Russmann, S., Kullak-Ublick, G. A., Grattagliano, I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr 
Med Chem. 2009;16(23):3041-53. 
35. Roth, R. A., Ganey, P. E. Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp 
Ther. 2010;332(3):692-7. 
36. Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q., Portincasa, P. Biochemical mechanisms in drug-
induced liver injury: certainties and doubts. World J Gastroenterol. 2009;15(39):4865-76. 
37. Singh, B. K., Tripathi, M., Chaudhari, B. P., Pandey, P. K., Kakkar, P. Natural terpenes prevent mitochondrial dysfunction, 
oxidative stress and release of apoptotic proteins during nimesulide-hepatotoxicity in rats. PLoS One. 2012;7(4):e34200. 
38. Timbrell, J. Introduction to toxicology. 3th ed. London: Taylor and Francis; 2002. 215 p. 
39. Boelsterli, U. A. Mechanistic Toxicology. First Edition ed: Francis and Taylor; 2005. 314 p. 
40. Padda, M. S., Sanchez, M., Akhtar, A. J., Boyer, J. L. Drug-induced cholestasis. Hepatology. 2011;53(4):1377-87. 
41. Liu, J., Waalkes, M. P. Liver is a target of arsenic carcinogenesis. Toxicol Sci. 2008;105(1):24-32. 
42. Dumas, E. O., Pollack, G. M. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J. 
2008;10(4):537-51. 
43. Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H., Schwab, M. Polymorphic CYP2B6: molecular 
mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8(7):743-59. 
44. Brockmoller, J., Tzvetkov, M. V. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug 
treatment. Eur J Clin Pharmacol. 2008;64(2):133-57. 
45. Tonder, J. J. V., Steenkamp, V., Gulumian, M. Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of 
Candidate Drugs [Inernet] In: Gowder, Sivakumar ed, New Insights into Toxicity and Drug Testing, Chapter 1. Jan 2013. 
Available from: https://www.intechopen.com/books/new-insights-into-toxicity-and-drug-testing/pre-clinical-assessment-
of-the-potential-intrinsic-hepatotoxicity-of-candidate-drugs 
46. Gebhardt, R., Hengstler, J. G., Muller, D., Glockner, R., Buenning, P., Laube, B., et al. New hepatocyte in vitro systems 
for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, 
standard operation procedures. Drug Metab Rev. 2003;35(2-3):145-213. 
47. Chapin, R. E., Stedman, D. B. Endless possibilities: stem cells and the vision for toxicology testing in the 21st century. 
Toxicol Sci. 2009;112(1):17-22. 
48. Mandenius, C. F., Andersson, T. B., Alves, P. M., Batzl-Hartmann, C., Bjorquist, P., Carrondo, M. J., et al. Toward 
preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human 
embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. Altern Lab Anim. 2011;39(2):147-
71. 
49. Society of Toxicology (SOT) Express Statement on Alternative toxicity test methods: Reducing, Refining, and Replacing, 
Animal Use for Safety Testing; Available from: http://www.toxicology.org/pubs/docs/pr/ToxTopics/TT3_InVitro_SOT.pdf 
Apr 2015  
50. Gerets, H. H., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., et al. Characterization of primary human 
hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their 
predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28(2):69-87. 
51. Sartipy, P., Bjorquist, P., Strehl, R., Hyllner, J. The application of human embryonic stem cell technologies to drug 
discovery. Drug Discov Today. 2007;12(17-18):688-99. 
52. Westerink, W. M., Schoonen, W. G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human 
Bibliography 
 166 
hepatocytes and their induction in HepG2 cells. Toxicol In Vitro. 2007;21(8):1581-91. 
53. Westerink, W. M., Schoonen, W. G. Phase II enzyme levels in HepG2 cells and cryopreserved primary human 
hepatocytes and their induction in HepG2 cells. Toxicol In Vitro. 2007;21(8):1592-602. 
54. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., Guguen-Guillouzo, C. The human hepatoma HepaRG cells: a 
highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact. 2007;168(1):66-
73. 
55. Bort, R., Signore, M., Tremblay, K., Martinez Barbera, J., Zaret, K. Hex homeobox gene controls the transition of the 
endoderm to a pseudostratified, cell emergent epithelium for liver bud development. Dev Biol. 2006;290(1):44-56. 
56. Lubberstedt, M., Muller-Vieira, U., Mayer, M., Biemel, K. M., Knospel, F., Knobeloch, D., et al. HepaRG human hepatic 
cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol 
Methods. 2011;63(1):59-68. 
57. Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouet, S., Morel, F., et al. Expression of cytochromes P450, 
conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2006;34(1):75-83. 
58. Ulvestad, M., Darnell, M., Molden, E., Ellis, E., Asberg, A., Andersson, T. B. Evaluation of organic anion-transporting 
polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-
dimensional bioreactor system. J Pharmacol Exp Ther. 2012;343(1):145-56. 
59. Bachour-El Azzi, P., Sharanek, A., Burban, A., Li, R., Guevel, R. L., Abdel-Razzak, Z., et al. Comparative Localization 
and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes. Toxicol 
Sci. 2015;145(1):157-68. 
60. Tibbitt, M., Anseth, K. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol Bioeng. 2009;103(4):655-
63. 
61. Miranda, J. P., Rodrigues, A., Tostoes, R. M., Leite, S., Zimmerman, H., Carrondo, M. J., et al. Extending hepatocyte 
functionality for drug-testing applications using high-viscosity alginate-encapsulated three-dimensional cultures in 
bioreactors. Tissue Eng Part C Methods. 2010;16(6):1223-32. 
62. Müller, D., Tascher, G., Muller-Vieira, U., Knobeloch, D., Nuessler, A. K., Zeilinger, K., et al. In-depth physiological 
characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J Tissue Engineering Regen Med. 
2011;5(8):e207-18. 
63. Zeilinger, K., Schreiter, T., Darnell, M., Soderdahl, T., Lubberstedt, M., Dillner, B., et al. Scaling down of a clinical three-
dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an 
analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods. 2011;17(5):549-
56. 
64. Lubberstedt, M., Muller-Vieira, U., Biemel, K. M., Darnell, M., Hoffmann, S. A., Knospel, F., et al. Serum-free culture of 
primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies. J 
Tissue Engineering Regen Med. 2012. 
65. Schyschka, L., Sanchez, J. J., Wang, Z., Burkhardt, B., Muller-Vieira, U., Zeilinger, K., et al. Hepatic 3D cultures but not 
2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch Toxicol. 
2013;87(8):1581-93. 
66. Fey, S. J., Wrzesinski, K. Determination of drug toxicity using 3D spheroids constructed from an immortal human 
hepatocyte cell line. Toxicol Sci. 2012;127(2):403-11. 
67. Molina-Jimenez, F., Benedicto, I., Dao Thi, V. L., Gondar, V., Lavillette, D., Marin, J. J., et al. Matrigel-embedded 3D 
culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology. 2012;425(1):31-9. 
68. Wrzesinski, K., Rogowska-Wrzesinska, A., Kanlaya, R., Borkowski, K., Schwammle, V., Dai, J., et al. The Cultural Divide: 
Exponential Growth in Classical 2D and Metabolic Equilibrium in 3D Environments. PLoS One. 2014;9(9):e106973. 
69. Lu, H. F., Lim, S. X., Leong, M. F., Narayanan, K., Toh, R. P., Gao, S., et al. Efficient neuronal differentiation and 
maturation of human pluripotent stem cells encapsulated in 3D microfibrous scaffolds. Biomaterials. 2012;33(36):9179-
87. 
70. Tostoes, R. M., Leite, S. B., Miranda, J. P., Sousa, M., Wang, D. I., Carrondo, M. J., et al. Perfusion of 3D encapsulated 
hepatocytes--a synergistic effect enhancing long-term functionality in bioreactors. Biotechnol Bioeng. 2011;108(1):41-9. 
71. Miranda, J. P., Leite, S. B., Muller-Vieira, U., Rodrigues, A., Carrondo, M. J., Alves, P. M. Towards an extended functional 
hepatocyte in vitro culture. Tissue Eng Part C Methods. 2009;15(2):157-67. 
72. Conway, D. E., Sakurai, Y., Weiss, D., Vega, J. D., Taylor, W. R., Jo, H., et al. Expression of CYP1A1 and CYP1B1 in 
human endothelial cells: regulation by fluid shear stress. Cardiovasc Res. 2009;81(4):669-77. 
73. Shvartsman, I., Dvir, T., Harel-Adar, T., Cohen, S. Perfusion cell seeding and cultivation induce the assembly of thick 
and functional hepatocellular tissue-like construct. Tissue Eng Part A. 2009;15(4):751-60. 
74. Vinci, B., Duret, C., Klieber, S., Gerbal-Chaloin, S., Sa-Cunha, A., Laporte, S., et al. Modular bioreactor for primary human 
hepatocyte culture: medium flow stimulates expression and activity of detoxification genes. Biotechnol J. 2011;6(5):554-
64. 
75. Lauschke, V. M., Hendriks, D. F., Bell, C. C., Andersson, T. B., Ingelman-Sundberg, M. Novel 3D Culture Systems for 
Bibliography 
 167 
Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Chem Res 
Toxicol. 2016. 
76. Haycock, J. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol. 2011;695:1-15. 
77. Lin, R. Z., Chang, H. Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. 
Biotechnol J. 2008;3(9-10):1172-84. 
78. Novik, E., Maguire, T. J., Chao, P., Cheng, K. C., Yarmush, M. L. A microfluidic hepatic coculture platform for cell-based 
drug metabolism studies. Biochem Pharmacol. 2010;79(7):1036-44. 
79. Domansky, K., Inman, W., Serdy, J., Dash, A., Lim, M. H., Griffith, L. G. Perfused multiwell plate for 3D liver tissue 
engineering. Lab Chip. 2010;10(1):51-8. 
80. Chan, C., Berthiaume, F., Nath, B. D., Tilles, A. W., Toner, M., Yarmush, M. L. Hepatic tissue engineering for adjunct 
and temporary liver support: critical technologies. Liver Transpl. 2004;10(11):1331-42. 
81. Bavli, D., Prill, S., Ezra, E., Levy, G., Cohen, M., Vinken, M., et al. Real-time monitoring of metabolic function in liver-on-
chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc Natl Acad Sci U S A. 2016;113(16):E2231-40. 
82. Tsamandouras, N., Kostrzewski, T., Stokes, C. L., Griffith, L. G., Hughes, D. J., Cirit, M. Quantitative Assessment of 
Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological 
System. J Pharmacol Exp Ther. 2017;360(1):95-105. 
83. Guillouzo, A. Liver cell models in in vitro toxicology. Environ Health Perspect. 1998;106 Suppl 2:511-32. 
84. Zeilinger, K., Freyer, N., Damm, G., Seehofer, D., Knospel, F. Cell sources for in vitro human liver cell culture models. 
Exp Biol Med (Maywood). 2016;241(15):1684-98. 
85. Leite, S. B., Teixeira, A. P., Miranda, J. P., Tostoes, R. M., Clemente, J. J., Sousa, M. F., et al. Merging bioreactor 
technology with 3D hepatocyte-fibroblast culturing approaches: Improved in vitro models for toxicological applications. 
Toxicol In Vitro. 2011;25(4):825-32. 
86. Leite, S. B., Wilk-Zasadna, I., Zaldivar, J. M., Airola, E., Reis-Fernandes, M. A., Mennecozzi, M., et al. Three-dimensional 
HepaRG model as an attractive tool for toxicity testing. Toxicol Sci. 2012;130(1):106-16. 
87. Bell, C. C., Hendriks, D. F., Moro, S. M., Ellis, E., Walsh, J., Renblom, A., et al. Characterization of primary human 
hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep. 2016;6:25187. 
88. Alimperti, S., Lei, P., Wen, Y., Tian, J., Campbell, A. M., Andreadis, S. T. Serum-free spheroid suspension culture 
maintains mesenchymal stem cell proliferation and differentiation potential. Biotechnol Prog. 2014;30(4):974-83. 
89. Wang, Y. H., Wu, J. Y., Chou, P. J., Chen, C. H., Wang, C. Z., Ho, M. L., et al. Characterization and evaluation of the 
differentiation ability of human adipose-derived stem cells growing in scaffold-free suspension culture. Cytotherapy. 
2014;16(4):485-95. 
90. Ramaiahgari, S. C., Den Braver, M. W., Herpers, B., Terpstra, V., Commandeur, J. N., Van De Water, B., et al. A 3D in 
vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput 
toxicity studies. Arch Toxicol. 2014;88(5):1083-95. 
91. Pinheiro, P. F., Pereira, S. A., Harjivan, S. G., Martins, I. L., Marinho, A. T., Cipriano, M., et al. Hepatocyte spheroids as 
a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study. Arch Toxicol. 
2017;91(3):1199-211. 
92. Darnell, M., Schreiter, T., Zeilinger, K., Urbaniak, T., Soderdahl, T., Rossberg, I., et al. Cytochrome P450-dependent 
metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos. 2011;39(7):1131-
8. 
93. Darnell, M., Ulvestad, M., Ellis, E., Weidolf, L., Andersson, T. B. In vitro evaluation of major in vivo drug metabolic 
pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional 
bioreactor system. J Pharmacol Exp Ther. 2012;343(1):134-44. 
94. Hoffmann, S. A., Muller-Vieira, U., Biemel, K., Knobeloch, D., Heydel, S., Lubberstedt, M., et al. Analysis of drug 
metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies. Biotechnol Bioeng. 
2012;109(12):3172-81. 
95. Knöspel, F., Jacobs, F., Freyer, N., Damm, G., De Bondt, A., Van Den Wyngaert, I., et al. In Vitro Model for Hepatotoxicity 
Studies Based on Primary Human Hepatocyte Cultivation in a Perfused 3D Bioreactor System. Int Mol Sci. 2016;17(4). 
96. Gerlach, J. C., Mutig, K., Sauer, I. M., Schrade, P., Efimova, E., Mieder, T., et al. Use of primary human liver cells 
originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem 
cells in bioreactors: a morphologic study. Transplantation. 2003;76(5):781-6. 
97. Soldatow, V. Y., Lecluyse, E. L., Griffith, L. G., Rusyn, I. In vitro models for liver toxicity testing. Toxicol Res. 2013;2(1):23-
39. 
98. Marinho, A. T., Dias, C. G., Pinheiro, P. F., Lemos, A. R., Antunes, A. M., Marques, M. M., et al. Nevirapine modulation 
of paraoxonase-1 in the liver: An in vitro three-model approach. Eur J Pharm Sci. 2016;82:147-53. 
99. Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., et al. A long-term three dimensional liver co-
culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol. 
Bibliography 
 168 
2013;268(1):1-16. 
100. Tostões, R. M., Leite, S. B., Serra, M., Jensen, J., Bjorquist, P., Carrondo, M. J., et al. Human liver cell spheroids in 
extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology. 2012;55(4):1227-36. 
101. Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., Noor, F. 3D organotypic cultures of 
human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci. 2013;133(1):67-78. 
102. Boelsterli, U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 
2003;192(3):307-22. 
103. Xu, J., Ma, M., Purcell, W. M. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in 
vitro models and their application in hepatotoxicity studies. II. Spheroid cell spreading inhibition as a new cytotoxic marker. 
Toxicol Appl Pharmacol. 2003;189(2):112-9. 
104. Bort, R., Ponsoda, X., Jover, R., Gomez-Lechon, M. J., Castell, J. V. Diclofenac toxicity to hepatocytes: a role for drug 
metabolism in cell toxicity. J Pharmacol Exp Ther. 1999;288(1):65-72. 
105. Lauer, B., Tuschl, G., Kling, M., Mueller, S. O. Species-specific toxicity of diclofenac and troglitazone in primary human 
and rat hepatocytes. Chem Biol Interact. 2009;179(1):17-24. 
106. Lin, J., Schyschka, L., Muhl-Benninghaus, R., Neumann, J., Hao, L., Nussler, N., et al. Comparative analysis of phase I 
and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug 
metabolism. Arch Toxicol. 2012;86(1):87-95. 
107. Ponsoda, X., Bort, R., Jover, R., Gomez-Lechon, M. J., Castell, J. V. Molecular mechanism of diclofenac hepatotoxicity: 
Association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol In Vitro. 1995;9(4):439-44. 
108. Wang, K., Shindoh, H., Inoue, T., Horii, I. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in 
comparison with established cell lines. J Toxicol Sci. 2002;27(3):229-37. 
109. Goda, K., Takahashi, T., Kobayashi, A., Shoda, T., Kuno, H., Sugai, S. Usefulness of in vitro combination assays of 
mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury. J 
Toxicol Sci. 2016;41(5):605-15. 
110. Chojkier, M. Troglitazone and liver injury: in search of answers. Hepatology. 2005;41(2):237-46. 
111. Sahi, J., Hamilton, G., Sinz, M., Barros, S., Huang, S. M., Lesko, L. J., et al. Effect of troglitazone on cytochrome P450 
enzymes in primary cultures of human and rat hepatocytes. Xenobiotica. 2000;30(3):273-84. 
112. Kassahun, K., Pearson, P. G., Tang, W., Mcintosh, I., Leung, K., Elmore, C., et al. Studies on the metabolism of 
troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving 
quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol. 2001;14(1):62-70. 
113. Smith, M. T. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol. 2003;16(6):679-87. 
114. Shen, M. Nodal signaling: developmental roles and regulation. Development. 2007;134(6):1023-34. 
115. Izumi, T., Enomoto, S., Hosiyama, K., Sasahara, K., Shibukawa, A., Nakagawa, T., et al. Prediction of the human 
pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an 
animal scale-up approach. J Pharmacol Exp Ther. 1996;277(3):1630-41. 
116. Hendriks, D. F., Fredriksson Puigvert, L., Messner, S., Mortiz, W., Ingelman-Sundberg, M. Hepatic 3D spheroid models 
for the detection and study of compounds with cholestatic liability. Sci Rep. 2016;6:35434. 
117. Oecd. OECD Test No 417: Toxicokinetics. Guideline for the testing of chemicals. Paris: OECD; 2010. 
118. Coecke, S., Pelkonen, O., Leite, S. B., Bernauer, U., Bessems, J. G., Bois, F. Y., et al. Toxicokinetics as a key to the 
integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol In Vitro. 2013;27(5):1570-7. 
119. Toxicity Testing in the 21st Century: A Vision and a Strategy. Committee on Toxicity Testing and Assessment of 
Environmental Agents; Board on Environmental Studies and Toxicology; Institute for Laboratory Animal Research; 
Division on Earth and Life Studies. Washington DC: The National Academies Press; 2007. 
120. Daneshian, M., Kamp, H., Hengstler, J., Leist, M., Van De Water, B. Highlight report: Launch of a large integrated 
European in vitro toxicology project: EU-ToxRisk. Arch Toxicol. 2016;90(5):1021-4. 
121. Andersen, M. E., Krewski, D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci. 2009;107(2):324-
30. 
122. Baharvand, H., Hashemi, S. M., Kazemi Ashtiani, S., Farrokhi, A. Differentiation of human embryonic stem cells into 
hepatocytes in 2D and 3D culture systems in vitro. Int J Dev Biol. 2006;50(7):645-52. 
123. Davila, J. C., Cezar, G. G., Thiede, M., Strom, S., Miki, T., Trosko, J. Use and application of stem cells in toxicology. 
Toxicol Sci. 2004;79(2):214-23. 
124. Giri, S., Nieber, K., Bader, A. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible 
solutions in preclinical stages. Expert Opin Drug Metab Toxicol. 2010;6(8):895-917. 
125. Krewski, D., Andersen, M. E., Mantus, E., Zeise, L. Toxicity testing in the 21st century: implications for human health risk 
assessment. Risk Anal. 2009;29(4):474-9. 
126. Shukla, S. J., Huang, R., Austin, C. P., Xia, M. The future of toxicity testing: a focus on in vitro methods using a quantitative 
Bibliography 
 169 
high-throughput screening platform. Drug Discov Today. 2010;15(23-24):997-1007. 
127. Trosko, J. E. Commentary on ''Toxicity testing in the 21st century: a vision and a strategy'': stem cells and cell-cell 
communication as fundamental targets in assessing the potential toxicity of chemicals. Hum Exp Toxicol. 2010;29(1):21-
9. 
128. Balls, M. Modern alternative approaches to the problem of drug-induced liver injury. Altern Lab Anim. 2011;39(2):103-7. 
129. Kandarova, H., Letasiova, S. Alternative methods in toxicology: pre-validated and validated methods. Interdiscip Toxicol. 
2011;4(3):107-13. 
130. Zuang V. D., Barroso J., Belz S., Bopp S.; Bostroem A.C., Boufid M., et al.. EURL ECVAM Status Report on the 
Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2016) [Internet]. Health, 
Consumers and Reference Materials, JRC103522; Out 2016, Available from: 
http://publications.jrc.ec.europa.eu/repository/handle/JRC103522  
131. Suter-Dick, L., Alves, P. M., Blaauboer, B. J., Bremm, K. D., Brito, C., Coecke, S., et al. Stem cell-derived systems in 
toxicology assessment. Stem Cells Dev. 2015;24(11):1284-96. 
132. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., et al. Embryonic stem 
cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7. 
133. Zuba-Surma, E. K., Jozkowicz, A., Dulak, J. Stem cells in pharmaceutical biotechnology. Curr Pharm Biotechnol. 
2011;12(11):1760-73. 
134. Stummann, T. C., Bremer, S. Embryonic stem cells in safety pharmacology and toxicology. Adv Exp Med Biol. 
2012;745:14-25. 
135. European Commission Press Release, European Commission proposes strict ethical guidelines on EU funding of human 
embryonic stem cell research [Internet]. IP/03/969, Brussels, July 2003, Available from: http://europa.eu/rapid/press-
release_IP-03-969_en.htm?locale=en 
136. Greely, H. T. Moving human embryonic stem cells from legislature to lab: remaining legal and ethical questions. PLoS 
Med. 2006;3(5):e143. 
137. Vojnits, K., Bremer, S. Challenges of using pluripotent stem cells for safety assessments of substances. Toxicology. 
2010;270(1):10-7. 
138. Behbahan, I. S., Duan, Y., Lam, A., Khoobyari, S., Ma, X., Ahuja, T. P., et al. New approaches in the differentiation of 
human embryonic stem cells and induced pluripotent stem cells toward hepatocytes. Stem Cell Rev. 2011;7(3):748-59. 
139. Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., et al. Vascularized and functional human liver 
from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481-4. 
140. Toivonen, S., Ojala, M., Hyysalo, A., Ilmarinen, T., Rajala, K., Pekkanen-Mattila, M., et al. Comparative analysis of 
targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals 
variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. Stem Cells Transl Med. 
2013;2(2):83-93. 
141. Herberts, C. A., Kwa, M. S., Hermsen, H. P. Risk factors in the development of stem cell therapy. J Transl Med. 2011;9:29. 
142. Peterson, S. E., Loring, J. F. Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol 
Chem. 2014;289(8):4578-84. 
143. Cai, J., Weiss, M. L., Rao, M. S. In search of "stemness". Exp Hematol. 2004;32(7):585-98. 
144. Filipe, E. C. Optimization of low serum umbilical cord matrix mesenchymal stem cell (ucmMSC) culture for conditioned 
media preparation: in vitro ans in vivo wound healing applications. Lisboa: Universidade de Lisboa; 2011.Available from: 
http://repositorio.ul.pt/bitstream/10451/6309/1/ulfc092793_tm_elysse_filipe.pdf 
145. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 
2006;8(4):315-7. 
146. Campagnoli, C., Roberts, I. A., Kumar, S., Bennett, P. R., Bellantuono, I., Fisk, N. M. Identification of mesenchymal 
stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98(8):2396-402. 
147. In 'T Anker, P. S., Scherjon, S. A., Kleijburg-Van Der Keur, C., De Groot-Swings, G. M., Claas, F. H., Fibbe, W. E., et al. 
Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22(7):1338-45. 
148. In 'T Anker, P. S., Scherjon, S. A., Kleijburg-Van Der Keur, C., Noort, W. A., Claas, F. H., Willemze, R., et al. Amniotic 
fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003;102(4):1548-9. 
149. Erices, A., Conget, P., Minguell, J. J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 
2000;109(1):235-42. 
150. Buyl, K., De Kock, J., Najar, M., Lagneaux, L., Branson, S., Rogiers, V., et al. Characterization of hepatic markers in 
human Wharton's Jelly-derived mesenchymal stem cells. Toxicol In Vitro. 2014;28(1):113-9. 
151. La Rocca, G., Anzalone, R., Corrao, S., Magno, F., Loria, T., Lo Iacono, M., et al. Isolation and characterization of Oct-
4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new 
markers. Histochemistry and cell biology. 2009;131(2):267-82. 
Bibliography 
 170 
152. La Rocca, G., Lo Iacono, M., Corsello, T., Corrao, S., Farina, F., Anzalone, R. Human Wharton's jelly mesenchymal stem 
cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and 
chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther. 2013;8(1):100-13. 
153. Secunda, R., Vennila, R., Mohanashankar, A. M., Rajasundari, M., Jeswanth, S., Surendran, R. Isolation, expansion and 
characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: 
a comparative study. Cytotechnology. 2014. 
154. Santos JMS, Soares R, Martins JP, Basto V, Coelho M, Cruz P, et al. Optimised and defined method for isolation and 
preservation of precursor cells from human umbilical cord. INPI PAT20081000083882;PCT/IB2008/054067; 
WO2009044379. Medinfar, ECBio. 2008. Avaible from: 
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009044379. 
155. Da Silva Meirelles, L., Chagastelles, P. C., Nardi, N. B. Mesenchymal stem cells reside in virtually all post-natal organs 
and tissues. J Cell Sci. 2006;119(Pt 11):2204-13. 
156. Muller, I., Kordowich, S., Holzwarth, C., Spano, C., Isensee, G., Staiber, A., et al. Animal serum-free culture conditions 
for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy. 2006;8(5):437-44. 
157. Barry, F. P., Murphy, J. M. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem 
Cell Biol. 2004;36(4):568-84. 
158. Zeddou, M., Briquet, A., Relic, B., Josse, C., Malaise, M. G., Gothot, A., et al. The umbilical cord matrix is a better source 
of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int. 2010;34(7):693-701. 
159. Fukuda, K. Molecular characterization of regenerated cardiomyocytes derived from adult mesenchymal stem cells. 
Congenit Anom (Kyoto). 2002;42(1):1-9. 
160. De Kock, J., Najar, M., Bolleyn, J., Al Battah, F., Rodrigues, R. M., Buyl, K., et al. Mesoderm-derived stem cells: the link 
between the transcriptome and their differentiation potential. Stem Cells Dev. 2012;21(18):3309-23. 
161. Anzalone, R., Lo Iacono, M., Corrao, S., Magno, F., Loria, T., Cappello, F., et al. New emerging potentials for human 
Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells 
Dev. 2010;19(4):423-38. 
162. Rodrigues, R. M., Branson, S., De Boe, V., Sachinidis, A., Rogiers, V., De Kock, J., et al. In vitro assessment of drug-
induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016;90(3):677-89. 
163. Guillouzo, A., Guguen-Guillouzo, C. Evolving concepts in liver tissue modeling and implications for in vitro toxicology. 
Expert Opin Drug Metab Toxicol. 2008;4(10):1279-94. 
164. Duan, Y., Ma, X., Zou, W., Wang, C., Bahbahan, I. S., Ahuja, T. P., et al. Differentiation and characterization of 
metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells. 2010;28(4):674-86. 
165. Safinia, N., Minger, S. L. Generation of hepatocytes from human embryonic stem cells. Methods Mol Biol. 2009;481:169-
80. 
166. Takayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., et al. Efficient generation of functional 
hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction. Mol Ther. 
2012;20(1):127-37. 
167. Touboul, T., Hannan, N. R., Corbineau, S., Martinez, A., Martinet, C., Branchereau, S., et al. Generation of functional 
hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. 
Hepatology. 2010;51(5):1754-65. 
168. Snykers, S., Vanhaecke, T., De Becker, A., Papeleu, P., Vinken, M., Van Riet, I., et al. Chromatin remodeling agent 
trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. 
BMC Dev Biol. 2007;2;7:24. 
169. Dong, X., Pan, R., Zhang, H., Yang, C., Shao, J., Xiang, L. Modification of histone acetylation facilitates hepatic 
differentiation of human bone marrow mesenchymal stem cells. PLoS One. 2013;8(5):e63405. 
170. Banas, A. Purification of adipose tissue mesenchymal stem cells and differentiation toward hepatic-like cells. Methods 
Mol Biol. 2012;826:61-72. 
171. Li, X., Yuan, J., Li, W., Liu, S., Hua, M., Lu, X., et al. Direct differentiation of homogeneous human adipose stem cells 
into functional hepatocytes by mimicking liver embryogenesis. J Cell Physiol. 2014;229(6):801-12. 
172. Campard, D., Lysy, P. A., Najimi, M., Sokal, E. M. Native umbilical cord matrix stem cells express hepatic markers and 
differentiate into hepatocyte-like cells. Gastroenterology. 2008;134(3):833-48. 
173. Cipriano, M., Freyer, N., Knospel, F., Oliveira, N. G., Barcia, R., Cruz, P. E., et al. Self-assembled 3D spheroids and 
hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2016. 
174. Zhang, Y. N., Lie, P. C., Wei, X. Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton's jelly 
into hepatocyte-like cells. Cytotherapy. 2009;11(5):548-58. 
175. Zhang, S., Chen, L., Liu, T., Zhang, B., Xiang, D., Wang, Z., et al. Human umbilical cord matrix stem cells efficiently 
rescue acute liver failure through paracrine effects rather than hepatic differentiation. Tissue Eng Part A. 2012;18(13-
14):1352-64. 
Bibliography 
 171 
176. Zhao, Q., Ren, H., Li, X., Chen, Z., Zhang, X., Gong, W., et al. Differentiation of human umbilical cord mesenchymal 
stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy. 2009;11(4):414-26. 
177. Zhou, R., Li, Z., He, C., Li, R., Xia, H., Li, C., et al. Human umbilical cord mesenchymal stem cells and derived hepatocyte-
like cells exhibit similar therapeutic effects on an acute liver failure mouse model. PLoS One. 2014;9(8):e104392. 
178. Liang, X. J., Chen, X. J., Yang, D. H., Huang, S. M., Sun, G. D., Chen, Y. P. Differentiation of human umbilical cord 
mesenchymal stem cells into hepatocyte-like cells by hTERT gene transfection in vitro. Cell Biol Int. 2012;36(2):215-21. 
179. Yoon, H. H., Jung, B. Y., Seo, Y. K., Song, K. Y., Park, J. K. In vitro hepatic differentiation of umbilical cord-derived 
mesenchymal stem cell. Process Biochem. 2010;45(12):1857-64. 
180. Snykers, S., De Kock, J., Rogiers, V., Vanhaecke, T. In vitro differentiation of embryonic and adult stem cells into 
hepatocytes: state of the art. Stem Cells. 2009;27(3):577-605. 
181. Zorn, A. M. Liver Development. StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute Oct 2008 Available 
from: http://www.stembook.org/node/512.html 
182. D'amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., Baetge, E. E. Efficient differentiation of human 
embryonic stem cells to definitive endoderm. Nat Biotechnol. 2005;23(12):1534-41. 
183. Hay, D. C., Zhao, D., Fletcher, J., Hewitt, Z. A., Mclean, D., Urruticoechea-Uriguen, A., et al. Efficient differentiation of 
hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells. 
2008;26(4):894-902. 
184. Freyer, N., Knospel, F., Strahl, N., Amini, L., Schrade, P., Bachmann, S., et al. Hepatic Differentiation of Human Induced 
Pluripotent Stem Cells in a Perfused Three-Dimensional Multicompartment Bioreactor. Biores Open Access. 
2016;5(1):235-48. 
185. Calmont, A., Wandzioch, E., Tremblay, K., Minowada, G., Kaestner, K., Martin, G., et al. An FGF response pathway that 
mediates hepatic gene induction in embryonic endoderm cells. Dev Cell. 2006;11(3):339-48. 
186. Mclin, V., Rankin, S., Zorn, A. Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver 
and pancreas development. Development. 2007;134(12):2207-17. 
187. Chen, Y., Pan, F., Brandes, N., Afelik, S., Sölter, M., Pieler, T. Retinoic acid signaling is essential for pancreas 
development and promotes endocrine at the expense of exocrine cell differentiation in Xenopus. Dev Biol. 
2004;271(1):144-60. 
188. Zaret, K. Liver specification and early morphogenesis. Mech Develop. 2000;92:83-8. 
189. Ben Z. Stanger, D. K. P. Basic mechanisms of normal and abnormal gastrointestinal function: Development of the 
gastrointestinal system (Part 1: Section 23). In: Yamada, T., editor. Textbook of Gastroenterology. 1. Fifth Edition ed. 
West Sussex, PO19 8SQ, UK: Blackwell Publishing/John Wiley & Sons; 2009. p. 1744. 
190. Ameri, J., Stahlberg, A., Pedersen, J., Johansson, J., Johannesson, M., Artner, I., et al. FGF2 specifies hESC-derived 
definitive endoderm into foregut/midgut cell lineages in a concentration-dependent manner. Stem Cells. 2010;28(1):45-
56. 
191. Rossi, J., Dunn, N., Hogan, B., Zaret, K. Distinct mesodermal signals, including BMPs from the septum transversum 
mesenchyme, are required in combination for hepatogenesis from the endoderm. Gene Dev. 2001;15(15):1998-2009. 
192. Wang, Z., Dollé, P., Cardoso, W., Niederreither, K. Retinoic acid regulates morphogenesis and patterning of posterior 
foregut derivatives. Dev Biol. 2006;297(2):433-45. 
193. Kamiya, A. K., T.; Miyajima, A. . Oncostatin M and Hepatocyte Growth Factor Induce Hepatic Maturation Via Distinct 
Signaling Pathways. FEBS Lett. 2001(492):90-4. 
194. Kamiya, A., Kinoshita, T., Ito, Y., Matsui, T., Y., M., Senba, E., et al. Fetal Liver Development requires a paracrine action 
of Oncostatin M Through the gp130 Signal Transducer. EMBO J. 1999;18(8):2127-36. 
195. Odom, D., Zizlsperger, N., Gordon, D., Bell, G. W., Rinaldi, N., Murray, H., et al. Control of pancreas and liver gene 
expression by HNF transcription factors. Science. 2004;303(5662):1378-81. 
196. Michalopoulos, G. K., Bowen, W. C., Mule, K., Luo, J. HGF-, EGF-, and dexamethasone-induced gene expression 
patterns during formation of tissue in hepatic organoid cultures. Gene Expr. 2003;11(2):55-75. 
197. Tasnim, F., Toh, Y. C., Qu, Y., Li, H., Phan, D., Narmada, B. C., et al. Functionally Enhanced Human Stem Cell Derived 
Hepatocytes in Galactosylated Cellulosic Sponges for Hepatotoxicity Testing. Mol Pharm. 2016;13(6):1947-57. 
198. Lee, H. J., Jung, J., Cho, K. J., Lee, C. K., Hwang, S. G., Kim, G. J. Comparison of in vitro hepatogenic differentiation 
potential between various placenta-derived stem cells and other adult stem cells as an alternative source of functional 
hepatocytes. Differentiation. 2012;84(3):223-31. 
199. Paganelli, M., Dallmeier, K., Nyabi, O., Scheers, I., Kabamba, B., Neyts, J., et al. Differentiated umbilical cord matrix 
stem cells as a new in vitro model to study early events during hepatitis B virus infection. Hepatology. 2013;57(1):59-69. 
200. Lee, H. J., Cha, K. E., Hwang, S. G., Kim, J. K., Kim, G. J. In vitro screening system for hepatotoxicity: comparison of 
bone-marrow-derived mesenchymal stem cells and Placenta-derived stem cells. J Cell Biochem. 2011;112(1):49-58. 
201. Snykers, S., Henkens, T., De Rop, E., Vinken, M., Fraczek, J., De Kock, J., et al. Role of epigenetics in liver-specific 
gene transcription, hepatocyte differentiation and stem cell reprogrammation. J Hepatol. 2009;51(1):187-211. 
Bibliography 
 172 
202. An, S. Y., Han, J., Lim, H. J., Park, S. Y., Kim, J. H., Do, B. R., et al. Valproic acid promotes differentiation of hepatocyte-
like cells from whole human umbilical cord-derived mesenchymal stem cells. Tissue Cell. 2014;46(2):127-35. 
203. Mortezaee, K., Minaii, B., Sabbaghziarani, F., Ragerdi Kashani, I., Hassanzadeh, G., Pasbakhsh, P., et al. Retinoic Acid 
as the Stimulating Factor for Differentiation of Wharton's Jelly-Mesenchymal Stem Cells into Hepatocyte-like Cells. 
Avicenna J Med Biotechnol. 2015;7(3):106-12. 
204. Raut, A., Khanna, A. Enhanced expression of hepatocyte-specific microRNAs in valproic acid mediated hepatic trans-
differentiation of human umbilical cord derived mesenchymal stem cells. Exp Cell Res. 2016;343(2):237-47. 
205. El-Serafi, A. T., Oreffo, R. O., Roach, H. I. Epigenetic modifiers influence lineage commitment of human bone marrow 
stromal cells: Differential effects of 5-aza-deoxycytidine and trichostatin A. Differentiation. 2011;81(1):35-41. 
206. Mahmud, N., Petro, B., Baluchamy, S., Li, X., Taioli, S., Lavelle, D., et al. Differential effects of epigenetic modifiers on 
the expansion and maintenance of human cord blood stem/progenitor cells. Biol Blood Marrow Transplant. 
2014;20(4):480-9. 
207. Zych, J., Stimamiglio, M. A., Senegaglia, A. C., Brofman, P. R., Dallagiovanna, B., Goldenberg, S., et al. The epigenetic 
modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells. 
Braz J Med Biol Res. 2013;46(5):405-16. 
208. Santi, D. V., Norment, A., Garrett, C. E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA 
containing 5-azacytosine. Proc Natl Acad Sci U S A. 1984;81(22):6993-7. 
209. Komashko, V. M., Farnham, P. J. 5-azacytidine treatment reorganizes genomic histone modification patterns. 
Epigenetics. 2010;5(3). 
210. Bhuvanagiri, M., Lewis, J., Putzker, K., Becker, J. P., Leicht, S., Krijgsveld, J., et al. 5-azacytidine inhibits nonsense-
mediated decay in a MYC-dependent fashion. EMBO Mol Med. 2014. 
211. Bhuvanagiri, M., Schlitter, A. M., Hentze, M. W., Kulozik, A. E. NMD: RNA biology meets human genetic medicine. 
Biochem J. 2010;430(3):365-77. 
212. Rothrock, R., Lee, K. L., Isham, K. R., Kenney, F. T. Changes in hepatic differentiation following treatment of rat fetuses 
with 5-azacytidine. Arch Biochem Biophys. 1988;263(2):237-44. 
213. Seeliger, C., Culmes, M., Schyschka, L., Yan, X., Damm, G., Wang, Z., et al. Decrease of global methylation improves 
significantly hepatic differentiation of Ad-MSCs: possible future application for urea detoxification. Cell Transplant. 
2013;22(1):119-31. 
214. Yoshida, Y., Shimomura, T., Sakabe, T., Ishii, K., Gonda, K., Matsuoka, S., et al. A role of Wnt/beta-catenin signals in 
hepatic fate specification of human umbilical cord blood-derived mesenchymal stem cells. Am J Physiol Gastrointest 
Liver Physiol. 2007;293(5):G1089-98. 
215. Van Roozendaal, K. E., Darling, D., Farzaneh, F. DMSO and retinoic acid induce HL-60 differentiation by different but 
converging pathways. Exp Cell Res. 1990;190(1):137-40. 
216. Kamiya, A., Kojima, N., Kinoshita, T., Sakai, Y., Miyaijma, A. Maturation of fetal hepatocytes in vitro by extracellular 
matrices and oncostatin M: induction of tryptophan oxygenase. Hepatology. 2002;35(6):1351-9. 
217. Liu, W. H., Liu, Z. C., You, N., Zhang, N., Wang, T., Gong, Z. B., et al. Several important in vitro improvements in the 
amplification, differentiation and tracing of fetal liver stem/progenitor cells. PLoS One. 2012;7(10):e47346. 
218. Koyama, T., Ehashi, T., Ohshima, N., Miyoshi, H. Efficient proliferation and maturation of fetal liver cells in three-
dimensional culture by stimulation of oncostatin M, epidermal growth factor, and dimethyl sulfoxide. Tissue Eng Part A. 
2009;15(5):1099-107. 
219. Sakai, Y., Jiang, J., Kojima, N., Kinoshita, T., Miyajima, A. Enhanced in vitro maturation of fetal mouse liver cells with 
oncostatin M, nicotinamide, and dimethyl sulfoxide. Cell Transplant. 2002;11(5):435-41. 
220. Alizadeh, E., Zarghami, N., Eslaminejad, M. B., Akbarzadeh, A., Barzegar, A., Mohammadi, S. A. The effect of dimethyl 
sulfoxide on hepatic differentiation of mesenchymal stem cells. Artif Cells Nanomed Biotechnol. 2016;44(1):157-64. 
221. Banas, A., Teratani, T., Yamamoto, Y., Tokuhara, M., Takeshita, F., Osaki, M., et al. Rapid hepatic fate specification of 
adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol. 2009;24(1):70-7. 
222. Pal, R., Mamidi, M. K., Das, A. K., Bhonde, R. Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential 
of human embryonic stem cells. Arch Toxicol. 2012;86(4):651-61. 
223. Czysz, K., Minger, S., Thomas, N. DMSO efficiently down regulates pluripotency genes in human embryonic stem cells 
during definitive endoderm derivation and increases the proficiency of hepatic differentiation. PLoS One. 
2015;10(2):e0117689. 
224. Medine, C. N., Lucendo-Villarin, B., Zhou, W., West, C. C., Hay, D. C. Robust generation of hepatocyte-like cells from 
human embryonic stem cell populations. StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute Jun 2010. 
Available from: http://www.stembook.org/node/736.html 
225. Chetty, R., Slavin, J. L. Epithelioid sarcoma with extensive chondroid differentiation. Histopathology. 1994;24(4):400-1. 
226. Calder, A., Roth-Albin, I., Bhatia, S., Pilquil, C., Lee, J. H., Bhatia, M., et al. Lengthened G1 Phase Indicates Differentiation 
Status in Human Embryonic Stem Cells. Stem Cells Dev. 2013;22(2):279-95. 
Bibliography 
 173 
227. Earp, H. S., Rubin, R. A., Austin, K. S., Dy, R. C. DMSO increases tyrosine residue phosphorylation in membranes from 
murine erythroleukemia cells. Biochem Biophys Res Commun. 1983;112(2):413-8. 
228. Yen, A., Varvayanis, S. DMSO, sodium butyrate, and TPA induce hypophosphorylation of RB with HL-60 cell 
differentiation. In Vitro Cell Dev Biol Anim. 1995;31(3):164-7. 
229. Rubbini, S., Cocco, L., Manzoli, L., Lutterman, J., Billi, A. M., Matteucci, A., et al. Phosphoinositide signalling in nuclei of 
Friend cells: DMSO-induced differentiation reduces the association of phosphatidylinositol-transfer protein with the 
nucleus. Biochem Biophys Res Commun. 1997;230(2):302-5. 
230. Notman, R., Noro, M., O'malley, B., Anwar, J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. 
J Am Chem Soc. 2006;128(43):13982-3. 
231. He, F., Liu, W., Zheng, S., Zhou, L., Ye, B., Qi, Z. Ion transport through dimethyl sulfoxide (DMSO) induced transient 
water pores in cell membranes. Mol Membr Biol. 2012;29(3-4):107-13. 
232. Su, T., Waxman, D. J. Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes 
P450 in primary rat hepatocytes. Arch Biochem Biophys. 2004;424(2):226-34. 
233. Li, Y., Guo, G., Li, L., Chen, F., Bao, J., Shi, Y. J., et al. Three-dimensional spheroid culture of human umbilical cord 
mesenchymal stem cells promotes cell yield and stemness maintenance. Cell Tissue Res. 2015. 
234. Zhang, S., Liu, P., Chen, L., Wang, Y., Wang, Z., Zhang, B. The effects of spheroid formation of adipose-derived stem 
cells in a microgravity bioreactor on stemness properties and therapeutic potential. Biomaterials. 2015;41:15-25. 
235. Zhang, R. R., Takebe, T., Miyazaki, L., Takayama, M., Koike, H., Kimura, M., et al. Efficient hepatic differentiation of 
human induced pluripotent stem cells in a three-dimensional microscale culture. Methods Mol Biol. 2014;1210:131-41. 
236. Subramanian, K., Owens, D. J., Raju, R., Firpo, M., O'brien, T. D., Verfaillie, C. M., et al. Spheroid culture for enhanced 
differentiation of human embryonic stem cells to hepatocyte-like cells. Stem Cells Dev. 2014;23(2):124-31. 
237. Takayama, K., Kawabata, K., Nagamoto, Y., Kishimoto, K., Tashiro, K., Sakurai, F., et al. 3D spheroid culture of 
hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials. 2013;34(7):1781-9. 
238. Kim, S. J., Park, M. H., Moon, H. J., Park, J. H., Ko Du, Y., Jeong, B. Polypeptide thermogels as a three dimensional 
culture scaffold for hepatogenic differentiation of human tonsil-derived mesenchymal stem cells. ACS Appl Mater 
Interfaces. 2014;6(19):17034-43. 
239. Okura, H., Komoda, H., Saga, A., Kakuta-Yamamoto, A., Hamada, Y., Fumimoto, Y., et al. Properties of hepatocyte-like 
cell clusters from human adipose tissue-derived mesenchymal stem cells. Tissue Eng Part C Methods. 2010;16(4):761-
70. 
240. Lin, N., Lin, J., Bo, L., Weidong, P., Chen, S., Xu, R. Differentiation of bone marrow-derived mesenchymal stem cells into 
hepatocyte-like cells in an alginate scaffold. Cell Prolif. 2010;43(5):427-34. 
241. Li, J., Tao, R., Wu, W., Cao, H., Xin, J., Li, J., et al. 3D PLGA scaffolds improve differentiation and function of bone 
marrow mesenchymal stem cell-derived hepatocytes. Stem Cells Dev. 2010;19(9):1427-36. 
242. Kazemnejad, S., Allameh, A., Seoleimani, M., Gharehbaghian, A., Mohammadi, Y., Amirizadeh, N., et al. Functional 
hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel 3-dimensional biocompatible 
nanofibrous scaffold. International J Artif Organs. 2008;31(6):500-7. 
243. Sivertsson, L., Synnergren, J., Jensen, J., Bjorquist, P., Ingelman-Sundberg, M. Hepatic differentiation and maturation of 
human embryonic stem cells cultured in a perfused three-dimensional bioreactor. Stem Cells Dev. 2013;22(4):581-94. 
244. Gieseck, R. L., 3rd, Hannan, N. R., Bort, R., Hanley, N. A., Drake, R. A., Cameron, G. W., et al. Maturation of induced 
pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One. 2014;9(1):e86372. 
245. Kazemnejad, S., Allameh, A., Soleimani, M., Gharehbaghian, A., Mohammadi, Y., Amirizadeh, N., et al. Biochemical and 
molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel 
three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol. 2009;24(2):278-87. 
246. Sjogren, A. K., Liljevald, M., Glinghammar, B., Sagemark, J., Li, X. Q., Jonebring, A., et al. Critical differences in toxicity 
mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes. Arch 
Toxicol. 2014;88(7):1427-37. 
247. Holmgren, G., Sjogren, A. K., Barragan, I., Sabirsh, A., Sartipy, P., Synnergren, J., et al. Long-term chronic toxicity testing 
using human pluripotent stem cell-derived hepatocytes. Drug Metab Dispos. 2014;42(9):1401-6. 
248. Medine, C. N., Lucendo-Villarin, B., Storck, C., Wang, F., Szkolnicka, D., Khan, F., et al. Developing high-fidelity 
hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med. 2013;2(7):505-9. 
249. Kang, S. J., Lee, H. M., Park, Y. I., Yi, H., Lee, H., So, B., et al. Chemically induced hepatotoxicity in human stem cell-
induced hepatocytes compared with primary hepatocytes and HepG2. Cell Biol Toxicol. 2016;32(5):403-17. 
250. Kajiwara, M., Aoi, T., Okita, K., Takahashi, R., Inoue, H., Takayama, N., et al. Donor-dependent variations in hepatic 
differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012;109(31):12538-43. 
251. Rodrigues, R. M., De Kock, J., Branson, S., Vinken, M., Meganathan, K., Chaudhari, U., et al. Human skin-derived stem 
cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals. Stem Cells Dev. 2014;23(1):44-55. 
252. Guguen-Guillouzo, C., Corlu, A., Guillouzo, A. Stem cell-derived hepatocytes and their use in toxicology. Toxicology. 
Bibliography 
 174 
2010;270(1):3-9. 
253. Wobus, A. M., Loser, P. Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch 
Toxicol. 2011;85(2):79-117. 
254. Martins, J. P., Santos, J. M., De Almeida, J. M., Filipe, M. A., De Almeida, M. V., Almeida, S. C., et al. Towards an 
advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality 
and safety data. Stem Cell Res Ther. 2014;5(1):9. 
255. Gomez-Lechon, M. J., Tolosa, L., Conde, I., Donato, M. T. Competency of different cell models to predict human 
hepatotoxic drugs. Expert Opin Drug Metab Toxicol. 2014;10(11):1553-68. 
256. Godoy, P., Schmidt-Heck, W., Natarajan, K., Lucendo-Villarin, B., Szkolnicka, D., Asplund, A., et al. Gene networks and 
transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. J Hepatol. 2015;63(4):934-
42. 
257. Miranda, J. P., Filipe, E., Fernandes, A. S., Almeida, J. M., Martins, J. P., De La Fuente, A., et al. The Human Umbilical 
Cord Tissue-Derived MSC Population UCX® Promotes Early Motogenic Effects on Keratinocytes and Fibroblasts and G-
CSF-Mediated Mobilization of BM-MSCs When Transplanted In Vivo. Cell Transplant. 2015;24(5):865-77. 
258. Santos, J. M., Barcia, R. N., Simoes, S. I., Gaspar, M. M., Calado, S., Agua-Doce, A., et al. The role of human umbilical 
cord tissue-derived mesenchymal stromal cells (UCX®)) in the treatment of inflammatory arthritis. J Transl Med. 
2013;11:18. 
259. Santos, J. M., Camoes, S. P., Filipe, E., Cipriano, M., Barcia, R. N., Filipe, M., et al. Three-dimensional spheroid cell 
culture of umbilical cord tissue-derived mesenchymal stromal cells leads to enhanced paracrine induction of wound 
healing. Stem Cell Res Ther. 2015;6:90. 
260. Brolen, G., Sivertsson, L., Bjorquist, P., Eriksson, G., Ek, M., Semb, H., et al. Hepatocyte-like cells derived from human 
embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol. 2010;145(3):284-94. 
261. Ulvestad, M., Nordell, P., Asplund, A., Rehnstrom, M., Jacobsson, S., Holmgren, G., et al. Drug metabolizing enzyme 
and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. 
Biochem Pharmacol. 2013;86(5):691-702. 
262. Rajan, N., Habermehl, J., Cote, M. F., Doillon, C. J., Mantovani, D. Preparation of ready-to-use, storable and reconstituted 
type I collagen from rat tail tendon for tissue engineering applications. Nat Protocol. 2006;1(6):2753-8. 
263. Warnes, G. R., Bolker, B., Bonebakker, L., Gentleman, R., Huber, W., Liaw, A., Lumley, T., Maechler, M., Magnusson, 
A., Moeller, S. And Schwartz, M. gplots: Various R programming tools for plotting data. . R package version, 2(4). 2009. 
264. Oliveros, J. C. VENNY. An interactive tool for comparing lists with Venn Diagrams. 
http://bioinfogp.cnb.csic.es/tools/venny/index.html. 2007. 
265. Schwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T., et al. Multipotent adult progenitor cells from 
bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002;109(10):1291-302. 
266. Chen, M. L., Lee, K. D., Huang, H. C., Tsai, Y. L., Wu, Y. C., Kuo, T. M., et al. HNF-4alpha determines hepatic 
differentiation of human mesenchymal stem cells from bone marrow. World J Gastroenterol. 2010;16(40):5092-103. 
267. Wilkening, S., Bader, A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human 
hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol. 2003;17(4):207-13. 
268. Wilkening, S., Stahl, F., Bader, A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard 
to their biotransformation properties. Drug Metab Dispos. 2003;31(8):1035-42. 
269. Snykers, S., Vanhaecke, T., Papeleu, P., Luttun, A., Jiang, Y., Vander Heyden, Y., et al. Sequential exposure to cytokines 
reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-
like cells. Toxicol Sci. 2006;94(2):330-41. 
270. Kubo, A., Kim, Y. H., Irion, S., Kasuda, S., Takeuchi, M., Ohashi, K., et al. The homeobox gene Hex regulates hepatocyte 
differentiation from embryonic stem cell-derived endoderm. Hepatology. 2010;51(2):633-41. 
271. Cahan, P., Li, H., Morris, S. A., Lummertz Da Rocha, E., Daley, G. Q., Collins, J. J. CellNet: network biology applied to 
stem cell engineering. Cell. 2014;158(4):903-15. 
272. Denson, L. A., Mcclure, M. H., Bogue, C. W., Karpen, S. J., Jacobs, H. C. HNF3beta and GATA-4 transactivate the liver-
enriched homeobox gene, Hex. Gene. 2000;246(1-2):311-20. 
273. Zhao, R., Watt, A. J., Li, J., Luebke-Wheeler, J., Morrisey, E. E., Duncan, S. A. GATA6 is essential for embryonic 
development of the liver but dispensable for early heart formation. Mol Cell Biol. 2005;25(7):2622-31. 
274. Kang, M., Piliszek, A., Artus, J., Hadjantonakis, A. K. FGF4 is required for lineage restriction and salt-and-pepper 
distribution of primitive endoderm factors but not their initial expression in the mouse. Development. 2013;140(2):267-
79. 
275. Zhang, W., Yatskievych, T. A., Baker, R. K., Antin, P. B. Regulation of Hex gene expression and initial stages of avian 
hepatogenesis by Bmp and Fgf signaling. Dev Biol. 2004;268(2):312-26. 
276. Dessimoz, J., Opoka, R., Kordich, J. J., Grapin-Botton, A., Wells, J. M. FGF signaling is necessary for establishing gut 
tube domains along the anterior-posterior axis in vivo. Mech Dev. 2006;123(1):42-55. 
Bibliography 
 175 
277. Andersson, T. B. The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug 
compounds. Methods Mol Biol. 2010;640:375-87. 
278. Hengstler, J. G., Brulport, M., Schormann, W., Bauer, A., Hermes, M., Nussler, A. K., et al. Generation of human 
hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol. 2005;1(1):61-74. 
279. Vyhlidal, C. A., Gaedigk, R., Leeder, J. S. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A 
expression. Drug Metab Dispos. 2006;34(1):131-7. 
280. Rui, L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177-97. 
281. Godoy, P., Widera, A., Schmidt-Heck, W., Campos, G., Meyer, C., Cadenas, C., et al. Gene network activity in cultivated 
primary hepatocytes is highly similar to diseased mammalian liver tissue. Arch Toxicol. 2016;90(10):2513-29. 
282. Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., et al. Human adipose tissue is a source of 
multipotent stem cells. Mol Biol Cell. 2002;13(12):4279-95. 
283. Wang, H. S., Hung, S. C., Peng, S. T., Huang, C. C., Wei, H. M., Guo, Y. J., et al. Mesenchymal stem cells in the 
Wharton's jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330-7. 
284. Jaiswal, N., Haynesworth, S. E., Caplan, A. I., Bruder, S. P. Osteogenic differentiation of purified, culture-expanded 
human mesenchymal stem cells in vitro. J Cell Biochem. 1997;64(2):295-312. 
285. Matsuda, C., Takagi, M., Hattori, T., Wakitani, S., Yoshida, T. Differentiation of Human Bone Marrow Mesenchymal Stem 
Cells to Chondrocytes for Construction of Three-dimensional Cartilage Tissue. Cytotechnology. 2005;47(1-3):11-7. 
286. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. Multilineage potential of 
adult human mesenchymal stem cells. Science. 1999;284(5411):143-7. 
287. Gang, E. J., Jeong, J. A., Hong, S. H., Hwang, S. H., Kim, S. W., Yang, I. H., et al. Skeletal myogenic differentiation of 
mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells. 2004;22(4):617-24. 
288. Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., et al. Cardiomyocytes can be generated from 
marrow stromal cells in vitro. J Clin Invest. 1999;103(5):697-705. 
289. Wu, L. F., Wang, N. N., Liu, Y. S., Wei, X. Differentiation of Wharton's jelly primitive stromal cells into insulin-producing 
cells in comparison with bone marrow mesenchymal stem cells. Tissue Eng Part A. 2009;15(10):2865-73. 
290. Ma, L., Feng, X. Y., Cui, B. L., Law, F., Jiang, X. W., Yang, L. Y., et al. Human umbilical cord Wharton's Jelly-derived 
mesenchymal stem cells differentiation into nerve-like cells. Chin Med J. 2005;118(23):1987-93. 
291. Bartaula-Brevik, S., Pedersen, T. O., Blois, A. L., Papadakou, P., Finne-Wistrand, A., Xue, Y., et al. Leukocyte 
transmigration into tissue-engineered constructs is influenced by endothelial cells through toll-like receptor signaling. 
Stem Cell Res Ther. 2014;5(6):143. 
292. Chen, J. S., Wong, V. W., Gurtner, G. C. Therapeutic potential of bone marrow-derived mesenchymal stem cells for 
cutaneous wound healing. Front Immunol. 2012;3:192. 
293. Troyer, D. L., Weiss, M. L. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells. 
2008;26(3):591-9. 
294. Nascimento, D. S., Mosqueira, D., Sousa, L. M., Teixeira, M., Filipe, M., Resende, T. P., et al. Human umbilical cord 
tissue-derived mesenchymal stromal cells attenuate remodeling following myocardial infarction by pro-angiogenic, anti-
apoptotic and endogenous cell activation mechanisms. Stem Cell Res Ther. 2014;5(1):5. 
295. Barcia, R. N., Santos, J. M., Teixeira, M., Filipe, M., Pereira, A. R., Ministro, A., et al. Umbilical cord tissue-derived 
mesenchymal stromal cells maintain immunomodulatory and angiogenic potencies after cryopreservation and 
subsequent thawing. Cytotherapy. 2016. 
296. Gartner, A., Pereira, T., Armada-Da-Silva, P., Amado, S., Veloso, A., Amorim, I., et al. Effects of umbilical cord tissue 
mesenchymal stem cells (UCX®) on rat sciatic nerve regeneration after neurotmesis injuries. J Stem Cells Regen Med. 
2014;10(1):14-26. 
297. Baraniak, P. R., Mcdevitt, T. C. Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves 
multilineage potential. Cell Tissue Res. 2012;347(3):701-11. 
298. Bartosh, T. J., Ylostalo, J. H., Mohammadipoor, A., Bazhanov, N., Coble, K., Claypool, K., et al. Aggregation of human 
mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U 
S A. 2010;107(31):13724-9. 
299. Frith, J. E., Thomson, B., Genever, P. G. Dynamic three-dimensional culture methods enhance mesenchymal stem cell 
properties and increase therapeutic potential. Tissue Eng Part C Methods. 2010;16(4):735-49. 
300. Arufe, M. C., De La Fuente, A., Fuentes-Boquete, I., De Toro, F. J., Blanco, F. J. Differentiation of synovial CD-105(+) 
human mesenchymal stem cells into chondrocyte-like cells through spheroid formation. J Cell Biochem. 2009;108(1):145-
55. 
301. Sabapathy, V., Sundaram, B., V, M. S., Mankuzhy, P., Kumar, S. Human Wharton's Jelly Mesenchymal Stem Cells 
plasticity augments scar-free skin wound healing with hair growth. PLoS One. 2014;9(4):e93726. 
302. Hsu, S. H., Hsieh, P. S. Self-assembled adult adipose-derived stem cell spheroids combined with biomaterials promote 
wound healing in a rat skin repair model. Wound Repair Regen. 2014. 
Bibliography 
 176 
303. Ballotta, V., Smits, A. I., Driessen-Mol, A., Bouten, C. V., Baaijens, F. P. Synergistic protein secretion by mesenchymal 
stromal cells seeded in 3D scaffolds and circulating leukocytes in physiological flow. Biomaterials. 2014;35(33):9100-13. 
304. Rettinger, C. L., Fourcaudot, A. B., Hong, S. J., Mustoe, T. A., Hale, R. G., Leung, K. P. In vitro characterization of 
scaffold-free three-dimensional mesenchymal stem cell aggregates. Cell Tissue Res. 2014;358(2):395-405. 
305. Serra, M., Brito, C., Sousa, M. F., Jensen, J., Tostoes, R., Clemente, J., et al. Improving expansion of pluripotent human 
embryonic stem cells in perfused bioreactors through oxygen control. J Biotechnol. 2010;148(4):208-15. 
306. Cardoso, T. C., Ferrari, H. F., Garcia, A. F., Novais, J. B., Silva-Frade, C., Ferrarezi, M. C., et al. Isolation and 
characterization of Wharton's jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord 
and maintained in a defined serum-free three-dimensional system. BMC Biotechnol. 2012;12:18. 
307. Cesarz, Z., Tamama, K. Spheroid Culture of Mesenchymal Stem Cells. Stem Cells Int. 2016;2016:9176357. 
308. Bellas, E., Chen, C. S. Forms, forces, and stem cell fate. Curr Opin Cell Biol. 2014;31:92-7. 
309. Wang, W., Itaka, K., Ohba, S., Nishiyama, N., Chung, U. I., Yamasaki, Y., et al. 3D spheroid culture system on 
micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells. Biomaterials. 
2009;30(14):2705-15. 
310. Qihao, Z., Xigu, C., Guanghui, C., Weiwei, Z. Spheroid formation and differentiation into hepatocyte-like cells of rat 
mesenchymal stem cell induced by co-culture with liver cells. DNA Cell Biol. 2007;26(7):497-503. 
311. Serra, M., Correia, C., Malpique, R., Brito, C., Jensen, J., Bjorquist, P., et al. Microencapsulation technology: a powerful 
tool for integrating expansion and cryopreservation of human embryonic stem cells. PLoS One. 2011;6(8):e23212. 
312. Yirme, G., Amit, M., Laevsky, I., Osenberg, S., Itskovitz-Eldor, J. Establishing a dynamic process for the formation, 
propagation, and differentiation of human embryoid bodies. Stem Cells Dev. 2008;17(6):1227-41. 
313. Moreira, J. L., Alves, P. M., Aunins, J. G., Carrondo, M. J. Hydrodynamic effects on BHK cells grown as suspended 
natural aggregates. Biotechnol Bioeng. 1995;46(4):351-60. 
314. Edmondson, R., Broglie, J. J., Adcock, A. F., Yang, L. Three-dimensional cell culture systems and their applications in 
drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207-18. 
315. Stein, A. Decreasing variability in your cell culture. Biotechniques. 2007;43(2):228-9. 
316. Mannello, F., Tonti, G. A. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: 
conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; 
serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells. 
2007;25(7):1603-9. 
317. Wu, M., Han, Z. B., Liu, J. F., Wang, Y. W., Zhang, J. Z., Li, C. T., et al. Serum-free media and the immunoregulatory 
properties of mesenchymal stem cells in vivo and in vitro. Cell Physiol Biochem. 2014;33(3):569-80. 
318. Oskowitz, A., Mcferrin, H., Gutschow, M., Carter, M. L., Pochampally, R. Serum-deprived human multipotent 
mesenchymal stromal cells (MSCs) are highly angiogenic. Stem Cell Res. 2011;6(3):215-25. 
319. Riebeling, C., Schlechter, K., Buesen, R., Spielmann, H., Luch, A., Seiler, A. Defined culture medium for stem cell 
differentiation: applicability of serum-free conditions in the mouse embryonic stem cell test. Toxicol In Vitro. 
2011;25(4):914-21. 
320. Lei, Y., Jeong, D., Xiao, J., Schaffer, D. V. Developing Defined and Scalable 3D Culture Systems for Culturing Human 
Pluripotent Stem Cells at High Densities. Cell Mol Bioeng. 2014;7(2):172-83. 
321. Lei, Y., Schaffer, D. V. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and 
differentiation. Proc Natl Acad Sci U S A. 2013;110(52):E5039-48. 
322. Zhao, G., Liu, F., Lan, S., Li, P., Wang, L., Kou, J., et al. Large-scale expansion of Wharton's jelly-derived mesenchymal 
stem cells on gelatin microbeads, with retention of self-renewal and multipotency characteristics and the capacity for 
enhancing skin wound healing. Stem Cell Res Ther. 2015;6:38. 
323. Ruiz, S. A., Chen, C. S. Emergence of patterned stem cell differentiation within multicellular structures. Stem Cells. 
2008;26(11):2921-7. 
324. Mcbeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K., Chen, C. S. Cell shape, cytoskeletal tension, and RhoA regulate 
stem cell lineage commitment. Dev Cell. 2004;6(4):483-95. 
325. Baraniak, P. R., Cooke, M. T., Saeed, R., Kinney, M. A., Fridley, K. M., Mcdevitt, T. C. Stiffening of human mesenchymal 
stem cell spheroid microenvironments induced by incorporation of gelatin microparticles. J Mech Behav Biomed Mater. 
2012;11:63-71. 
326. Hao, H., Chen, G., Liu, J., Ti, D., Zhao, Y., Xu, S., et al. Culturing on Wharton's jelly extract delays mesenchymal stem 
cell senescence through p53 and p16INK4a/pRb pathways. PLoS One. 2013;8(3):e58314. 
327. Nanaev, A. K., Kohnen, G., Milovanov, A. P., Domogatsky, S. P., Kaufmann, P. Stromal differentiation and architecture 
of the human umbilical cord. Placenta. 1997;18(1):53-64. 
328. Potapova, I. A., Brink, P. R., Cohen, I. S., Doronin, S. V. Culturing of human mesenchymal stem cells as three-
dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol 
Chem. 2008;283(19):13100-7. 
Bibliography 
 177 
329. Potapova, I. A., Gaudette, G. R., Brink, P. R., Robinson, R. B., Rosen, M. R., Cohen, I. S., et al. Mesenchymal stem cells 
support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells. 
2007;25(7):1761-8. 
330. Lee, J. H., Han, Y. S., Lee, S. H. Long-Duration Three-Dimensional Spheroid Culture Promotes Angiogenic Activities of 
Adipose-Derived Mesenchymal Stem Cells. Biomol Ther (Seoul). 2016;24(3):260-7. 
331. Schwartz, R. E., Fleming, H. E., Khetani, S. R., Bhatia, S. N. Pluripotent stem cell-derived hepatocyte-like cells. 
Biotechnol Adv. 2014;32(2):504-13. 
332. Woo, D. H., Kim, S. K., Lim, H. J., Heo, J., Park, H. S., Kang, G. Y., et al. Direct and indirect contribution of human 
embryonic stem cell-derived hepatocyte-like cells to liver repair in mice. Gastroenterology. 2012;142(3):602-11. 
333. Cipriano, M., Medeiros, A., Filipe, E., Santos, J. M., Barcia, R., Cruz, H., et al. UCX® cells: A primordial stem cell source 
for in vitro differentiation into hepatocyte-like cells (HLCs). Toxicol Lett. 2014;229:S140-S. 
334. Sengupta, S., Johnson, B. P., Swanson, S. A., Stewart, R., Bradfield, C. A., Thomson, J. A. Aggregate culture of human 
embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity 
testing. Toxicol Sci. 2014;140(1):236-45. 
335. Ramasamy, T. S., Yu, J. S., Selden, C., Hodgson, H., Cui, W. Application of three-dimensional culture conditions to 
human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality. 
Tissue Eng Part A. 2013;19(3-4):360-7. 
336. Tanimizu, N., Mitaka, T. Re-evaluation of liver stem/progenitor cells. Organogenesis. 2014;10(2):208-15. 
337. Talaei-Khozani, T., Khodabandeh, Z., Jaberipour, M., Hosseini, A., Bahmanpour, S., Vojdani, Z. Comparison of hepatic 
nuclear factor-4 expression in two- and three-dimensional culture of Wharton's jelly-derived cells exposed to hepatogenic 
medium. Rom J Morphol Embryol. 2015;56(4):1365-70. 
338. Ong, S. Y., Dai, H., Leong, K. W. Inducing hepatic differentiation of human mesenchymal stem cells in pellet culture. 
Biomaterials. 2006;27(22):4087-97. 
339. Haruna, Y., Saito, K., Spaulding, S., Nalesnik, M. A., Gerber, M. A. Identification of bipotential progenitor cells in human 
liver development. Hepatology. 1996;23(3):476-81. 
340. Fausto, N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology. 2004;39(6):1477-87. 
341. Strassburg, C. P., Strassburg, A., Kneip, S., Barut, A., Tukey, R. H., Rodeck, B., et al. Developmental aspects of human 
hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259-65. 
342. Hamilton, G. A., Jolley, S. L., Gilbert, D., Coon, D. J., Barros, S., Lecluyse, E. L. Regulation of cell morphology and 
cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. 
2001;306(1):85-99. 
343. Tasnim, F., Phan, D., Toh, Y. C., Yu, H. Cost-effective differentiation of hepatocyte-like cells from human pluripotent stem 
cells using small molecules. Biomaterials. 2015;70:115-25. 
344. Sharma, A. M., Novalen, M., Tanino, T., Uetrecht, J. P. 12-OH-nevirapine sulfate, formed in the skin, is responsible for 
nevirapine-induced skin rash. Chem Res Toxicol. 2013;26(5):817-27. 
345. Sharma, A. M., Li, Y., Novalen, M., Hayes, M. A., Uetrecht, J. Bioactivation of nevirapine to a reactive quinone methide: 
implications for liver injury. Chem Res Toxicol. 2012;25(8):1708-19. 
346. Riska, P., Lamson, M., Macgregor, T., Sabo, J., Hattox, S., Pav, J., et al. Disposition and biotransformation of the 
antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27(8):895-901. 
347. Luzuriaga, K., Bryson, Y., Mcsherry, G., Robinson, J., Stechenberg, B., Scott, G., et al. Pharmacokinetics, safety, and 
activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis. 1996;174(4):713-21. 
348. Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., Keirns, J. J. Characterization of the in vitro biotransformation of 
the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 
1999;27(12):1488-95. 
349. Hall, D. B., Macgregor, T. R. Case-control exploration of relationships between early rash or liver toxicity and plasma 
concentrations of nevirapine and primary metabolites. HIV Clin Trials. 2007;8(6):391-9. 
350. Kranendonk, M., Alves, M., Antunes, P., Rueff, J. Human sulfotransferase 1A1-dependent mutagenicity of 12-hydroxy-
nevirapine: the missing link? Chem Res Toxicol. 2014;27(11):1967-71. 
351. Antunes, A. M., Godinho, A. L., Martins, I. L., Justino, G. C., Beland, F. A., Marques, M. M. Amino acid adduct formation 
by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity. Chem Res Toxicol. 
2010;23(5):888-99. 
352. Dekker, S. J., Zhang, Y., Vos, J. C., Vermeulen, N. P., Commandeur, J. N. Different Reactive Metabolites of Nevirapine 
Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation. Chem Res Toxicol. 2016;29(12):2136-44. 
353. Cipriano, M., Correia, J. C., Camoes, S. P., Oliveira, N. G., Cruz, P., Cruz, H., et al. The role of epigenetic modifiers in 
extended cultures of functional hepatocyte-like cells derived from human neonatal mesenchymal stem cells. Arch Toxicol. 
2016. 
354. Spandidos, A., Wang, X., Wang, H., Seed, B. PrimerBank: a resource of human and mouse PCR primer pairs for gene 
Bibliography 
 178 
expression detection and quantification. Nucleic Acids Res. 2010;38(Database issue):D792-9. 
355. Antherieu, S., Chesne, C., Li, R., Camus, S., Lahoz, A., Picazo, L., et al. Stable expression, activity, and inducibility of 
cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos. 2010;38(3):516-25. 
356. Justino, G. C., Santos, M. R., Canario, S., Borges, C., Florencio, M. H., Mira, L. Plasma quercetin metabolites: structure-
antioxidant activity relationships. Arch Biochem Biophys. 2004;432(1):109-21. 
357. Babu, S. R., Lakshmi, V. M., Huang, G. P., Zenser, T. V., Davis, B. B. Glucuronide conjugates of 4-aminobiphenyl and 
its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochem Pharmacol. 1996;51(12):1679-
85. 
358. Marinho, A. T., Rodrigues, P. M., Caixas, U., Antunes, A. M., Branco, T., Harjivan, S. G., et al. Differences in nevirapine 
biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions. J Antimicrob Chemother. 
2014;69(2):476-82. 
359. Grilo, N. M. C., M.J.; Miranda, J.P.; Cipriano, M.; Serpa, J.; Marques, M.M.; Monteiro, E.C.; Antunes, A.A; Diogo, L.L.; 
Pereira, S.A. Unmasking efavirenz neurotoxicity: time matters to the underlying mechanisms. Eur J of Pharm Sci. 2017; 
105:47-54 
360. Przemyslaw, W., Piotr, K., Grazyna, C., Danuta, K. P., Malgorzata, I., Bernadeta, M., et al. Total, free, and protein-bound 
thiols in plasma of peritoneal dialysis and predialysis patients. Int Urol Nephrol. 2011;43(4):1201-9. 
361. De Sousa Mendes, M., Lui, G., Zheng, Y., Pressiat, C., Hirt, D., Valade, E., et al. A Physiologically-Based 
Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. Clin 
Pharmacokinet. 2017; 56 (5), 537-550. 
362. Fan-Havard, P., Liu, Z., Chou, M., Ling, Y., Barrail-Tran, A., Haas, D. W., et al. Pharmacokinetics of phase I nevirapine 
metabolites following a single dose and at steady state. Antimicrob Agents Chemother. 2013;57(5):2154-60. 
363. Marinho, A. T., Godinho, A. L. A., Novais, D. A., Antunes, A. M. M., Marques, M. M., Ramos, T., et al. Development and 
validation of an HPLC-UV method for quantifying nevirapine and its main phase I metabolites in human blood. Anal 
Methods. 2014;6(5):1575-80. 
364. Riska, P. S., Joseph, D. P., Dinallo, R. M., Davidson, W. C., Keirns, J. J., Hattox, S. E. Biotransformation of nevirapine, 
a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug 
Metab Dispos. 1999;27(12):1434-47. 
365. Chang, B. X., You, S. L., Liu, H. L., Mao, P. Y., Xin, S. J. Establishment of cytochrome P450 3A4 and glutathione S-
transferase A1-transfected human hepatoma cell line and functional analysis. Genet Mol Res. 2014;13(3):6949-61. 
366. Coles, B. F., Kadlubar, F. F. Human alpha class glutathione S-transferases: genetic polymorphism, expression, and 
susceptibility to disease. Methods Enzymol. 2005;401:9-42. 
367. Kim, S. G., Lee, S. J. PI3K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci. 2007;96(2):206-
13. 
368. Lu, S. C. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30(1-2):42-59. 
369. Forman, H. J., Zhang, H., Rinna, A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol 
Aspects Med. 2009;30(1-2):1-12. 
370. Lopes-Coelho, F., Gouveia-Fernandes, S., Goncalves, L. G., Nunes, C., Faustino, I., Silva, F., et al. HNF1beta drives 
glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). Tumour 
Biol. 2016;37(4):4813-29. 
371. Mcgarry, D. J., Chakravarty, P., Wolf, C. R., Henderson, C. J. Altered protein S-glutathionylation identifies a potential 
mechanism of resistance to acetaminophen-induced hepatotoxicity. J Pharmacol Exp Ther. 2015;355(2):137-44. 
372. Stummann, T. C., Bremer, S. The possible impact of human embryonic stem cells on safety pharmacological and 
toxicological assessments in drug discovery and drug development. Curr Stem Cell Res Ther. 2008;3(2):118-31. 
373. Hay, D. C., Fletcher, J., Payne, C., Terrace, J. D., Gallagher, R. C., Snoeys, J., et al. Highly efficient differentiation of 
hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A. 
2008;105(34):12301-6. 
374. De Kock, J., Vanhaecke, T., Biernaskie, J., Rogiers, V., Snykers, S. Characterization and hepatic differentiation of skin-
derived precursors from adult foreskin by sequential exposure to hepatogenic cytokines and growth factors reflecting 
liver development. Toxicol In Vitro. 2009;23(8):1522-7. 
375. Perrimon, N., Pitsouli, C., Shilo, B. Z. Signaling mechanisms controlling cell fate and embryonic patterning. Cold Spring 
Harb Perspect Biol. 2012;4(8):a005975. 
376. Bohm, F., Kohler, U. A., Speicher, T., Werner, S. Regulation of liver regeneration by growth factors and cytokines. EMBO 
Mol Med. 2010;2(8):294-305. 
377. Snykers, S., De Kock, J., Tamara, V., Rogiers, V. Hepatic differentiation of mesenchymal stem cells: in vitro strategies. 
Methods Mol Biol. 2011;698:305-14. 
378. Snykers, S., Vinken, M., Rogiers, V., Vanhaecke, T. Differential role of epigenetic modulators in malignant and normal 
stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy. Arch Toxicol. 2007;81(8):533-44. 
Bibliography 
 179 
379. Hay, D. C., Zhao, D., Ross, A., Mandalam, R., Lebkowski, J., Cui, W. Direct differentiation of human embryonic stem 
cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells. 2007;9(1):51-62. 
380. Duncan, S. A. Mechanisms controlling early development of the liver. Mech Dev. 2003;120(1):19-33. 
381. Pettinato, G., Ramanathan, R., Fisher, R. A., Mangino, M. J., Zhang, N., Wen, X. Scalable Differentiation of Human 
iPSCs in a Multicellular Spheroid-based 3D Culture into Hepatocyte-like Cells through Direct Wnt/beta-catenin Pathway 
Inhibition. Sci Rep. 2016;6:32888. 
382. Reif, S., Sykes, D., Rossi, T., Weiser, M. M. Changes in transcripts of basement components during rat liver development: 
increase in laminin messenger RNAs in the neonatal period. Hepatology. 1992;15(2):310-5. 
383. Reif, S., Terranova, V. P., El-Bendary, M., Lebenthal, E., Petell, J. K. Modulation of extracellular matrix proteins in rat 
liver during development. Hepatology. 1990;12(3 Pt 1):519-25. 
384. Zaret, K. S. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet. 2002;3(7):499-
512. 
385. Wells, J. M., Melton, D. A. Vertebrate endoderm development. Annu Rev Cell Dev Biol. 1999;15:393-410. 
386. Torre, C., Perret, C., Colnot, S. Transcription dynamics in a physiological process: beta-catenin signaling directs liver 
metabolic zonation. Int J Biochem Cell Biol. 2011;43(2):271-8. 
387. Mccarty, W. J., Usta, O. B., Yarmush, M. L. A Microfabricated Platform for Generating Physiologically-Relevant 
Hepatocyte Zonation. Sci Rep. 2016;6:26868. 
388. Rodrigues, J. S. The use of MSC derived hepatocyte-like cells (HLCs) in microfluidic culture systems: an approach for 
studying the metabolic syndrome: Instituto Superior Técnico, Universidade de Lisboa; 2016. Available from: 
https://fenix.tecnico.ulisboa.pt/cursos/mebiom/dissertacao/565303595501027 
389. Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., Turner, N. D. Glutathione metabolism and its implications for health. J Nutr. 
2004;134(3):489-92. 
390. Prodanov, L., Jindal, R., Bale, S. S., Hegde, M., Mccarty, W. J., Golberg, I., et al. Long-term maintenance of a microfluidic 
3D human liver sinusoid. Biotechnol Bioeng. 2016;113(1):241-6. 
391. Pascussi, J. M., Drocourt, L., Gerbal-Chaloin, S., Fabre, J. M., Maurel, P., Vilarem, M. J. Dual effect of dexamethasone 
on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. 
Eur J Biochem. 2001;268(24):6346-58. 
392. Ferris, H. A., Kahn, C. R. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin 
Invest. 2012;122(11):3854-7. 
393. Deharde, D., Schneider, C., Hiller, T., Fischer, N., Kegel, V., Lubberstedt, M., et al. Bile canaliculi formation and biliary 
transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition. Arch Toxicol. 
2016;90(10):2497-511. 
394. Boyer, J. L. Bile formation and secretion. Compr Physiol. 2013;3(3):1035-78. 
395. Avior, Y., Levy, G., Zimerman, M., Kitsberg, D., Schwartz, R., Sadeh, R., et al. Microbial-derived lithocholic acid and 
vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes. Hepatology. 
2015;62(1):265-78. 
396. Sawitza, I., Kordes, C., Gotze, S., Herebian, D., Haussinger, D. Bile acids induce hepatic differentiation of mesenchymal 
stem cells. Sci Rep. 2015;5:13320. 
 
